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Abstract 
 
Filarial nematodes are an important group of human pathogens that affect more than 157 million people 
worldwide and contribute to serious public health and socio-economic problems. These parasites are 
responsible for the neglected tropical diseases lymphatic filariasis (LF) and onchocerciasis and taken together, 
these diseases are a leading cause of global morbidity. Currently, treatment of LF relies on diethylcarbamazine 
plus albendazole in areas which are not co-endemic for onchocerciasis and ivermectin which is used to treat 
onchocerciasis in areas which are co-endemic. The current anthelmintic therapies have undesirable adverse 
effects, activity restricted to the immature worm stage and contraindicated patient groups. In addition to 
these drawbacks, drug resistance is another important factor that is driving research efforts to identify and 
generate safer alternative drugs with novel mechanisms of action. Wolbachia is an essential endosymbiotic 
bacterium that lives inside the cells of the filarial worms. As the filariae are dependent on Wolbachia for 
survival and fertility, eliminating the bacteria with antibiotic drugs cures patients, blocks transmission and 
delivers a new strategy for eradicating lymphatic filariasis and onchocerciasis while avoiding the severe 
adverse effects with current therapies. Doxycycline is the current gold standard for anti-Wolbachia activity, but 
requires treatment for at least 4 weeks and is contraindicated in children less than 9 years of age and pregnant 
women. The anti-Wolbachia (AWOL) drug discovery and development consortium, which is funded by the Bill 
& Melinda Gates foundation, aims to identify alternative drugs that are suitable for a wider patient range and 
require a shorter treatment regimen. The work presented is focused on the identification and development of 
novel small-molecule therapies for these diseases. Initially, a brief introduction to Lymphatic Filariasis and 
Onchocerciasis will be presented followed by current therapies before discussion of the target bacteria 
Wolbachia. A phenotypic screen of the Medicines for Malaria venture diversity library revealed many hits that 
showed promising anti-Wolbachia activity. Chemoinformatic analysis of these hits identified the most 
promising chemical scaffolds to enter a medicinal chemistry optimization phase. This thesis primarily focuses 
on the establishment of SAR for molecules containing a pyrazolopyrimidine core, with subsequent 
optimization of metabolic stability and solubility profiles in line with our target candidate profile. Several 
synthetic pathways have been explored that allow for modification at key positions around the 
pyrazolopyrimidine core. These pathways have enabled extensive functionalization, generating a large library 
of over 190 compounds where many analogues possess nanomolar activity against Wolbachia in vitro and 
display greatly improved in vitro DMPK parameters over the initial hit. The 2-pyridyl ring seen in the initial hit 
appears essential for anti-Wolbachia activity and SAR studies focused on reducing ClogP revealed that 
bioisosteric replacement of the phenyl ring seen with a tetrahydropyran group was tolerated in terms of anti-
Wolbachia potency with an improvement in measured DMPK properties. Data on the most advanced molecule 
in this series shows similar efficacy to that of the current gold-standard doxycycline. Based on the work 
contained in this thesis, there are several options available for further modification of both the 
pyrazolopyrimidine core and substituents that could allow for further improvement of both DMPK properties 
and compound potency. 
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1 – Introduction 
 
1.1 Lymphatic filariasis (LF) 
 
1.1.1 Global prevalence of LF 
 
The parasitic disease filariasis is a vector-borne disease caused by a range of nematodes which are able to 
infect a number of diverse environments within a human host.5 Filariasis can be divided into three categories; 
lymphatic filariasis (LF), subcutaneous filariasis and serous cavity filariasis. In 2012 greater than 120 million 
people suffered from these diseases with a further 1.3 billion people at risk of infection in over 72 endemic 
countries. Currently these cases have been reduced to an estimated 40 million people suffering from 
lymphatic filariasis who experience serious incapacitation or disfigurement.6 Due to control programmes 
initiated by the WHO over 350 million people no longer require prophylactic chemotherapy. However, 947 
million people are still at risk of infection in over 54 countries, many of whom live within Africa, Asia or Brazil 
(Fig. 1.1).1,6 Filarial diseases contribute to a further decline in health in patients suffering from life-threatening 
infections such as HIV, TB or malaria.7 Filariasis is responsible for significant losses to productivity within the 
agricultural industry attributed to the loss of livestock and additional cost incurred in the treatment measures 
required to preserve remaining livestock, this is estimated at an annual loss of US$1.3 billion.8–10 
Fig. 1.1 Map displaying LF global prevalence with endemic countries and state of MDA programmes displayed 
(2016).1 
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The causative agents for LF are the group of nematodes; Wuchereria bancrofti, Brugia malayi and Brugia 
timor, with the majority (~90%) of cases due to W. bancrofti infection.6 A wide range of mosquitoes are 
responsible for the transmission of LF while mosquitoes of the Culex genus, which are spread around urban or 
semi-urban areas, are generally the most efficient for transmitting W. bancrofti.11 Chronic cases of LF can lead 
to a condition known as elephantiasis, which is characterised by the swelling and disfiguring of the lower 
extremities. This condition significantly decreases the number of able-bodied workers in populations 
experiencing a high incidence of transmission; in severe cases, healthy individuals are forced to become full-
time carers for incapacitated family members with severe conditions.  This produces huge socio-economic 
issues within areas of high incidence where the burden of the disease is related to the intensity and duration 
of the infection therefore LF has a greater impact on older age groups when the disease has had a greater time 
to develop.12 
1.1.2 Life cycle of Wuchereria bancrofti. 
 
The life cycle of the W. bancrofti nematode is displayed in Fig. 1.2, this cycle initiates with the transfer of the 
infectious stage larvae (L3) onto a host’s skin during a the bite of an Anopheles or Culex mosquito.13 Once 
within the human host the infectious larvae migrate around the body within the bloodstream until they reach 
the lymphatic system where they develop into adult worms. Once capable, the adult worms form nests and 
begin to reproduce; this forms many immature worms in the form of microfilariae (mf) which then circulate 
the body within the blood.  
 
 
 
 
 
 
 
 
 
 
Fig 1.2 Life-cycle of the nematode W. bancrofti.2 
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Microfilariae can be transferred from the blood to a feeding mosquito to again develop into immature (L1) 
larvae and subsequently infectious larvae (L3) which remain within the thoracic muscles of the mosquito and 
are primed for retransmission.5 
Female adult worms can grow up to 10 cm in length and typically live for five to seven years, while the smaller 
male worms will grow to approximately 2-4 cm in length.2  It is possible for these adult worm nests to grow 
large enough to cause fluid blockages within human lymph nodes, resulting in fever due to swelling of the 
lymphatic system. The first classified manifestation of LF is termed acute adenolymphangitis (ADL). Symptoms 
of ADL are characterised by the sudden onset of fever and inflammation of the lymphatic system. Tropical 
pulmonary eosinophilia (TPE) is a syndrome that develops in some suffers of LF, normally in people aged 
between 30 to 40 and is about four times more likely to affect males than females. Symptoms of TPE include 
excessive coughing and asthma attacks which can occasionally be mistaken for tuberculosis, if left untreated 
TPE can result in lung disease.14 The World Health Organisation (WHO) has published a grading system to 
classify the severity of lymphatic filariasis cases within the clinic. Grade 1 cases display pitting oedema that is 
reversible upon elevation of the leg while Grade 2 indicates non-pitting oedema that is not reversible by 
elevating the leg. A Grade 3 category indicates non-pitting oedema with increased swelling relative to Grade 2 
cases.  Additionally, grade 3 cases are associated with sclerosis and papillomatous changes to the skin surface 
and many of grade 2 and grade 3 patients suffer from elephantiasis.15  
1.1.3 Diagnosis of LF 
 
Diagnosis of LF is difficult. Traditional diagnostic methods involve the use of microscopy to detect mf within 
the blood; however, since mf exhibit a marked periodicity the time of specimen collection is important. 
Microfilariae of the Brugia or Wuchereria species primarily circulate at night which results in added difficulty to 
obtain appropriate blood samples for analysis.16 There are assays available which detect the presence of W. 
bancrofti antigens within the blood. The enzyme-linked immunosorbent assay (ELISA) and the 
immunochromatographic card tests are the primary methods used for detection of LF. These tests are very 
specific for the condition with almost 100 percent reliability.17 They are however subject to some 
disadvantages; the tests only detect for W. bancrofti, therefore overlooking the other causative species of 
Brugia, they are expensive costing US$ 2-4 per person which makes them unsuitable for programmes which 
screen over 380 million people per year and it is also possible for these tests to produce false-positives due to 
the detection of antigens present after worm death.17 The identification of adult worms within the scrotum of 
males or the breasts of females is possible using high frequency ultrasound imaging to detect for worm 
movement.18 These techniques are necessary as diagnosis of adult worms present within the nodes of the 
lymphatic system is extremely difficult. The implementation of these techniques is expensive and therefore is 
unsuitable for use in endemic areas.  
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1.2 Onchocerciasis 
 
1.2.1 Global prevalence of onchocerciasis 
 
Onchocerciasis (or river blindness) is caused by the parasitic nematode Onchocerca Volvulus (O. Volvulus) and 
is the world’s second leading infectious cause of blindness.19 There are 120 million people at risk of 
Onchocerciasis, 96% of which are located in Africa as shown in Fig. 1.3. The disease however also exists in 
Yemen and throughout a number of Latin American nations.10 Individuals who are at greatest risk of 
contracting onchocerciasis are those who live near to suitable river habitats for the vectors, Simulium 
blackflies, which transmit the parasite O. Volvulus to its host. The most efficient vector of O. Volvulus 
throughout Africa is Simulium damnosum sensus lato, whilst within the Western hemisphere there are many 
important vectors including S. ochraceum and S. metallicum. At present, approximately 37 million humans are 
infected with O. Volvulus although symptoms may not appear until several months after initial infection once 
the mf count within the human host has increased to a sufficient level. 
Fig. 1.3  Map displaying global prevalence of Onchocerciasis distribution map (Figure adapted from WHO, 
Onchocerciasis distribution map - 2013).20 
Onchocerciasis is responsible for the suffering of over 6.5 million people with associated skin-conditions, a 
further half a million people suffering from visual impairments and almost 300,000 of these individuals are 
blind.21 The abnormal skin conditions are known as localized and chronic papular onchodermatitis, these 
account for 60% of the disease burden or Disability-adjusted life-years (DALYS), the number of years those 
afflicted lose due to ill-health caused by onchocerciasis.19 Food shortages and a struggling economy resulting 
from insufficient able-bodied workers has forced people residing within endemic regions to abandon their 
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homes, leaving fertile river valleys in order to move to area’s which experience reduced transmission. These 
forested areas are generally difficult to farm and further contribute to food shortages and a struggling 
economy.19 Therefore, the impact of these infectious diseases goes far beyond the impairment of health by 
compromising working societies in affected regions. 
1.2.2 Onchocerca Volvulus Life Cycle 
 
The infective larvae of O. Volvulus are transmitted onto the skin of humans during the bite of an infected 
blackfly. Larvae enter the human body by penetrating the wound inflicted by the fly bite then migrate to 
subcutaneous tissues and slowly develop into adult worms.19 Female adult worms can measure up 40 cm in 
length and remain in nodules; male adult worms measure ~20 cm in length and can migrate between nodules 
fertilising the larger female worm.22 This results in the production of approximately 1600 mf per day which are 
then released into the bloodstream and surrounding tissue. Female worms remain fertile for up to nine years 
and the average life-expectancy of adult worms is 15 years. Mf are primarily found near the surface of the skin 
where it is possible for them to be ingested by feeding blackflies and allows for diagnosis of the condition. 
Immature forms of the worm cannot mature into infective larvae without transmission to feeding blackflies; 
therefore, the adult worm count within an individual can be associated with the number of infectious bites 
incurred. Once transmitted to a black-fly the immature larvae penetrate the stomach wall of the black fly and 
move towards the thoracic muscles were they remain and develop into infectious larvae over the next seven 
days, after which larvae are now primed for transmission to further humans.22 The life cycle of O.Volvulus is 
summarised in Fig. 1.43 and is divided into the human and blackfly stages of the nematode life cycle with the 
infectious larvae and diagnostic mf worm stages labelled. 
 
 
 
 
 
 
 
 
 
 
Fig  1.4 Flow diagram depicting the different stages of the Onchocerca volvulus parasite life cycle.3 
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Microfilariae (mf) typically live for one to two years and are responsible for the disease pathology of 
onchocerciasis including inflammatory reactions within the skin, lymph nodes and eyes. The majority of this 
inflammation can be associated with dead or dying mf which causes the release of endogenous substances 
into surrounding tissue.19 This poses an issue with the use of filaricidal therapies that act directly on the worm 
and result in the release of further harmful substances into the body at the sites of worm death. Onchocercal 
skin disease (OSD) is caused by mf migration throughout the body allowing continuous secretion of enzymes 
such as collagenase which cause damage to skin collagen and elastin,  resulting in the loss of skin elasticity 
ultimately causing disfigurement.23 Visual impairment is caused by mf invasion of the eyes, exposing these 
organs to harmful enzymes on worm death resulting in serious inflammation. Inflammatory reactions within 
the eye produce opaque spots on the cornea which can later develop into a permanently cloudy cornea 
causing loss of vision and potentially, blindness.19 In addition to the symptoms of blindness, dermatitis, skin 
atrophy and inflammation, a high mf load has been identified as a factor which reduces the life span of 
infected people. Those afflicted with OSD can suffer from significant psychological trauma contributing to a 
number of negative socio-economic effects such as productivity losses in the agricultural industry and 
decreased school attendance.24–28  
 
1.2.3 Diagnosis of Onchocerciasis 
 
There are several techniques that are used to diagnose individuals infected with onchocerciasis, the most 
common of which is the skin snip test which is used to detect the presence of mf within the skin. This can be a 
challenging method of diagnosis since the time when mf are present within the skin (the optimum time for 
skin snip diagnosis) occurs between 3 and 15 months following initial infection. The removed skin sample is 
placed in a saline solution causing any mf to emerge therefore allowing detection. It is also possible to use 
polymerase chain reaction (PCR) to diagnose patients with low levels of infection; however, this technique is 
relatively expensive compared to other diagnostic methods and is therefore unsuitable to administer in large-
scale programs within developing countries.29 Mf within the eye can be detected using a slit-lamp (microscope 
and a lamp) with skin nodules being surgically removed to detect for adult worms. It is also possible to test for 
circulating antigens of O.Volvulus within the blood through the use of Ov16 card tests which are employed 
within the onchocerciasis elimination program for the Americas (OEPA) as a means of determining if 
transmission has been eliminated.29  
1.3 Existing Anti-Filarial Treatments 
 
Currently the treatment of filariasis involves drugs such as diethylcarbamazine (DEC), ivermectin (IVM)  and 
albendazole (Fig 1.5).30 DEC is a synthetic piperazine derived anthelmintic (compound efficacious against 
parasitic worms, helminths) used for the treatment of filarial infections in humans and animals which displays 
activity against both microfilariae and macrofilariae (the adult worm).  
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Fig. 1.5 Structure of diethylcarbamazine (DEC), macrocyclic lactone Ivermectin (IVM) and benzimidazole 
compound Albendazole (ABZ) 
DEC is thought to exert its anti-filarial activity via a number of mechanisms including inhibition of arachidonic 
acid synthesis31 and induction of cellular immune responses by up-regulating the activity of lymphocytes,32 
eosinophils, macrophages33 and other natural killer cells.34 DEC’s efficacy has also been linked with an 
accumulation of mf in the liver, lung, kidney and spleen, therefore serving to expose mf to a greater 
concentration of immune cells. This mechanism can cause issues with DEC therapy when worm death in these 
organs expels harmful substances resulting in serious inflammatory reactions. In addition to systemic 
inflammatory responses, localised reactions are known to occur at the site of adult worm infections following 
treatment with diethylcarbamazine. The Mazzotti reaction, first described in 1948,35 is characterized by fever, 
tachycardia, hypotension, adenitis, pruritus and arthralgia following the treatment of onchocerciasis with DEC. 
Such severe inflammatory reactions and adverse effects preclude the use of DEC for patients with 
Onchocerciasis. In addition, DEC therapy is not suitable for patients residing within areas which are co-endemic 
with loiasis, another form of filariasis caused by the parasitic worm L.loa, as they are at risk of potentially fatal 
adverse effects upon treatment with DEC. It is therefore essential that this category of patients are not treated 
with DEC and this presents a huge issue with the mass drug administration of DEC. 
The orally administered benzimidazole compound, albendazole (ABZ) is an anthelmintic with proven efficacy 
against many intra and extraluminal parasites, ABZ can be considered a prodrug with the active form being the 
bioactivated albendazole sulfoxide. Albendazole in combination with diethylcarbamazine is the recommended 
treatment for LF in areas that are not co-epidemic with onchocerciasis.36 The intrinsic anthelmintic action of 
benzimidazoles relies on a progressive disruption of basic cell functions which arises from binding of the drug 
to parasite tubulin and causing depolymerisation of microtubules.37 The lipophilicity of benzimidazole 
anthelmintics enables passive diffusion through cell membranes into the intestinal cells of nematodes.38 
benzimidazoles have also been shown to inhibit glucose uptake in nematodes, causing the depletion of 
glycogen stores and ATP formation, representing a plausible mechanism by which ABZ causes parasite death. 
One major issue with ABZ treatment is poor absorption which results in reduced drug exposure; however, 
                                                                          Chapter 1 _____________________________________                                                                                               
 
22 
 
administration with a fatty meal can increase ABZ absorption up to five-fold.39 ABZ is rapidly metabolised via 
CYP1A2 and CYP3A4 P450 enzymes with repeated dosing of ABZ known to up-regulate its own metabolism by 
induction of metabolising enzymes.40,41  
Another existing anti-filarial treatment is Ivermectin (IVM), a potent anthelmintic  discovered from the 
actinomycete bacteria Streptomyces avermitilis, exhibiting broad spectrum activity against gastrointestinal and 
lung nematodes however; is not macrofilaricidal.34,35 IVM targets mf via binding to glutamate-gated chloride 
channels, increasing the permeability of nerve and muscle cells to chloride ions which results in paralysis, and 
ultimately death of the immature worms within the blood and any present within adult worms.7,19 Some 
observations have been made which support the possibility of an active involvement of the immune system in 
the mechanism of action of IVM, although further investigation is required.45 Depletion of microfilariae serves 
to prevent disease progression, providing relief from severe itching and visual impairment which are 
associated with Onchocerciasis. Depletion of mf also decreases the possibility of parasite transmission to 
vectors. Therefore, treatment with IVM once a year remains a standard prophylactic approach although in 
practice it is common to treat infected people up to three times a year with IVM.19 Whilst IVM has no known 
significant drug-drug interactions it is necessary to screen communities that may be at risk of contracting 
another form of filariasis, loiasis, since these people would be at risk of severe, potentially fatal, adverse 
reactions on treatment with IVM.46 Since IVM has no efficacy against adult worms and as the adult Onchocerca 
Volvulus parasite can live for up to 15 years, it is necessary to continue patient treatment for this prolonged 
time period. Other contraindications with IVM treatment involve conditions associated with impaired blood-
brain barrier penetration, since penetration of the drug into the CNS can cause lethargy, tremors and death. 
Consequently, IVM is not approved for children weighing less than 15 kg, pregnant women or mothers nursing 
infants during the first week of life.19 Despite requiring such a long treatment period and a number of 
contraindicated patient groups, IVM remains the current recommended treatment for onchocerciasis and for 
LF in areas which are co-endemic with onchocerciasis.  
It has been recommended that IVM is given in combination with albendazole for treatment in areas 
experiencing a high risk of both LF and onchocerciasis. It is necessary to use such a treatment regimen in these 
areas due to the severe adverse reactions associated with treating onchocerciasis patients with DEC.47 Co-
administration of two drugs acting against LF which have different molecular targets has the advantage of 
halting the development of resistance which remains a concern with single drug treatment programs.  
Natural product research has led to the discovery of some outstanding new drugs including moxidectin (Fig. 
1.6) a semisynthetic macrocyclic lactone derived from nemadectin, a milbemycin produced from fermentation 
of Streptomyces cyanogriseus.48 Moxidectin results in the paralysis and death of parasites as it binds to 
glutamate-gated chloride ion channels which are essential for neurotransmission within muscle cells and has 
been shown to result in the sterilisation of female adult worms.7 Moxidectin is commonly used in veterinary 
medicine for treatment of and prophylactic measures against heartworm infections.7,48  Some studies 
assessing the efficacy of moxidectin in controlling filariae as a therapeutic alternative to IVM displayed 
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promising results however further evaluation is required to determine if moxidectin is safe for introduction 
into the clinic. 49 
 
 
 
 
 
 
Fig 1.6 Structure of the macrocyclic lactone moxidectin 
Arsenical drugs have been the mainstay in heart-worm adulticidal therapy for the past four to five decades, 
Melasormine (MEL) (Fig. 1.7), a key example and is the only drug approved in the USA by the food and drug 
administration (FDA) which is an adulticide. Melasormine is a trivalent arsenical compound, like melarsoproll, 
which can penetrate the CNS of the host. However, patients may therefore be exposed to the adverse 
associated with CNS penetration such as encephalopathy.  While the mechanism of action of melasormine is 
not fully understood, it is possible that it is involved in blocking glycolysis in worms through inhibiting the 
activity of phosphopyruvate kinase, known to be sensitive to trivalent arsenicals.50 The exacerbated 
inflammatory reactions associated with rapid worm death, as discussed previously, impose a high risk 
associated with MEL treatment and therefore encourage the use of alternative therapies for heartworm 
infection which pose fewer risks to the patient.51  
 
 
 
 
Fig. 1.7 Structure of Melasormine, the arsenical drug with adulticidal properties. 
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1.3.2 Control programs 
 
In the 1970s the investigation of onchocerciasis in endemic villages and districts of West Africa began.  Studies 
discovered that within endemic areas, more than 60% of the population carried the parasite with 10% of the 
adult population suffering from blindness, with half of those afflicted being males above the age of 40.52,53 
Within affected countries, the ‘river blindness partnership’ was formed by the agencies of the World Bank, the 
World Health Organisation (WHO), the Food and Agriculture Organization (FAO) and the United Nations 
Development Program (UNDP). This partnership was responsible for the work of the Onchocerciasis Control 
Program (OCP) (1974 - 2002) and more recently, the African Programme for Onchocerciasis Control (APOC) 
(1996 - 2015). Prevention of blindness was the major goal for the OCP and this programme was established to 
cover zones endemic for onchocerciasis. This covered 11 countries in total, with the objective being to 
eliminate onchocerciasis as a disease of public health and socio-economic importance. The program utilised 
vector control strategies using seven different insecticides in addition to IVM (Mectizan) which was donated by 
Merck.54 Since the initiation of the OCP, a number of countries have been verified as free from infection with 
over 25 million hectares of land now primed for resettlement. This accounts for the prevention of 
approximately 600,000 cases of blindness and over 16 million children  born into areas where onchocerciasis is 
not considered a disease of concern.55 Furthermore, widespread control programmes using more specialised 
therapies for area’s co-endemic for various filarial diseases, will allow further progress towards the ultimate 
goal of elimination of filarial infections as a disease of public-health concern. The APOC covers a larger area of 
19 countries and intends to treat over 90 million people, protecting an at-risk population of 115 million people 
by annual treatment with IVM.  
The Global Programme to Eliminate Lymphatic Filariasis (GPELF)56 is based on mass drug administration (MDA), 
comprising either a single annual dose of DEC with ABZ, or ABZ with IVM were onchocerciasis is also endemic.  
Vector control efforts for GPELF include residual indoor spraying and insecticide treated nets like control 
strategies used for other diseases such as malaria. These efforts serve to minimise and then restrict the 
transmission of infection, managing morbidity and prevent disability. Since initiation of this programme, 18 
countries have carried out the necessary interventions and are currently reviewing the success of these efforts 
to confirm elimination of the disease; a further 22 countries are progressing towards the stage of elimination. 
The control of these diseases involves the combined use of IVM, DEC and ABZ over long time periods, 
therefore creating a growing concern for the development of resistance against these current front-line 
therapies. This has promoted research into alternative drugs which are suitable for wider patient ranges and 
exhibit novel mechanisms of action in the on-going pursuit for treatment of these conditions. 
 
1.3.3 Drug Resistance  
 
Ivermectin 
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Selective pressure from the mass administration of IVM as a single drug, in addition to the need for decades of 
sustained treatment during the OCP and APOC (Section 1.4), has resulted in resistance development to IVM in 
a number of parasites including Onchocerca volvulus.57 Such resistance has been documented in a number of 
nematodes and arthropods resulting from insensitivity of the glutamate-gated chloride channel (GluCl) 
receptors which prevents efficient drug binding.58,59 In the nematode Caenorhabditis elegans, IVM resistance 
has been associated with the over-expression of the multi-drug resistance protein (mrp-1), permeability 
glycoprotein-1 (pgp-1),60 which is also observed in the IVM resistant mites Sarcoptes scabiei.61  
Benzimidazoles 
Mutations to benzimidazole binding sites within the homologous tubulin genes in parasites have been 
associated with benzimidazole resistance. It has also been proposed that up-regulated catalase activity 
effectively protects Haemonchus contortus from benzimidazole action.62,63 Glutathione S-transferase (GST) is 
an important enzyme involved the detoxification of potentially harmful substances including reactive oxygen 
species, lipid peroxidation products and electrophilic compounds.63 It has been proposed that increased GST 
activity may participate in benzimidazole drug resistance which is seen in the triclabendazole (TCBZ) resistant 
strain of Facsiola hepatica. In the bodies of nematodes, higher amounts of ABZ glucosides were found in 
benzimidazole-resistant strains relative to BDZ-sensitive strains, suggesting that increased glucoronidation 
promotes benzimidazole resistance. Meanwhile, peroxidase activity has been shown to be significantly 
diminished in resistant strains compared susceptible strains, suggesting the involvement of peroxidise in the 
bioactivation of benzimidazole compounds. 
The main treatment options which are available for LF and onchocerciasis, DEC, ABZ and IVM respectively each 
possess undesirable adverse effects and lead to contraindicated patient groups; DEC’s effects on 
onchocerciasis patients and the complications of IVM and DEC in Loaisis paitents (see Section 1.3). Coupled 
with concerns of resistance development, these factors are driving current research efforts to identify and 
generate safe therapeutic alternatives which are suitable for all patient groups and which ideally possess 
unique mechanisms of action to avoid the risk of resistance development that exists with current treatments. 
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1.4 Wolbachia – A Common Target for LF and Onchocerciasis 
 
1.4.1 Wolbachia as obligate mutualists with filarial nematodes 
 
A large number of the nematodes responsible for causing filarial diseases share an endosymbiotic relationship 
with the bacterium Wolbachia.51,64,65 Wolbachia is a highly common and a widely distributed gram-negative 
bacterium which infects a large number of insect species and nematodes of the arthropod phylum.66 
Wolbachia are intracellular alpha-proteobacteria that are divided into seven groups.67–70 Two groups of 
Wolbachia infecting nematodes are classified into two sub groups (C and D), while four supergroups (A, B, E, H) 
infect exclusively arthropods and finally an additional group of Wolbachia (F) which are capable of infecting 
both nematodes and arthropods.71 The Wolbachia which infect the nematodes responsible for Onchocerciasis 
and LF are the most distantly related strains, Wolbachia pipientis which are estimated to have diverged 60-100 
million years ago.72 
Wolbachia are maternally transmitted from mother nematodes to offspring as they are present within oocytes 
and developing embryos in the female reproductive tract,73,74 in contrast infected males produce sperm that 
does not contain Wolbachia. Cytoplasmic incompatibility is a term which describes the inability of infected 
males to mate with uninfected females, while eggs produced by infected females are compatible with 
unmodified sperm and with sperm produced by males infected with the same strain of Wolbachia. Infected 
females therefore have a more significant impact on the Wolbachia presence within the next generation of 
nematodes, whereas the presence of infected males within a population prevents the reproduction of 
uninfected females which also results in an increased percentage of Wolbachia-containing nematodes within 
the population.72 Wolbachia infection causes the death of a number of male nematodes during larval 
development which allows for a greater ratio of female worms to develop through a process termed male-
killing. In addition, it is possible for male nematodes to develop as females through a process known as 
feminisation; this is another technique by which Wolbachia distorts the sex ratio within a population to further 
raise its own prevalence within a population. The presence of Wolbachia within nematodes does not appear to 
activate an immune response during any phase of the host’s lifecycle, this is likely due to stealth on the part of 
Wolbachia, as there is presently no evidence suggesting Wolbachia to actively suppress host immunity.75 
The specific endosymbiotic relationship that Wolbachia shares with infected filariae is unclear, it has however 
been observed that the bacteria are important during the process of embryo development, embryogenesis, in 
infected filariae.76–78 It has been suggested that Wolbachia can provide their host with additional detoxification 
pathways, as it has been previously observed that insecticide-resistant mosquitoes harbour higher densities of 
Wolbachia than insecticide susceptible mosquitoes. Similar observations suggest that Wolbachia are 
responsible for the synthesis of detoxification enzymes such as catalase,79 while other research suggests that 
Wolbachia may have a pivotal role in nutrition for the nematodes.80 Gene sequencing of Wolbachia pipientis 
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has shown that a limited number of amino acids can be synthesised by the bacteria while the remainder must 
be imported from their hosts. It has also become apparent that Wolbachia has incomplete pathways for the 
biosynthesis of various enzymes and cofactors such as NAD, biotin, lipoic acid, ubiquinone, folate, pyridoxal 
phosphate and Coenzyme A71 which could serve as tractable pathways for small-molecule anti-Wolbachia drug 
development. The work of Sharma and Kumar has revealed 61 potential drug targets within Brugia malayi 
Wolbachia which could be further validated experimentally through drug discovery pipelines for programmes 
exploring the treatment opportunities for lymphatic filariasis.13 These targets are presented in a database 
named the FiloBase which may be used for further research and drug development against filariasis.81 
1.4.2 Potential drug targets for the development of anti-Wolbachia agents 
 
Wolbachia have been validated as a tractable target for the treatment of filarial infections such as LF and 
Onchocerciasis as they are necessary for oogenesis, embryogenesis and the correct development of adult 
worms.82 Heme is an iron-containing tetrapyrrole which is an essential cofactor for many proteins such as 
cytochromes, haemoglobins, peroxidases and catalases. Data suggests that the heme biosynthetic pathway in 
Wolbachia is a potential anti-filarial drug target due to its requirement for the survival of both Wolbachia and 
its filarial host. All but one heme biosynthetic gene, ferrochelatase, which encodes proteins that are essential 
in the final step of the biosynthesis of heme are absent in the B.malayi genome.83 This implies that filarial 
nematodes are incapable of de novo heme biosynthesis, a condition that is characteristic of all or most 
nematodes, including Caenorhabditis.84 Although heme biosynthesis is a proposed drug target, it remains 
unknown how heme and heme intermediates might be transferred from Wolbachia to the filarial host. Two 
inhibitors of heme biosynthesis with distinct biological targets (aminolevulinic acid dehydratase and 
ferrochelatase, succinyl acetone and N-methyl mesoporphyrin respectively) have been shown to have negative 
effects on adult worms and mf.85 This suggests that these enzymes are indeed viable targets for the 
development of anti-Wolbachia agents. 
Fortunately, there is a larger evolutionary distinction between Wolbachia and mammals than between 
nematodes and mammals which presents a good opportunity for the development of selective therapies. A 
number of potential targets have been identified by genomic analysis including membrane proteins, ankyrins, 
lipoprotein biosynthesis, enzymes of lipid II biosynthesis and the glycolytic enzymes, all of these could be 
utilised in the development of anti-Wolbachia therapies.86–89 Two enzymes which are essential for glycolysis 
are absent within the Wolbachia genome, 6-phosphofructokinase and pyruvate kinase, are replaced with the 
gluconeogenic enzyme, fructose-1,6-biphosphate, and by pyruvatephosphate dikinase (PPDK). As PPDK is 
absent within mammals this enzyme presents a promising target for chemotherapeutic intervention for the 
treatment of filarial infections through Wolbachia removal.71 
Filamenting temperature sensitive proteins play a central role during bacterial cytokinesis, while Z-interacting 
protein is a membrane-anchored protein in gram negative bacteria which forms the septal ring, a collection of 
these proteins  (FtsZ) which localise at the site of cell division and regulate this process.90 FtsZ which is the 
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most highly conserved protein present in all bacteria, except Chlamydia spp, and is essential for cell division.86 
FtsZ is responsible for recruiting and coordinating more than a dozen other proteins required for cell 
division.90–92 In E. coli, temperature sensitive mutations in the FtsZ gene inhibit cell division therefore limiting 
cell growth. Up-regulation of Wolbachia FtsZ gene expression is found in fourth-stage larvae and adult female 
worms containing mf which could prove a promising target for anti-Wolbachia drug development, with  
several small molecule inhibitors of FtsZ having been identified.93–95 ZipA is also recognised as a new target for 
antimicrobial drug development, with a number of potential hits which have been identified through high-
throughput screening (HTS).96 
1.4.3 Treatments to remove Wolbachia bacteria from hosts 
 
Treatment of Wolbachia-infected nematodes with antibiotics has been shown to result in sterility and 
eventually death of nematodes.4,97 Typically long-term sterilization, as well as adult-killing of O.Volvulus and 
lymphatic filarial nematodes (B. malayi and W. bancrofti), occurs using three to eight-week courses of 
antibiotic treatment.98–103 Treatment of filarial diseases with antibiotics can avoid the adverse effects 
associated with filaricidal therapies which causes severe inflammatory reactions at the site of worm death due 
to the release of Wolbachia bacterium and other endogenous substances, as discussed previously.104,105 
Testing the effects of tetracycline’s, both doxycycline and minocycline (Fig. 1.8), on Wolbachia-containing 
filarial nematodes has suggested that antibiotics have the potential to be macrofilaricidal in humans which 
presents a potential new approach for the treatment of a range of filarial infections.  
 
 
 
Fig 1.8 Structure of the antibiotics doxycycline (DOXY) and minocycline (MIN) respectively. 
A microscopic image displaying the effects of doxycycline on female adult worms following 18 months of 
treatment with doxycycline is displayed in Fig. 1.9; Wolbachia cells are shown in red and microfilariae 
contained within oocytes are coloured blue,4 this figure shows reduced Wolbachia burden within the female 
worm cells following treatment with doxycycline. Female nematodes have proven to be more sensitive to 
tetracycline antibiotics than males nematodes30,106 which is likely due to increased Wolbachia levels in female 
worms due to the positive effects that Wolbachia bacteria  has on embryogenesis.  
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Fig 1.9 Microscopic images displaying the anti-Wolbachia efficacy of doxycycline after 18 months; Image B: 
untreated female worm cells, Image D:  doxycycline treated cells. Figure adapted from the work of Hoerauf et 
al.4  
The macrofilaricidal effects observed with antibiotic therapy have been associated with the depletion of 
Wolbachia which leads to the degeneration and sterility of adult worms.59,65 Fig. 1.10 provides a pictorial 
representation of doxycycline’s efficacy within a clinical setting. The images depict the effects of a six-week 
treatment plan following an 18-month observation period 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.10 Doxycycline’s clinical efficacy against LF after 6 weeks of treatment and following an 18-month 
observation period. (Unpublished, personal communication from Mark Taylor). 
Tetracycline antibiotics have been used for over half a century and act via inhibition of protein synthesis during 
amino acid translation through binding to the 30S ribosomal subunit in the mRNA translation complex of gram-
positive and gram-negative bacteria. Doxycycline completely suppresses normal early-stage embryonic 
development of Wolbachia in nematodes which is followed by a progressive loss of intact sperm-cell 
formation, spermatogenesis. The effects of doxycycline on mf densities were found to be slow compared to 
that of IVM and DEC,4 this is a benefit of antibiotic-mediated therapy since the inflammation which is often 
seen with rapid acting filaricidal treatments, is avoided. 
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Doxycycline has been shown to have negative effects on the development of bones and teeth in infants and 
babies when taken by woman during pregnancy;107 consequently the use of doxycycline  is contraindicated in 
infants and pregnant women. As with all tetracycline antibiotics, doxycycline is also known to cause skin 
photosensitivity and drug induced lupus. Also, to gain sufficient efficacy against Wolbachia, long treatment 
periods, of at least 4 weeks are required.  To efficiently treat conditions such as LF and onchocerciasis, it is 
necessary to shorten these treatment periods and is therefore necessary to find alternative drugs which 
require shorter treatment plans. It is also possible that ‘resting’ bacteria may begin to multiply in worms 3-15 
years following doxycycline treatment.4 These dormant organisms are thought to represent a persistent non-
replicating form of the bacteria with greatly reduced antibiotic susceptibility which could explain the 
difficulties in achieving complete Wolbachia depletion.  Similar observations have been reported for other 
parasites infected with intracellular bacteria such as chlamydia,30 anaplasma108 and mycobacterium.109  
As has been discussed earlier, Wolbachia expulsion at the site of worm-death contributes to the inflammatory 
responses associated with filaricidal therapies. There is however evidence to suggest that the anti-filarial 
effects exhibited by antibiotics is a consequence of dead or dying Wolbachia cells that have been expelled 
from the worm and are toxic to the surrounding nematode tissues.110 Accelerated Wolbachia clearance from 
nematodes is observed following drug withdrawal which could be associated with a greater capacity of the 
host cells to eliminate the damaged bacteria.111 This observation could also be a result of the high 
concentrations of tetracycline therapy which inhibits mitochondrial lipid metabolism resulting in a toxic effect 
associated with abnormal lipid retention within cells termed steatosis.112   
Minocycline has been shown to have similar anti-Wolbachia activity to doxycycline in vitro with improved in 
vivo efficacy, therefore making it an ideal candidate for further pharmacokinetic and pharmacodynamic (PK 
and PD) investigation.113 At bioequivalent exposures, minocycline was found to deplete Wolbachia levels by 
more than 99% after a 28-day treatment regimen in a Brugia malayi murine model. Although this data is 
promising, minocycline is subject to a risk of more severe adverse effects than doxycycline114 and further work 
is therefore required to evaluate the efficacy of minocycline within a clinical setting. 
Rifampicin (Fig 1.11)  is a bactericidal antibiotic which is the second most commonly used for anti-Wolbachia 
therapy and acts via inhibition of DNA-dependent RNA polymerase, causing the inhibition of DNA 
synthesis.115,116 Rifampicin has been shown to deplete mf release from adult female worms with low 
concentration therapies and is known to kill both adult worms and mf with higher-concentration treatment 
plans.117 Longer observation periods following rifampicin treatment have shown a less pronounced effect on 
Wolbachia depletion than is seen with doxycycline therapy which can result in greater than 90% depletion of 
Wolbachia from B.malayi adult worms and mf. 103 
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   Fig 1.11 Structure of the antibiotic rifampicin 
Rifampicin is known to cause hepatotoxicity and is also responsible for the up-regulation of many CYP450 
enzymes which can cause a number of adverse effects when taken with other drugs.118,119 
In summary, Wolbachia is an essential endosymbiotic bacterium within filarial worms which offers a novel 
target for chemotherapeutic intervention. Drugs targeting Wolbachia will be prophylactic, curative and 
macrofilaricidal. Due to its high efficacy; well understood mechanism of action, minimal associated adverse 
effects when compared to rifampicin and minocycline and finally proven clinical efficacy, doxycycline is 
considered the current gold-standard for anti-Wolbachia therapy. However, doxycycline requires a long 
treatment plan of at least 4 weeks and is contraindicated in pregnant women and children. This is problematic 
within MDA programs and therefore hampers transmission blocking and limits efforts towards disease 
eradication. 
Having highlighted the urgent need for improved therapies to treat LF and onchocerciasis. The main aims of 
this research project will now be covered, followed by results and associated discussions. 
 
1.5 Aims 
 
Anti-Wolbachia therapy delivers safe macrofilaricidal activity with superior therapeutic outcomes compared to 
all standard anti-filarial treatments. In principle, this treatment can be achieved with currently registered drugs 
such as doxycycline which is both affordable and available to endemic communities. The main barriers to 
doxycycline use are the required long treatment period (4-6 weeks) and contraindication in children under 
eight years of age and pregnant women. Therefore, the primary goal of the Anti-Wolbachia drug discovery and 
development programme is to identify alternate drugs that are suitable for a wider patient range and require 
shorter treatment regimens (7 days or less). A secondary goal is to refine and develop regimens of existing 
antibiotics suitable for a more restricted use that is compatible with MDA prior to the availability of a new 
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regimen resulting from the discovery project. This developed regimen could serve as a successful treatment in 
individuals with high loiasis co-infection at risk of severe adverse effects upon ivermectin treatment. 
The objective of this current work is to optimise small molecule Anti-Wolbachia agents to provide novel 
chemotherapeutic molecules that are also suitable for clinical development or that can behave as a suitable 
series of drug compounds to support other candidate compounds selected from within the program. The 
selected molecular candidate will ideally possess an excellent DMPK profile which translates to good exposure 
and activity within the in vivo Severe-combined immunodeficient (SCID) mouse model. The Target candidate 
profile for a suitable lead should be able to deplete >99% of the Wolbachia within the in vivo model during 
seven days of treatment. Identification of such a compound will involve a rigorous discovery, lead optimization 
and candidate selection process from work within the AWOL II: Macrofilaricidal drug discovery program. 
 
1.6 Identification of small molecule anti-Wolbachia agents 
 
1.6.1 Target vs Phenotypic screening 
 
Structure-based drug discovery usually starts with the identification of a target of interest for a disease state. 
This can normally be elucidated through clinical observations of patient phenotypes or screening of chemical 
libraries against specific enzymes or cells. Knowledge of the molecular target can assist the development of 
SAR in new drug compounds.120,121,121  Known natural substrates of targets can offer insight into the 
pharmacophores that are essential for biological activity. Target-based assays can sometimes express higher 
concentrations of the target protein than the native biological system which may lead to inaccurate efficacy 
readouts.122 These assays unfortunately limit the identification of drugs with novel targets to those which act 
against targets with target-based assays available.123 Finally, hit compounds resulting from target-based 
screening need to be tested in cell-based or phenotypic assays containing a range of targets and complexes 
which can interact with the optimised candidate to discover if translation is seen from the target-based screen. 
124,125 
Consequently, phenotypic drug discovery is carried out without knowledge of the drug target, using a whole-
cell based assay approach. This encompasses greater complexity as cells are expressed in their native 
environment making the assay generally more physiologically relevant. Phenotypic screening is useful in 
identifying new targets for the treatment of diseases which can occur through screening large libraries of 
compounds or repurposing known drugs for new indications. Repurposing known and well understood drugs 
for new indications can save time and resources during compound development.126,127 Cell viability assays are 
one of the most common phenotypic assays where active compounds are identified which kill cells, these 
assays are commonly used in the search for anti-cancer and bactericidal agents.  
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1.6.2 In vitro assay development  
 
Early in this research project, the AWOL consortium developed a cell-based assay containing the whole 
Wolbachia organism as the primary in vitro screen. This allowed rapid and sensitive screening of chemical 
libraries, where a mosquito (Aedes albopictus) cell line was infected with the Wolbachia bacteria.128 Following 
incubation with compounds, the remaining Wolbachia surface protein (wsp) is measured  using a quantitative 
PCR readout with each viable Wolbachia cell containing one wsp.129 More recently, the primary assay has been 
enhanced to allow for higher throughput by using an Operetta imaging system to image fluorescently stained 
non-viable Wolbachia cells following compound incubation, which removes the need for quantitative PCR. This 
assay now forms the primary screen in our anti-Wolbachia screening cascade within the project which is 
carried out by the Liverpool School of Tropical Medicine. 
1.6.3 HTS: Chemotype identification 
 
Similarity searching is a procedure which was described over 20 years ago, by which it is possible to scan 
through the chemical space of a large library of compounds and rank the compounds by their similarity to a 
reference compound or user defined set of queries representing a collection of compounds.130 These queries, 
from a medicinal chemistry standpoint, are usually the most common attributes that a set of known bioactive 
molecules possess. It has therefore become a valuable tool for identifying novel bioactive molecules. Searching 
through a chemical library for compounds with similar chemical properties should elucidate several 
compounds which possess similar activity at a biological target. 1D Molecule descriptors are numerical values 
which represent a property that the compound possesses such as; molecular weight, heteroatom count, 
number of rotatable bonds, logP etc.  2D descriptors are more complex and can be used as queries, searching 
for size and degrees of branching. 130 
An initial screen of 10,000 compounds from the BioFocus diversity library yielded 50 actives (hit rate of 0.5%) 
which were then used as queries in a range of similarity searches of the 500,000 compounds from within the 
Medicines for Malaria Venture (MMV) library, this HTS cascade is summarised in Fig.1.12. Following the initial 
screen, there was sufficient knowledge of active and inactive molecules to develop machine learning models 
with the hits and misses from Screen one informing the similarity searching for Screen two and these results 
then informed the second screen of the MMV library (Screen
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Fig 1.12 HTS screening cascade for three screens of the MMV library 
The screening resulted in several templates suitable for medicinal chemistry optimisation, identifying 
compounds suitable for candidate selection and subsequent pre-clinical studies. The initial screen of the 
BioFocus diversity library generated several hits within six possible templates which are suitable for further 
investigation (Fig 1.13). Hits were defined as active if they possessed > 50% of doxycycline activity and potent 
hits if they possessed > 90% of doxycycline’s activity. 
 
 
 
 
 
 
 
 
 
 
Fig. 1.13 The six templates identified from screening the BioFocus Diversity Library  
These six templates were then investigated by medicinal chemists at the University of Liverpool or by external 
partners WuXi App Tech. Screening of the MMV library also identified several additional templates as starting 
points for medicinal chemistry optimisation (Fig. 1.14), these templates were also investigated at the 
University of Liverpool or WuXi App Tech. 
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Fig. 1.14 The four templates generated from the MMV Diversity Library  
Phenotypic screening of the MMV library identified 45 hits within the pyrazolopyrimidine template (Hit series 
9 Fig 1.14) which displayed potent anti-Wolbachia activity. One of the most promising hits from this 
chemotype is displayed in Fig. 1.15. It contained the 7-(2-pyridylmethanamine) motif, an allyl group at the 6-
position and a phenyl ring at the 3-position of the pyrazolopyrimidine core. A generalised structure for this 
template is depicted in Fig. 1.15 with the numbering system for the core scaffold displayed.  
 
 
 
 
 
 
Fig 1.15 Initial hit for the pyrazolopyrimidine template and a General structure 
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1.7 Strategy for the discovery of small molecule anti-Wolbachia 
agents 
 
1.7.1 Screening cascade 
 
The overall screening cascade used for our medicinal chemistry optimisation is presented in Fig 1.16 where the 
experimental read-outs were used to drive and inform the molecular design highlighted. Target compound 
design was guided by Drug-Metabolism and Pharmacokinetics (DMPK) predictions, carried out by AstraZeneca, 
since the primary objective of this work was to improve DMPK properties as the potency of this chemotype 
was demonstrated in the initial hit. Evaluation of in vitro potency was performed in parallel to in vitro DMPK 
analysis on all synthesised compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.16 Screening cascade for the design, synthesis and testing of new compounds. 
In vitro potency evaluation was carried against a C6/36 (wALbB) cell line which has been described 
previously.131 Briefly, this is a mosquito (Aedes albopictus) derived cell-line which has been stably infected with 
Wolbachia pipientis (wALbB). Small molecule anti Wolbachia agents were dissolved in DMSO with each 
compound added to two wells of a 384-well plate (assayed in duplicate) giving a final concentration of 5 µM. 
Control samples in each plate consisted of 12 wells of vehicle control (DMSO) and 6 wells of the following 
controls: 5 µM doxycycline (positive control— the gold standard for Wolbachia reduction; SigmaAldrich) and a 
suboptimal 50 nM doxycycline concentration. After seven days of sterile incubation at 26 oC, DNA staining 
media was added to each well which caused staining of the host cell nucleus and the Wolbachia. The Operetta 
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high-content automated imaging system (PerkinElmer) and the Perkin Elmer software Harmony were used to 
measure the fluorescence resulting from 6 fields (6 pictures) per well. The system locates the nucleus, then the 
cytoplasm and uses an algorithm to determine how ‘spotty’ the remaining cytoplasm appears, cytoplasm 
containing a large amount of Wolbachia will have a high spot edge ridge (SER) texture score but doxy treated 
cells with no Wolbachia will have a low score (Fig 1.17). 
Fig 1.17 Operetta fluorescence imaging and SER texture scoring readout for Wolbachia infected cells.  
Images C and D in Fig 1.17 represent the readout from each well with each dot representing one cell, a 
threshold is set on the texture score and all cells above that score are classified as infected and below the 
score classified as uninfected. From this readout, each well has a % number of infected cells calculated, where 
DMSO control cells will have infection levels of >70% and DOXY or hit-treated cells will have <20% infection 
level. Some of the best compounds with a good balance of activity and DMPK properties were then advanced 
into the in vitro Brugia malayi mf efficacy screens.  
The in vitro mf assay was developed to provide a link between the in vitro insect cell-based assay and in vivo B. 
malayi screening, to enable greater throughput whilst actively seeking compounds with the ability to reduce 
Wolbachia load in the targeted parasite. The compounds were incubated in five wells with 8000 B. malayi mf 
for six days before DNA extraction and performing qPCR to calculate the ratio of Wolbachia Surface Protein 
(wsp) copy number to Glutathione S-Transferase (GST) copy number, which is used as a worm-size biomarker 
in drug treated wells versus control wells. This gives a good indication of the remaining Wolbachia load 
accounting for larger worms which would initially possess a higher Wolbachia count. The most optimal 
compounds which emerge from secondary screening were advanced to the in vivo PK and PD study within SCID 
mouse model infected with larvae of B. malayi (See Chapter 4). 
The anti-Wolbachia activities observed from the two in vitro assays may differ slightly due to differences in 
strains and biomass of Wolbachia in these two assays. In general, tested compounds show higher EC50 in the 
Mf assay than in the insect cell line assay, and the translation of anti-Wolbachia potency from the mf assay to 
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in vivo efficacy is clearer than the one from insect cell line assay.132  This may demonstrate the increased 
difficulty that compounds have diffusing across multiple membranes into bacteria which reside within the 
internal organs of nematodes.133 In order to obtain sufficient exposure within a biological system it is essential 
that our compounds possess suitable DMPK properties. 
1.7.2 Drug-metabolism and Pharmacokinetics (DMPK) 
 
For over a decade, medicinal chemists have been aware of desirable molecular properties which constitute 
promising drug compounds. Lipinski et al., published a set of guidelines which molecules should ideally fall 
within if they are likely to possess good oral bioavailability.134 This ‘rule of five’ predicts that poor absorption or 
permeation is more likely to occur for a compound that fails two or more of the guidelines: posseses greater 
than 5 H-bond donors, 10-H bond acceptors, a molecular weight of 500 or a ClogP value of 5. Hansch et al., 
stated in 1987, that prospective drug compounds should be as hydrophilic as possible without compromising 
efficacy.135 This has been further explained as a measure of lipophilic ligand efficiency.136,137 More recently, the 
GlaxoSmithKline 4/400 rule has been proposed to provide a more accurate set of guidelines to highlight 
promising drug-like space.138 The 4/400 rule states that compounds with a molecular mass between 250-400 
and a CLogP value between 2-4, will more likely have a favourable absorption, distribution, metabolism, 
excretion and toxicity (ADMET) profile.138–140 These early property design efforts allow the development of SAR 
to be directed towards designing compounds with good oral bioavailability by setting specific goals and using 
predictive computational methods prior to synthesis.141 During work on this project, in silico DMPK predictions 
were carried out as discussed above (Fig. 1.16, Chapter 1.9.1) by our collaborators, AstraZeneca, and used to 
direct compound design to prioritise synthesis. 
Following compound synthesis, in vitro DMPK analysis was also performed by AstraZeneca, including logD 
determination, an aqueous solubility, metabolic stability assessment and plasma protein binding studies.  
A thermodynamic solubility assay was performed using a stock solution of DMSO were a known amount of 
compound can be dried and dissolved in phosphate buffer. After shaking for 24 hours the solution was then 
filtered and the resulting concentration analysed by LCMS and HPLC. 
Lipophilicity (LogD7.4) was measured using a shake flask method by adding a stock solution of DMSO to a 1:1 
mixture of octanol and phosphate buffer solution to give a 10 µM compound concentration. The solutions 
were shaken for three hours to equilibrate before separating the layers and diluting them several times. The 
ratio of the compound concentration was analysed within the diluted samples by UPLC-MS/MS and used to 
calculate the LogD values. 
Human plasma protein binding (PPB) was measured by addition of compounds (10 µM) to phosphate buffered 
saline and incubated for 3 hours, proteins were then precipitated by the addition of acetonitrile and the 
centrifuged supernatant analysed by LC-MS/MS. The percentage human plasma protein binding as expected to 
be seen following compound dosing was determined by (total plasma concentration – free 
concentration)/(total plasma + buffer concentration) x 100.  
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Rat hepatocyte clearance (R.Heps.CL) and human microsomal clearance (H.Mic.CL) were measured by 
equilibration of substrate with hepatocyte cells or microsomal proteins before activation of the metabolic 
reactions by addition of 1-aminobenzotriazole or β- NADPH respectively. At eight time points, ranging up to 
120 minutes, aliquots were removed and quenched with methanol before sedimentation of precipitated 
proteins and quantification of remaining substrate using HPLC/MS. Microsomes retain activity of key 
metabolising enzymes that reside in the smooth endoplasmic reticulum, such as cytochrome P450s (CYPs), 
flavin monooxygenases and glucurononosyl-transferases. Hepatocytes offer a valuable insight into a broader 
scope of enzyme reactions than microsomal studies including reticular systems, cytosolic and mitochondrial 
enzymes. 
A traffic light system will be used within the results chapters of this thesis to document and visualise desirable, 
acceptable and poor in vitro potency and DMPK properties were favourable properties are coloured green, 
acceptable parameters are coloured amber while poor/unacceptable properties are shown in red. The 
boundaries for these different properties are documented below in Table. 1.1 which are supported by a 
number of analyses carried out recently on tractable chemical space and DMPK properties.139,142 
 
 EC50 (nM) LogD 7.4 Aq.Sol 
(µM) 
H.M.Cl 
(µL/min/mg) 
R.HepsCl  
(µL/min 10-6) 
Human PPB 
(%) 
Desired <100 1-4 >50 <20 <20 <99 
Acceptable 100-300 0-1,4-5 20-50 20-60 20-60 <99.5 
Poor 300+ <0, >5 <20 >60 <60 >99.5 
Aq.Sol – Aqueous solubility, H.M.Cl – Human microsomal clearance, R.HepsCl- Rat hepatocyte clearance,     
Human PPB – Human plasma protein binding           
Table 1.1 Appropriate and inappropriate potency and DMPK values and margins.  
These potencies and DMPK parameters will be optimised throughout the studies on this pyrazolopyrimidine 
chemotype. There are many advantages to prospective drug compounds possessing enhanced metabolic 
stability; the increased bioavailability and longer half-life (t1/2) should allow for less frequent dosing and 
improve patient compliance of any resulting candidate. Improvement of metabolic stability should also reduce 
intra-patient variability in drug exposure as this is majorly affected by differences in patient drug metabolising 
capacity.143 Reduction in clearance from different species should allow for better extrapolation of animal data 
and in turn, more accurate PK prediction in humans.144 Finally, improving aqueous solubility (reducing overall 
lipophilicity/logD) will improve absorption and should also improve the metabolic stability since the binding 
sites of metabolising enzymes are lipophilic in nature and readily accept more lipophilic molecules.145 
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1.7.3 Development of synthetic methodology and biological relevance of Pyra-
zolopyrimidines  
 
Synthesis of pyrazolopyrimidines is commonly achieved by the condensation of 3-amino pyrazole with either; a 
1,3 dicarbonyl compound146, 1,2 allenic ketones147, enaminones148 or enamine nitriles.149 The use of 1,2 allenic 
compounds has its advantages including the use of mild reaction conditions (Scheme. 1.1) and for the 
substrates studied by the authors F.Xuesen et al., high yielding (75-95%) reactions.147 
 
 
 
 
Scheme 1.1 Synthesis of pyrazolopyrimidines by condensation of 3-amino pyrazole with 1,2 allenic com-
pounds. 
The described reaction proceeds efficiently in a variety of polar aprotic solvents by reaction of the amine with 
the central allene carbon, allowing the pyrazole to react at the ketone carbonyl group. This gives the major 
product with the R2 group adjacent to the pyridine nitrogen, along with trace amounts of the regio isomer.147 
This reaction is useful for the introduction of a variety of aliphatic or aryl groups at the 5- and 7- positions and 
has been successfully applied to produce pyrazolopyrimidine nucleoside analogues.147 To introduce an amine 
at the 7-position of the pyrazolopyrimidine core, an alternative strategy would be needed as the amide 
starting material would most likely be much more difficult to react via the above procedure.  
Another possible approach would induce the condensation of a 3-amino pyrazole with an enamine nitrile. 
These pyrazole starting materials can be produced by reaction of the necessary nitrile with hydrazine (Scheme. 
1.2).150 the resulting intermediate can then be reacted with the enamine nitrile to give a secondary amine 
opposite the pyrimidine nitrogen of the pyrazolopyrimidine core.149 
 
 
  
 
 
Scheme 1.2 Synthesis of various pyrazole starting materials and pyrazolopyrimidines 
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These reactions allow for the installation of an amine adjacent to the pyridine nitrogen at the 5-position, with 
various secondary amines at the 7-position of the pyrazolopyrimidine core. To produce pyrazolopyrimidines 
comparable to the hit molecule (Fig. 1.15), it is necessary to install a primary amine at the 7-position. The 
synthesis of similar pyrazolopyrimidine compounds have been reported with a number of pharmacological 
implications including their behaviour as kinase inhibitors, K+ channel blockers and anti-depressants.151–161 
More specifically, pyrazolopyrimidines can act as anxiolytics via antagonism of the human corticotrophin 
releasing factor-1 (CRF-1) receptor161 and as anti-cancer agents by inhibition of the cyclin-dependent kinase-
2.159 A robust method by which 7-aminopyrazolo pyrimidines can be generated has been reported by the 
group of J.Y Hwang et al., during optimisation of analogues as hepatitis C virus inhibitors. Throughout their 
work, J.Y Hwang et al., synthesised many compounds with various groups in the R1-6 positions, a general 
scheme for this synthesis is outlined in Scheme.1.3.153  
 
 
 
 
 
 
 
 
Scheme. 1.3 Reagents: (a) Na, EtOH, reflux: (b) N2H4, EtOH, reflux; (c) beta-ketoester, AcOH. 110oC, 3h (d) 
POCl3, 100oC, 1h (e) R4R5NH, DIPEA, DMF, rt, overnight.153 
The amino pyrazole 1.34 is formed by reaction of the necessary nitrile 1.31 with the substituted ethyl ester 
1.32 and the formed alpha cyano-ketone 1.33 can be treated with hydrazine before subsequent 
cyclocondensation with the dicarbonyl compound 1.35 to give the pyrazolopyrimidine core. Chlorination of the 
intermediate 1.36 and subsequent substitution with various amines can provide many target compounds. 
The authors found that ortho-chlorination of the phenyl ring at the R1 position resulted in over a 30-fold 
increase in binding affinity for the CRF-1 receptor over the unsubstituted phenyl analogue 10a (Fig 1.18). The 
4-chlorophenyl derivative also possessed improved binding affinity and combination of these beneficial 
modifications resulted in compound 10d with high affinity for the CRF-1 receptor. Finally, modification of the 
R4 and R5 positions from the initial ethyl and butyl group to a propyl and the cyclopropyl methyl side chain in 
10j further improved compound potency.  
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Fig 1.18 Optimisation of a series of CRF-1 receptor antagonists 
During their studies, a variety of pyrazolopyrimidines with high affinity for the CRF-1 receptor were 
characterised. Further studies detailing the consequences of their antagonistic effects towards the CRF-1 
receptor in vitro and in vivo are underway. Pyrazolopyrimidines have also been designed as cyclin-dependent 
kinase inhibitors, synthesised by K.Paruch et al., using a more diverse synthetic route which allows for easier 
customisation of the R1 position: their synthesis is depicted below in Scheme. 1.4. 162 
 
 
 
 
 
 
 
 
Scheme. 1.4 Reagents: (a) HCO2Et t-BuOK, THF: (b) N2H4, AcOH, EtOH; (c) R2COCH2CO2Me, PhCH3; (d) POCl3, N-
N-dimethylaniline; (e) R4R5NH2, DIPEA, dioxane, (f) Boc2O, DMAP, CH2Cl2; (g) NBS, CH3CN; (h) R1B(OH)2, 
Pd(PPh3)4, Na2CO3, DME:H2O; (i) TFA, CH2Cl2163 
This synthesis enables late-stage functionalisation of the R1 position via coupling with various aryl boronic 
acids, which represents an attractive design route concerning study of this position.  
Some of the most promising analogues resulting from this body of work are displayed below in (Fig 1.19) 
alongside the initial hit. The authors elucidate that substitution at the R1 position is important for promoting 
potent inhibition of CDK-2 (14j) as is halogenation of the phenyl ring at the R2 position (compounds 5 and 14j 
as named by the authors). The 3-pyridyl methanamine side chain at the 7 position of the pyrazolopyrimidine 
core provides the most potent inhibitors, forming the N-oxide of this ring in forming 15j allows for greater 
selectivity against CDK-2 over other CDK’s. 
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                                      Fig 1.19 Optimisation of a series of selective CDK-2 inhibitions162  
Compound 15j was screened against a panel of 50 kinases without observing any CDK cross-reactivity 
demonstrating its selective potency against CDK-2. This compound was moderately protein-bound in 17 
different tumour cell-lines demonstrated clongenic IC50 values in the range 120-390 nM. 15j was orally 
bioavailable and demonstrated efficacy in a tumour xenograft model in a mouse study at 40 mpk, PO for 10 
days observing a 96% tumour growth inhibition. This demonstrates that properly substituted 
pyrazolopyrimidines can serve as orally bioavailable efficacious CDK2 inhibitors. These results offer 
encouragement that compounds containing this pyrazolopyrimidine core could be optimised to produce drugs 
that are orally bioavailable and possess high activity against the Wolbachia bacteria.  
1.7.3 Initial pyrazolopyrimidine target selection 
 
In the interest of validating the potency of the chemotype identified in original hit (Fig 1.15), compounds 
which were commercially available and contained this template, with the addition of the relevant substituents 
for our SAR studies, were purchased and tested against Wolbachia in vitro (Fig. 1.20)   
 
 
 
 
 
  Fig. 1.20 Results obtained from whole-cell assays for commercially available pyrazolopyrimidines 
These results validated the high anti-Wolbachia activity that this template possesses, with EC50 values from the 
in vitro assay measured in the range of 19 nM to 1854 nM (Fig. 1.20). One early SAR observation resulting from 
these compounds, is that extension or branching of the alkyl group at the 5-position appears to result in a 
significant decrease in anti-Wolbachia activity. 
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The methylene linker at the 7-position of the pyrazolopyrimidine core and allyl group displayed in the initial hit 
are predicted to be metabolic hot spots. SmartCyp is an online tool used for predicting the CYP450-related 
metabolic stability of the many different functionalities within a compound. Displayed in Fig 1.21 are the 
results calculated for analysing the initial hit using this tool.164–168 
 
 
Atom Score Energy Accessibility 2DSA 
C12 34.59 41.1 0.69 24.31 
N4 48.89 54.1 0.62 7.27 
C4 53.42 59.9 0.69 23.48 
 
Fig 1.21 SmartCyp scoring information for the initial hit AWF911.164–168 
The software scores all atoms within a compound, considering their susceptibility to metabolising enzymes, 
with the three most metabolically labile atoms displayed in the figure and highlighted on the chemical 
structure. The value ranges from 0 to 998, with lower scores representing less stable atoms. This score is 
calculated using many parameters including an approximate activation energy for the catalytic site of various 
CYP450 enzymes with the molecule at specific atoms, the accessibility of an atom to these enzymes, which is 
the relative measure of topological distance of an atom from the centre of the molecule is (always between 
0.5 (atom at the centre) and 1 (atom at the end)) and the solvent accessible surface area (2DSA) which 
represents the local accessibility of an atom.164–168 
These positions were the focus of SAR studies with the specific aim of improving the overall stability of our 
template. Organic synthesis at the University of Liverpool and WuXi App Tech has enabled extensive 
functionalization at key positions of the pyrazolopyrimidine core primarily at the 3 and 7 positions (R1 and R4/5 
- Fig. 1.15), generating over 200 compounds with more than 80 analogues possessing nanomolar activity 
against Wolbachia in vitro, with improved DMPK parameters compared to the initial hit. 
Having discussed synthetic strategies towards similar pyrazolopyrimidine compounds, the chosen routes for 
synthesis of selected compounds and subsequent biological activities will be discussed. Initially the 2-pyridyl 
ring displayed in the initial hit was modified and study commenced towards modification of the 7-position 
(R4/R5) at the pyrazolopyrimidine core. 
All compounds presented within the chapters to follow which are defined by an AWZ9 compound code were 
synthesised by the CRO WuXi App Tech while the AWF9 analogues were synthesised in-house. The detailed 
experimental and analytical data for these AWZ9 compounds are contained within Appendix 1. To provide a 
clear justification of the rationale for compound design throughout this work, several of these compounds 
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have been included and discussed. Mainly, discussions of these compounds centre around biological data 
however, when relevant for the validation of new chemistry, brief synthetic schemes are presented and 
discussed during the pyrazolopyrimidine optimisation in the chapters to follow. The SAR studies discussed in 
the following chapter (Chapter 2) will focus on the 2-pyridyl ring and methylene linker displayed in the initial 
hit, followed by extensive analysis of the lower phenyl ring at the 3-positipon of the pyrazolopyrimidine core 
(Chapter 3). Finally, the current leads from this work are evaluated in Chapter 4 and the advanced biological 
evaluation of these compounds is displayed and discussed here. 
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Chapter 2 Initial SAR studies: 2-pyridyl ring and linker modifi-
cations 
 
2.1  R4 and R5- Substituted Pyrazolopyrimidines 
 
2.11 Series 1 Target selection and development of a synthetic route 
 
The general scaffold for series 1 is displayed in Fig 2.1 with the numbering system used for the core also 
displayed. Early SAR studies focused on exploring the chemical space around the 2-pyridyl ring which is present 
in the initial hit from the MMV library, DT2009-0128388, defined here as AWF911 (Fig 2.1). In this chapter, the 
chemical modification will focus on the methylene linker and the C-6 allyl group present in the initial hit 
molecule. Both sites were predicted to be prone to rapid P450 metabolism (Chapter 1 Section 7.3). Analogues 
were designed for synthesis incorporating alternative aryl rings and halogenated pyridyl rings at the R5 position 
which could also serve to deteriorate the metabolic liability of the linker and pyridine nitrogen to metabolism.  
 
 
 
 
 
 
Fig. 2.1 General scaffold for pyrazolopyrimidine core. 
One early SAR observation from biological evaluation of the initial hit and the commercially available 
compounds discussed earlier in Fig 1.21 (Chapter 1 Section 7.3) and displayed again below (Fig 2.2), suggest 
that the 6-position (R3) can be modified without abolishing compound potency. The commercially available 
analogues (Fig 2.2) demonstrated that a methyl substituent is tolerated at this R3 position in terms of anti-
Wolbachia potency.  Removal of the allyl functionality of AWF911 was explored to mitigate the potential 
metabolic instability with this functionality, which is highlighted by the SmartCyp predictions (Fig 1.21 Chapter 
1 Section 7.3) and in silico DMPK predictions carried out by AstraZeneca (AZ) (Fig. 2.3).  
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Fig. 2.2 Results obtained from whole-cell assays for the commercially available pyrazolopyrimidines. 
These initial screening results suggest that extension or branching of the alkyl substituent at the R2 position 
results in decreased anti-Wolbachia activity. Our first series of analogues examined the effect of removal of 
this 6-methyl group on potency, DMPK predictions carried out by AstraZeneca also suggest this chemical 
modification might improve the overall metabolic stability of our compounds (Fig 2.3). 
 
 
 
 
 
Fig. 2.3 DMPK predictions for early analogues designed for synthesis. 
In addition to removal of the methyl group at the 6-(R3) position, a range of analogues were selected for 
synthesis and biological evaluation which modified the 2-pyridyl ring seen in the initial hit with various aryl ring 
systems including halogenated pyridyl and phenyl rings. The DMPK predictions displayed above in Fig. 2.3 
support removal of the methyl and incorporation of a 2-pyridyl 4-CF3 ring as a promising approach to improve 
compound stability. The synthetic route (Scheme 2.1) was established to provide a point of divergence at the 
final product forming step. This synthesis was adopted by the work previously published from the groups of J.Y 
Hwang et al.,1 and K. Paruch et al2 and their approach allows multiple analogues to be accessed from a 
common intermediate. To probe the chemical space surrounding the R4/5 position, the initial targets 
maintained the R1 phenyl and R2 methyl substitution. The R1 phenyl ring was chosen as an appropriate starting 
point due to promising activity in the initial hit and the commercial availability of 1a, the 3-amino 4-phenyl 
pyrazole starting material (£12/g – Fluorochem, United Kingdom). 
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Scheme. 2.1 Synthetic pathway to pyrazolopyrimidine analogues with modified R4/5 positions 
The pyrazolopyrimidine ring was formed in near quantitative yields by a condensation reaction between 3-
amino, 4-phenyl pyrazole 1a and the 1,3-dicarbonyl compound 2a. Subsequent chlorination of the 7-hydroxy 
pyrimidine (3a) provided very high yields of the important 7-chloro intermediate 4a which granted access to 
multiple analogues (AWF90X – see Table 2.1) with various R4 & R5 positions upon substitution with the 
necessary amines (5a-i). 
While most of the yields in the final product forming step were ~40%, there was some variations depending on 
the substituent at the R5 position as for this set of analogues the R4 groups was remained constant (R4 = H). 
These various yields for the first compounds synthesised are documented below in Table 2.1 alongside the 
biological evaluation results. Most of these reactions gave similar yields of 37-40%, while the 2-pyridyl 4- tri-
fluoromethyl methanamine (9b, Scheme 2.2) resulted in the isolation of a greater amount of the desired prod-
uct (58%).  
Where possible the amine side chain (5a-i) used in the product forming steps (Scheme 2.1) were purchased. 
For more complex amines that were unavailable or expensive (2-pyridyl 3 CF3 £690/g – Apollo Scientific), they 
were synthesised by reduction of the corresponding nitrile derivative. Reduction of the nitrile compounds was 
first attempted utilising LiAlH4 as the reducing agent following the work of Yang et al.3 This procedure did not 
prove very successful due to poor yields which further complicated the difficult purification of the desired 
amines which resulted in impure material being isolated. Due to these problems, an alternative reduction 
procedure following the work of Caddick et al., was utilised (Scheme 2.2). Within this procedure the nitriles 7a-
b are reduced by Nickel borohydride prepared from nickel(II)chloride hexahydrate and sodium borohydride to 
afford the free amines which are then Boc-protected in situ.4 This allowed for simpler purification of the amine 
precursors 8a-b which forms the desired methanamine intermediates 9a-b by Boc-deprotection using TFA.   
 
 
 
Scheme. 2.2 Two-step reduction of nitriles to their corresponding aryl-methanamines. 
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2.12 Biological Evaluation of initial targets R4 & R5 substituted pyra-
zolopyrimidines 
The in vitro Wolbachia activity and DMPK measurements obtained for the first series of pyrazolopyrimidine 
analogues with various R5 aryl rings are all shown in Table 2.2, as noted these analogues contain an 
unsubstituted phenyl ring at the R1 position.  
 
 
 
Compound 
code 
R5 
Reaction 
Yield (%) 
EC50 
(nM) 
LogD 
7.4 
Aq.Sol 
(µM) 
H.MicsCl 
(µLmin-1mg-1) 
R.HepsCl 
(µLmin-110-6) 
Human 
PPB 
(%) 
AWF901 
 
40 3012 4.6 0.06 80.1 77.2 99.95 
AWF902 
 
39 5176 2.9 0.08 34.5 30.9  99.95 
AWF903 
 
13 1384 3.8 4.00 78.9 91.3 99.43 
AWF904 
 
37 NA 3.6 2.00 41.5 55.2 98.00 
AWF905 
 
39 145 3.6 ND 23.6 54.8 98 
AWF906 
 
40 NA 3.5 2.00 67.7 83.2 99.03 
AWF907 
 
54 NA 4.3 0.20 14.0 38.1 99.82 
AWF908 
 
11 NA 4.3 0.60 ND 40.7 99.93 
NA – No activity at highest concentration (5 μM)  ND – Not determined       
Table 2.2 First series of analogues with modified aromatic side-chains at the R5 position, in vitro potency and 
calculated DMPK data 
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Introduction of a more hydrophobic phenyl ring (AWF901-2 aq. Sol = 0.06 µM) reduces the aqueous solubility 
over the pyridyl analogues AWF904-6 (Aq. Sol = 2.00µM) and produces analogues with very weak anti-
Wolbachia activity (AWF901-2 EC50 = >2500 nM) over the 2-pyridyl analogue AWF905 (EC50 = 145 nM). There is 
a notable improvement in aqueous solubility through the incorporation of 3 or 4 pyridyl rings (AWF904 & 
AWF906) (2.00 µM) over the parent 2-pyridyl analogue AWF900(0.4 µM) however these regio-isomers possess 
no anti-Wolbachia activity at the highest tested concentration (5 µM). It is possible that an intramolecular 
hydrogen bonding interaction may occur within the 2-pyridyl analogue between the pyridine nitrogen and 
amine linker. This will increase molecular planarity and may be essential for entry of the analogues into the 
active site of the drug target. This interaction will also, bring the 2-pyridyl ring more in plane with the 
pyrazolopyrimidine core increasing crystal packing energy and may ultimately reduce the  aqueous solubility of 
our analogues.5 
Studies of a range of strong and weak intramolecular hydrogen bonds in a variety of different solvent systems 
have determined that the distance and angle around the hydrogen bond provides a good indication of the di-
rectionality of such interactions. This is an essential characteristic of a hydrogen bonds with angles near to 
180o and distances between 1.2–1.5 A˚ corresponding to very strong hydrogen bonds. Hydrogen bonds can 
occur over larger distances were 1.5–2.2 A˚ would be found in strong interactions and 2.0–3.0 A˚ would corre-
spond to a weak hydrogen bong.31 
Analysis of AWF900 in Spartan166  were each compound was energy minimised using the MMFF94 force field 
and a conformational energy searches were performed using default settings allows the lowest energy 
conformers for the 6-methyl, 2-pyridyl compound to be studied. These conformers with low relative energy 
between 5 and 7 kJmol—1 (Fig 2.4) are absent in the analysis of analogues not containing the 2-pyridyl nitrogen 
such as the modelled 6-Methyl 3-pyridyl analogue (AWF904, Fig 2.5). Also, this model depicts 2 to 2.6 
angstroms between the amine hydrogen and 2-pyridyl functionalities which suggests that there is an 
intramolecular hydrogen bond present at this position (Fig 2.4). This interaction is displayed in the 3D model in 
Fig 2.4 which brings the 2-prydiyl ring in plane with the pyrazolopyrimidine core. 
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Fig 2.4 Low-energy conformers (M0006-8) displayed by analysis of AWF900 in Spartan. And corresponding 
conformers in 10d 
Some of these lower energy conformers (5-7 kJmol-1 – Fig 2.4) within AWF900 are absent in the 3-pyridyl 
structure 10a (Fig. 2.5) when subjected to the same analysis. This supports the hypothesis that the 
intramolecular hydrogen bond between the 2-pyrdiyl and the amine linker promotes low energy planar 
conformations in that part of the molecule which may result in the reduced aqueous solubility of the 2-pyridyl 
analogue seen during DMPK analysis.2 
According to the work of Bader32, a bond or interaction between a pair of atoms can be characterized by the 
properties of electron density at a point, known as the bond critical point (BCP). This BCP corresponds to a 
centre point in the electron density surface between these atoms.  
The analysis displayed below was carried out by Isabel Rozas33 were the structure was optimized at DFT level 
using the functional M06-2X34 and the basis set 6-311++G(d,p)35 with the Gaussian09 package36. This figure 
highlights the intramolecular bond angles and distances between the pyrazole and pyridine nitrogen’s and the 
hydrogen of the amine linker. The  bond distances (2.18 Å & 2.32 Å) and the bond angles (~100o) suggest that 
moderately strong hydrogen bonds will be present at these positions with the bond critical point highlighted in 
green. Finally, the package also picked out another potential hydrogen bond present between the pyridine of 
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the pyrazolopyrimidine core and an ortho-hydrogen of the lower R1 phenyl ring. All this evidence supports the 
argument that intramolecular hydrogen bonding will have an impact on the resultant aqueous solubility of 
these pyrazolopyrimidine compounds and therefore disrupting this molecular planarity could serve as a viable 
approach to improve the aqueous solubility of later analogues. 
 
Fig 2.6 Modelling of the hydrogen bond interactions present within AWF900 using the Gaussian 09 package. 
 
The improvement in aqueous solubility with a 3 or 4 pyridyl ring system could be explained by disruption of 
this intramolecular interaction however unfortunately these compounds proved entirely inactive against 
Wolbachia at the highest tested concentration (5 µM). Also, the nitrogen atom within the 3 and 4-pyridyl ring 
systems will be more exposed to an aqueous environment and this will also increase aqueous solubility. 
 
The 2-pyridyl 3-CF3 analogue AWF907 exhibits reduced clearance compared to the 2-pyrdyl parent analogue 
when incubated with rat hepatocyte cells and human microsomal protein. This suggests that the carbon 
adjacent to the pyridine nitrogen may be prone to metabolism and blocking this position would improve the 
stability of our compounds. However, these results did not elucidate any successful modifications that the R5 
position tolerated in terms of anti-Wolbachia activity. Small modifications such as the introduction of a 4-F 
(AWF903) or 4-Cl (AWF908) caused a significant decrease or complete removal of activity.  These results 
suggest that the 2-pyridyl nitrogen is a crucial moiety within this chemotype, perhaps forming an essential H-
bond with the putative target. 
2.2 Further R4 and R5- Substituted Pyrazolopyrimidines 
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2.21 Series two target selection and synthesis 
The R3 position (6-position of the pyrazolopyrimidine ring – Fig 2.6) also appears to play an important role in 
driving anti-Wolbachia activity, comparison of results from AWF905 (145 nM) and that of methyl containing 
substituent AWF900 (1.23) (Fig 2.6) (19 nM) indicate a significant seven-fold difference in potency.  
 
 
 
 
 
 
 
Fig 2.6 Comparison of AWF905 with the 6-Me parent analogue which possesses greater anti-Wolbachia 
activity. 
We incorporated this beneficial substitution into our core scaffold during the study of the R4/5 positions by 
incorporation of the methylated carbonyl compound, ethyl 2-methyl-3-oxobutanoate (2b) into the 
pyrazolopyrimidine cyclisation step (Scheme. 2.3). 
 
 
Scheme. 2.3 Synthetic pathway to pyrazolopyrimidine analogues with modified R4/5 positions 
This second series of analogues were designed to increase the metabolic stability through modification of the 
benzylic position to block metabolism at this position. There are many successful examples in the literature 
were removal or blocking a benzylic position has served to improve the metabolic stability of potential drug 
candidates. Palani et al.,7 introduced an oxime at the benzylic position of compound 14a to produce the more 
stable 14b during their metabolism-driven optimisation of CCR5 antagonists (Fig 2.7) which resulted in greater 
drug exposure (AUC0-6h).7 
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Fig 2.7 Introduction of ethyl oxime to alleviate the metabolic liability of the benzylic position 
Initially we considered the incorporation of a single methyl substituent on the benzylic carbon atom. DMPK 
predictions from AZ supported the hypothesis that this modification would improve the metabolic stability of 
these compounds (Fig 2.8).   
Substitution of heteroaromatics with more hydrophilic saturated heterocyclic ring systems is an established 
medicinal chemistry strategy for the improvement of aqueous solubility and metabolic stability. Such a 
strategy has been employed successfully by Morwick et al.,8 in their development of bisbenzimide Rho kinase 
inhibitors which possess multiple therapeutic opportunities including; neuropathic pain,9 cancer,10  bronchial 
asthma,11 and glaucoma.12 Reduction in unsaturated heterocycle ring size or substitution with a saturated 
heterocyclic ring systems are useful strategies for improving aqueous solubility.13 Furthermore, the in silico 
DMPK predictions carried out by AZ, concerning the replacement of a 2-pyridyl ring system with a 2-pyrrolidyl 
ring suggests that such a modification would greatly improve aqueous solubility and metabolic stability (Fig. 
2.8).  
 
 
 
 
 
 
Fig 2.8 Predicted DMPK properties for methylation of the linker and replacement of the 2-pyridyl ring with a 
saturated 2-pyrrolidyl ring system. 
Drug compounds containing pyridyl ring systems can often be exposed to N-oxidation as a primary route of 
metabolism.13 There are several ways to reduce this liability within analogues such as removal of the nitrogen 
or substitution of the pyridyl ring system to make the nitrogen less accessible to oxidation. As previous studies 
demonstrated that the replacement of the pyridyl ring with a phenyl ring or small substitutions to the pyridyl 
ring system completely removed anti-Wolbachia activity therefore as removal of the nitrogen was not a viable 
option (Table 2.1), alternative bioisosteres were sought. During the work to synthesise the potent HIV 
protease inhibitor ritonavir, Kempf and colleagues successfully replaced two pyridyl ring systems in the 
compound 15a to eliminate pyridyl N-oxidation as a primary route of metabolism which resulted in a 15b 
which experienced a near twofold improvement in bioavailability (Fig 2.9).14  
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Fig 2.9 Metabolism-driven optimisation of HIV protease inhibitors through introduction of two thiazole rings. 
This improvement in stability resulted in greater drug exposure demonstrated by a larger Area-under curve 
(AUC) and greater bioavailability following oral dosing. 
 
2.22 Further R4 and R5 SAR exploration – in vitro DMPK and potency results 
 
In addition to examining the hydrophilic pyrrolidine ring and methylated linker, installation of a thiazole was 
also considered. These analogues were reached by chemistry discussed above in Scheme 2.4, the results for 
these analogues with various R4/5 functionalities are displayed in Table. 2.3. The pyrolidyl analogue AWF915 
was reached by reaction of the Boc-protected commercially available derivative 16a with 11a which gives the 
desired product upon Boc-deprotection. (Scheme 2.4) 
 
 
 
 
 
 Scheme 2.4 Synthesis of AWF915 with the unsaturated 2-pyrrolidyl ring.  
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Code R4 R5 EC50 (nM) 
LogD 
7.4 
Aq.Sol 
(µM) 
H.M.Cl 
(µLmin-1mg-1) 
R.HepsCl  
(µLmin-1 10-6) 
Human 
PPB (%) 
AWF900 
 
H 19 4.2 0.40 ND 59.0 >99.90 
AWF913 
 
Me (Ra-
cemic) 
90 4.3 6.00 60.6 163.7 99.91 
AWF914 
 
H >2500 4 0.60 54.2 138.6 99.64 
AWF915 
 
H NA 10.0 511 10.05 133.9 ND 
NA – No activity at highest concentration (5 µM) ND – Not determined       
Table 2.3 Further analogues with modified R4/5 positions containing a 6-Me with in vitro potency and measured 
DMPK data 
Replacement of the 2-pyridyl ring with the 2-pyrollidinyl or thiazole rings both proved unsuccessful in terms of 
anti-Wolbachia activity; however, the 2-pyrrolidyl ring did prove to have greatly enhanced aqueous solubility 
(511 µM) and reduced clearance when incubated with human microsomes (10.1 µLmin-1mg-1) in line with in 
silico prediction. 
AWF913 with a methylated linker (R4=Me) was tested as a racemic mixture and despite a notable decrease in 
compound potency (EC50 = 19 nM to 90 nM) an increase in aqueous solubility (from 0.4 µM to 6.0 µM) was 
observed. This could again be attributed to disruption of any H-bonding between the 2-pyridyl nitrogen and 
amine linker.   
Spartan analysis of the compound AWF913 (Fig 2.10) containing the methylated linker displayed five fewer low 
energy conformers (between 3-7 kJmol-1) than the parent analogue AWF900 which experiences reduced 
solubility. This is likely to be due to the presence of the methyl group within the linker which interferes with 
the intramolecular hydrogen bonding capacity of AWF915 resulting in fewer low energy conformations where 
the hydrogen bond is present. The most stable conformation to form this hydrogen bond (M0011 Relative 
energy to lowest energy conformer found = 39.97 kJmol-1 – Fig 2.10) within the methylated analogue is 
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predicted to be of much higher energy compared to the benzylic linker variant (Relative energy = 6.35 kJmol-1 
Fig 2.5) 
 
 
 
 
 
 
 
Fig 2.10 Low-energy conformer analysis of analogue AWF915. 
Work conducted on the pyrazolopyrimidine template in parallel to the study of the R4 and R5 positions 
elucidated a beneficial modification to the lower phenyl ring at the 3/R1 position. We found that incorporation 
of a 4-F Ph group at this position was tolerated in terms of potency and could promote a large improvement in 
metabolic stability (Fig 2.11).  
 
 
 
 
 
 
 
 
       
 
Fig 2.11 in vitro potency and DMPK properties of methylated and 4-F Ph analogues. 
While the in vitro DMPK analysis for the methylated analogues AWF913 and AWZ9024 suggest that the 4-
fluoro phenyl ring results in a decrease in aqueous solubility (6.0 µM to 0.3 µM) this appears to be molecule 
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dependent as many other analogues such as AWF900 and AWF918 (0.4 µM to 0.9 µM) do not suffer this de-
creased solubility (Fig 2.11). 
2.3 Series 3: 3-(R1) 4-F Ph, R4- and R5- Substituted Pyrazolopyrim-
idines:  
 
2.31 Design and Synthesis  
The first analogue in this series AWF918 was synthesised by a more diverse route in respect to altering the R1 
position of the chemotype which is discussed later (Chapter 3 3-aryl pyrazolopyrimidines). However, during 
further assessment of the R4/5 positions the 4-F Ph modification was adopted into the core scaffold. To simplify 
the synthesis of these compounds, a 4-F substituted phenyl ring was installed into the initial pyrazole starting 
material 19a (Scheme 2.5). This was performed by the reaction of the nitrile compound 2-(4-
Fluorophenyl)acetonitrile (18a) with ethyl formate to form the aldehyde intermediate which cyclises upon 
reaction with hydrazine to give 19a (Scheme 2.5). This 4-F Ph 5-amino pyrazole could then be used within the 
synthesis discussed previously and presented here in Scheme 2.5 to give the important 7-chloro 
pyrazolopyrimidine 21a.  
 
 
 
 
Scheme 2.5 – Procedure for the synthesis of substituted pyrazole intermediates. 
Further modifications to the linker functionality were designed for synthesis during the next series of 
analogues following promising DMPK predictions (Fig 2.12). Introduction of an amide linker (AWF959) was 
predicted to improve metabolic stability despite a predicted three-fold drop in aqueous solubility. 
Incorporation of a methyl alcohol linker is predicted to offer a four-fold improvement to aqueous solubility and 
a predicted two-fold decrease in human microsomal clearance. 
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       Fig 2.12 Predicted DMPK values for analogues containing an amide and methyl alcohol linker moiety. 
 
  
 
 
 
 
 
Scheme 2.6 Installation of an amide linker between the pyrazolopyrimidine core and 2-pyridyl ring. 
Compounds designed following these predictions included a methyl alcohol linker and a cyclopropyl linker 
(AWZ9066) which were synthesised by previously discussed chemistry (Scheme 2.3). An amide linker was in-
stalled by the reaction of the 7-chloro intermediate 21a (Scheme. 2.6) and piccolinamide (22a). Pre-mixing 
picolinamide (22a) with sodium hydride allowed for reaction with the 7-chloro pyrazolopyrimidine 21a to form 
the desired product AWF959 (Scheme 2.6). The yield for this reaction was very low however enough of 
AWF959 was isolated for in vitro biological evaluation. 
 
2.32 Series 3 in vitro DMPK and Potency  
Series three molecules involved several analogues without the methylene linker and a variety of aliphatic side-
chains at the R4/5 positions since DMPK predictions (data not shown here) looked promising. These analogues 
were synthesised by our chemistry partner WuXi and the results from the in vitro biological and DMPK 
evaluation for this series of compounds are displayed in Table 2.4. 
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Table 
entry 
Compound R4 R5 
EC50 
(nM) 
LogD 
7.4 
Aq. 
Sol 
(µM) 
Human Mics 
Clint 
(µL/min/mg) 
Rat Heps 
Clint  
(µL/min -
10-6) 
Human 
PPB (%) 
1 AWF918 
 
H 17 4.3 0.90 49.2 67.7 99.8 
2 AWZ9003 
 
H >2500 3.2 37.0 9.03 217.4 94.5 
3 AWZ9027 
 
H >2,500 1.8 54 <3.0 62.5 93.4 
4 AWZ9028 
 
H >2500 ND ND ND ND ND 
5 AWF934 
 
H NA 2.55 49.0 1.7 6.7 95 
6 AWZ9001 
 
H > 2,500 3.9 0.50 65.3 128.9 98.9 
7 AWZ9002 
 
H >2500 3.10 148 15.52 57.49 96.2 
8 AWF963 
 
H NA 4.9 0.10 48.0 67.0 >99.96 
9 AWF937 
 
H 33 3.3 0.50 48.9 41.3 99 
10 AWF933 
 
H 183 3.4 2.00 35.68 95.85 99 
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11 AWF935 
 
H 518 3.15 1.00 27.32 68.6 98 
 
 
 
Table 
entry 
Compound R4 R5 EC50 (nM) LogD 7.4 
Aq. Sol 
(µM) 
Human Mics Clint 
(µL/min/mg) 
Rat Heps Clint  
(µL/min 10-6) 
Human PPB 
(%) 
12 AWZ9007 
 
R4 direct-
ly at-
tached 
>2,500 ND ND ND ND ND 
13 AWZ9008 
 
R4 direct-
ly at-
tached 
>2,500 ND ND ND ND ND 
14 AWF928 
 
 >2500 3.8 25.0 12.6 56.5 99.08 
15 AWF959 
  
456 4.1 0.80 53.6 13.1 99.6 
16 AWZ9066 
  
>2500 >5.00 ND 14.3 29.3 >99.95 
17 AWZ9024 
 
Me 93 4.3 0.3 24.5 75.4 ND 
NA – No activity at highest concentration (5 µM) ND – Not determined      
Table 2.4 Continued R4/5 exploration with a 4-F Ph ring at the R1 position 
Compounds containing hydrophilic aliphatic amines (AWZ9003, AWZ9027-8) in Table 2.4 (entries 2-4) were 
synthesised by our chemistry partner WuXi App Tech and served to greatly improve the aqueous solubility of 
these pyrazolopyrimidine compounds (AWZ9003 Aq. Sol = 37 µM, AWZ9027 Aq. sol = 54 µM) over AWF918 
(Table entry 1, Aq. sol = 0.9 µM) however such modifications removed anti-Wolbachia potency. The 
aromaticity of the R4 group also appeared to be essential for activity due to the complete loss of activity seen 
in compound AWF934 (table entry 5) with the saturated 2-piperidyl ring losing activity as seen earlier in the 
saturated 2-pyrrolidyl analogue AWF915. This lack of potency is also seen upon incorporation of the 
morpholine and piperidine heterocyclic systems (AWZ9001 and AWZ9002), table entries 6 and 7 respectively 
despite a large increase in aqueous solubility and reduced clearance in the piperidyl analogue AWZ9002 
compared to the 2-pyridyl parent analogue (entry 1). Introduction of the 2-oxetane ring system (AWF963 – 
entry 8) was also detrimental to anti-Wolbachia potency.  The only tolerated change at this position in terms 
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of potency was the 2,6-pyrimidine ring (AWF937 – table entry 9) which provided a negligible increase in 
metabolic stability at the cost of a near two-fold drop in potency compared to AWF918 (entry 1) (18 to 33 nM). 
Other pyrimidine regio-isomers, AWF933 and AWF935 (tables entries 10 and 11) resulted in a major decrease 
in compound potency (EC50 = 185 and 518 nM) respectively despite a small reduction in clearance from a 
metabolic system. 
Removal of the methylene linker functionality by insertion of various substituted amino pyridines proved to 
completely remove anti-Wolbachia activity seen by the analysis of AWZ9007-8 (table entries 12 and 13). 
Analysis of entry 14 containing a methyl alcohol substituent within the linker supports previous observations 
that modification of this position results in a major decrease in compound potency (EC50 = >2500 nM). 
Introduction of the amide linker group (AWF959 – entry 15) did not seem to positively benefit any of the 
assessed DMPK parameters compared to the parent analogue AWF918 and caused a significant drop in anti-
Wolbachia efficacy (18 nM to 456 nM). Introduction of a cyclopropyl ring system into the linker functionality 
(AWZ9056 – entry 16) increased logD compared with AWF918, which should lead to improved the aqueous 
solubility. Also, blocking the benzylic position should reduce clearance from both rat hepatocyte and human 
microsomes (clearance values < 30); however, completely removed anti-Wolbachia activity. This supports the 
theory that modification of the linker can distort intramolecular H-bonding to promote better solubility and 
that the specific modification of the benzyl linker can modulate metabolism. Further examination of a 
methylated linker in AWZ9024 (entry 17) displayed a notable 4-fold decrease in activity compared to AWF918 
(18 nM to 93 nM). Analogues synthesised by our chemistry partners demonstrated that N-methylation of the 
linker was also not tolerated in terms of compound potency (Fig 2.13); at this point methylation of the benzyl 
position was the only tolerated modification of the linker that maintains suitable potency.   
 
 
 
 
 
 
 
       Fig 2.13 N-methylation of the amine linker within pyrazolopyrimidine analogues 
In summary, further variations to the R4 position underlined the essential nature of the 2-pyridyl ring. These 
results support the idea that the NH linker is also an essential moiety, presumably as a H-bond donor at the 
drug target, while the 2-pyridyl nitrogen is an essential H-bond acceptor. Additionally, it is plausible that an 
intramolecular H-bond interaction between these two functionalities which is important for the compound 
conformation upon entering the necessary binding site. This could be an explaination for the complete loss of 
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activity seen upon modification of either functionality as opposed to a partial loss of activity which could be 
expected if both interactions were independently important for promoting good activity. 
2.4 6 (R3)- Substituted Pyrazolopyrimidines  
 
2.41 Target Design and Synthesis  
 
The initial hit AWF911 with the 6-(R3) allyl group was synthesised via previously discussed chemistry with the 
necessary allyl substituted beta-keto ester 24a which was produced in-house from methyl 3-oxobutanoate 23a 
using sodium hydride and allyl bromide (Scheme 2.7). Synthesis of the initial hit was carried out in parallel to 
the corresponding 4-pyridyl regio-isomer (Scheme 2.8), this was to verify the observations made thus far 
during analysis of the R5 position that alterations to this position are not only restricted but almost entirely 
prohibited to produce molecules with potent anti-Wolbachia activity.  
 
 
 
 Scheme. 2.7 Synthesis of methyl 2-acetylpent-4-enoate. 
 
 
 
Scheme 2.8 Re-synthesis of the initial hit AWF911 and the 4-pyridyl regio isomer AWF909  
 
 
 
 
 
 
                           Fig. 2.14 Structure of the initial hit AWF911 with the 4-pyridyl regio-isomer. 
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The resultant anti-Wolbachia activity of AWF911 and lack of in the regio-isomer AWF909 (Fig 2.14) confirmed 
the requirement of a terminal 2-pyridyl group for high activity whilst simultaneously displaying that lipophilic 
substituents are tolerated at the R2 position and promote good activity. AWF911 displayed increased human 
microsomal clearance, compared to the 6-H analogue AWF905 (63.2 Vs 23.6 µLmin-1mg-1). A 6-methyl 
substituent was tolerated in terms of anti-Wolbachia activity and had improved metabolic stability over the 
allyl displayed in the initial hit. 
Following the successful incorporation of a few groups at the C6 (R3) position (Me, H, allyl) additional 
analogues were designed for synthesis with modified R3 positions to further evaluate the SAR surrounding this 
position and to determine the optimum substituent in terms of potency and DMPK properties. DMPK 
predictions were carried out for a variety of analogues and the most promising selected for synthesis (Fig 
2.15). 
 
 
 
 
 
Fig 2.15 Predicted DMPK properties for analogues with various R3 positions 
Incorporation of a sulfonyl methyl substituent at the R3 position (AWZ9041) (Fig 2.15) is predicted to be more 
stable than the methyl-containing pyrazolopyrimidine compounds demonstrated by the reduced predicted 
clearance values. A chlorine atom at the R3 (AWZ9046) position is expected to at least maintain the stability 
and was selected for synthesis to study the effect that a halogen at this position has on the anti-Wolbachia 
activity of these analogues. Another analogue designed for synthesis by our chemistry partners contained a 
trifluoroethyl at the position (AWZ9067). SmartCyp predictions used previously to examine the predicted 
metabolic stability of the initial hit AWF911 (Chapter 1) were used to examine AWZ9067 containing the 
fluorinated alkyl chain and the parent analogue AWF918 (6-Me) (Fig 2.16) 
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       AWF918 
 
 
 
 
 
 
AWZ9067        
Fig. 2.16 SmartCyp predictions for trifluoroethyl analogue AWZ9067 and 5,6 dimethyl AWF918. 
These predictions suggest that the 6-position of the pyrazolopyrimidine core will be less susceptible to 
metabolism when a trifluoroethyl substituent is incorporated (AWZ9067) when compared to the 6-Me 
analogue AWF918. Albeit the predicted values only indicate a small increase in metabolic stability as the next 
most susceptible atom is the terminal methyl group at the 5-position of the core; however, this analogue was 
selected for synthesis to measure the difference to in vitro stability compared with DMPK data measured for 
AWF918 once the potential metabolism to the 6-position had been suitably blocked. 
   
 
 
Scheme 2.9 Synthesis of AWF920 containing a 6-chloro substituent 
                                                                          Chapter 2_____________________________________                                                                                                
 
78 
 
The various structures and biological activities of analogues within the first series of compounds exploring the 
R3 position are documented below in Fig 2.17 alongside the in vitro DMPK properties. 
 
2.42  (R3) Pyrazolopyrimidines Biological Evaluation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Fig. 2.17 Structures of analogues with varied 5-(R3) positions with in vitro Biological and DMPK results.  
These AWZ compounds were synthesised using the reactions discussed extensively throughout this chapter 
and are displayed above in Scheme 2.9, using the necessary di-carbonyl compounds (See Appendix 1). 
Analogues which were unsubstituted at the R2 position such as AWZ9067 required a base catalysed 
pyrazolopyrimidine ring formation (Appendix 1) which is discussed later (Ch. 4) during further study of this 
position when this reaction was utilised in-house. Incorporation of a fused cyclopentyl ring at the R2 and R3 
positions (AWZ9021) was well-tolerated in terms of anti-Wolbachia activity (EC50= 93 nM) and displayed that 
both positions could be varied without a significant loss of activity. This modification did not increase aqueous 
solubility; however, by removal of the two metabolically labile terminal methyl groups the metabolic stability 
increased as shown by a decreased rat hepatic clearance (41.3 µLmin-110-6) compared to the parent analogue 
AWF918 (67.7 µLmin-110-6). Incorporation of a polar SO2Me group at the R3 position in AWZ9041, whilst 
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promoting improved human microsomal stability, was not a suitable modification in terms of potency, 
producing a 35-fold drop in anti-Wolbachia efficacy (EC50 = 704 nM).  The bioisosteric incorporation of chlorine 
is a suitable substitution at the R3 position in terms of potency (AWF920 EC50 = 22 nM) and in some analogues 
resulted in decreased human microsomal clearance in comparison to the corresponding 6-methyl analogues. 
Introduction of the trifluoromethyl substituent at the 6/R3 position in compound AWZ9067 alongside removal 
of the 5-methyl provided good anti-Wolbachia activity (EC50 = 15 nM) and greatly reduced human microsomal 
clearance (5.64 µLmin-1mg-1). However, all analogues containing halogen substituents in the R3 position 
(chlorine, trifluoromethyl, trifluoroethyl) synthesised thus far were shown to produce undesired worm toxicity 
in the in vitro Brugia malayi mf assay. (See Ch.4 in vitro analysis section). As discussed earlier in Ch.1 it is 
essential that any compounds targeting Wolbachia act purely by targeting the bacteria and possess no direct 
efficacy against the worm to avoid the inflammatory reactions associated with filaricidal therapies. For this 
reason, it was decided that these modifications were unsuitable at this point; however, would be revisited in 
optimized analogues and tested for direct-worm toxicity.  
 
2.5 Conclusion 
 
Key modifications that improved the overall properties of this template are summarised in Fig 2.18. The allyl 
group which was present within the initial hit AWF911 was associated with metabolic instability and following 
its removal (R3 = H) there was improvement to stability but a decrease in compound potency. Several 
modifications were tolerated at this 6-(R3) position in terms of producing compounds which demonstrate 
acceptable in vitro anti-Wolbachia activity while the methyl group proved to offer the best balance of potency 
and DMPK properties. The 2-pyridyl group was essential for compound potency and whilst methylation of the 
linker generally offers a small improvement to stability when compared to other analogues and boosts the 
aqueous solubility this modification reduces compound potency. 
 
 
 
 
 
 
 
Fig 2.18 Summary of hit to early lead optimisation discussed in this chapter. 
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Compound optimisation by modification of the 2-pyridyl ring or methylene linker is limited by few suitable 
alterations being tolerated in terms of potency. One main success during the work discussed in this chapter 
concerning the optimisation of these pyrazolopyrimidine compounds is the over 85-fold improvement in 
aqueous solubility seen from the initial hit AWF911 to AWF913. Despite such a notable improvement to 
aqueous solubility it was still necessary to enhance DMPK properties of these analogues. Functionalisation of 
the lower phenyl ring offers further opportunities to improve the potency and DMPK properties of our 
pyrazolopyrimidines. The next chapter will focus on pyrazolopyrimidines containing various modifications to 
the phenyl ring system displayed in the initial hit AWF911. 
Of the analogues synthesised so far, the majority fall within the guidelines of promising chemical space for 
drug candidates set out by the GlaxoSmithKline 4/400 rule explained earlier in Ch. 1.7.2, these analogues are 
highlighted in green on Chart 2.1. While the outliers which are highlighted in orange are slightly outside this 
range they are compliant with Lipinski’s rule of 5,15 demonstrating suitable properties to potentially possess 
promising oral bioavailability. During the future optimisation of this template more analogues containing 
properties which fall within the 4/400 guidelines16,17 will be sought to maximise the opportunity of producing 
analogues with suitable ADMET properties. 
 
 
 
 
 
 
 
 
Chart 2.1 A plot of LogD against molecular weight for the pyrazolopyrimidines in this series. 
As expected during the design of these analogues, the reduction in LogD has enhanced the aqueous solubility 
throughout the optimisation of this series of analogues which is demonstrated in Chart 2.2. Improvement of 
aqueous solubility will remain a priority throughout the synthesis of a new series of analogues to ultimately 
produce pyrazolopyrimidines which are suitable for oral dosing.  
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            Chart 2.2 Plot of log Aq.sol against LogD for pyrazolopyrimidine analogues in this chapter. 
Finally, there appears to be a weak correlation (R2 =0.64) between LogD and log Rat hepatocyte clearance, as 
LogD decreases (or Aq. Solubility increases) the metabolic stability of our compounds increases as 
demonstrated by the reduced clearance values (Chart 2.3). It could be suggested that this increase in stability 
is due to the binding-pockets within enzymes which are responsible for metabolising the pyrazolopyrimidine 
compounds are lipophilic and less readily available for the more hydrophilic compounds.18 This correlation 
further supports the design of compounds with greater aqueous solubility which could also serve to boost the 
stability of our analogues within a metabolic system. 
 
 
 
 
 
 
 
 
 
 
Chart 2.3 Plot of LogD versus the log R.Hepatocyte clearance of pyrazolopyrimidines in chapter 1.  
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A summary of the SAR derived from this part of work is displayed in Fig.2.19 
 
 
 
 
 
 
 
 
 
 
 
    Fig 2.19 Summary of the SAR understood from the analogues studied so far.  
With the SAR restricted in terms of the 2-pyridyl ring and linker functionalities, our next series of analogues 
within chapter 3 will focus on the chemical space surrounding the phenyl ring at the 3-position (R1) of the 
pyrazolopyrimidine core. As demonstrated within this chapter, modification of the 6-position (R3) offers an 
opportunity to quite drastically alter compound potency and therefore future analogues will continue to probe 
this area to determine the optimum group at this position in terms of potency and DMPK properties. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                          Chapter 2_____________________________________                                                                                                
 
83 
 
2.6 Experimental 
 
Biological Evaluation (See Chapter 4 experimental for screening materials and methods) 
General 
 
Air- and moisture-sensitive reactions were performed in oven dried glassware sealed with rubber septa under 
an atmosphere of nitrogen from a manifold or balloon. Anhydrous solutions and sensitive liquids were 
transferred via syringe or stainless-steel cannula. Reactions were stirred using Teflon-coated magnetic stir 
bars. Organic solutions were concentrated using a Buchi rotary evaporator with a diaphragm vacuum pump. 
 
Purification of solvents and reagents  
 
Anhydrous solvents were either purchased from Sigma Aldrich or dried and distilled immediately prior to use 
under a constant flow of dry nitrogen. Tetrahydrofuran was distilled from Na, dichloromethane and Et3N were 
distilled from CaH2. All reagents were purchased from Sigma Aldrich, Alfa Aesar, Frontier Scientific, Apollo 
Scientific, Fluorochem and were used without any purification unless otherwise indicated. 
 
Purification of products 
 
Thin layer chromatography (TLC) was performed on 0.25 mm Merck silica gel 60 F254 plates and visualised by 
ultraviolet light. U.V. inactive compounds were visualised using iodine, p-anisaldehyde solution, ninhydrin or 
potassium permanganate followed by gentle heating. Flash column chromatography was performed on ICN 
ecochrom 60 (32-63 mesh) silica gel eluting with various solvent mixtures and using an airline to apply 
pressure. 
 
Analysis 
 
Melting points were determined by a Gallenkamp apparatus and are uncorrected. 1H NMR spectra were 
recorded on Bruker AMX 400 (400 MHz) spectrometer and reported as chemical shit on parts per million (ppm, 
δ) relative to tetramethylsilane as the internal reference, integration, multiplicity (s = singlet, br s = broad 
singlet, d = doublet, t = triplet, q =quartet, sex = sextat, m = multiplet), coupling constant (J, Hz), assignment. 
13C NMR spectra were recorded on Bruker AMX400 (101 MHz) spectrometer and reported in terms of chemical 
shit (ppm, δ) relative to residual solvent peak. Mass spectra (MS) and high-resolution mass spectra (HRMS) 
were recorded on a VG analytical 7070E machine, Fisons TRIO spectrometers using electron ionisation (EI) and 
chemical ionisation (CI), and Micromass LCT mass spectrometer using electron spray ionisation (ESI). All mass 
values are within error limits of ±5 ppm. Elemental analyses (%C, %H, %N) were either determined by the 
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University of Liverpool Microanalysis Laboratory or the London Metropolitan University Elemental Analysis 
Service. Reported percentages are within error limits of ±0.5 %. 
 
Synthesis of 4-(4-Fluorophenyl)-1H-pyrazol-3-amine19 
 
 
 
 
To a mixture of NaOEt (6.04 g, 88.7 mmol) and EtOH (100 ml) was added 2-(4-Fluorophenyl)acetonitrile (18a) 
(8.87 ml, 82.56 mmol) and the mixture was allowed to stir at 00C for 5minutes. Ethyl formate (14.88 ml, 1.85 
mmol) was added to the reaction which was then heated to 85oC and stirred for one hour. Volatiles were re-
moved under reduced pressure and the residue formed was diluted with H2O and 2M HCl to adjust to pH 3-4. 
The aqueous layer was extracted with EtOAc (3x 50 ml) and washed with brine (40 ml). Organics were dried 
using Na2SO4 and evaporated to dryness. To crude 2-(4-Fluorophenyl)-3-oxo-propane nitrile in EtOH (100 ml) 
was added NH2NH2.H2O (7.12 ml, 147.12 mmol) followed by AcOH (6 ml, 104.92 mmol). The reaction was al-
lowed to stir at 85oC for 2 hours before cooling to room temperature and evaporating to dryness, to afford the 
desired product 20a.   (10.62 g, 73%); 1H NMR (400 MHz, DMSO-D6) δ 11.69 (s, 1H), 7.65 (s, 1H), 7.52 (dd, J = 
8.6, 5.6 Hz, 2H), 7.15 (t, J = 8.9 Hz, 2H), 4.73 (s, 2H); 13C NMR (101 MHz, DMSO-d6) δ 160.3 (d, J = 240.9 Hz), 
156.1 (s), 130.6 (s) 131.0 (d, J = 3.0 Hz), 127.7 (d, J = 7.1 Hz, 2C), 119.7 (s), 115.7 (d, J = 21.0 Hz, 2C); MS (CI+ 
CH4): m/z (rel. Intensity) [M+H] 178.1 (100), HRMS (CI+) calcd for[(C9H8FN3)+H]: 178.0700 found:178.0780  
 
Synthesis of Methyl 2-acetylpent-4-enoate20                                                 
 
 
 
To Methyl acetoacetate 23a (5.4 ml, 50 mmol) in THF (15 ml) at 0oC was added NaH (1.32 g, 55 mmol) and the 
reaction was allowed to stir for 30 minutes. Allyl bromide (6.6 g, 55 mmol) was then added to the reaction 
mixture before allowing the reaction to warm to room temperature and stirring overnight. The reaction was 
evaporated to dryness, diluted with EtOAc and washed with water. Organic layer was dried with MgSO4 and 
evaporated to dryness to give the crude product which was purified by column eluting with 20% EtOAc:Hexane 
to afford the product 24a as a colourless oil in good yield (4.96 g, 64%); 1H NMR (400 MHz, CDCl3) δ 5.86 – 5.64 
(m, 1H), 5.10 (dd, J = 17.1, 1.41 Hz, 1H), 5.06 (dd. J = 10.2 Hz, 1.41 Hz, 1H) 3.74 (s, 3H), 3.55 (t, J = 7.4 Hz, 1H), 
2.60 (m, 2H), 2.24 (s, 3H); MS (ES+): m/z (rel. Intensity) 157.1 (100)  
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General procedure 2.1 for the synthesis of 5-methyl pyrazolo[1,5-a]pyrimidin-7-ol1 
 
 
 
To the 3-Amino, 1,2-pyrazole (5.16 mmol) in AcOH (8 ml) was added the appropriate beta-keto ester (20.64  
mmol) and the reaction was allowed to stir at 110oC for 3 hours. The reaction was cooled to room temperature 
and diluted with Et2O causing precipitation of the desired product which was filtered and washed with further 
Et2O.   
           
5-Methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-ol1 3a 
 
 
 
 
General procedure 2.1 to give 3a as a white solid (3.46 g, 92%); 1H NMR (400 MHz, DMSO-d6) δ 11.91 (s, 1H), 
8.11 (s, 1H), 7.57 (dd, J = 8.2, 1.1 Hz, 2H), 7.47 (dd, J = 10.6, 4.9 Hz, 2H), 7.39 – 7.28 (m, 1H), 5.67 (s, 1H), 2.35 
(s, 3H); MS (CI+ CH4): m/z (rel. Intensity) [M+H] 226.1 (100) 
5,6-Dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-ol 3b 
 
 
 
General procedure 2.1 to give 3b as a white solid (2.54 g, 84%); 1H NMR (400 MHz, DMSO-d6) δ 11.66 (s, 1H), 
8.09 (s, 1H), 7.57 (d, J = 7.3 Hz, 2H), 7.46 (t, J = 7.7 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 2.38 (s, 3H), 2.00 (s, 3H); 13C 
NMR (101 MHz, DMSO-d6) δ 157.3, 147.4, 142.3, 137.3, 131.4, 129.2 (2C), 127.8, 126.8 (2C), 103.9, 102.0, 
17.7, 10.9; MS (CI+ CH4): m/z (rel. Intensity) [M+H] 240.1135 (100), HRMS (CI+) calcd for 
[(C14H13N3O)+H]:240.1131; found: 240.1135 
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3-(4-Fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-ol 20a 
 
 
 
 
General procedure 2.1 to give 20a as an off-white solid (9.46 g, 81%); 1H NMR (400 MHz, DMSO-d6) δ 11.65 (s, 
1H), 8.06 (s, 1H), 7.59 (dd, J = 8.7, 5.5 Hz, 2H), 7.29 (t, J = 8.9 Hz, 2H), 2.37 (s, 3H), 2.00 (s, 3H); 13C NMR (101 
MHz, DMSO-d6) δ 172.5, δ 161.4 (d, J = 243.2 Hz), 157.3, 147.4, 142.3, 137.3, 129.8 (d, J = 8.0 Hz 2C), 127.8 (d, 
J = 3.0 Hz), 116.0 (d, J = 21.4 Hz 2C). 101.9, 21.5, 10.8; MS (CI+ CH4): m/z (rel. Intensity) [M+H] 258.1 (100), 
HRMS (CI+) calcd for [(C14H12N3O)+H]:258.1030; found: 258.1035 
 
6-Allyl-5-Methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-ol 25a 
 
 
 
 
General procedure 2.1 to give 25a as an off-white solid (2.34 g, 88%); 1H NMR (400 MHz, DMSO-d6) δ 11.75 (s, 
1H), 8.11 (s, 1H), 7.64 – 7.52 (m, 2H), 7.46 (t, J = 7.7 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 5.86 (ddt, J = 16.0, 10.1, 5.9 
Hz, 1H), 5.10 – 4.93 (m, 2H), 3.27 (d, J = 5.9 Hz, 2H), 2.38 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 156.9, 148.4, 
142.5, 137.3, 136.0, 131.3, 129.2 (2C), 127.8, 126.9 (2C), 115.3, 104.2, 104.1, 29.1, 17.2; MS (ES+): m/z (rel. 
Intensity) [M+H] 266.1 (100)  
 
5-Methyl 6-chloro-3-phenylpyrazolo[1,5-a]pyrimidin-7-ol 27a 
 
 
 
 
General procedure 2.1 to give 27a as an off-white solid (2.46 g, 79.5%); 1H NMR (400 MHz, DMSO-d6) δ 12.37 
(s, 1H), 8.17 (s, 1H), 7.57 (d, J = 7.6 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.35 (t, J = 7.3 Hz, 1H), 2.52 (s, 3H); 13C NMR 
(101 MHz, DMSO-d6) δ 153.4, 149.1, 143.3, 136.9, 130.8, 129.3 (2C), 128.1, 127.2 (2C), 105.2, 102.5, 18.4; MS 
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(CI+ CH4): m/z (rel. Intensity) [M+H] 258.1 (100), HRMS (CI+) calcd for [(C14H12ClN3O)+H]:258.1037; found: 
258.1042 
 
General procedure 2.2 for the synthesis of 7-Chloro-5-Methyl-pyrazolo[1,5-a]pyrimidines2 
 
 
 
To the pyrazolo-pyrimidine compound (1 equiv) and NEt3 (2 equiv) in MeCN was added POCl3 (3 equiv) and the 
solution stirred under reflux overnight. The reaction was cooled to room temperature, volatiles removed un-
der reduced pressure before pouring onto crushed ice. Basified with 2M NaOH and aqueous extracted with 
EtOAc, combined organic extracts washed with brine, dried with MgSO4 and evaporated to dryness to give the 
product.  
 
7-Chloro-5-methyl-3-phenylpyrazolo[1,5-a] pyrimidine1,21 
 
 
 
General procedure 2.2 to give 3a as a yellow solid (0.21 g, 83%); 1H NMR (400 MHz, DMSO-d6) δ 8.79 (s, 1H), 
8.13 (d, J = 7.1 Hz, 2H), 7.44 (t, J = 7.1 Hz, 2H), 7.38 (s, 1H), 7.26 (t, J = 7.1 Hz, 1H), 2.60 (s, 3H); MS (CI+ CH4): 
m/z (rel. Intensity) [M+H] 244.1 (100) , [M+H] 246.1 (28) 
7-Chloro-5,6-dimethyl-3-phenylpyrazolo[1,5-a] pyrimidine (11a) 
 
 
  
General procedure 2.2 to give 11a as a yellow solid. (2.55 g, 97%); 1H NMR (400 MHz, DMSO-d6) δ 8.71 (s, 1H), 
8.14 (d, J = 7.3 Hz, 2H), 7.44 (t, J = 7.7 Hz, 2H), 7.25 (t, J = 7.4 Hz, 1H), 2.61 (s, 3H), 2.38 (s, 3H); 13C NMR (101 
MHz, DMSO-d6) δ 172.3, 160.3, 150.6, 143.8, 142.2, 136.1, 132.3 (2C), 129.3, 126.5 (2C), 112.8, 21.4, 14.8; MS 
(CI+ CH4): m/z (rel. Intensity) [M+H] 182.0 (100), [M+H] 184.0 (26) HRMS (CI+) calcd for 
[(C8H9ClN3)+H]:182.0480; found: 182.0488 
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7-Chloro-3-(4-fluorophenyl)-5-methylpyrazolo[1,5-a]pyrimidine 21a 
 
 
 
 
General procedure 2.2 to give 21a as a yellow solid; 1H NMR (400 MHz, DMSO-d6) δ 8.68 (s, 1H), 8.15 (dd, J = 
8.9, 5.6 Hz, 2H), 7.27 (t, J = 8.9 Hz, 2H), 2.60 (s, 3H), 2.37 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ161.1 (d, J= 
242.9 Hz), 160.0, 143.6, 142.2, 135.0, 128.8 (d, J= 3.1 Hz), 127.8 (d, J = 7.8 Hz, 2C), 116.8, 115.9, (d, J = 21.3 Hz, 
2C), 108.9, 24.6, 14.8; MS (ES+): m/z (rel. Intensity) [M+H] 276.1 (100), [M+H] 278.1 (32) HRMS (ES+) calcd for 
[(C14H12N3F35Cl)+H]:276.0704; found: 276.0700. calcd for [(C14H12N3F37Cl)+H]:278.0674; found: 278.0681   
 
 6-Allyl-7-chloro-5-methyl-3-phenylpyrazolo[1,5-a] pyrimidine 26a 
  
 
 
General procedure 2.2 to give 26a as a yellow solid (2.05 g, 84%); 1H NMR (400 MHz, DMSO-d6) δ 8.81 (s, 1H), 
8.20 (d, J = 8.3 Hz, 2H), 7.50 (t, , J = 7.8 Hz 2H), 7.31 (t, J = 7.4 Hz, 1H), 6.03 (ddt, J = 17.1, 10.2, 5.6 Hz, 1H), 5.19 
(dd, J = 10.2, 1.5 Hz, 1H), 5.09 (dd, J = 17.2, 1.6 Hz, 1H), 3.66 (d, J = 5.6 Hz, 2H), 2.69 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 159.7, 144.0, 142.9, 137.2, 133.8, 132.1, 129.1 (2C), 126.6, 126.1 (2C), 117.8, 117.1, 110.0, 32.6, 
24.0; MS (ES+): m/z (rel. Intensity) [M+H] 284.1 (100) , [M+H] 286.1 (27) 
 
7-chloro-5,6-dimethyl-3-phenylpyrazolo[1,5-a] pyrimidine 28a 
 
 
  
 General procedure 2.2 to give 28a as a yellow solid (1.23 g, 88%); 1H NMR (400 MHz, DMSO-d6) δ 8.81 (s, 1H), 
8.11 (d, J = 7.3 Hz, 2H), 7.45 (t, J = 7.7 Hz, 2H), 7.28 (t, J = 7.4 Hz, 1H), 2.70 (s, 3H); 13C NMR (101 MHz, DMSO-
d6) δ 152.0, 133.2, 128.8, 123.1, 119.6, 117.4, 117.3, 107.8, 102.02, 88.4, 14.8; MS (CI+ CH4): m/z (rel. 
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Intensity) [M+H] 278.0 (100), [M+H] 280.0 (58.59) HRMS (CI+) calcd for [(C8H9ClN3)+H]:278.0246; found: 
278.0256       
 
Procedure for the synthesis of Tert-butyl ((5-chloropyridin-2-yl) methyl) carbamate 8a4,22 
 
 
 
To 2-Cyano-5-chloropyridine 7a (0.6 g, 4.33 mmol) in MeOH (20 ml) at 0 oC was added NiCl2.6H2O (0.05g, 0.43  
mmol) and Boc2O (1.89, 8.66 mmol). NaBH4 (0.85 g, 30.31 mmol) was added in portions over 25 minutes with 
vigorous stirring, the resultant black reaction mixture was warmed to room temperature and stirred for 5 
hours. The reaction was evaporated to dryness, diluted with EtOAc and washed with NaHCO3. Organic layer 
was dried with MgSO4 and concentrated under pressure, the crude product was purified by column eluting 
with 20% EtOAc in Hexane to give 8a. (0.54 g, 51.7%); 1H NMR (400 MHz, CDCl3) δ 8.47 (d, J = 2.2 Hz, 1H), 7.62 
(dd, J = 8.3, 2.3 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 6.01 (br s, 1H), 4.41 (d, J = 5.8 Hz, 2H), 1.46 (s, 9H); MS (ES+): 
m/z (rel. Intensity) 243.1 (3) 187.0 [M-t-Bu] (24.74), 143.1 [M-Boc] (100) 
 
Tert-butyl ((5-(trifluoromethyl)pyridin-2-yl)methyl)carbamate 8b 
 
 
 
Synthesised according to the procedure to reach 8a to give 8b (0.77 g, 48%); 1H NMR (400 MHz, MeOD) δ 8.81 
(s, 1H), 8.12 (d, J = 8.1 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 4.45 (s, 2H), 1.49 (s, 9H); 13C NMR (101 MHz, MeOD) δ 
163.5, 157.1, 145.4 (q, J = 4.2 Hz), 134.2 (q, J = 3.2 Hz), 124.9 (q, J = 33.0 Hz).  122.4, 120.8, 79.2, 45.2, 27.3; MS 
(ES+): m/z (rel. Intensity) [M-t-Bu] (3), 177.1 [M-Boc] (100) 
 
Synthesis of (5-Fluoropyridin-2-yl) methanamine23,24 
 
 
 
To 2-Cyano-5-fluoropyridine (1 g, 7.4 mmol) in THF (10 ml) was added LiAlH4 (0.55 g, 14.7 mmol) and the re-
sultant dark brown solution was allowed to stir at -78oC under a nitrogen atmosphere for 2 hours. The reaction 
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was quenched with water (0.5 ml), diluted with 2M NaOH (0.5 ml) and water (3 ml). To the mixture was added 
EtOAc then this was filtered through a pad of celite and MgSO4 washing with EtOAc. The crude product was 
evaporated to dryness and used directly within the next step without further purification. (0.42 g, 41%)    
 
General procedure 2.3 for Boc-removal. 
 
 
To the Boc-protected amine (2.23 mmol) in DCM (5 ml) was added TFA (21.8 mmol) and the reaction was 
allowed to stir at room temperature for 18 hours. Upon completion of the reaction the volatiles were removed 
under pressure, resultant reside was diluted with EtOAc and washed with NaHCO3.  
 
(5-Chloropyridin-2-yl)methanamine 9a25 
 
 
General procedure 2.3. Organics dried with MgSO4 and evaporated to dryness to give the crude amine which 
was used directly in the next step (0.21 g, 66%); MS (ES+): m/z (rel. Intensity) 143.0 (16) 
 
 (5-(Trifluoromethyl)pyridin-2-yl)methanamine 9b26 
 
 
General procedure 2.3. Organics dried with MgSO4 and evaporated to dryness to give the crude amine product 
which was used directly in the next step (71 mg, 17%); MS (ES+): m/z (rel. Intensity) 177.0 (100)  
 
General procedure 2.4 for amine substitution of 5-methyl pyrazolo[1,5-a]pyrimidines27 
 
 
 
To the chlorinated pyrazolo-pyrimidine 20 (0.85 mmol) in EtOH (10 ml) was added the aryl-amine (0.85 mmol) 
and DIPEA (1.02 mmol). The yellow solution was allowed to stir at 110 oC in a sealed tube overnight, once 
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completed the reaction was evaporated to dryness and the crude product loaded to silica. Purification by flash 
chromatography eluting with 40% to 80% EtOAc in hexanes allowed isolation of the desired products.  
 
 
N-Benzyl-5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-amine (AWF901)28 
 
 
 
 
 
General procedure 2.4 to give AWF901 as an off-white solid (0.19 g, 40%) ; 1H NMR (400 MHz, DMSO-d6) δ 
8.60 (s, 1H), 8.58 (m, 1H), 8.16 (d, J = 7.4 Hz, 2H), 7.38 (m, 6H), 7.26 (t, J = 7.2, 1H), 7.16 (t, J = 7.2, 1H), 6.10 (s, 
1H), 4.63 (d, J = 6.5 Hz, 2H), 2.41 (s, 3H).; Melting point: 154-155 oC 13C NMR (101 MHz, DMSO-d6) δ 159.7, 
147.0, 145.5, 141.8, 138.7, 133.4, 129.0(2C), 128.9, 127.6, 127.5(2C), 125.6, 125.4, 106.9, 86.5, 44.9, 25.4; MS 
(CI+ NH4): m/z (rel. Intensity) [M+H] 315.2 (100), [M+H] 225.1 (20) HRMS (ES+) calcd for 
[(C20H19N4)+H]:315.1600; found: 315.1604; CHN analysis: Calculated: C:76.41%, H:5.77%, N:17.82% Found  
C:75.58%, H:5.73%, N:17.60% 
 
N-(2-Chlorobenzyl)-5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-amine (AWF902) 
 
 
 
 
General procedure 2.4 to give AWF902 as an off-white solid (0.11 g 39%); Melting point: 152-153 oC 1H NMR 
(400 MHz, DMSO-d6) δ 8.63 (s, 1H), 8.51 (s, 1H), 8.17 (d, J = 7.9 Hz, 2H), 7.57 – 7.46 (m, 1H), 7.40 (t, J = 7.7 Hz, 
2H), 7.33 (m, 3H), 7.18 (t, J = 7.4 Hz, 1H), 6.07 (s, 1H), 4.71 (s, 2H), 2.42 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 
159.9, 147.0, 145.4, 141.9, 135.4, 133.5, 132.4, 129.9, 129.4, 128.9 (2C), 128.3, 127.9, 125.6 (2C), 125.5, 107.1, 
86.4, 43.1, 25.5; MS (CI+ NH4): m/z (rel. Intensity) [M+H] 349.1 (100), [M+H] 351.1 (26) HRMS (CI+) calcd for 
[(C20H18ClN4)+H]:349.1215; found: 349.1215; CHN analysis: Calculated: C:68.66%, H:4.91%, N:16.06%. Found 
C:68.88%, H:4.94%, N:15.86%;   
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N-((5-Fluoropyridin-2-yl)methyl)-5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-amine (AWF903) 
 
 
 
 
 
General procedure 2.4  (75 mg ,13%); Melting point: 183-184 oC 1H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 1H), 
8.57 (d, J = 2.8 Hz, 1H), 8.50 (t, J = 6.2 Hz, 1H), 8.16 (d, J = 7.6 Hz, 2H), 7.73 (td, J = 8.8, 2.8 Hz, 1H), 7.49 (dd, J = 
8.8, 4.4 Hz, 1H), 7.39 (t, J = 7.6 Hz, 2H), 7.17 (t, J = 7.6 Hz, 1H), 6.11 (s, 1H), 4.73 (d, J = 6.2 Hz, 2H), 2.43 (s, 3H).; 
13C NMR (101 MHz, DMSO-d6) δ 159.8, 158.9 (d, J = 251 Hz) 153.9 (d, J = 3.6 Hz), 147.0, 145.5, 141.8, 137.4 (d, 
J = 23.7 Hz),133.5, 128.9 (2C), 125.6 (2C) , 125.5, 124.5 (d, J = 18.6 Hz), ), 123.2 (d, J = 4.5 Hz), 107.0, 86.6, 46.2, 
25.5.; MS (CI+ NH4): m/z (rel. Intensity) [M+H] 332.0 (100), HRMS (CI+) calcd for [(C19H15FN5)+H]:332.1307; 
found: 332.1306; CHN analysis: Calculated: C:68.46%, H:4.84%, N:21.01%. Found C:68.25%, H:4.81%, 
N:20.94%; 
 
5-Methyl-3-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF904) 
 
 
 
 
 General procedure 2.4 to give AWF904 as an off-white solid (0.15 g, 37%); Melting point: 174-175 oC 1H NMR 
(400 MHz, CDCl3) δ 8.67 (d, J = 1.8 Hz, 1H), 8.64 (t, J = 6.6 Hz, 1H), 8.59 (s, 1H), 8.47 (dd, J = 4.8, 1.8 Hz, 1H), 
8.15 (dd, J = 8.0, 1.0 Hz, 2H), 7.82 (dt, J = 8.0, 1.8 Hz, 1H), 7.42 – 7.31 (m, 3H), 7.15 (t, J = 7.4 Hz, 1H), 6.19 (s, 
1H), 4.66 (d, J = 6.6 Hz, 2H), 2.42 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 164.7, 153.9, 153.7, 151.6, 150.3, 146.5, 
140.3, 139.1, 138.1, 133.5(2C), 130.3, 130.2, 128.9 (2C), 111.8, 91.2, 47.5, 30.2; MS (CI+ NH4): m/z (rel. Intensi-
ty) [M+H] 316 .0(100), HRMS (ES+) calcd for [(C19H18N5)+H]:316.1562; found: 316.1557; CHN analysis: Calculat-
ed: C:72.36%, H:5.43%, N:22.21%. Found C:71.95%, H:5.41%, N:22.10%; 
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5-Methyl-3-phenyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF905)29,30 
 
 
 
 
 
General procedure 2.4 to give AWF905 as an off-white solid (0.155 g, 39%); Melting point: 144-146 oC 1H NMR 
(400 MHz, DMSO-d6) δ 8.62 (s, 1H), 8.58 (d, J = 4.4 Hz, 1H), 8.49 (t, J = 6.1 Hz, 1H), 8.17 (d, J = 7.6 Hz, 2H), 7.79 
(t, J = 7.6 Hz, 1H), 7.45 – 7.35 (m, 3H), 7.35 – 7.27 (dd, J = 6.7, 5.4 Hz 1H), 7.17 (t, J = 7.3 Hz, 1H), 6.10 (s, 1H), 
4.74 (d, J = 6.1 Hz, 2H), 2.43 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 159.9, 157.4, 149.6, 147.1, 145.4, 141.8, 
137.6, 133.5, 128.8(2C), 125.6, 125.5 (2C), 123.1, 121.6, 106.9, 86.6, 46.5, 25.4; MS (ES+): m/z (rel. Intensity) 
[M+H] 316.2 (100), HRMS (ES+) calcd for [(C19H18N5)+H]:316.1562; found: 316.1569; CHN analysis: Calculated: 
C:72.36%, H:5.43%, N:22.21%. Found C:71.96%, H:5.36%, N:22.17%; 
 
 
 
5-Methyl-3-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF906) 
 
 
 
 
General procedure 2.4 to give AWF906 as an off-white solid (0.15 g, 39%); Melting point: 151-155 oC 1H NMR 
(400 MHz, DMSO-d6) δ 8.66 (t, J = 6.6 Hz, 1H), 8.63 (s, 1H), 8.53 (d, J = 5.6 Hz, 2H), 8.17 (d, J = 7.7 H z, 2H), 7.39 
(m, 4H), 7.17 (t, J = 7.3 Hz, 1H), 6.07 (s, 1H), 4.68 (d, J = 6.5 Hz, 2H), 2.41 (s, 3H).; 13C NMR (101 MHz, DMSO-d6) 
δ 159.9, 150.2(2C), 147.7, 147.0, 145.5, 141.9, 133.6, 129.1(2C), 125.6, 125.5 (2C), 122.4(2C), 107.1, 86.6, 43.8, 
25.4; MS (ES+): m/z (rel. Intensity) [M+H] 316.2 (100), HRMS (ES+) calcd for [(C19H18N5)+H]:316.1562; found: 
316.1560 CHN analysis: C: Calculated: C:72.36%, H:5.43%, N:22.21%. Found 71.57%, H:5.43%, N:22.02%. 
 
5-Methyl-3-phenyl-N-((6-(trifluoromethyl)pyridin-2-yl)methyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF907) 
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General procedure 2.4  (0.21 g, 54%); Melting point: 167-169 oC 1H NMR (400 MHz, DMSO-d6) δ 8.87 (s, 1H), 
8.75 (t, J = 6.6 Hz, 1H), 8.63 (s, 1H), 8.16 (d, J = 7.7 Hz, 2H), 8.09 (d, J = 8.1 Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.39 
(t, J = 7.7 Hz, 2H), 7.17 (t, J = 7.3 Hz, 1H), 6.24 (s, 1H), 4.79 (d, J = 6.5 Hz, 2H), 2.43 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 160.0, 149.8, 146.8, 145.8 (d, J = 33.9 Hz), 145.5, 141.9, 138.5 (d, J = 0.7 Hz), 137.2, 133.5, 128.9 
(2C), 125.6 (2C), 125.5, 122.17 (q, J = 273 Hz), 121.2 (d, J = 2.8 Hz), 107.1, 86.4, 42.3, 25.4; MS (ES+): m/z (rel. 
Intensity) [M+H] 384.1 (100), HRMS (ES+) calcd for [(C20H17N5F3)+H]:384.1436; found: 384.1446; CHN analysis: 
Calculated: C:62.66%, H:4.21%, N:18.27%. Found C:62.36%, H:4.14%, N:18.13%; 
 
N-((5-Chloropyridin-2-yl)methyl)-5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-amine (AWF908) 
 
 
 
 
 
General procedure 2.4  (55 mg, 11%); Melting point: 198-199 oC 1H NMR (400 MHz, DMSO-d6) δ 8.63 (m, 2H), 
8.53 (t, J = 6.3 Hz, 1H), 8.17 (d, J = 7.8 Hz, 2H), 7.92 (dd, J = 8.4, 2.2 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H),  7.33 (t, J = 
7.7 Hz, 2H),  7.17 (t, J = 7.3 Hz, 1H), 6.10 (s, 1H), 4.74 (d, J = 6.3 Hz, 2H), 2.42 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 159.9, 156.4, 148.1, 147.0, 145.5, 141.9, 137.3, 133.5, 130.2, 128.9 (2C), 125.6 (2C), 125.5, 123.1, 
107.0, 86.6, 46.1, 25.4; N:19.39%; MS (ES+): m/z (rel. Intensity) [M+H] 350.1 (100), HRMS (ES+) calcd for 
[(C19H17N5Cl)+H]:350.1172; found: 350.1173;  CHN analysis: Calculated: C:65.24%, H:4.61%, N:20.02%. Found 
C:64.99%, H:4.53%, 
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6-Allyl-5-methyl-3-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF909) 
 
 
 
 
 
General procedure 2.4 to give AWF909 as an off-white solid  (0.20 g, 52%); Melting point: 132-133 oC 1H NMR 
(400 MHz, DMSO-d6) δ 8.55 (s, 1H), 8.49 (d, J = 5.9 Hz, 2H), 8.16 (d, J = 7.4 Hz, 2H), 7.79 (t, J = 7.1 Hz, 1H), 7.38 
(t, J = 7.7 Hz, 2H), 7.28 (d, J = 5.8 Hz, 2H), 7.16 (t, J = 7.4 Hz, 1H), 6.00 (ddt, J = 15.2, 10.0, 4.9 Hz, 1H), 5.13 – 
5.06 (m, 3H), 4.91 (dd, J = 17.2, 1.4 Hz, 1H), 2.46 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 159.9, 150.1(2C), 
150.1, 146.3, 144.8, 141.3, 136.1, 133.4, 128.9(2C), 125.5, 125.5 (2C), 121.9(2C), 115.8, 106.3, 98.1, 46.9, 30.0 
23.9; MS (ES+): m/z (rel. Intensity) [M+H] 356.2 (100), HRMS (ES+) calcd for [(C22H22N5)+H]:356.18752; found: 
356.1877; CHN analysis: Calculated: C:74.34%, H:5.96%, N:19.70%. Found C:73.87%, H:5.89%, N:19.71% 
 
6-Allyl-5-methyl-3-phenyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF911) 
 
 
 
 
 
General procedure 2.4 to give AWF911 as an off-white solid  (0.28 g, 75%); Melting point: 158-160 oC 1H NMR 
(250 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.55 (s, 1H), 8.18 – 8.11 (m, 2H), 8.03 (t, J = 6.0 Hz, 1H), 7.77 (td, J = 7.7, 
1.7 Hz, 1H), 7.37 (m, 3H), 7.29 (dd, J = 6.9, 5.4 Hz, 1H), 7.14 (t, J = 7.4 Hz, 1H), 6.05 (ddt, J = 15.0, 9.8, 4.8 Hz, 
1H), 5.11 (m, 1H) 5,11 (d,  J = 6.4 Hz, 2H), 4.92 (dd, J = 17.2, 1.5 Hz, 1H), 3.49 (d, J = 4.6 Hz, 2H), 2.46 (s, 3H); 13C 
NMR (101 MHz, DMSO-d6) δ 160.1, 158.2, 149.3, 146.0, 144.4, 141.2, 137.5, 136.8, 133.5, 128.9(2C), 125.5, 
125.4, 122.9, 121.7(2C), 116.1, 106.6, 97.6, 48.7, 30.2, 24.0; MS (ES+): m/z (rel. Intensity) [M+H] 356.2 (100), 
HRMS (ES+) calcd for [(C22H22N5)+H]:356.1875; found: 356.1879; CHN analysis: Calculated: C:74.34%, H:5.96%, 
N:19.70%.  Found  C:74.10%, H:5.92%, N:19.40%.  
5,6-Dimethyl-3-phenyl-N-(1-(pyridin-2-yl)ethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF913) 
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General procedure 2.4 to give AWF913 as an off white solid  (0.47 g, 59%); Melting point: 111-113 oC 1H NMR 
(400 MHz, DMSO-d6) δ 8.61 (d, J = 4.3 Hz 1H), 8.55 (s, 1H), 8.14 (d, J = 7.4 Hz, 2H), 7.79 (td, J = 7.7, 1.6 Hz, 1H), 
7.50 (d, J = 7.8 Hz, 1H), 7.45 (d, J = 8.9 Hz, 1H), 7.38 (t, J = 7.7 Hz, 2H), 7.31 (dd, J = 7.0, 5.2 Hz, 1H), 7.15 (t, J = 
7.4 Hz, 1H), 5.76 (dq, J = 13.5 6.7 Hz 1H), 2.50 (s, 3H), 2.31 (s, 3H), 1.54 (d, J = 6.7 Hz, 3H);  13C NMR (101 MHz, 
DMSO-d6) δ 162.1, 159.9, 149.4, 145.1, 144.1, 141.1, 137.7, 133.5, 128.9(2C), 125.5, 125.5, 123.1, 121.5(2C), 
106.8, 98.0, 54.6, 24.8, 24.5, 13.3; MS (ES+): m/z (rel. Intensity) 344.2 (100), 345.2 (23) HRMS (ES+) calcd for 
(C21H21N5):336.1283; found: 336.1279; CHN analysis: Calculated: C:73.44%, H:6.16%, N:20.39%. Found 
C:73.19%, H:6.16%, N:20.07%.  
 
5,6-Dimethyl-3-phenyl-N-(thiazol-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF914) 
 
 
 
 
 General procedure 2.4, product purified by column chromatography eluting with 20% EtOAc:DCM (0.34 g, 
46%); Melting point: 144-146 oC  1H NMR (400 MHz, DMSO-d6) δ 9.07 (s, 1H), 8.52 (s, 1H), 8.15 (d, J = 7.4 Hz, 
2H), 7.55 (t, J = 6.7 Hz, 1H), 7.44 (s, 1H), 7.38 (t, J = 7.7 Hz, 2H), 7.15 (t, J = 7.4 Hz, 1H), 5.22 (d, J = 6.7 Hz, 2H), 
2.50 (s, 4H), 2.27 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 159.5, 156.2, 155.1, 155.1, 145.9, 144.3, 141.1, 
140.9, 133.6, 128.9, 125.4, 115.7, 115.6, 106.3, 97.4, 44.9, 24.6, 13.0; MS (ES+): m/z (rel. Intensity) 336.1 (100), 
337.1 (23) HRMS (ES+) calcd for (C8H18N5):344.1875; found: 344.1873; CHN analysis: Calculated: C:64.45%, 
H:5.11%, N:20.88%, S:9.56% Found  C:64.26%, H:5.10%, N:20.86%, S:9.61%.  
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Tert-butyl 2-(((5,6-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)pyrrolidine-1-
carboxylate(17a) 
 
 
 
 
General procedure 2.4  (0.59 g, 46%); 1H NMR (400 MHz, DMSO-d6) δ 8.50 (s, 1H), 8.15 (d, J = 7.4 Hz, 3H), 7.38 
(t, J = 7.7 Hz, 3H), 7.15 (t, J = 7.4 Hz, 1H), 7.06 (br s, 1H), 4.04 (br s, 1H), 3.96 – 3.80 (m, 2H), 3.27 – 3.13 (m, 2H), 
2.50 (s, 7H), 2.29 (s, 4H), 1.92 – 1.75 (m, 5H), 1.37 (s, 7H); 13C NMR (101 MHz, DMSO-d6) δ 158.6, 154.2, 146.3, 
145.3, 141.3, 133.8,, 128.8(2C), 125.4(2C), 125.2, 105.7, 78.3, 67.1, 43.7, 28.1, 28.0, 26.6, 25.6, 24.7, 19.4, 
13.0(3C); MS (ES+): m/z (rel. Intensity) 422.3 (100), 423.3 (23) HRMS (ES+) calcd for (C24H32N5O2):422.2556; 
found: 422.2556 
Tert-butyl 2-(((3-(4-fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)piperidine-1-
carboxylate 
 
 
 
 
 
General procedure 2.4 The crude product was purified by column chromatography eluting with 
30%EtOAc:Hexane (50%); 1H NMR (400 MHz, DMSO-d6) δ 8.48 (s, 1H), 8.18 (d, J = 2.4 Hz, 2H), 7.30 – 7.14 (m, 
2H), 6.96 (br s, 1H), 4.36 (br s, 1H), 4.16 (br s, 1H), 4.03 (br s, 1H), 3.88 (br s, 1H), 2.96 (t, J = 11.6 Hz, 1H), 2.47 
(s, 3H), 2.20 (s, 3H), 1.56 (t, J = 28.9 Hz, 5H), 1.02 (s, 9H). 13C NMR (101 MHz, DMSO-d6) δ 160.4 (d, J = 241.5 Hz 
), 158.7, 154.5, 146.3, 144.8, 141.0, 130.3 (d, J = 3.0 Hz), 127.0 (d, J = 7.6 Hz, 2C), 115.6 (d, J = 21.0 Hz, 2C). 
104.8, 96.9, 78.2, 623.0, 43.7, 28.0, 26.6, 25.6, 24.7, 19.4, 13.0; MS (ES+): m/z (rel. Intensity) 454.3 (100), 455.3 
(22) HRMS (ES+) calcd for (C25H33N5O2F):454.2618; found: 454.2609. 
 
5,6-Dimethyl-3-phenyl-N-(pyrrolidin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF915) 
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General procedure 2.4 (0.22 g, 50%); Melting point: 140-141 oC 1H NMR (400 MHz, DMSO-d6) δ 8.51 (s, 1H), 
8.15 (d, J = 7.4 Hz, 2H), 7.38 (t, J = 7.7 Hz, 2H), 7.15 (t, J = 7.4 Hz, 1H), 7.02 (t, J = 5.5 Hz, 1H), 3.82 – 3.52 (m, 
2H), 2.87 – 2.74 (m, 3H), 2.50 (s, 3H), 2.31 (s, 3H), 1.87 – 1.67 (m, 3H), 1.65 - 1.55 (m, 1H), 1.47 – 1.32 (m, 1H); 
13C NMR (101 MHz, DMSO-d6) δ 159.6, 146.2, 144.1, 140.9, 133.7, 128.9 (2C), 125.4 (2C), 125.3, 106.4, 96.6, 
58.3, 49.0, 46.3, 29.2, 25.9, 24.8, 13.5;  MS (ES+): m/z (rel. Intensity) 322.2 (100), 323.2 (23) HRMS (ES+) calcd 
for (C19H24N5):322.2032; found: 322.2029; CHN analysis: Calculated: C:71.00%, H:7.21%, N:21.79%. Found 
C:70.39%, H:7.15%, N:21.61%.  
5,6-Dimethyl-3-phenyl-N-(piperidin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF934) 
 
 
 
 
 
General procedure 2.4 The crude product was purified by column chromatography eluting with 60% 
EtOAc:Hexane, NEt3 (56%); Melting point: 157-160 oC  1H NMR (400 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.19 (dd, J 
= 8.4, 5.7 Hz, 2H), 7.22 (t, J = 8.8 Hz, 2H), 7.05 (br s, 1H), 3.87 – 3.60 (m, 2H), 3.35 (s, 2H), 2.99 (d, J = 11.7 Hz, 
1H), 2.74 (s, 1H), 2.49 (s, 3H), 2.29 (s, 3H), 1.73 (s, 1H), 1.55 (dd, J = 35.4, 7.7 Hz, 2H), 1.31 (s, 2H), 1.16 (dd, J = 
17.4, 9.6 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 160.4 (d, J = 241.5 Hz), 159.7, 146.2, 144.0, 140.8, 130.2 (d, J 
= 2.9 Hz), 127.0 (2C d, J = 7.5 Hz), 115.7 (2C d, J = 21.0 Hz). 105.4, 96.6, 56.8, 50.1, 46.3, 29.8, 26.4, 24.8, 24.35, 
13.4; MS (ES+): m/z (rel. Intensity) 354.2 (100), 355.2 (24) HRMS (ES+) calcd for (C20H25N5F):354.2094; found: 
354.2085; CHN analysis: Calculated: C:67.97%, H:6.84%, N:19.82%. Found C:67.06%, H:6.77%, N:19.19%.  
General procedure 2.5 for the synthesis of 5,6-Dimethylpyrazolo[1,5-a]pyrimidin-7-amines1 
 
 
 
To the chlorinated pyrazolo-pyrimidine (1 equiv) in DMF (1ml/0.1mmol) was added the aryl-amine (1 equiv) 
and K2CO3 (1.2 equiv). The solutions were stirred at 60oC in overnight, once completed the reactions were 
evaporated to dryness, diluted with EtOAc before washing with water and brine. Organics were dried over 
MgSO4 before loading the crude product to silica gel and purifying by column chromatography.  
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 6-Chloro-5-methyl-3-phenyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF920) 
 
 
 
 
General procedure 2.5 The crude product was washed with water and the grey precipitate triturated with Et2O 
to afford AWF920. (0.37 g, 65%); Melting point: 170-171 oC 1H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.54 
(d, J = 4.5 Hz, 1H), 8.41 (br s, 1H), 8.13 (d, J = 7.4 Hz, 2H), 7.79 (td, J = 7.7, 1.6 Hz, 1H), 7.40 (m, 3H), 7.30 (dd, J = 
6.9, 5.3 Hz, 1H), 7.19 (t, J = 7.4 Hz, 1H), 5.39 (s, 2H), 2.56 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 158.0, 157.1, 
149.2, 144.3, 143.9, 142.3, 137.4, 132.9, 129.0 (2C), 125.9, 125.7 (2C), 122.8, 121.5, 107.3, 96.6, 48.8, 24.4; MS 
(ES+): m/z (rel. Intensity) 350.1 (100), 352.1 (32) HRMS (ES+) calcd for (C19H17N535Cl):350.1172; found: 
350.1169. calcd for (C19H17N537Cl):352.1143; found: 352.1148; CHN analysis: Calculated: C:65.24%, H:4.61%, 
N:20.02%. Found C:64.24%, H:4.54%, N:19.86%.  
 
 
 3-(4-Fluorophenyl)-5,6-dimethyl-N-(pyrazin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF933) 
 
 
 
 
 
 
General procedure 2.5 The crude product was purified by column chromatography eluting with 60% 
EtOAc:Hexane,NEt3 to afford AWF933  as an off-white solid. (29%); Melting point: 151-153 oC 1H NMR (400 
MHz, DMSO-d6) δ 8.70 (s, 1H), 8.58 (s, 1H), 8.53 (s, 1H), 8.48 (s, 1H), 8.17 (d, J = 3.7 Hz, 2H), 7.69 (s, 1H), 7.21 
(d, J = 5.6 Hz, 2H), 5.30 (s, 2H), 2.50 (s, 3H), 2.28 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.1 (d, J = 120.8 
Hz), 159.5, 154.8, 146.1, 144.3, 144.2, 143.9, 143.7, 141.0, 130.0 (d, J = 3.0 Hz), 127.1 (2C , d, J = 7.6 Hz), 115.6 
(2C d, J = 21.1 Hz), 105.3, 97.4, 47.6, 24.7, 13.0; MS (ES+): m/z (rel. Intensity) 349.2 (100), 350.2 (22) HRMS 
(ES+) calcd for (C19H18N6F):349.1577; found: 349.1571; CHN analysis: Calculated: C:65.50%, H:4.92%, N:24.12%. 
Found C:64.91%, H:4.83%, N:23.58%. 
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3-(4-Fluorophenyl)-5,6-dimethyl-N-(pyrimidin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF935) 
 
 
 
 
 
 
 
General procedure 2.5 The crude product was purified by column chromatography eluting with 60% 
EtOAc:Hexane, NEt3 to 80% EtOAc:Hexane, NEt3 afford  AWF935 as an off-white solid. (20%); Melting point: 
157-159 oC 1H NMR (400 MHz, DMSO-d6) δ 9.13 (s, 1H), 8.73 (d, J = 5.2 Hz, 1H), 8.47 (s, 1H), 8.17 (dd, J = 8.8, 
5.6 Hz, 2H), 7.75 (t, J = 6.5 Hz, 1H), 7.50 (d, J = 5.1 Hz, 1H), 7.21 (t, J = 8.9 Hz, 2H), 5.26 (d, J = 6.5 Hz, 2H), 2.50 
(s, 3H), 2.26 (s, 3H). MS (ES+): m/z (rel. Intensity) 349.2 (100), 350.2 (21) HRMS (ES+) calcd for 
(C19H18N6F):349.1577; found: 349.1576; CHN analysis: Calculated: C:65.50%, H:4.92%, N:24.12%. Found 
C:64.85%, H:4.83%, N:23.81%. 
Synthesis of 3-(4-Fluorophenyl)-5,6-dimethyl-N-(pyrimidin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWF937) 
 
 
 
 
 
 
General procedure 2.5 The crude product was purified by column chromatography eluting with 60% 
EtOAc,NEt3 to afford  AWF937 as an off-white solid. (24.5%); Melting point: 181-183 oC 1H NMR (400 MHz, 
DMSO-d6) δ 8.8 (d,  J = 4.9 2H), 8.47 (s, 1H), 8.18 (dd, J = 8.8, 5.6 Hz, 2H), 7.78 (t, J = 5.9 Hz, 1H), 7.42 (t, J = 4.9 
Hz, 1H), 7.21 (t, J = 8.9 Hz, 2H), 5.35 (d, J = 5.9 Hz, 2H), 2.50 (s, 3H), 2.30 (s, 3H); 13C NMR (101 MHz, DMSO-d6) 
δ 160.1  (d, J = 120.7 Hz), 159.4, 159.2, 158.0, 146.2, 144.2, 140.9, 130.1 ( d, J = 3.0 Hz), 127.0 (2C d, J = 7.6 Hz), 
120.4, 115.7 (2C d, J = 21.1 Hz), 105.1, 96.8, 50.1, 24.8, 13.0; MS (ES+): m/z (rel. Intensity) 349.2 (100), 350.2 
(21) HRMS (ES+) calcd for (C19H18N6F):349.1577; found: 349.1568; CHN analysis: Calculated: C:65.50%, 
H:4.92%, N:24.12%. Found C:63.76%, H:4.74%, N:23.43%. 
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Chapter 3 Pyrazolopyrimidines - R1 exploration 
 
3.1 Early lead optimisation 
 
Improved template modifications as reported in Chapter 2 are summarised in Fig 3.1. Several modifications 
were tolerated at thie 6-(R3) position in terms of producing compounds with acceptable in vitro anti-Wolbachia 
activity and so far, a methyl group was shown to provide the best balance of potency and DMPK properties. 
The 2-pyridyl group was essential for anti-Wolbachia activity and while in the analogue displayed, AWF913 in 
Fig 3.1, methylation of the linker resulted in reduced metabolic stability within Rat hepatocyte cells; this 
modification seems substrate dependent as it can provide an improvement to metabolic stability and aqueous 
solubility when introduced into other analogues (Chapter 2 – Fig 2.11). 
 
 
 
 
  
 
 
 
 
Fig 3.1 Summary of hit to early lead optimisation discussed in the previous chapter. 
Compound optimisation by modification of the 6-position of the pyrazolopyrimidine core or the 2-pyridyl ring 
is limited; the main improvement to the pyrazolopyrimidine properties from the work carried out in the 
previous chapter is the over 85-fold improvement in aqueous solubility seen from the initial hit AWF911 to 
AWF913. Despite such a notable improvement to aqueous solubility it was still necessary to enhance this 
property further, whilst simultaneously improving the metabolic stability profile to the target region. The 
desired, acceptable and poor properties as presented earlier are defined below in Table 3.1. The early lead 
AWF918 demonstrates that modification of the lower phenyl ring is tolerated in terms of anti-Wolbachia 
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activity and has the potential to boost the aqueous solubility and metabolic stability of our pyrazolopyrimidine 
analogues. 
 EC50 (nM) LogD 7.4 
Aq.Sol 
(µM) 
H.M.Cl 
(µL/min/mg) 
R.HepsCl  
(µL/min 10-6) 
Human 
PPB (%) 
Desired <100 1-4 >50 <20 <20 <99 
Acceptable 100-300 0-1,4-5 20-50 20-60 20-60 <99.5 
Poor 300+ <0, >5 <20 >60 <60 >99.5 
Table 3.1 A table highlighting appropriate and inappropriate potency and DMPK values.  
Considering the large improvement to DMPK properties required to reach the target values as defined above, 
further modifications to the pyrazolopyrimidines were necessary. Molecules 1-5 displayed in Fig 3.2 are 
several of the hits identified from the initial screening campaign with their activity compared to doxycycline 
highlighted in orange (50% activity of doxycycline) or green (90% of the activity of doxycycline). These hits 
demonstrate that the chemical space around the R1 position (Fig 3.2) can be manipulated without complete 
loss of anti-Wolbachia activity. With the SAR restricted around the R3, R4, and R5 positions, we shifted our 
attention to the 3-(R1) position of the pyrazolopyrimidine core (Fig. 3.2) since analysis of the HTS data 
suggested that this position may tolerate a wider range of modifications. 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.2 Pyrazolopyrimidine core with the general scaffold for the focus of SAR study and initial HTS hits  
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3.2 Development of synthetic strategies for analogues with diverse R1 
substituents 
 
The initial synthetic route was developed to allow for the synthesis of several analogues with modified R2-5 
positions around the pyrazolopyrimidine core. While it is possible to initiate synthesis with the appropriate 
alcohol to allow for the synthesis of compounds with diverse R1 functionalities which requires 7 steps in total 
(Fig 3.2), a point of divergence at a later point in the synthetic pathway was desirable to produce a range of 
analogues from a common intermediate in fewer steps. One potential strategy to achieve this would be to 
couple various aryl rings at the R1 position following halogenation as suggested in Scheme 3.1. 
 
 
 
 
 
 
 
 
Scheme 3.1 Synthetic strategies to install side-chains at the R1 position 
This late-stage functionalisation of the R1 position (Scheme 3.1) can be achieved via halogenation and 
subsequent Suzuki coupling on the pyrazolopyrimidine core as reported by K Paruch et al.,1 and was adopted 
to give the synthesis depicted in Scheme 3.2. This strategy allows for fewer steps than synthesis of the initial 
pyrazole (Scheme 3.1) to introduce various groups at the R1 position from the common intermediate 5a. 
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Scheme. 3.2 Synthetic route to compound AWF912  
Phosphoryl chloride mediated chlorination of 1a to form the pyrazolopyrimidine intermediate 1b (Scheme 3.1) 
provided poor yields using the original conditions of refluxing overnight. Modifying the reaction conditions to 
incorporate N,N-dimethylaniline as the base and by limiting the reaction time to 1 hour appeared to be 
optimal conditions for production of the desired product. Bromination of 1b was performed using NBS to give 
2a and the subsequent substitution with 2-pyridyl methanamine (3a) afforded 4a in moderate yields (66%) and 
allowed for easy purification of the intermediate. The palladium catalyst utilised for the Suzuki reaction in the 
production of this first in series analogue was Pd(dppf).Cl2 (Fig 3.3) as the ferrocene ligands appear to be used 
quite frequently in the literature for coupling reactions at the 3-position of pyrazolopyrimidines.2–6  
 
 
 
Fig. 3.3 Structure of the palladium catalyst dppf (diphenylphosphinoferrocene) 
This pathway required Boc-protection of the bromide intermediate 5a to avoid the free amine interfering with 
the Suzuki reaction and to allow for successful coupling to occur on 7a in the production of the first compound 
in this series AWF912 (Scheme 3.1). This analogue is the only example to be unsubstituted at the R3 position as 
this synthesis was performed in parallel to study of the R3 position before a 6-methyl substituent was 
incorporated into the pyrazolopyrimidine core.  
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The in vitro anti-Wolbachia potency and DMPK properties of AWF912 are displayed below in Fig 3.4 with the 
parent analogue AWF905 containing an unsubstituted phenyl ring. AWF912 shows enhanced in vitro metabolic 
stability over the original AWF905, unfortunately, this modification led to over a 4-fold drop in compound 
potency compared to AWF905. However, after acknowledging the importance of a substituted 6-(R3) position 
in achieving potent anti-Wolbachia effects, we decided to incorporate a methyl substituent at this position. 
With this beneficial methyl incorporated into the pyrazolopyrimidine several analogues with various aryl ring 
systems were designed for synthesis.  
 
 
 
 
 
 
 
 
Fig 3.4 Introduction of a 4-Cl Ph at the 3-(R1) position  
 
3.3 R1 Mono-substituted phenyl ring systems 
 
A variety of substituted aryl groups were designed to probe the SAR around this position. In silico DMPK 
predictions were carried out by collaborators in AstraZeneca and are displayed in Fig 3.5. The predicted data 
suggests there will be a two-fold reduction in clearance from a metabolic system in a 4-SO2Me Ph analogue 
(AWZ9014) in comparison to the 4-F Ph analogue (AWF918). Also, several alternative aromatic heterocycles 
were selected for synthesis following promising in silico DMPK predictions. These included a 2-pyridyl, 2,4,5 
trimethyl pyrazole and a 3-N-methyl pyrazole ring system. The predicted DMPK parameters for the 3-N-Me 
pyrazole (AWZ9030) are displayed in Fig 3.5 alongside the predicted properties for the 4-F Phenyl analogue, 
AWF918. These predictions suggest that AWZ9030 will have a five-fold improvement in aqueous solubility and 
over a two-fold improvement in metabolic stability over AWF918. 
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Fig 3.5 Predicted DMPK properties used in the design of a variety of aryl ring systems for the R1 position 
Ortho methylation is a common strategy to boost solubility of compounds by increasing the torsion angle 
between ring systems. By reducing the overall molecular planarity between two aryl ring systems crystal 
packing energy can be reduced and consequently aqueous solubility should increase.7,8 There are various 
examples of ortho-methylation which result in a significant increase in compound potency as well.9–12  
Whilst establishing a simple synthesis to compounds containing various R1 side-chains, our chemistry partner 
WuXi App Tech revealed that it is possible to synthesise these targets without Boc-protection by using a more 
reactive 3-iodo intermediate. However, upon attempting such reactions we observed that without Boc-
protection reaction yields were poor and purification heavily relied on HPLC. The more reactive iodo 
intermediate 12a (Scheme 3.3) was incorporated into our synthesis. This involved iodination of the 
unsubstituted analogue 11a using the electrophilic iodinating agent NIS. The coupling reactions on 14a were 
performed with the catalyst, Pd(dtbpf).Cl2 (Fig 3.6), which upon cessation of the reaction monitored by TLC 
and purification of the mixture appears to result in generally higher yields for couplings performed on our 
substrate in comparison to using Pd(PPh3) or Pd(dppf).Cl2 as the catalyst. 
 
 
 
 
    Fig 3.6 Structure of the palladium catalyst dtbpf (ditertiarybutylphosphino ferrocene). 
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With a consistent 2-pyridyl functionality at the R5 position we could perform the substitution reaction on the 
7-chloro intermediate in DMF which allowed for shorter reaction times and generally superior yields allowing 
easier purification by recrystallization over column chromatography; the synthesis adopted for this series of 
analogues is shown in Scheme.3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme. 3.3 Advanced synthetic route to analogues with modified R1 positions. 
Several analogues were synthesised with various aryl rings at the R1 position with the general scaffold depicted 
below in Fig 3.7 and the measured in vitro anti-Wolbachia potency and DMPK properties displayed in Table 3.2 
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                               Fig.3.7 General structure for compounds with varied R1 positions. 
Table 
entry 
Compound R1 
EC50 
(nM) 
LogD 
7.4 
Aq. Sol 
(µM) 
H.MicCl 
(µL/min/mg) 
R.HepCl 
(µL/min 10-6) 
PPB 
(%) 
1 AWF900 Ph 19 4.2 0.04 ND 59.0 99.90 
2 AWZ9012 4-CF3 Ph 789 4.4 0.03 3.0 16.9 > 99.95 
3 AWZ9013 4-OCF3 Ph 664 4.5 5.00 8.8 156.6 97.9 
4 AWZ9014 4-SO2Me Ph 143 3.3 2.00 21.8 27.6 99.81 
5 AWZ9015 4-CN Ph 664 4.1 1.00 3.0 14.8 > 99.93 
6 AWF917 4-Cl Ph 84 4.7 0.30 22.8 27.9 > 99.95 
7 AWF918 4-F Ph 17 4.3 0.90 49.2 67.7 99.8 
8 AWF945 2-SO2Me Ph >2500 2.3 11.00 74.2 >300 88 
9 AWF941 3-SO2Me Ph >2500 3 2.00 12.1 147.8 96.6 
10 AWF919 2-Me Ph 102 4.0 10.0 72.0 245.7 99.17 
11 AWZ9009 2-Cl Ph 33 4.0 7.00 90.7 173.1 99.89 
12 AWF936 2-F Ph 11 4 0.60 84.0 113.2 99.88 
13 AWZ9010 3-Cl Ph 266 4.1 0.50 60.7 85.0 >99.95 
14 AWF925 3-F Ph >1000 4.1 1.00 
59.3 
 
86.2 
 
> 99.90 
 
15 AWF938 4-CO2Me Ph 179 4.4 0.70 39.4 >300 99.8 
16 AWF940 4-SO2NHMe Ph >2,500 3.5 0.50 15.1 >300 97.9 
17 AWF942 4-CONH2 Ph NA ND ND ND ND ND 
18 AWF943 4-SO2iPr Ph 175 3.8 0.70 26.7 62.1 98.7 
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Table 
entry 
Compound R1 
EC50 
(nM) 
LogD 
7.4 
Aq. Sol 
(µM) 
H.MicCl 
(µL/min/mg) 
R.HepCl 
(µL/min 10-6) 
PPB 
(%) 
19 AWF944 4-SO2Et Ph 131 3.4 0.20 8.2 49.1 97.8 
20 AWZ9029 3-pyridyl 4-CF3 >2500 ND ND ND ND ND 
21 AWZ9031 
 
1479 2.9 101 14.65 80.69 85 
22 AWZ9030 
 
119 2.7 43.00 44.8 10.3 91.8 
23 AWZ9033 
 
43 2.3 30.00 243.6 144.9 97.4 
 NA – No activity at highest concentration (5 µM) ND – Not determined                          
Table 3.2 Potency, DMPK and solubility analysis of compounds containing various aryl rings at the R1 position. 
As demonstrated by table entries 2-7 and 13-18 para-substitution of the phenyl ring is normally tolerated with 
a range of substituents. The 4-OCF3 substituent AWZ9013 (entry 3) proved successful in improving aqueous 
solubility and reducing human microsomal clearance over the parent phenyl analogue; however, suffered over 
a 30-fold drop in activity (EC50=664 nM). Incorporation of the polar SO2Me group at the para position of the 
phenyl ring (entry 4 - AWZ9014) was successful in reducing logD, increasing aq. solubility and improving 
metabolic stability over the phenyl and 4-F phenyl analogue. While the 4-CN Ph analogue AWZ9015 (entry 5) 
did prove to have enhanced aqueous solubility over the parent phenyl analogue and a promising metabolic 
stability profile (both rat and human clearance values <20 – Table 3.1) this compound suffered over a 30-fold 
drop in anti-Wolbachia activity (EC50 = 84 nM) compared to the phenyl parent analogue (entry 1). The 4-Cl Ph 
containing analogue did possess suitable anti-Wolbachia activity and possessed acceptable clearance values 
during in vitro assessments however as with several of these mono-substituted phenyl rings a larger boost to 
aqueous solubility was necessary to reach a suitable level. 
The 4-F substitution (entry 7 - AWF918) appears to be optimal for activity (EC50=15 nM), both compounds 
AWF918 and AWZ9014 were considered early-leads resulting from this work. These compounds were both 
evaluated for in vitro potency within the in vitro mf study and AWZ9014 subjected to PK and PD analysis within 
the in vivo SCID mouse model (see Chapter 4). Table entries 8 (AWF945) and 9 (AWF941) demonstrate that 
large groups are not tolerated in the ortho or meta positions of the phenyl ring in terms of anti-Wolbachia 
activity. Meanwhile, smaller substituents at the ortho-position such as methyl (entry 10), chlorine (entry 11) or 
fluorine (entry 12), are tolerated in terms of potency. Ortho-methylation of the phenyl ring at the R1 position 
(entry 8 - AWF919) provided a 250-fold improvement to aqueous solubility (Aq.sol = 10 µM) over the parent 
analogue AWF900 (entry 1, Aq.sol = 0.04 µM). Unfortunately, this analogue suffered from a 5-fold drop in 
potency, possessed poor metabolic stability and further improvement of solubility was still required to reach 
the desired solubility levels (Table 3.2), therefore further optimisation was necessary.  
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Substitution at the 3 position of the phenyl ring was not tolerated in terms of potency with any substituent 
studied which is demonstrated here by tables entries 13 and 14 which contain the 3-Cl Ph ring (AWF924) and 
the 3-F Ph ring (AWF935) respectively. The analogues AWF938-944 (entries 15-19) offer further evidence that 
a variety of substituents are tolerated in terms of activity at the para position. It appears that there is space 
within the drug binding site that tolerates an additional phenyl ring at this position (entry 15, 18 and 19) while 
incorporation of an amine at this position completely removes anti-Wolbachia activity.   
To reduce log D further our collaborators WuXi (see appendix 1 for experimental details) prepared the 
analogues (table entries 20-23) containing nitrogen heterocyclic ring systems where the CF3 substituted pyridyl 
ring (AWZ9029 – entry 20) possessed no anti-Wolbachia activity as did the 2,3,4 trimethyl pyrazole analogue 
AWZ9031 (entry 21). The analogues AWZ9030 (entry 22) and AWZ9033 (entry 23) containing the 4-N-Me, 3,4-
pyrazole and 2-pyridyl rings respectively, were both tolerated in terms of potency and greatly increased the 
aqueous solubility of our pyrazolopyrimidine analogues. The 4-N-Me, 3,4-pyrazole analogue, AWZ9030 
possessed promising stability and solubility; however, suffered from a 6-fold decrease in activity (EC50= 119 
nM) compared to the phenyl analogue (entry 1 EC50 = 19 nM) and while the 2-pyridyl analogue AWZ9033 
maintained most of its activity (EC50 = 43 nM) it suffered from very poor metabolic stability (Human liver 
microsomal clearance = 244 µLmin-1mg-1). These results supported investigation into additional aryl ring 
groups bearing basic nitrogen centres to enhance solubility and allow potential formulation as amine salts.
   
3.4 R1 position biaryl ring systems 
  
After exploring the SAR around the R1 position with several substituted aromatic ring systems we discovered 
that it is possible to manipulate the para position with various functionalities to produce compounds with 
acceptable anti-Wolbachia activities. Incorporation of saturated heterocycles as solubilising groups attached to 
phenyl ring systems has proven to be a successful strategy to greatly improve aqueous solubility in previous 
medicinal chemistry programs.13 Also, DMPK predictions for the two molecules T1 and T2 below in Fig 3.8 
demonstrate that such side-chains should possess much superior aqueous solubility than our previous 
analogues.  
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   Fig. 3.8 Predicted solubility changes upon incorporation of a terminal heterocyclic ring. 
Therefore, we designed compounds containing extended side-chains with terminal saturated heterocyclic ring 
systems like the examples above (Fig 3.8) containing terminal saturated nitrogen-containing heterocycles. One 
of these selected targets, AWF939 (Table 3.2), could be synthesised via the previously discussed chemistry 
(Scheme 3.4), from the commercially available 4-morpholino(phenyl)methanone boronic acid. Compounds 
AWF946-7 were prepared via Mitsunobu reactions using DEAD as an activating reagent (Scheme.3.4) from the 
phenol intermediate 16o (Scheme 3.4) produced from Suzuki coupling of (4-hydroxyphenyl)boronic acid. 
 
 
 
  
 
 
Scheme. 3.4 Synthetic route to AWF946 & AWF947 
The whole-cell anti-Wolbachia activity and measured DMPK properties for analogues containing additional ring 
systems are displayed in Table 3.3. 
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Table 
entry 
Compound A 
EC50 
(nM) 
LogD 
7.4 
Aq. Sol 
(µM) 
H.MicsCL 
(µL/min/mg) 
R.HepsCL  
(µL/min 10-6) 
PPB (%) 
1 AWF939 
 
680 3.2 5.00 9.8 15.6 96 
2 AWF946 
 
844 3.6 2.00 43.7 95.0 98.1 
3 AWF947 
 
1228 2.7 71.00 30.8 258.7 91.9 
Table. 3.3 Results for analogues containing extended side chains at the R1 position. 
These compounds possessed improved aqueous solubility over most of the mono substituted phenyl ring 
analogues (Table 3.1). The 4-morpholino phenyl methanone analogue AWF939 (table entry 1) experienced a 6-
fold improvement in metabolic stability (Clearance values <20) compared to the mono substituted phenyl 
analogues which is demonstrated by greatly reduced human microsomal and rat hepatocyte clearance values. 
The morpholine ring proved more potent than the N-methyl piperidine group within the ether-linked 
analogues in table entries 2 and 3 (AWF946-7) and it appears from these results that extension of the linker 
leads to reduced potency. Unfortunately, these analogues had greatly reduced anti-Wolbachia potency 
therefore alternative modifications to this position were deemed necessary. 
Reducing the aromatic ring count within prospective drug compounds is an established strategy for the 
improvement of aqueous solubility.14 Therefore, we decided at this point it may be worth studying the effect 
that removal of the aromatic ring system all together would have in our analogues. This would allow us to 
determine whether the aromatic side-chain at the R1 position is essential for potency and to potentially 
improve the ligand efficiency of our analogues.  
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3.5 Small R1 substitutions - Aryl-Removed analogues. 
 
These unsubstituted (R1=H) analogues (Fig 3.9) can be produced via amination of the unsubstituted 7-Cl 
intermediate 11a (Scheme 3.3) used in the production of the 3-iodo intermediate (Scheme 3.3) during study of 
the R1 position. AWF930 (Fig 3.9), which was unsubstituted at this position, was evaluated for biological 
activity to study the effect that removal of the aryl ring system induces. The potency of compound AWF930 
(EC50 = 105 nM) (Fig 3.9) revealed that a phenyl ring at the R1 position is not an essential functionality for 
pyrazolopyrimidine compounds to possess anti-Wolbachia activity. 
 
 
 
 
Fig. 3.9 Structure and measured biological activity for AWF930 with an unsubstituted at the R1 position. 
Compared to the parent 4-fluoro phenyl-containing analogue AWF918, AWF930 displayed greatly improved 
(>600 fold) aqueous solubility. AWF930 maintained most of its potency; however, suffered from very poor 
metabolic stability during in vitro DMPK analysis. To alleviate the metabolic liability associated with this labile 
unsubstituted R1 position, alternative analogues were designed with various small substitutions at the R1 
position to identify the optimal group at this position in terms of potency and DMPK properties.   
During chemical modification, the 3-position of the pyrazolopyrimidine core displays both electrophilic and 
nucleophilic nature which will leave it exposed to both electrophilic and nucleophilic metabolising enzymes. 
Double bonded carbons within an aromatic ring are exposed to a range of different routes of oxidative 
metabolism15,16 such as epoxidation which can lead to addition of glutathione unit (Fig 3.10) or hydrogen 
abstraction followed by hydroxylation and subsequent conjugation to larger groups such as glucuronic acid (Fig 
3.10).16 
 
 
 
 
                        Fig 3.10 Potential metabolism pathway for drugs containing aromatic ring systems 
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It is quite possible that metabolism at this position is a result of hydrogen abstraction and subsequent 
oxidation, one of the most commonly utilised medicinal chemistry strategies for blocking this metabolism is by 
incorporating a fluorine atom to block metabolism. This strategy is dependent on the strength of the C-F bond, 
which at approximately 109 kcal mol-1 is one of the strongest single bonds that can be made to a carbon 
atom,17–24 this allows the C-F bond to be inert under most biological conditions. Throughout the optimisation 
of the cholesterol absorption inhibitor ezetimibe, the introduction of two fluorine atoms into A1 were critical 
steps among others during the improvement of metabolic stability (Fig 3.11), which allowed for a reduced 
dose of the resultant more-stable compound.19,25 
 
 
 
 
 
Fig 3.11 Optimization towards cholesterol absorption inhibitor ezetimibe (Zetia). 
Halogenation of the R1 position of the pyrazolopyrimidine core was achieved as previously discussed (Scheme 
3.3) using electrophilic halogen sources, however now using NCS, NBS or selecfluor (Fig 3.12).26–28 A nitrile 
group was installed at the R1 position of the pyrazolopyrimidine core by initiating synthesis from 5-amino 
pyrazole-4-carbonitrile 17a (Scheme 3.5) using previously discussed chemistry (Scheme 2.3 - Chapter 2). This 
nitrile-containing intermediate was used to produce the 3-carboxamide 7-chloro intermediate 19a (Scheme 
3.5) by sulphuric acid-mediated hydrolysis of 18a (Scheme.3.5), which, when subjected to substitution with 2-
pyridiyl methanamine afforded the carboxamide analogue AWF953. 
 
 
 
Fig 3.12 Structures of electrophilic halogenating agents, used for installing halogens at the R1 position 
 
  
 
Scheme. 3.5 Synthesis of R2 carboxamide analogue AWF953 
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The anti-Wolbachia activities and measured DMPK properties for this series of analogues are displayed in 
Table 3.3 with the variable groups in this study depicted in the generalised structure below. 
 
 
 
  
Table 
entry 
Molecule 
Name 
R1 R3 
EC50 
(nM) 
LogD 
7.4 
Aq.Sol 
(µM) 
H.MicCL  
(µLmin-1mg-1) 
Rat Heps CL           
(µLmin-110-6) 
PPB 
(%) 
1 AWF930 H Me 105 2 561 261.8 109.6 ND 
2 AWF931 Br Me 176 ND ND ND ND ND 
3 AWF948 Cl Me 122 2.5 47.00 287.0 170 91.2 
4 AWF951 F Me 164 2.2 96.00 276.9 ND ND 
5 AWF932 CN Me NA 1.5 12.00 64.4 129.1 ND 
6 AWF953 CONH2 Me >2,500 1.7 9.00 18.9 63.33 65 
NA – No activity at highest concentration  ND – Not determined        
Table. 3.4 First series of analogues containing small substitutions at the R1 position 
The measured whole-cell potencies within Table 3.4 demonstrate that a range of small groups are tolerated at 
the R1 position in terms of maintaining reasonable anti-Wolbachia activity. Aqueous solubility is greatly 
enhanced upon removal of the aromatic ring system (entry 1 – AWF930); however, due to this modification 
there is an observed reduction in metabolic stability. Halogenation of the R1 position (entries 2-4) maintains 
acceptable anti-Wolbachia activity and aqueous solubility; however, this did not alleviate the poor metabolic 
stability. Introduction of a nitrile (entry 5 - AWF932) or an amide moiety (entry 6 -AWF953) at the R1 position 
results in a complete loss in activity. 
Further exploration of the R1 position was conducted by our chemistry partners WuXi App Tech by the 
introduction of small halogenated alkyl groups. These compounds were prepared by installation of a boronic 
ester at the R1 position (Appendix 1), which once treated with hydrogen peroxide and sodium hydroxide can 
be alkylated with the necessary alkyl halide as presented in Appendix 1.  
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Molecule 
Name 
R1 
EC50 
(nM) 
LogD 
7.4 
Aq. Sol 
(µM) 
H. Mic Cl 
(µL/min/mg) 
R. Hep Cl 
(µL/min 10-6) 
PPB 
(%) 
AWZ9097 -OCHF2 251 2.6 62.00 84.3 84.3 89 
AWZ9099 -OCH2F 629 2.8 8.00 171.0 42.2 95 
NA – No activity at highest concentration  ND – Not determined    
 Table. 3.5 Analogues containing halogenated groups chains at the R1 position 
These compounds containing small halogenated alkyl chains generally demonstrate acceptable potency 
however of the examples tested, none offered an improvement to the poor metabolic stability this series of 
analogues experienced (>80 H.Mics Cl µLmin-1mg-1). 
Incorporation of an extra nitrogen atom into the 2-pyridyl ring system during the examination of the R5 
position seemed tolerable in terms of anti-Wolbachia activity (Table 2.4 – Chapter 2.3). Therefore, several 
compounds with a 2,6-pyrimidine ring system at the R5 position were synthesised. Another modification which 
proved beneficial in earlier studies was the substitution of the methyl group at the R3 position for a chloride, 
this was also revisited in the following series of analogues. These analogues were reached by previously 
discussed chemistry which is summarised below in Scheme 3.6 utilising the chlorinated β-keto ester 20a upon 
formation of the pyrazolopyrimidine core and the biological activities are presented in Table 3.6. 
 
 
 
 
 
 
 
 
Scheme 3.6 Synthesis of pyrazolopyrimidines containing varied R1 positions. (R3 = Me/Cl) 
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Table 
entry 
Molecule 
Name 
R1 R3 
EC50 
(nM) 
LogD 
7.4 
Aq. Sol 
(µM) 
H. Mic Cl 
(µL/min/mg) 
R. Hep Cl    
(µL/min 10-6) 
PPB (%) 
1 AWF949 Cl Cl 311 2.5 10.00 160.5 147.6 92.3 
2 AWF950 Cl Me >1,250 1.8 43.00 113.7 146.4 79 
3 AWF952 F Me >1,250 1.4 107.0 129.0 146.8 73 
4 AWF954 F Cl 774 ND ND 225.0 ND  
NA – No activity at highest concentration (5  µM) ND – Not determined               
Table. 3.6 Whole-cell assay Wolbachia activity for R3 pyrimidine compounds 
This data supports previous observations that analogues containing small substitutions at the R1 position 
demonstrate greatly improved solubility; however, they all suffer from poor metabolic stability. All but one 
analogue tested at this point containing the 2,6-pyrimidine ring displayed insufficient in vitro anti-Wolbachia 
activity. While AWF937 (R1 = 4-F Ph, R3= Me) (Table 2.4) displayed acceptable potency (EC50 = 33 nM), there 
was no increase in aqueous solubility and no sufficient increase in compound stability to justify this 
modification compared to the 2-pyridyl parent analogue AWF918. While the 2,6-pyrimidine ring-containing 
analogues with a chlorine at the R3 position seemed to produce some activity they still proved less potent than 
the parent 2-pyridyl analogues. In addition to the drop in anti-Wolbachia activity halogenated substituents 
were shown to result in undesired worm toxicity as explained earlier (Ch. 2.4). For this reason, it was essential 
to avoid such halogenated substituents at the R3 position in the design of future analogues to avoid 
introducing a liability for adverse effects associated with targeting the filarial nematodes directly.  
 
3.6 Bioisosteric replacement of the R1 phenyl ring 
 
Following the unsuccessful incorporation of small groups at the R1 position to improve both potency and 
DMPK properties we sought to identify alternative modifications. For several years, medicinal chemists have 
employed the strategy known as bioisosteric replacement to chemically alter compounds to modulate the 
biological and physicochemical properties. The rationale for this strategy is to replace a functionality with one 
that has some similarity in the size, shape, polarity, polarizability or lipophilicity and due to the similar 
chemical nature, the modified compound should possess similar biological activity to the original.29  
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This approach was applied to our pyrazolopyrimidine compounds in our efforts to enhance aqueous solubility. 
One option was to replace the phenyl ring seen in the initial hit with a ring of similar size but less hydrophobic, 
more polar and less planar. All the suggsted alterations should promote improved aq.  solubility and there are 
several examples in the literature where saturated ring systems have been successfully installed for gthis 
purpose into drug compounds without abolishing potency.30,31 In the example shown below (Fig. 3.13) the 
authors Sébastien L. Degorce et al.,32 used a tetrahydropyran (THP) ring to replace a phenyl ring in 25a and this 
served to drastically decrease the LogD which should significantly increase the aqueous solubility the resultant 
compound 26a which also maintained its biological activity. 
 
 
 
 
 
 
 
 
    Fig 3.13 Replacement of a 4-Cl Ph ring with a THP to lower LogD 
As already noted, various small groups are tolerated in terms of potency at the R1 position, therefore reducing 
the size of the ring system incorporated at this position offered another viable approach to reduce the 
hydrophobicity caused by the aryl ring systems at this position. There are several examples within the 
literature where a lipophilic cyclopropyl ring has been used to replace a phenyl ring system without effecting 
potency.33,34 One of these examples is depicted in Fig 3.14 where the authors carried out this replacemant on 
27a alongside other key modifications during their optimisation of a series of selective allosteric inhibitors of 
mitogen/extracellular signal-regulated kinases for the development of Trametinib, approved for the treatment 
of metastatic melanoma.33 Also displayed in Fig 3.14 is the optimisation of a series of 2-amino-5-
carboxamidothiazoles as novel Lymphocyte-specific protein tyrosine kinase inhibitors were the less lipophilic 
cyclopropyl moiety has been introduced into compound 28a in place of a phenyl ring which also improved 
biological activity in the resultant analogue 29a.34 The reduction in CLogP from 2.91 in compound 28a to 2.01 
in 29a supports that this modification may promote increased aqueous solubility. 
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Fig 3.14 Optimisation of various compound series involving the replacement of phenyl ring with a cyclopropyl 
moiety. 
 
Using the AZ DMPK predictive software, compounds containing a tetrahydropyran and cyclopropyl ring had 
their DMPK predictions calculated and are displayed below in Fig 3.15  
 
 
 
 
 
 
 
Fig 3.15 Predicted DMPK properties for analogues AWZ9035 and AWZ9036 containing the cyclopropyl and THP 
analogues respectively. 
 
DMPK predictions for AWZ9035 and AWZ9036 containing the cyclopropyl and THP rings respectively 
demonstrate greatly improved aqueous solubility over the 4-F phenyl analogue AWF918. The prediction 
results also suggested that the THP analogue may possess improved metabolic stability compared to the 4-F Ph 
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analogue AWF918. Therefore, these analogues could positively address the poor metabolic stability seen upon 
removal of the phenyl ring. 
These analogues were both synthesised by collaborators WuXi App Tech from chemistry previously discussed 
in this chapter (Scheme 3.7), optimised for coupling of various functionalities at the R1 position (See appendix 
1 for experimental details). The THP analogue AWZ9036 required an extra step prior to Boc removal to 
hydrogenate the dihydropyran in 34a added during the coupling reaction on 33a. These reactions are depicted 
below in Scheme 3.7, with measured in vitro potency and DMPK properties displayed. 
 
 
 
 
 
 
 
Scheme 3.7 Synthesis and biological evaluation of AWZ9035 & AWZ9036 
Both compounds demonstrate greatly improved aqueous solubility associated with removal of the aromatic 
ring system whilst maintaining potent anti-Wolbachia activity. AWZ9035 suffered from poor stability like other 
compounds containing small substituents at this position. AWZ9036 however, possessed the best balance of in 
vitro potency and DMPK properties seen so far in this chemotype.  
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3.7 Conclusion 
 
Throughout the work conducted on this series, two of the analogues discussed in this section (AWZ9014 and 
AWZ9036) were considered as frontrunners and were examined in further biological studies to assess their in 
vitro mf potency and in vivo efficacy against Wolbachia (see Chapter 4 - biological evaluation section). The 
optimisation of pyrazolopyrimidine compounds described in this Chapter is briefly summarised in Fig 3.16.  
 
 
 
 
 
 
 
 
Fig 3.16 Summary of early lead optimisation discussed in this chapter. 
In this Chapter, the 3 (R1)-position has been thoroughly examined and it has been shown that a variety of 
substituents are tolerated in terms of anti-Wolbachia activity at the 4-position and whilst 4-F Ph is optimal in 
terms of activity, 4-SO2Me Ph possessed the best balance of potency and DMPK properties at the time of 
study. Removal of the hydrophobic phenyl ring maintained most of the compound potency and resulted in 
compounds with greatly enhanced aqueous solubility; however, suffered from very poor metabolic stability. 
Study of a variety of small substituents at the R1 position proved unsuccessful in terms of elucidating groups 
tolerated in terms of both potency and DMPK properties. Bioisosteric replacement of the phenyl ring seen in 
the initial hit with a THP group provided a compound with promising anti-Wolbachia potency and DMPK 
properties. A summary of the SAR from this body of work is displayed in Fig 3.17. Following lessons learnt from 
the introduction of heterocyclic ring systems at the R1 position, the following series of optimisation will focus 
on investigation of other saturated ring systems at the R1 position. 
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Fig 3.17 SAR summary from study of the R1 position of the pyrazolopyrimidine core. 
Finally, reviewing the analogues in this section reveals that further optimisation is still necessary to enhance 
specifically the aqueous solubility and metabolic stability of the next series of pyrazolopyrimidines, by doing so 
this will provide the greatest opportunity for our compounds to result in desirable in vivo efficacy. The 
promising potency and DMPK properties demonstrated by AWZ9036 prompted further investigation into THP 
analogues and other saturated ring systems substituted at the R1 position which will be discussed in the 
following chapter.  
Chart 3.1 displays the logD of analogues presented within this chapter plotted against their Mw values. The 
Chart shows that all of our analogues within this chapter fall within promising drug space as defined by the 
Lipinski rule of 5 and the GlaxoSmith 4/400 rule as mentioned earlier in Chapter 1.7.2.35,36  
 
 
 
 
 
 
 
 
Chart 3.1 LogD values plotted against Mw (gmol-1) for analogues presented within this chapter 
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The logD of analogues within this section also seems to be closely correlated to the aq. Solubility (R2 = > 0.8, 
Chart 3.2) as seen within analogues from Chapter 2. Unfortunately, there does not appear to be any strong 
correlation between solubility/logD and any other property.  
 
Chart 3.2 LogD values plotted against log Aq.Sol (mgmL-1) for compounds within this chapter. 
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3.8 Experimental 
 
Biological Evaluation (See Chapter 4 experimental for screening materials and methods) 
General 
 
Air- and moisture-sensitive reactions were performed in oven dried glassware sealed with rubber septa under 
an atmosphere of nitrogen from a manifold or balloon. Anhydrous solutions and sensitive liquids were 
transferred via syringe or stainless-steel cannula. Reactions were stirred using Teflon-coated magnetic stir 
bars. Organic solutions were concentrated using a Buchi rotary evaporator with a diaphragm vacuum pump. 
 
Purification of solvents and reagents  
 
Anhydrous solvents were either purchased from Sigma Aldrich or dried and distilled immediately prior to use 
under a constant flow of dry nitrogen. Tetrahydrofuran was distilled from Na, dichloromethane and Et3N were 
distilled from CaH2. All reagents were purchased from Sigma Aldrich, Alfa Aesar, Frontier Scientific, Apollo 
Scientific, Fluorochem and were used without any purification unless otherwise indicated. 
 
Purification of products 
 
Thin layer chromatography (TLC) was performed on 0.25 mm Merck silica gel 60 F254 plates and visualised by 
ultraviolet light. U.V. inactive compounds were visualised using iodine, p-anisaldehyde solution, ninhydrin or 
potassium permanganate followed by gentle heating. Flash column chromatography was performed on ICN 
ecochrom 60 (32-63 mesh) silica gel eluting with various solvent mixtures and using an airline to apply 
pressure. 
 
Analysis 
 
Melting points were determined by a Gallenkamp apparatus and are uncorrected. 1H NMR spectra were 
recorded on Bruker AMX 400 (400 MHz) spectrometer and reported as chemical shit on parts per million (ppm, 
δ) relative to tetramethylsilane as the internal reference, integration, multiplicity (s = singlet, br s = broad 
singlet, d = doublet, t = triplet, q =quartet, sex = sextat, m = multiplet), coupling constant (J, Hz), assignment. 
13C NMR spectra were recorded on Bruker AMX400 (101 MHz) spectrometer and reported in terms of chemical 
shit (ppm, δ) relative to residual solvent peak. Mass spectra (MS) and high resolution mass spectra (HRMS) 
were recorded on a VG analytical 7070E machine, Fisons TRIO spectrometers using electron ionisation (EI) and 
chemical ionisation (CI), and Micromass LCT mass spectrometer using electron spray ionisation (ESI). All mass 
values are within error limits of ±5 ppm. Elemental analyses (%C, %H, %N) were either determined by the 
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University of Liverpool Microanalysis Laboratory or the London Metropolitan University Elemental Analysis 
Service. Reported percentages are within error limits of ±0.5 %. 
General procedure 2.1 for the synthesis of 5-Methyl pyrazolo[1,5-a]pyrimidin-7-ol37 
 
 
 
 
To the 3-Amino, 1,2-pyrazole (5.16 mmol) in AcOH (8 ml) was added the appropriate β-keto ester (20.64 
mmol) and the reaction was allowed to stir at 110oC for 3 hours. The reaction was cooled to room temperature 
and diluted with Et2O to precipitate the desired product which was filtered and washed with further Et2O.  
  
 
5-Methylpyrazolo[1,5-a]pyrimidin-7-ol38 (1a) 
 
 
 
General procedure 2.1 to give 1a as a white solid. (5.84 g, 82%); 1H NMR (400 MHz, DMSO-d6) δ 12.27 (s, 1H), 
7.82 (s, 1H), 6.09 (s, 1H), 5.57 (s, 1H), 2.29 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 156.8, 150.7, 143.2, 142.1 
95.3, 88.7, 19.0; MS (CI+ CH4): m/z (rel. Intensity) [M+H] 150.1 (100)  
5,6-Dimethylpyrazolo[1,5-a]pyrimidin-7-ol39 10a 
 
 
 
General procedure 2.1 was followed to give 10a  as an off-white solid (99%); 1H NMR (400 MHz, DMSO-d6) δ 
12.11 (s, 1H), 7.80 (d, J = 2.0 Hz 1H), 6.04 (d, J = 2.0 Hz 1H), 2.30 (s, 3H), 1.96 (s, 3H); 13C NMR (101 MHz, DMSO 
-d6) δ 157.5, 146.3, 143.0, 141.2, 100.9, 87.7, 17.86, 10.8;  MS (CI+ CH4): m/z (rel. Intensity) [M+H] 164.1 (100) 
HRMS (CI+) calcd for [(C8H10N3O)+H]:164.0818; found: 164.0821 
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6-Chloro-5-methylpyrazolo[1,5-a]pyrimidin-7-ol40 (21a) 
 
 
 
To a solution of 1H-pyrazol-3-amine (2.5 g, 30.1 mmol, 1 eq) and methyl 2-chloro-3-oxo-butanoate (4.5 g, 30.1 
mmol, 1 eq) in toluene (20 mL) was added TsOH.H2O (572 mg, 3 mmol, 0.1 eq). The mixture was allowed to stir 
at 100 °C for 20 mins. A light-yellow solid was formed. TLC (EtOAc) showed that 1H-pyrazol-3-amine was 
consumed completely and a new spot has formed. The mixture was cooled to room 
temperature. The solid was filtered and was washed (Petroleum ether, 20 mL) to give 21a (5 g, 27.2 mmol, 
91% yield) as a grey solid. 1H NMR (400MHz, DMSO-d6) δ 7.91 (d, J=2.01 Hz, 1H), 6.18 (d, J=1.88 Hz, 1H), 2.45 
(s, 3H);  13C NMR (101 MHz, DMSO-d6) δ 153.4, 147.9, 144.0, 140.9, 101.5, 89.2, 18.8; MS (CI+ CH4): m/z (rel. 
Intensity)[M+H] 150.1 (100), 184.0 (16); HRMS (CI+) calcd for [(C7H7ClN3O)+H]:189.0771; found:189.0778 
7-Hydroxy-5,6-dimethylpyrazolo[1,5-a]pyrimidine-3-carbonitrile (17a) 
 
 
 
Synthesised via general procedure 2.1 to give 17a as an off-white solid. (96%). 1H NMR (400 MHz, DMSO-d6) δ 
13.08 (s, 1H), 8.34 (s, 1H), 2.35 (s, 3H), 1.98 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 156.5, 147.5, 145.2, 144.3, 
113.4, 105.1, 73.9, 17.5, 10.8; MS (CI+ CH4): m/z (rel. Intensity)[M+H] 189.1 (100);  HRMS (CI+) calcd for 
[(C9H8N4O)+H]:189.0771; found:189.0778  
 
6-Chloro-5-methylpyrazolo[1,5-a]pyrimidin-7-ol40 (21a) 
 
 
 
To a solution of 1H-pyrazol-3-amine (2.5 g, 30.1 mmol, 1 eq) and methyl 2-chloro-3-oxo-butanoate (4.5 g, 30.1 
mmol, 1 eq) in toluene (20 mL) was added TsOH.H2O (572 mg, 3 mmol, 0.1 eq). The mixture was allowed to stir 
at 100 °C for 20 mins. A light-yellow solid was formed. TLC (EtOAc) showed that 1H-pyrazol-3-amine was 
consumed completely and a new spot. The mixture was cooled to room temperature. The solid was filtered 
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and was washed (Petroleum ether, 20 mL) to give 21a (5 g, 27.2 mmol, 91% yield) as a grey solid. 1H NMR 
(400MHz, DMSO-d6) 7.91 (d, J=2.01 Hz, 1H), 6.18 (d, J=1.88 Hz, 1H), 2.45 (s, 3H). 
 
General procedure 2.2 for the synthesis of 7-Chloro-5-Methyl-pyrazolo[1,5-a]pyrimidines2 
 
 
 
To the pyrazolo-pyrimidine compound (1 equiv) and NEt3 (2 equiv) in MeCN was added POCl3 (3 equiv) and the 
solution stirred under reflux overnight. The reaction was cooled to room temperature, volatiles removed 
under reduced pressure before pouring the resultant crude onto crushed ice. The mixture was basified with 
2M NaOH and aqueous extracted with EtOAc, combined organic extracts washed with brine, dried with MgSO4 
and evaporated to dryness to give the product.  
General procedure 3.1 - synthesis of 3-substituted 7-chloro-5-methyl-pyrazolo[1,5-a]pyrimidines1 
 
 
 
To the pyrazolo-pyrimidine compound (1 equiv) and NEt3 was added POCl3 (3 equiv) and the solution was 
allowed to stir under reflux overnight. Upon cooling to room temperature, the excess POCl3 was quenched by 
diluting the reaction mixture with DCM and adding dropwise to ice-cold saturated sodium hydrogen carbonate 
with stirring and external cooling. The organic layer was separated and the aqueous re-extracted with DCM 
(3x) before washing the combined extracts with brine, drying with Na2SO4, evaporating to dryness and then 
purifying the crude mixture by column chromatography. 
7-Chloro-5-methylpyrazolo[1,5-a]pyrimidine41 (1b) 
 
 
 
General procedure 3.1 to give 1b as a light-yellow solid (3.55 g, 63%). 1H NMR(400 MHz, MeOD) 8.10 (d, J = 2.2 
Hz 1H), 6.97 (s, 1H), 6.54 (d, J = 2.2 Hz 1H), 2.49 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 156.6, 155.5, 152.4, 
150.7, 142.9, 142.2, 19.4; MS (CI+ CH4): m/z (rel. Intensity) [M+H] 168.0(100) 
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7-Chloro-5,6-dimethylpyrazolo[1,5-a]pyrimidine39 (11a) 
 
 
 
General procedure 3.1 to give 11a as a light-yellow solid (71%). 1H NMR(400 MHz, DMSO-d6) δ 8.18 (d, J = 2.3 
Hz 1H), 6.68 (d, J = 2.3 Hz 1H), 2.55 (s, 3H), 2.37 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 159.5, 147.6, 144.6, 
135.6, 116.2, 97.0, 24.3, 14.8; MS (CI+ CH4): m/z (rel. Intensity) [M+H] 182.0488 (100), [M+H] 184.0488 (26)  
HRMS (CI+) calcd for [(C8H9N335Cl)+H]:182.0480; found: 182.0488  
6,7-Dichloro-5-methylpyrazolo[1,5-a]pyrimidine (22a) 
 
 
 
To 21a (4.6 g, 25.95 mmol) in dimethylaniline (6.35 ml) was added to POCl3 (6.87 ml, 75.16 mmol) in one por-
tion at 25 °C under N2. The mixture was heated to 110 °C and stirred for 1 hour. The reaction was quenched 
with ice-cold water and diluted with DCM, organic layers were washed with brine (100 mL*2), dried over 
Na2SO4 and concentrated to give 22a (0.995 g, 19.74%). 1H NMR (400MHz, CDCl3-d) δ 8.18 (d, J=2.38 Hz, 1H), 
6.73 (d, J=2.38 Hz, 1H), 2.75 (s, 3H). 
 
7-Chloro-5,6-dimethylpyrazolo[1,5-a]pyrimidine-3-carbonitrile (18a) 
 
 
 
Synthesised via general procedure 2.2 to give 18a as a yellow solid 70%. 1H NMR(400 MHz, DMSO-d6) δ 8.76 
(s, 1H), 2.66 (s, 3H), 2.42 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 164.7, 149.1, 147.4, 137.7, 119.9, 113.6, 81.7, 
24.6, 15.0;  MS (CI+ CH4): m/z (rel. Intensity)[M+H] 207.0 (100), 209.0 (32); HRMS (CI+) calcd for 
[(C9H8N4Cl)+H]:168.0323; found: 168.0328 
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3-Bromo-7-chloro-5-methylpyrazolo[1,5-a]pyrimidine2,26 (2a) 
 
 
 
 
To 1a (781 mg, 4.67 mmol) in DCM (10  ml) was added NBS (997 mg, 5.61 mmol) and the reaction was allowed 
to stir at room temperature for 1 hour. The reaction was evaporated to dryness and the crude product was 
purified by column chromatography eluting with 40% EtOAc:Hexane to give 2a. (0.76 g, 66%). 1H NMR (400 
MHz, DMSO-d6) δ 8.43 (s, 1H), 7.46 (s, 1H), 2.57 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.6, 146.0, 145.2, 
138.0, 110.9, 83.5, 24.6.; MS (ES+): m/z (rel. Intensity) 245.9 (76), 246.9 (15), 247.9  (100), 248.9 (9), 249.9 (23) 
3-Bromo-7-chloro-5,6-dimethylpyrazolo[1,5-a]pyrimidine (2b) 
 
 
 
Synthesised using the procedure to give 2a, used without any further purification (7.03 g, 89%); MS (CI+ CH4): 
m/z (rel. Intensity)[M+H] 261.9 (100), 259.9 (80), 263.9 (15); HRMS (CI+) calcd for [(C8H8BrClN3)+H]:259.9585; 
found: 259.9590 
 
General procedure 3.2  for the synthesis of 3,7-Dichloro pyrazolo[1,5-a]pyrimidine intermediates28 
 
 
 
The chlorinated substrate (330 mg, 1.63 mmol) and NCS (261 mg, 1.956  mmol) were stirred in dry DCM (15 
ml) at room temperature for two hours. Un-reacted NCS was quenched with water, the organic layer 
separated and the aqueous layer extracted with DCM (3 x 10 ml), the combined organic washed with brine (10 
ml), dried with MgSO4 and evaporated to dryness.  
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3,7-Dichloro-5,6-dimethylpyrazolo[1,5-a]pyrimidine (23a) 
 
 
 
 
General procedure 3.2   The crude product was purified by column chromatography eluting with 20%EtOAc in 
Hexane to give the 23a (0.433 g, 61%). 1H NMR(400 MHz, DMSO-d6) δ 8.34 (s, 1H), 2.59 (s, 3H), 2.38 (s, 3H); 
13C NMR (101 MHz, DMSO-d6) δ 161.0, 143.0, 142.3, 136.2, 117.5, 98.5, 24.4, 14.8; MS (CI+ CH4): m/z (rel. In-
tensity) 216.0(100), 218.0 (60) HRMS (CI+) calcd for (C8H7Cl2IN3):216.0090; found: 216.0098 
 
3,6,7-Trichloro-5-methylpyrazolo[1,5-a]pyrimidine (23b) 
 
 
 
 
General procedure 3.2  The crude product was purified by column chromatography eluting with 
20%EtOAc:Hexane to give 23b (0.23 g, 59%). 1H NMR(400 MHz, DMSO-d6) δ 8.50 (s, 1H), 2.70 (s, 3H); 13C NMR 
(101 MHz, DMSO-d6) δ 158.1, 143.7, 142.6, 137.0, 117.5, 99.7, 24.3; MS (CI+ CH4): m/z (rel. Intensity) 
236.0(100), 238.0 (97) 240.0 (27.42)  HRMS (CI+) calcd for (C7H4Cl3IN3):235.9544; found: 235.9548 
 
Synthesis of 7-Chloro-3-iodo-5,6-dimethylpyrazolo[1,5-a]pyrimidine  
 
 
 
Intermediate 38 (463 mg, 2.55 mmol) and NIS (573  mg, 2.55 mmol) in dry MeCN (25 ml) were stirred at room 
temperature for one hour. Volatiles were removed under vacuum upon completion of the reaction shown by 
TLC, the residue was diluted with DCM (20 ml) washed with water (10 ml) and brine (10 ml). The organic por-
tion was dried with MgSO4 and evaporated to dryness, the crude product was purified by column chromatog-
raphy eluting with DCM. (0.54 g, 71%). 1H NMR(400 MHz, DMSO-d6) δ 8.28 (s, 1H), 2.59 (s, 3H), 2.38 (s, 3H); 
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13C NMR (101 MHz, DMSO-d6) δ 148.8, 136.0, 117.2, 75.8, 62.2, 51.2, 24.0, 14.9; MS (ES+): m/z (rel. Intensity) 
307.9(100), 309.9 (23) HRMS (CI+) calcd for (C8H8ClIN5):307.9446; found: 307.9450 
 
General procedure for the synthesis of 3-Fluoro, 7-chloro pyrazolo[1,5-a]pyrimidine intermediates 27 
 
 
 
To the chlorinated substrate (450 mg, 2.23 mmol) in dry acetonitrile (20 ml) at 0oC was added selectfluor (789 
mg, 2.23 mmol).The reaction was allowed to return to room temperature before warming to 60oC and stirring 
overnight.  Volatiles were removed under reduced pressure, extracted with DCM (3 x 15ml), combined 
organics washed with brine (10  ml), dried with MgSO4 and evaporated to dryness.  
 
 
7-Chloro-3-fluoro-5,6-dimethylpyrazolo[1,5-a]pyrimidine (23c) 
 
 
 
Crude product was purified by column chromatography eluting with 10%EtOAc in Hexane to afford the desired 
fluorinated product 23c. (0.12 g, 13%). 1H NMR(400 MHz, MeOD) δ 7.99 (d, J = 3.2 Hz, 1H), 2.51 (s, 3H), 2.33 (s, 
3H); 13C NMR (101 MHz, MeOD) δ 159.4, 141.6, 137.7 (d, J = 245.7 Hz), 134.2 (d, J = 23.7 Hz). 130.0 (d, J = 11.7 
Hz), 116.7, 22.7, 13.3; MS (CI+ CH4): m/z (rel. Intensity) 200.0(100), 202.0 (29) HRMS (CI+) calcd for 
(C8H8ClFN3):200.0385; found: 200.0390 
 
6,7-Dichloro-3-fluoro-5-methylpyrazolo[1,5-a]pyrimidine (23d) 
 
 
 
Crude product was purified by column chromatography eluting with 10%EtOAc in Hexane to afford the desired 
fluorinated product 23d (70 mg, 16%). 1H NMR(400 MHz, MeOD) δ 8.09 (d, J = 2.8 Hz, 1H), 2.61 (s, 3H); 13C 
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NMR (101 MHz, MeOD) δ 158.0, 156.6, 143.4 (d, J = 203.2 Hz), 143.0, 131.6 (d, J = 11.9 Hz), 117.2 (d, J = 36.9 
Hz). 22.7; MS (CI+ CH4): m/z (rel. Intensity) 220.0(98), 222.0 (62) HRMS (CI+) calcd for (C7H5Cl2FN3):219.9839; 
found: 219.9843 
 
7-Chloro-5,6-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide (19a) 
 
 
 
 
To 18a (150 mg, 0.73 mmol) was added concentrated H2SO4 (7 ml) dropwise while cooling in ice. The reaction 
was allowed to stir for 5 hours before adding to ice-cold water dropwise and basifying to pH 7 with 30% 
aqueous NH3. The solid 19a formed was collected and dried under vacuum. (156 mg, 95%). 1H NMR(400 MHz, 
DMSO-d6) δ 8.51 (s, 1H), 7.52 (br s, 2H), 2.68 (s, 3H), 2.43 (s, 3H); MS (CI+ CH4): m/z (rel. Intensity)[M+H] 225.1 
(100), 227.1  (30); HRMS (CI+) calcd for [(C9H10N4ClO)+H]:225.0538; found: 225.0546; MS (CI+ CH4): m/z (rel. 
Intensity) [M+H] 127.0 (100), [M+H]  125.1 (12) 
 
General procedure 2.5 (from Chapter 2) for the synthesis of 5,6-Dimethylpyrazolo[1,5-a]pyrimidin-7-
amines37 
 
 
 
 
To the chlorinated pyrazolo-pyrimidine (1 equiv) in DMF was added the aryl-amine (1 equiv) and K2CO3 (1.2 
equiv). The solutions were stirred at 60oC overnight, once completed the reactions were evaporated to 
dryness, diluted with EtOAc before washing with water and brine. Organics were dried using MgSO4 before 
loading the crude product to silica gel and purifying by column chromatography eluting with 60% EtOAc in 
Hexanes. 
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5-Methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF929) 
 
 
 
 
General procedure 2.5 to give AWF929 as an off-white solid 81%. 1H NMR(400 MHz, DMSO-d6) δ 8.57 (d, J = 
4.0 Hz, 1H), 8.39 (t, J = 6.2 Hz, 1H), 8.06 (d, J = 2.2 Hz, 1H), 7.78 (td, J = 7.7, 1.8 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 
7.31 (dd, J = 7.4, 4.9 Hz, 1H), 6.31 (d, J = 2.2 Hz, 1H), 5.99 (s, 1H), 4.70 (d, J = 6.2 Hz, 2H), 2.32 (s, 3H); 13C NMR 
(101 MHz, DMSO-d6) δ 159.1, 157.4, 149.5, 149.1, 146.8, 143.9, 137.5, 123.0, 121.6, 94.1, 85.8, 46.7, 25.1; MS 
(ES+): m/z (rel. Intensity) [M+H] 240.1 (100), [M+H] 241.1 (15) HRMS (ES+) calcd for [(C13H14N5)+H]:240.1249; 
found: 240.1249; CHN analysis: Calculated: C:65.25%, H:5.48%, N:29.27%. Found C:65.14%, H:5.45%, N:29.48% 
 
3-Bromo-5-methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine2 (4a) 
 
 
 
 
 
General procedure 2.5 to give 4a as an off-white solid. (87%). 1H NMR(400 MHz, DMSO-d6) δ 8.64 – 8.50 (m, 
2H), 8.22 (s, 1H), 7.79 (t, J = 7.0 Hz, 1H), 7.37 (d, J = 7.3 Hz, 1H), 7.32 (brs, 1H), 6.11 (s, 1H), 4.72 (s, 2H), 2.37 (s, 
3H); 13C NMR (101 MHz, DMSO-d6) δ 160.6, 157.2, 149.5, 147.1, 145.7, 143.6, 137.6, 123.1, 121.6, 86.8, 80.4, 
46.7, 25.1; MS (ES+): m/z (rel. Intensity) [M+H] 318.0 (100), [M+H] 320.0 (99) HRMS (ES+) calcd for 
[(C13H13N579Br)+H]:318.0354; found: 318.0349, calcd for (C13H13N581Br):320.0334; found: 320.0332,     
 
 
 
 
5,6-Dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF930) 
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General procedure 2.5 to give AWF930 as an off-white solid 68%. 1H NMR(400 MHz, DMSO-d6) δ 8.56 (d, J = 
4.7 Hz, 1H), 7.97 (d, J = 2.2 Hz, 1H), 7.81 – 7.74 (m, 2H), 7.37 (d, J = 7.9 Hz, 1H), 7.29 (dd, , J = 7.1, 5.2 Hz 1H), 
6.27 (d, J = 2.2 Hz, 1H), 5.16 (d, J = 6.1 Hz, 2H), 2.41 (s, 3H), 2.27 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 159.1, 
158.5, 149.3, 147.8, 145.7, 143.1, 137.4, 122.8, 121.7, 96.0, 93.6, 49.3, 24.4, 13.0; MS (ES+): m/z (rel. Intensity) 
[M+H] 254.1 (100), [M+H] 255.1 (15) HRMS (ES+) calcd for [(C14H16N5)+H]:254.1406; found: 254.1401; CHN 
analysis: Calculated: C:66.38%, H:5.97%, N:27.65%.  Found C:66.14%, H:5.91%, N:27.81%; 
 
3-Bromo-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF931) 
 
 
 
 
 
 
General procedure 2.5 to give AWF931 (0.69 g, 87%). Melting point: 116-118 oC  1H NMR(400 MHz, DMSO-d6) 
δ 8.54 (d, J = 4.7 Hz, 1H), 8.11 (s, 1H), 7.90 (t, J = 6.1 Hz, 1H), 7.78 (td, J = 7.7, 1.7 Hz, 1H), 7.36 (d, J = 7.9 Hz, 
1H), 7.29 (dd, J = 6.9, 5.3 Hz, 1H), 5.18 (d, J = 6.1 Hz, 2H), 2.44 (s, 3H), 2.28 (s, 3H); 13C NMR (101 MHz, DMSO-
d6) δ 179.8, 160.4, 158.2, 149.2, 146.0, 144.4, 142.7, 137.4, 122.8, 121.6, 97.0, 79.7, 24.4, 13.0.; MS (ES+): m/z 
(rel. Intensity) [M+H] 332.1 (100), [M+H] 334.0 (95) HRMS (ES+) calcd for [(C14H15N579Br)+H]:332.0511; found: 
332.0503. calcd for [(C14H15N581Br)+H]:334.0490; found: 334.0486; CHN analysis: Calculated: C:50.62%, 
H:4.25%, N:21.08%. Found C:50.63%, H:4.23%, N:20.98%; 
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3-Chloro-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF948) 
 
 
 
 
 
General procedure 2.5 The crude product was washed with water and the grey precipitate triturated with Et2O 
to afford AWF948. Melting point: 156-158 oC  (66 mg, 33%). 1H NMR(400 MHz, DMSO-d6) δ 8.54 (d, J = 4.6 Hz, 
1H), 8.12 (s, 1H), 7.91 (t, J = 5.9 Hz, 1H), 7.78 (apt, J = 7.7 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.29 (t, J = 6.1  1H), 
5.19 (d, J = 6.0 Hz, 2H), 2.44 (s, 3H), 2.28 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.3, 158.3, 149.3, 146.0, 
143.2, 140.8, 137.4, 122.8, 121.6, 97.0, 94.9, 49.2, 24.5, 13.0; MS (ES+): m/z (rel. Intensity) 288.1 (100), 290.1 
(30) HRMS (ES+) calcd for (C14H15N535Cl):288.1016; found: 288.1012; CHN analysis: Calculated: C:58.44%, 
H:4.90%, N:24.34%. Found C:58.20%, H:4.87%, N:24.29%.  
 
3,6-Dichloro-5-methyl-N-(pyrimidin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF949) 
 
 
 
 
 
 
General procedure 2.5 The crude product was purified by column chromatography eluting with 60% 
EtOAc,NEt3 to afford  AWF949. Melting point: 175-180 oC   (60 mg, 27%). 1H NMR(400 MHz, DMSO-d6) δ 8.76 
(d, J = 4.8 Hz, 2H), 8.32 (t, J = 6.1 Hz, 1H), 8.15 (s, 1H), 7.40 (t, J = 4.8 Hz, 1H), 5.44 (d, J = 6.2 Hz, 1H), 2.51 (s, 
3H); 3C NMR (101 MHz, DMSO-d6) δ 166.7, 158.0 (2C), 157.6, 144.8, 143.1, 142.1, 120.3, 97.0, 96.0, 49.7, 24.1; 
MS (ES+): m/z (rel. Intensity) 309.0 (100), 311.0 (62) HRMS (ES+) calcd for (C12H11N6F35Cl2):309.0422; found: 
309.0423; CHN analysis: Calculated: C:46.62%, H:3.26%, N:27.18%. Found C:45.42%, H:3.18%, N:26.33%. 
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Synthesis of 3-Chloro-5,6-dimethyl-N-(pyrimidin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF950) 
 
 
 
 
 
General procedure 2.5 The crude product was purified by column chromatography eluting with 60% 
EtOAc,NEt3 to afford  AWF950 as an off-white product. (0.16 g, 81%). Melting point: 205-207 oC   1H NMR(400 
MHz, DMSO-d6) δ 8.78 (d, J = 4.8 Hz, 2H), 8.06 (s, 1H), 7.77 (t, J = 5.9 Hz, 1H), 7.41 (t, J = 4.8 Hz, 1H), 5.34 (d, J = 
5.9 Hz, 2H), 2.46 (s, 3H), 2.28 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 167.0, 160.0, 158.0 (2C), 146.3, 143.3, 
140.8, 120.4, 97.1, 94.7, 50.1, 24.4, 12.9; MS (ES+): m/z (rel. Intensity) 289.1 (100), 291.1 (30) HRMS (ES+) 
calcd for (C13H14N635Cl):289.0968; found: 289.0975; CHN analysis: Calculated: C:54.08%, H:4.54%, N:29.11%. 
Found C:53.15%, H:4.42%, N:28.66%. 
3-Fluoro-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF951) 
 
 
 
 
General procedure 2.5 The crude product was purified by column chromatography eluting with 60% 
EtOAc:Hexane AWF951 as an off-white solid. (38 mg, 47%). Melting point: 142-144 oC   1H NMR(400 MHz, 
DMSO-d6) δ 8.55 (d, J = 4.6 Hz, 1H), 8.11 (d, J = 3.5 Hz, 1H), 7.87 (t, J = 5.9 Hz, 1H), 7.78 (t, J = 7.7 Hz, 1H), 7.37 
(d, J = 7.9 Hz, 1H), 7.29 (t, J = 6.9  1H), 5.16 (d, J = 6.0 Hz, 2H), 2.43 (s, 3H), 2.27 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 159.3, 158.3, 149.3, 145.1, 137.4, 136.3 (d, J = 238.2 Hz), 134.5 (d, J = 24.1 Hz), 129.2 (d, J = 10.9 
Hz) 122.8, 121.7, 96.2, 49.1, 24.4, 13.0; MS (ES+): m/z (rel. Intensity) 271.1 (100), 273.1 (15) HRMS (ES+) calcd 
for (C14H15N5F):272.1311; found: 272.1316; CHN analysis: Calculated: C:61.98%, H:5.20%, N:25.81%. Found 
C:60.98%, H:5.10%, N:25.42%.  
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3-Fluoro-5,6-dimethyl-N-(pyrimidin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF952) 
 
 
 
 
General procedure 2.5 The crude product was purified by column chromatography eluting with EtOAc to afford 
AWF952 as an off-white solid. (35 mg, 43%).  1H NMR(400 MHz, DMSO-d6) δ 8.80 (d, J = 4.7 Hz, 2H), 8.06 (d, J = 
3.0 Hz, 1H), 7.74 (t, J = 5.2 Hz, 1H), 7.42 (t, J = 4.6 Hz, 1H), 5.31 (d, J = 5.7 Hz, 2H), 2.44 (s, 3H), 2.28 (s, 3H); 13C 
NMR (101 MHz, DMSO-d6) δ 166.9, 159.1, 158.0, 145.4, 136.2 (d, J = 238.1 Hz), 134.6 (d, J = 24.1 Hz), 129.2 (d, 
J = 10.9 Hz). 120.1, 96.3, 50.0, 24.4, 12.9; MS (ES+): m/z (rel. Intensity) 273.1 (100), [M+Na] 295.1 (70) HRMS 
(ES+) calcd for (C13H14N6F):273.1264; found: 273.1266; CHN analysis: Calculated: C:57.34%, H:4.81%, N:30.87%. 
Found C:56.80%, H:4.81%, N:30.10%. 
6-Chloro-3-fluoro-5-methyl-N-(pyrimidin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF954) 
 
 
 
 
General procedure 2.5 The crude product was purified by column chromatography eluting with 80%EtOAc:Hex 
to afford AWF954. (31%).  1H NMR(400 MHz, MeOD) δ 8.78 (d, J = 4.2 Hz, 2H), 7.91 (d, J = 4.1 Hz, 1H), 7.73 (s, 
1H), 7.39 (t, J = 4.8 Hz, 1H), 5.53 (s, 2H), 2.57 (s, 3H); 13C NMR (101 MHz, MeOD) δ 165.6 (s), 157.4 (s, 2C), 
157.0 (s), 138.9 (d, J = 202.7 Hz), 133.7 (d, J = 24.9 Hz), 132.2 (s), 130.2 (d, J = 11.7 Hz), 119.9 (s), 96.3 (s), 22.4 
(s), 8.1 (s); MS (ES+): m/z (rel. Intensity) 293.1 (100), 295.1 (29) HRMS (ES+) calcd for 
(C12H11N6F35Cl):293.0718; found: 293.0715; CHN analysis: Calculated: C:49.24%, H:3.44%, N:28.71%. Found 
C:47.13%, H:4.25%, N:23.27%. 
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7-Chloro-5,6-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide (AWF953) 
 
 
 
 
 
General procedure 2.5 to give AWF953, (49 mg, 18%). 1H NMR(400 MHz, DMSO-d6) δ 8.54 (s, 1H), 8.29 (s, 1H), 
8.07 (s, 1H), 7.84 – 7.67 (m, 2H), 7.37 (s, 1H), 7.30 (s, 1H), 7.24 (s, 1H), 5.27 (d, J = 0.8 Hz, 2H), 2.51 (s, 3H), 2.29 
(s, 2H); 13C NMR (101 MHz, DMSO-d6) δ 163.9, 160.9, 158.2, 149.3, 146.8, 145.9, 144.5, 137.4, 122.8, 121.6, 
102.6, 98.1, 49.2, 24.6, 13.0; MS (ES+): m/z (rel. Intensity)[M+H] 319.1 (100), 320.1  (22); HRMS (ES+) calcd for 
[(C15H16N6O23Na)+H]:319.1283; found: 319.1278; CHN analysis: Calculated: C:60.80%, H:5,44%, N:28.36%.  
Found C:58.03%, H:5.30%, N:27.82%. 
 
N-Benzyl-3-iodo-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-amine (13a) 
 
 
 
 
 
To the intermediate 12a (4.95 g, 16.1 mmol) and pyridine 2-methanamine (3a) (1.7 ml, 16.1 mmol) in DMF 
(125 ml) was added K2CO3 (2.67 g, 19.32 mmol) and the reaction mixture was allowed to stir at reflux under 
nitrogen for 2 hours. The orange mixture was allowed to cool to room temperature and the crude product 
precipitated out upon addition of ice-cold water with external cooling in ice. Crude solid filtered and triturated 
with ice cold methanol and filtered to afford the desired product 13a. (5.92 g, 97%). 1H NMR(400 MHz, DMSO-
d6) δ 8.53 (d, J = 4.4 Hz, 1H), 8.28 (s, 1H), 8.09 (t, , J = 6.0, 1H), 7.76 (td, J = 7.7, 1.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, 
1H), 7.28 (dd, J = 6.8, 5.3 Hz, 1H), 5.27 (d, , J = 6.0 2H), 2.42 (s, 3H), 2.26 (s, 3H); 13C NMR (101 MHz, DMSO-d6) 
δ 160.4, 158.9, 149.3, 146.9, 146.9, 146.1, 137.4, 122.8, 121.6, 97.0, 49.2, 46.5, 24.5, 13.0; MS (ES+): m/z (rel. 
Intensity) 380.0(100), 381.0 (23), 402.0, 403.0 HRMS (CI+) calcd for (C14H15N5127I):380.0372; found: 380.0369 
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 Tert-butyl (3-bromo-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate2 (5a) 
 
 
 
 
To the bromo pyrazolo-pyrimidine 4a (1.24 g, 3.74 mmol) and DMAP (63.16 mg, 0.517 mmol) in DCM (40 ml) 
was added Boc2O (1.355 g, 6.21 mmol). The reaction was allowed to stir at room temperature overnight; the 
DCM layer was washed with brine and dried with MgSO4 before evaporating to dryness and purifying the crude 
product by column chromatography eluting with 60%EtoAc in Hexane to give the Boc-protected intermediate 
5a. (0.38 g, 85%). 1H NMR(400 MHz, DMSO-d6) δ 8.49 (br s, 1H), 8.36 (s, 1H), 7.78 (t, J = 7.4 Hz, 1H), 7.50 (d, J = 
7.6 Hz, 1H), 7.28 (br s, 1H), 7.19 (s, 1H), 5.01 (s, 2H), 2.56 (s, 3H), 1.24 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 
157.1, 152.4, 149.6, 146.0, 144.5, 143.9, 140.5, 137.3, 123.1, 121.9, 117.2, 106.88, 8.2, 54.3, 27.9, 24.9; MS 
(ES+Na): m/z (rel. Intensity) 440.1 (100), 442.1 (100) HRMS (ES+) calcd for (C18H20N5O223Na79Br):440.0698; 
found: 440.0707. calcd for (C18H20N5O223Na81Br):442.0678; found: 442.0683. 
Tert-butyl (3-iodo-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
 
 
 
 
 
To intermediate 13a (1.13 g, 2.97 mmol), DIPEA (1.24 ml, 5.95 mmol), and DMAP (0.182 g, 1.49 mmol) in dry 
THF (20 ml) was added Boc2O (1.30 g, 5.95 mmol) and the reaction was allowed to stir at 70oC under nitrogen 
for 2 hours. Upon completion of the reaction volatiles were removed under pressure and purified by column 
chromatography eluting with 3:1 pet ether in EtoAc to isolate the desired product 14a. (51%). 1H NMR(400 
MHz, DMSO-d6) δ 8.43 (d, J = 4.3 Hz, 1H), 8.27 (s, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.31 (dd, J 
= 5.2, 1.9 Hz, 1H), 5.60 (d, J = 15.0 Hz  1H), 4.71 (d, J = 15.0 Hz  1H), 2.58 (s, 3H), 2.05 (s, 3H), 1.29 (s, 9H); 13C 
NMR (101 MHz, DMSO-d6) δ 162.3, 156.2, 152.9, 149.6, 147.8, 146.9, 140.0, 137.2, 123.6, 123.2, 116.5, 82.0, 
52.3, 28.0, 24.1, 13.3; MS (ES+): m/z (rel. Intensity) 480.1(100) HRMS (ES+) calcd for (C19H23IN5O2):480.0897; 
found: 480.0892 
Tert-butyl(3-(4-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
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To the Boc-protected 5a (362 mg, 0.87 mmol) was added 4-chloro benzene boronic acid (6a) (180 mg, 10.4 
mmol) and K3PO4 (554 mg, 2.61 mmol). A de-gassed 3:1 mixture of DME:H2O (12 ml) was added and nitrogen 
bubbled through the mixture for 20 minutes before adding Pd(dppf).Cl2 (64 mg, 0.087 mmol). The reaction was 
heated to reflux and was allowed to stir overnight, once completed the reaction mixture was allowed to cool 
to room temperature and evaporated to dryness before diluting with EtOAc. Organic layer was washed with 
brine, dried with MgSO4 and evaporated to dryness to give the crude product which was purified by column 
eluting with 1% MeOH in DCM to give 7a.(0.23 g, 59%). 1H NMR(400 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.50 (s, 
1H), 8.21 (d, J = 8.0 Hz, 2H), 7.79 (t, J = 6.4 Hz, 1H), 7.54 (m, 1H), 7.50 (d, J = 8.1 Hz, 2H), 7.29 (br s, 1H), 7.18 (s, 
1H), 5.05 (s, 2H), 2.61 (s, 3H), 1.26 (s, 9H).; 13C NMR (101 MHz, DMSO-d6) δ 161.0, 157.2, 152.6, 149.6, 145.7, 
144.3, 142.4, 137.3, 131.6, 130.6, 129.1, 127.5, 123.0, 121.9, 107.7, 106.7, 82.4, 54.5, 27.9, 25.2; MS (ES+Na): 
m/z (rel. Intensity) (35ClM+H)450.2 (83), (37Cl M+H) 452.2 (28). (35Cl, M+23Na) 472.2 (100), (37Cl, M+Na) 
474.2 (32); HRMS (ES+) calcd for (C24H25N5O235Cl):450.1697; found: 450.1690. calcd for 
(C24H25N5O237Cl):442.0678; found: 442.0683.  calcd for (C24H25N5O235Cl23Na):472.1516; found: 472.1515. calcd 
for (C24H25N5O237Cl23Na):474.1487; found: 474.1504. 
General procedure 3.3 for Suzuki couplings1 
 
 
 
 
 
 
To the Boc-protected iodo intermediate 41 (1 equiv), Na2CO3 (2 equiv), the necessary boronic acid (1.2 equiv) 
and Pd(dtbf)Cl2 (0.1 equiv) was added a de-gassed 10:1 mixture of dioxane:H2O. The mixture was heated to 
100oC and stirred overnight. Once complete the reaction was filtered through a pad of celite washing with 
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EtOAc, filtrate concentrated to dryness to give the crude product which was purified by column 
chromatography to afford the Boc protected product. 
 
Tert-butyl (3-(4-chlorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
(16a) 
 
 
 
 
 
The crude product was purified by column chromatography eluting with 50% EtOAc in Hexane to afford the 
Boc protected product 16a. (69%). 1H NMR(400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.40 (d, J = 4.7 Hz, 1H), 8.20 (d, 
J = 8.6 Hz, 2H), 7.75 (t, J = 7.5 Hz, 1H), 7.70 (d, J = 8.5 Hz, 2H), 7.50 (m, 1H), 7.26 (m, 1H).5.16 (d, J = 15.2 Hz 
1H), 4.71 (,15.1 Hz 1H),  2.58 (s, 3H), 2.03 (s, 3H), 1.25 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 161.6, 156.3, 
152.9, 149.4, 141.7, 138.1, 137.3, 133.2, 131.6, 130.5 (2C), 129.4 (2C0, 128.9, 127.4, 123.2, 117.4, 107.8, 81.9, 
52.4, 28.0 (2C), 24.4, 13.3;  MS (ES+): m/z (rel. Intensity) 464.2 (100), 466.2 (31) HRMS (ES+) calcd for 
(C25H27N5O235Cl):464.1853; found: 464.1840. calcd for (C25H27N5O237Cl):466.1824; found: 466.1833 
 
Tert-butyl (3-(3-chlorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
(16b) 
 
 
 
 
 
A suspension of (3-chlorophenyl)boronic acid (15b) (39.15 mg, 250.36 µmol), compound 14a (100.00 mg, 
208.63 µmol), Na2CO3 (44.23 mg, 417.26 µmol), ditert-
butyl(cyclopentyl)phosphane;dichloropalladium;iron(13.60 mg, 20.86 µmol) in dioxane (10 mL)  and water (2 
mL) and was allowed to stir  at 100°C under nitrogen atmosphere for 2 hr. TLC (petroleum ether/ethyl acetate= 
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3:1) showed starting material was consumed and a new spot formed . Solvent was removed under vacuum to 
give a residue which used without further purification (60.00 mg, 129.32 µmol, 62% yield). 
 
 
Tert-butyl (5,6-dimethyl-3-(o-tolyl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (16c) 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 50% 
EtOAc:Hexane to afford the Boc protected product 16c. (295 mg, 29%). 1H NMR(400 MHz, DMSO-d6) δ 8.42 (d, 
J = 3.4 Hz, 1H), 8.27 (s, 1H), 7.76 (t, J = 7.3 Hz, 1H), 7.57 – 7.48 (m, 2H), 7.33 – 7.24 (m, 4H), 5.16 (d, J = 14.7 Hz, 
1H), 4.74 (d, J = 14.8 Hz, 1H), 2.51 (s, 3H), 2.33 (s, 3H), 2.03 (s, 3H), 1.27 (s, 9H); 13C NMR (101 MHz, DMSO-d6) 
δ 160.7, 156.5, 153.1, 149.4, 144.4, 143.3, 139.8, 137.2, 136.6, 131.7, 130.9, 130.7, 127.3, 126.1, 123.5, 123.2, 
115.7, 109.9, 81.7, 52.6, 28.0 (3C), 24.2, 21.2, 13.3; MS (ES+): m/z (rel. Intensity) 466.2 (100), 467.2 (21) HRMS 
(ES+) calcd for (C26H29N5O223Na):466.2219; found: 466.2214.  
 
 
 
Tert-butyl (3-(4-fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
(16d) 
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General procedure 3.3 The crude product was purified by column chromatography eluting with 50% 
EtOAc:Hexane to afford the Boc protected product 16d. (80%). 1H NMR(400 MHz, DMSO-d6) δ 8.66 (s, 1H), 
8.40 (d, J = 4.5 Hz, 1H), 8.22 – 8.17 (m, 2H), 7.75 (t, J = 7.4 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.32 – 7.22 (m,  3H), 
5.16 (d, J = 15.0 Hz, 1H), 4.70 (d, J = 15.0 Hz, 1H), 2.59 (s, 3H), 2.02 (s, 3H), 1.26 (s, 9H); MS (ES+): m/z (rel. In-
tensity) 470.2 (100), 471.22 (28) HRMS (ES+) calcd for (C25H26N5O2F23Na):470.1968; found: 470.1964.  
 
 
Tert-butyl (3-(2-fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
(16e) 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 50% 
EtOAc:Hexane to afford the Boc protected product 16e. (79%). 1H NMR(400 MHz, DMSO-d6) δ 8.49 (m, 2H), 
8.41 (d, J = 4.6 Hz 1H), 7.75 (t, J = 7.7 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.31 (m, 3H), 7.27 (dd, J = 7.1, 5.1 Hz 1H), 
5.18 (d, J = 15.1 Hz 1H), 4.72 (d, J = 15.1 Hz 1H), 2.58 (s, 3H), 2.04 (s, 3H), 1.26 (s, 9H); 13C NMR (101 MHz, 
DMSO-d6) δ 161.8, 159.3 (d, J = 245.8 Hz), 156.3, 152.9, 149.4, 144.4, 143.4, 139.9, 137.2, 129.4 (d, J = 4.0 Hz),  
128.1, 125.1 (d, J = 3.2 Hz),  123.6, 123.2 (d, J = 1.6 Hz), δ 120.2 (d, J = 13.0 Hz),  116.7, 116.3 (d, J = 21.9 Hz), 
103.3 (d, J = 21.9 Hz), 81.9, 52.5, 29.0 (3C), 24.4, 13.3; MS (ES+): m/z (rel. Intensity) 448.2 (100), 449.22 (22) 
HRMS (ES+) calcd for (C25H27N5O2F):448.2149; found: 448.2148.  
Tert-butyl (3-(3-fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
(16f) 
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General procedure 3.3 The crude product was purified by column chromatography eluting with 50% 
EtOAc:Hexane to afford the Boc protected crude product 16f which was used without further purification. 
(81%).           
Methyl 4-(7-((tert-butoxycarbonyl)(pyridin-2-ylmethyl)amino)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-3-
yl)benzoate (16g) 
 
 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 20% 
EtOAc:Hexane, NEt3 to afford the Boc protected product 16g. (75%). 1H NMR(400 MHz, MeOD) δ 8.78 (s, 1H), 
8.39 (d, J = 4.3 Hz, 1H), 8.32 (d, J = 8.4 Hz, 2H), 8.01 (d, J = 8.4 Hz, 2H), 7.73 (td, J = 7.7, 1.5 Hz, 1H), 7.45 (d, J = 
7.8 Hz, 1H), 7.25 (m, 1H), 5.14 (d,  J = 15.2 Hz 1H), 4.71 (d , J = 15.1 Hz 1H), 3.86 (s, 3H), 2.59 (s, 3H), 2.03 (s, 
3H), 1.24 (s, 9H); 13C NMR (101 MHz, MeOD) δ 165.9, 161.6, 155.6, 152.1, 148.7, 143.6, 141.6, 139.4, 136.5, 
129.4 (2C), 126.0, 124.8 (2C), 122.8, 122.5, 116.0, 107.1, 81.2, 53.1, 51.7, 27.2 (3C), 23.8, 12.6; MS (ES+): m/z 
(rel. Intensity) 510.2 (100), 511.2 (24) HRMS (ES+) calcd for (C27H29N5O423Na) :510.2117; found: 510.2126.  
Tert-butyl (5,6-dimethyl-3-(4-(morpholine-4-carbonyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (16h) 
 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 60% 
EtOAc:Hexane, NEt3 to afford the Boc protected product (16h). (62%).    1H NMR (400 MHz, DMSO-d6) δ 8.74 
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(s, 1H), 8.40 (d, J = 4.1 Hz, 1H), 8.24 (d, J = 8.2 Hz, 2H), 7.75  (td, J = 7.7, 1.6 Hz, 1H), 7.49 (d, J = 8.3 Hz, 2H), 7.27 
(dd, J = 7.3, 5.1Hz  1H), 5.13 (d, , J = 15.3Hz 1H), 4.70 (d, , J = 15.1 Hz  1H),  3.72-3.45 (br s, 8H), 2.59 (s, 3H), 
2.03 (s, 3H), 1.25 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 169.6, 161.8, 156.4, 152.9, 149.3, 144.2, 142.0, 
139.94, 137.2, 134.1, 132.9, 128.2 (2C), 125.4 (2C), 123.5, 123.2, 116.4, 108.3, 81.9, 66.6, 53.9, 52.5, 27.7 (3C), 
24.4, 13.3; MS (ES+): m/z (rel. Intensity) 565.3 (100), 566.3 (30) HRMS (ES+) calcd for (C30H34N6O423Na): 
565.2539; found: 565.2526.  
 
Tert-butyl (5,6-dimethyl-3-(4-(N-methylsulfamoyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (16i) 
 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 60% EtOAc in 
Hexane, (~1%NEt3) to afford the Boc protected product 16i. (63%). 1H NMR(400 MHz, DMSO-d6) δ 8.79 (s, 
1H),8.40 (d, J = 4.4Hz)  8.39 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.5 Hz, 2H), 7.75 (td, J = 7.7, 1.6 Hz, 1H), 7.47 (d, J = 
7.8 Hz, 1H), 7.42 (q, J = 4.9 Hz, 1H), 7.27 (m, 1H), 5.15 (d, J = 15.2 Hz 1H), 4.72 (d, J = 15.1 Hz  1H), 2.61 (s, 3H), 
2.44 (s, 3H), 2.05 (s, 3H), 1.25 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 162.4, 156.3, 152.9, 149.4, 144.4, 142.4, 
140.1, 137.2, 136.8, 136.2, 127.7 (2C), 125.9 (2C), 123.6, 123.3, 116.8, 107.5, 82.0, 52.6, 29.2, 28.0 (3C), 24.5, 
13.3; MS (ES+): m/z (rel. Intensity) 523.2 (100), 524.4 (27) HRMS (ES+) calcd for (C26H31N6O4S):523.2128; found: 
523.2126. 
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Tert-butyl (5,6-dimethyl-3-(3-(methylsulfonyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate 16j 
 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 50% EtOAc in 
Hexane, (~1%NEt3) to afford the Boc protected product 16j. (94%). 1H NMR(400 MHz, DMSO-d6) δ 8.88 (s, 1H),  
8.77 (m, 1H), 8.58 (dd, J = 7.6, 1.1 Hz, 1H), 8.45 (d, J = 4.1 Hz, 1H), 7.88 – 7.76 (m, 3H), 7.52 (d, J = 7.8 Hz, 1H), 
7.32 (m, 1H), 5.21 (d, J = 15.0 Hz 1H), 4.78 (d, J = 15.1 Hz 1H), 3.34 (s, 3H) 2.66 (s, 3H), 2.10 (s, 3H), 1.30 (s, 9H); 
13C NMR (101 MHz, DMSO-d6) δ 162.2, 157.0, 156.3, 152.9, 149.4, 144.2, 142.2, 141.9, 140.1, 137.2, 134.0, 
130.5, 130.3, 124.2, 123.6, 123.3, 116.7, 107.4, 81.9, 52.5, 44.0, 28.0 (3C), 24.6, 13.3; MS (ES+): m/z (rel. Inten-
sity) [M+23Na] 530.2 (100), [M+23Na]  531.2 (22) HRMS (ES+) calcd for (C26H29N5O423NaS):530.1838; found: 
530.1845.  
Tert-butyl (3-(4-carbamoylphenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
(16k) 
 
 
 
 
 
 
 
General procedure 3.3  The crude product was purified by column chromatography eluting with 80% EtOAc in 
Hexane, (~1%NEt3) to afford the Boc protected product 16k. (18%). 1H NMR(400 MHz, DMSO-d6) δ 8.76 (s, 
1H), 8.46 (d, J = 4.5 Hz, 1H), 8.26 (d, J = 8.3 Hz, 2H), 7.95 (d, J = 8.3 Hz, 2H), 7.73 (td, J = 7.7, 1.5 Hz, 1H), 7.50 (d, 
J = 7.8 Hz, 1H), 7.34 (s, 2H), 7.32 (m, 1H), 5.13 (d, J = 15.1 Hz 1H), 4.72 (d, J = 15.1 Hz 1H), 2.60 (s, 3H), 2.03 (s, 
3H), 1.31 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 168.0, 161.9, 156.4, 152.9, 149.4, 144.3, 142.1, 140.0, 137.2, 
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135.5, 131.6, 128.5(2C), 125.2(2C), 123.6, 123.2, 116.5, 108.2, 81.9, 52.4, 28.0 (3C), 24.6, 13.3; MS (ES+): m/z 
(rel. Intensity) [M+23Na] 495.2 (100), [M+23Na]496.2 (24)  
 Tert-butyl (3-(4-(isopropylsulfonyl)phenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (16l) 
 
 
 
 
 
 
 
General procedure 3.3  The crude product was purified by column chromatography eluting with 60% EtOAc in 
Hexane, (~1%NEt3+) to afford the Boc protected product 16l. (28%). 1H NMR(400 MHz, DMSO-d6) δ 8.83 (s, 
1H), 8.45 (d, J = 8.3 Hz, 2H), 8.40 (d, J = 4.4 Hz, 1H), 7.89 (d, J = 8.2 Hz, 2H), 7.75 (t, J = 7.6 Hz, 1H), 7.47 (d, J = 
7.7 Hz, 1H), 7.29 – 7.24 (m, 1H), 5.15 (d, J = 14.9 Hz, 1H), 4.73 (d, J = 14.9 Hz, 1H), 3.43 (s, J = 6.7Hz  1H), 2.62 (s, 
3H), 2.06 (s, 3H), 1.25 (s, 9H), 1.19 (d, J = 6.7 Hz, 6H);13C NMR (101 MHz, DMSO-d6) δ 162.6, 158.0, 156.6, 
152.8, 149.4, 142.7, 138.3, 137.3, 133.5, 132.6, 131.4, 129.6 (2C), 125.9(2C), 123.1, 107.4, 104.6, 82.0, 54.8, 
52.5, 28.1 (3C), 24.6, 15.9, 13.5; MS (ES+): m/z (rel. Intensity) [M+23Na] 558.2 (100), [M+23Na]  559.2 (28) 
HRMS (ES+) calcd for (C28H33N5O423NaS):558.2151; found: 558.2148.  
Tert-butyl (3-(4-(ethylsulfonyl)phenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (16m) 
 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 60% EtOAc in 
Hexane, (NEt3) to afford the Boc protected product 16m. (78%). 1H NMR(400 MHz, DMSO-d6) δ 8.86 (s, 1H), 
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8.47 (d, J = 8.4 Hz, 2H), 8.43 (d, J = 4.0 Hz, 1H), 7.95 (d, J = 8.4 Hz, 2H), 7.77 (m, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.29 
(dd, J = 7.4, 4.8Hz  1H), 5.18 (d, J = 15.3 Hz 1H), 4.76 (d, J = 15.0 Hz  1H), 3.34 (q, J = 7.3 Hz, 2H), 2.64 (s, 3H), 
2.09 (s, 3H), 1.28 (s, 9H), 1.19 – 1.14 (m, 3H); 13C NMR (101 MHz, DMSO-d6) δ 162.6, 160.4, 156.3, 152.8, 
149.4, 144.5, 142.5, 140.2, 138.2, 137.2, 135.2, 128.8 (2C), 126.0 (2C), 123.2, 116.9, 107.4, 82.0, 52.5, 49.8, 
28.0, 24.5, 13.4, 7.7; MS (ES+): m/z (rel. Intensity) [M+23Na] 544.2 (100), [M+23Na]  545.2 (31) HRMS (ES+) 
calcd for (C27H31N5O423NaS):4544.1994; found: 544.2006.  
 
 
Tert-butyl (5,6-dimethyl-3-(2-(methylsulfonyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (16n) 
 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 60% EtOAc in 
Hexane, (~1%NEt3) to afford the Boc protected product 16n. (23%). 1H NMR(400 MHz, MeOD) δ  8.24 (d J = 4.6 
Hz 1H) 8.16 (s, 1H), 8.12 – 8.07 (m, 1H), 7.77 – 7.60 (m, 2H), 7.53 (m, 3H), 7.19 (dd, J = 6.8, 5.1Hz  1H), 5.11 (d, J 
= 14.9Hz 1H), 4.72 (d, J = 14.9 Hz 1H),  2.7 (s,3H), 2.38 (s, 3H),  1.91 (s, 3H), 1.22 (s, 9H); 13C NMR (101 MHz, 
MeOD) δ 164.8, 162.0, 155.7, 153.1, 148.4, 145.2, 144.2, 142.0, 139.9, 139.6, 139.1, 137.5, 134.4, 133.1, 131.2, 
128.7, 127.8, 124.3, 123.1, 116.4, 107.0, 82.1, 51.9, 41.9, 26.9, 22.3, 12.00; MS (ES+): m/z (rel. Intensity) 
[M+23Na]  530.2 (100), [M+23Na]  531.2 (28) HRMS (ES+) calcd for (C25H27N5O223NaS):530.1838; found: 
530.1838.  
 
 
 
 
 
                                                                          Chapter 3 _____________________________________                                                                                                
 
 
 
154 
 
Tert-butyl (3-(4-hydroxyphenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
(16o) 
 
 
 
 
 
 
General procedure 3.3 The crude product was purified by column chromatography eluting with 60% 
EtOAc:Hexane to afford the Boc protected product (16o). (84%). 1H NMR(400 MHz, DMSO-d6) δ 9.40 (s, 1H), 
8.52 (s, 1H), 8.41 (d, J = 4.4 Hz, 1H), 7.95 (d, J = 8.5 Hz, 2H), 7.74 (td, J = 7.7, 1.4 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 
7.26 (dd, J = 7.2, 5.4 Hz, 1H), 6.84 (d, J = 8.6 Hz, 2H), 2.54 (s, 3H), 1.99 (s, 3H), 1.25 (s, 9H); 13C NMR (101 MHz, 
DMSO-d6) δ 170.8, 160.3, 156.45, 156.1, 153.0, 149.4, 143.4, 140.9, 139.6, 137.2 (2C), 127.3, 123.6, 123.2, 
115.9, 109.4, 81.8, 52.0, 28.0 (3C), 24.4, 13.3; MS (ES+): m/z (rel. Intensity) [M+23Na] 468.2 (100), [M+23Na]  
469.2 (30) HRMS (ES+) calcd for (C25H27N5O323Na):468.2012; found: 468.2012.  
 
Tert-butyl (5,6-dimethyl-3-(4-(2-morpholinoethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (AWF946-Boc) 
 
 
 
 
 
 
To a solution of the Boc-protected phenol intermediate 16o (250 mg, 0.56 mmol), 2-morpholinoethan-1-ol 
(147 mg, 1.12mmol) and triphenylphosphine (294 mg, 1.12 mmol) in THF  (15 ml)  at 0 oC was added a solution 
of 40%  DEAD in toluene (195 mg, 1.12 mmol). The reaction was allowed to stir at room temperature for 48 h. 
Silica was added to the reaction and the mixture concentrated. The crude product was purified by column 
chromatography eluting with EtOAc to afford the Boc protected product AWF946-Boc. (69%). 1H NMR(400 
MHz, DMSO-d6) δ 8.58 (s, 1H), 8.41 (d, J = 4.6 Hz, 1H), 8.06 (d, J = 8.5 Hz, 2H), 7.74 (t, J = 7.6 Hz, 1H), 7.46 (d, J 
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= 7.8 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.03 (d, J = 8.4 Hz, 2H), 5.16 (d, J = 15.1 Hz, 1H), 4.69 (d, J = 15.1 Hz, 1H), 4.12 
(t, J = 5.6 Hz, 2H), 3.61 – 3.58 (m, 4H), 2.71 (t, J = 5.4 Hz, 2H), 2.56 (s, 3H), 2.48 (br s, 4H), 2.00 (s, 3H), 1.26 (s, 
9H); 13C NMR (101 MHz, DMSO-d6) δ 164.8, 160.6, 157.3, 156.5, 153.0, 149.4, 143.5, 141.1, 139.6, 137.2, 127.2 
(2C), 125.2, 123.5, 123.3, 115.2 (2C), 108.9, 81.8, 66.7 (2C), 61.2, 57.5, 54.1 (2C), 52.3, 28.0, 24.4, 13.3; MS 
(ES+): m/z (rel. Intensity) 559.3(100), 560.3 (30) HRMS (ES+) calcd for (C31H39N6O4):559.3033; found: 559.3024.  
 
Tert-butyl (5,6-dimethyl-3-(4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-7-
yl)(pyridin-2-ylmethyl)carbamate (f-Boc) 
 
 
 
 
 
 
 
To a solution of the Boc-protected phenol intermediate (250 mg, 0.56 mmol), 2-(4-methylpiperazin-1-yl)ethan-
1-ol (161 mg, 1.12mmol) and triphenylphosphine (294 mg, 1.12 mmol) in THF(15ml)  at 0 oC was added a 
solution of 40%  DEAD in toluene (195 mg, 1.12 mmol). The reaction was allowed to stir at room temperature 
for 48 h. Silica was add to the reaction and the mixture concentrated. The crude product was purified by 
column chromatography eluting with EtOAc to 5% MeOH:EtOAc to afford the Boc protected product AWF947-
Boc. (75%). 1H NMR(400 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.41 (d, J = 4.6 Hz, 1H), 8.06 (d, J = 8.5 Hz, 2H), 7.75 (t, J 
= 7.7 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.29 – 7.23 (m, 1H), 7.02 (d, J = 8.5 Hz, 2H), 5.16 (d, J = 15.1 Hz, 1H), 4.69 
(d, J = 15.1 Hz, 1H), 4.10 (t, J = 5.7 Hz, 2H), 2.70 (t, J = 5.7 Hz, 2H), 2.56 (s, 3H), 2.44 – 2.25 (m, 8H), 2.16 (s, 3H), 
2.00 (s, 3H), 1.26 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 156.4, 153.0, 149.4, 147.1, 143.4, 141.1, 139.6, 
132.4, 131.8, 127.2 (2C), 125.2, 123.6, 123.2, 115.2 (2C), 108.9, 93.3, 81.8, 66.0, 57.1, 55.2 (4C), 53.5, 46.2, 
28.0 (3C), 24.4, 13.3; MS (ES+): m/z (rel. Intensity) 572.3(100), 573.3 (30) HRMS (ES+) calcd for 
(C32H42N7O3):572.3349; found: 572.3353.  
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General procedure 3.4 - Boc-removal 
 
To the Boc-protected amine suspended in DCM was added TFA and the reaction was allowed to stir at room 
temperature for 18 hours. Upon completion of the reaction the volatiles were removed under reduced pres-
sure, the resultant residue was diluted with EtOAc and washed with NaHCO3 before drying and evaporating to 
dryness to give the crude product. 
7-Chloro-5-methylpyrazolo[1,5-a]pyrimidine 3-(4-chlorophenyl)-5-methyl-N-(pyridin-2-
ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine2 (AWF912) 
 
 
 
 
 
 
 
General procedure 3.4 Purified eluting with 80% EtOAc in Hexanes (0.10 g, 55%). Melting point: 144-146 oC   
1H NMR(400 MHz, DMSO-d6) δ 8.67 (s, 1H), 8.56 (m, 2H), 8.21 (d, J = 8.6 Hz, 2H), 7.79 (td, J = 7.7, 1.7 Hz, 1H), 
7.45 (d, J = 8.6 Hz, 2H), 7.39 (d, J = 7.9 Hz, 1H), 7.32 (dd, J = 7.0, 5.2 Hz, 1H), 6.13 (s, 1H), 4.74 (d, J = 6.1 Hz, 2H), 
2.43 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.1, 157.4, 149.6, 147.1, 145.7, 141.9, 137.6, 132.4, 129.6, 
128.8, 126.9, 123.1, 121.7, 105.6, 86.9, 46.7, 25.4; MS (ES+): m/z (rel. Intensity) 350.1 (100), 352.1 (23) HRMS 
(ES+) calcd for (C19H17N535Cl):350.1172; found: 350.1165. calcd for (C19H17N537Cl):352.1155; found: 352.1143; 
CHN analysis: Calculated: C:65.24%, H:4.61%, N:20.02%.  Found C:64.40%, H:4.66%, N:19.23%.                  
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3-(4-Chlorophenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF917) 
 
 
 
 
 
 
 
General procedure 3.4 Product was isolated from crude by column chromatography eluting with DCM to 2% 
MeOH:DCM giving AWF917 in moderate yield. (53%).  1H NMR(400 MHz, DMSO-d6) δ 8.55 (d, J = 4.8 Hz, 1H), 
8.30 (s, 1H), 8.05 (d, J = 8.5 Hz, 2H), 7.80 (t, J = 7.1 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.32 
(dd, J = 7.1, 5.3 Hz, 1H), 5.21 (s, 2H), 2.55 (s, 3H), 2.34 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.1, 158.5, 
149.24, 146.0, 144.4, 141.2, 137.6, 129.3, 128.9 (2C), 126.8 (2C), 122.8, 121.9, 105.0, 97.0, 513, 30.0, 24.8, 
13.1; MS (ES+): m/z (rel. Intensity) 364.1(100), 366.1 (32), 365.1 (22) HRMS (ES+) calcd for 
(C20H19N535Cl):364.1329; found: 364.1320, calcd for (C20H19N537Cl):366.1299; found: 366.1305; CHN analysis: 
Calculated: C:66.02%, H:4.99%, N:19.25%. Found C:65.07%, H:4.81%, N:19.07%. 
 3-(4-Fluorophenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF918) 
 
 
 
 
 
General procedure 3.4 The crude product was purified by column chromatography eluting with 50% 
EtOAc:Hexane to give AWF918  as an off-white solid. (86%). Melting point: 146-148 oC   1H NMR(400 MHz, 
DMSO-d6) δ 8.57 (d, J = 4.3 Hz, 1H), 8.52 (s, 1H), 8.19 (dd, J = 8.8, 5.6 Hz, 2H), 7.90 (t, J = 6.1 Hz, 1H), 7.79 (td, J 
= 7.7, 1.7 Hz, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.30 (dd, J = 6.9, 5.3 Hz, 1H), 7.22 (t, J = 9.0 Hz, 2H), 5.21 (d, J = 6.1 
Hz, 2H), 2.51 (s, 3H), 2.31 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.5 (J = 236.3 Hz), 159.7, 158.5, 149.3, 
145.0, 144.1, 140.9, 137.4, 130.1 (d, J = 2.9 Hz),  129.9, 127.1 (2C, d, J = 7.5 Hz),  122.2, 115.7 (2C, d, J = 21.0 
Hz). 105.4, 96.9, 49.3, 24.8, 13.1; MS (ES+): m/z (rel. Intensity) 348.2 (100), 349.2 (31) HRMS (ES+) calcd for 
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(C20H19N5F):348.1624; found: 348.1620; CHN analysis: Calculated: C:69.15%, H:5.22%, N:20.16%. Found 
C:68.65%, H:5.28%, N:19.80%.  
5,6-Dimethyl-N-(pyridin-2-ylmethyl)-3-(o-tolyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF919) 
 
 
 
 
 
 
General procedure 3.4 The crude product was purified by column chromatography eluting with 50% 
EtOAc:Hexane to afford the product AWF919 as an off-white solid. (126 mg, 57%). Melting point: 158-161 oC   
1H NMR(400 MHz, DMSO-d6) δ 8.59 (s, 1H), 8.14 (s, 1H), 7.89 (s, 1H), 7.81 (s, 1H), 7.53 (d, J = 3.0 Hz, 1H), 7.43 
(d, J = 4.9 Hz, 1H), 7.34 – 7.26 (m, 2H), 7.21 (m, 2H), 5.20 (s, 2H), 2.42 (s, 3H), 2.34 (s, 3H), 2.32 (s, 3H); 13C NMR 
(101 MHz, DMSO-d6) δ 159.4, 158.4, 149.3, 145.8, 144.4, 142.8, 137.4, 136.4, 132.6, 130.8, 130.6, 126.6, 
125.9, 122.8, 121.8, 107.6, 96.4, 49.3, 24.6, 21.4, 13.1; MS (ES+): m/z (rel. Intensity) 344.2 (100),345.2 (15) 
HRMS (ES+) calcd for (C21H22N5):344.1875; found: 344.1867. CHN analysis: Calculated: C:73.44%, H:6.16%, 
N:20.39%. Found C:72.15%, H:6.07%, N:19.82%.  
 
Synthesis of 3-(3-Chlorophenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9010) 
 
 
 
 
 
AWZ9010 – Synthesised by Wuxi (Experimental details in Appendix 1). 1H NMR (400MHz, DMSO-d6)  = 8.76 
(d, J=4.8 Hz, 1H), 8.49 (s, 1H), 8.38 - 8.26 (m, 2H), 8.12 (s, 1H), 7.97 (d, J=7.5 Hz, 1H), 7.86 (d, J=8.3 Hz, 1H), 7.78 
- 7.71 (m, 1H), 7.42 (t, J=7.9 Hz, 1H), 7.25 (d, J=7.7 Hz, 1H), 5.52 (br. s., 3H), 2.56 (s, 3H), 2.30 (s, 3H). 
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3-(2-Fluorophenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF936) 
 
 
 
 
 
 
General procedure 3.4 The crude product was purified by column chromatography eluting with 50% 
EtOAc:Hexane, NEt3 to afford AWF936. (67%). Melting point: 145-147 oC   1H NMR(400 MHz, DMSO-d6) δ 8.64 
8.64 (td, J = 7.7, 1.2 Hz, 1H), 8.56 (d, J = 4.5 Hz, 1H), 8.38 (d, J = 3.7 Hz, 1H), 7.98 (t, J = 6.0 Hz, 1H), 7.79 (td, J = 
7.7, 1.6 Hz, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.33 – 7.18 (m, 4H), 5.21 (d, J = 6.0 Hz, 2H), 2.49 (s, 3H), 2.31 (s, 3H); 
13C NMR (101 MHz, DMSO-d6) δ 160.0, 159.1 (d, J = 245.5 Hz), 158.4, 149.3, 146.0, 144.7, 142.8 (d, J = 13.6 Hz), 
137.5, 128.9 (d, J = 4.2 Hz), 126.9 (d, J = 8.2 Hz), 124.9 (d, J = 3.2 Hz), 122.8, 121.1 (d, J = 12.6 Hz) 121.7, 116.0 
(d, J = 22.2 Hz), 100.3, 97.3, 49.2, 24.8, 13.2; MS (ES+): m/z (rel. Intensity) 348.2 (100), 349.2 (21) HRMS (ES+) 
calcd for (C20H19N5F):348.1624; found: 348.1617; CHN analysis: Calculated: C:69.15%, H:5.22%, N:20.16%. 
Found C:68.44%, H:5.16%, N:19.84%.  
 
Methyl 4-(5,6-dimethyl-7-((pyridin-2-ylmethyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)benzoate (AWF938) 
 
 
 
 
 
 
General procedure 3.4 The crude product was purified by column chromatography eluting with 50% 
EtOAc:Hexane to give AWF938 as an off-white solid. (41%). Melting point: 165-168 oC   1H NMR(400 MHz, 
DMSO-d6) δ 8.66 (s, 1H), 8.56 (d, J = 4.4 Hz, 1H), 8.32 (d, J = 8.4 Hz, 2H), 8.03 – 7.96 (m, 2H), 7.95 (s, 1H), 7.79 
(t, J = 7.0 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 6.8, 5.5 Hz  1H), 5.22 (d, J = 5.9 Hz, 2H), 3.85 (s, 3H), 2.52 
(s, 3H), 2.31 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 166.7, 160.3, 158.4, 149.3, 146.2, 144.8, 141.8, 138.8, 
137.4, 130.0(2C), 125.8, 124.8(2C), 122.8, 121.7, 105.2, 97.5, 52.3, 49.3, 24.9, 13.1; MS (ES+): m/z (rel. Intensi-
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ty) 388.2 (100), 389.2 (22) HRMS (ES+) calcd for (C22H22N5O2):388.1774; found: 388.1771.; CHN analysis: Calcu-
lated: C:68.20%, H:5.46%, N:18.08%. Found C:67.50%, H:5.41%, N:17.70%. 
  
(4-(5,6-Dimethyl-7-((pyridin-2-ylmethyl)amino)pyrazolo[1,5-a]pyrimidin-3 
yl)phenyl)(morpholino)methanone (AWF939) 
 
 
 
 
 
 
 
General procedure 3.4 The crude product was purified by column chromatography eluting with EtOAc (~1% 
NEt3) AWF939 (23%). Melting point: 206-207 oC   1H NMR(400 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.57 (d, J = 4.3 
Hz, 1H), 8.23 (d, J = 8.2 Hz, 2H), 7.96 (t, J = 5.9 Hz, 1H), 7.79 (td, J = 7.7, 1.4 Hz, 1H), 7.44 (d, J = 8.2 Hz, 2H), 7.39 
(d, J = 7.8 Hz, 1H), 7.31 (dd, J = 7.1, 5.3 Hz 1H), 5.21 (d, J = 5.9 Hz, 2H), 3.62 (br s, 4H), 3.53 (br s, 4H), 2.51 (s, 
3H), 2.31 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 169.8, 160.0, 158.4, 149.3, 146.1, 144.5, 141.4, 137.4, 135.2, 
131.9, 128.1 (2C), 124.9 (2C), 122.8, 121.7, 105.5, 97.1, 66.6, 49.3 (2C), 24.9, 13.2; MS (ES+): m/z (rel. Intensity) 
443.2 (100), 444.2 (26) HRMS (ES+) calcd for (C25H27N6O2):443.2195; found: 443.2191; CHN analysis: Calculat-
ed: C:67.86%, H:5.92%, N:18.99%.  Found C:67.19%, H:5.94%, N:18.66%. 
 
 4-(5,6-Dimethyl-7-((pyridin-2-ylmethyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-N-methylbenzenesulfonamide 
(AWF940) 
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General procedure 3.4 The crude product was purified by trituration with EtOAc and Et2O to give AWF940 as 
an off-white solid (69%). Melting point: 181-182 oC   1H NMR(400 MHz, DMSO-d6) δ  8.66 (s, 1H), 8.56 (d, J = 
4.4 Hz, 1H), 8.37 (d, J = 8.4 Hz, 2H), 7.99 (t, J = 6.0 Hz, 1H), 7.80 (t, J = 7.7 Hz, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.39 
(d,  J = 7.7 Hz, 1H), 7.36 (q, J = 5.0 Hz,  1H), 7.31 (dd, J = 7.0, 5.4 Hz 1H), 5.22 (d, J = 5.9 Hz, 2H), 2.52 (s, 3H), 
2.43 (d, J = 5.0 Hz, 3H), 2.31 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.3, 158.4, 149.3, 146.2, 144.8, 141.8, 
137.9, 137.5, 135.0, 127.5(2C), 125.2(2C), 122.8, 121.6, 104.8, 97.6, 49.3, 29.2, 24.9, 13.2; MS (ES+): m/z (rel. 
Intensity) 423.2 (100), 424.2 (31) HRMS (ES+) calcd for (C21H23N6O2S):423.1603; found: 423.1600; CHN analysis: 
Calculated: C:59.70%, H:5.25%, N:19.89%, S:7.59%. Found C:59.40%, H:5.32%, N:19.81%, S:7.33% 
 
 
 
 5,6-Dimethyl-3-(3-(methylsulfonyl)phenyl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine AWF941 
 
 
 
 
 
General procedure 3.4 The crude product was purified by trituration with Et2O to afford AWF941 as an off-
white solid. (56%).  1H NMR(400 MHz, DMSO-d6) δ 8.73 (s, 1H), 8.70 (s, 1H), 8.57 (d, J = 4.0 Hz, 1H), 8.53 (d, J = 
6.9 Hz, 1H), 8.00 (t, J = 5.9 Hz, 1H), 7.79 (td, J = 7.7, 1.6 Hz, 1H), 7.71 – 7.62 (m, 2H), 7.39 (d, J = 7.9 Hz, 1H), 
7.30 (dd, J = 6.8, 5.3 Hz 1H), 5.22 (d, J = 6.0 Hz, 2H), 3.27 (s, 3H), 2.52 (s, 3H), 2.32 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 160.2, 158.4, 149.3, 146.3, 144.5, 141.7, 141.5, 137.5, 135.0, 130.0, 129.7, 123.2, 123.0, 122.8, 
121.7, 104.6, 97.4, 49.3, 44.0, 25.0, 13.2; MS (ES+): m/z (rel. Intensity) 408.2 (100), 409.2 (23) HRMS (ES+) 
calcd for (C21H22N5O2S):408.1494; found: 408.1495; CHN analysis: Calculated: C:61.90%, H:5.19%, N:17.19%, 
S:7.87.  Found C:61.44%, H:5.24%, N:16.70%, S:7.62% 
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4-(5,6-Dimethyl-7-((pyridin-2-ylmethyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)benzamide (AWF942) 
 
 
 
 
 
 
General procedure 3.4 The crude product was purified by column chromatography eluting with 50% EtOAc, 
(~1% NEt3) to afford AWF942. Melting point: 212-213 oC  (6%). 1H NMR(400 MHz, DMSO-d6) δ 8.63 (s, 1H), 
8.57 (d, J = 4.3 Hz, 1H), 8.24 (d, J = 8.4 Hz, 2H), 7.97 (t, J = 6.1 Hz, 1H), 7.92 (br s, 2H), 7.90 (d, J = 8.4 Hz, 2H), 
7.79 (td, J = 7.7, 1.6 Hz, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.30 (t, J = 5.8 Hz, 2H), 5.22 (d, J = 6.0 Hz, 2H), 2.52 (s, 3H), 
2.31 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 168.2, 160.0, 158.4, 149.3, 146.1, 144.6, 141.6, 137.5, 136.7, 
130.6, 128.2(2C), 124.6(2C), 122.8, 121.6, 105.5, 97.2, 49.3, 24.9, 13.2; MS (ES+): m/z (rel. Intensity) 373.2 
(100), 374.2 (31) HRMS (ES+) calcd for (C21H21N6O):373.1777; found: 373.1775; CHN analysis: Calculated: 
C:67.73%, H:5.41%, N:22.57%. Found C:66.62%, H:5.51%, N:21.37%. 
 
3-(4-(Isopropylsulfonyl)phenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWF943) 
 
 
 
 
 
General procedure 3.4 The crude product was purified by trituration with EtOAc and Et2O to afford AWF943 as 
an off-white solid. (66%). Melting point: 198-199 oC   1H NMR(400 MHz, DMSO-d6) δ 8.69 (s, 1H), 8.56 (d, J = 
4.3 Hz, 1H), 8.44 (d, J = 8.4 Hz, 2H), 8.01 (t, J = 5.9 Hz, 1H), 7.82 (d, J = 8.3 Hz, 2H), 7.78 (t, J = 7.7 Hz, 1H), 7.39 
(d, J = 7.8 Hz, 1H), 7.30 (t, J = 6.1 1H), 5.23 (d, J = 5.9 Hz, 2H), 3.42 (s, J = 6.8 Hz, 1H), 2.52 (s, 3H), 2.31 (s, 3H), 
1.17 (d, J = 6.8 Hz, 6H); 13C NMR (101 MHz, DMSO-d6) δ 160.5, 158.3, 149.3, 146.3, 144.9, 142.0, 139.3, 137.5, 
132.3, 129.4(2C), 125.1(2C), 122.8, 121.7, 104.6, 97.7, 54.7, 49.3, 24.9, 15.8, 13.1; MS (ES+): m/z (rel. Intensity) 
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436.2 (100), 437.2 (26) HRMS (ES+) calcd for (C23H26N5O2S):436.1807; found: 436.1805; CHN analysis: Calculat-
ed: C:63.43%, H:5.79%, N:16.08%, S:7.36%. Found C:63.06%, H:5.74%, N:16.02%, S:7.22%. 
3-(4-(Ethylsulfonyl)phenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF944) 
 
 
 
 
 
 
General procedure 3.4 The crude product was purified by trituration with EtOAc and Et2O to afford AWF944  as 
an off-white solid. (89%). Melting point: 175-177 oC   1H NMR(400 MHz, DMSO-d6) δ 8.69 (s, 1H), 8.56 (br s, 
1H), 8.43 (d, J = 8.3 Hz, 2H), 8.03 (t, J = 5.9 Hz,  1H), 7.85 (d, J = 8.3 Hz, 2H), 7.79 (t, J = 7.6 Hz, 1H), 7.39 (d, J = 
7.7 Hz, 1H), 7.31 (t, J = 5.9 Hz,  1H), 5.22 (d, J = 5.6 Hz, 2H), 3.27 (q, J = 7.2 Hz, 2H), 2.51 (s, 3H), 2.30 (s, 3H), 
1.12 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 160.5, 158.3, 149.3, 146.2, 144.9, 142.0, 139.2, 137.5, 
134.1, 129.1, 128.6(2C), 125.0(2C), 122.8, 104.6, 97.7, 49.9, 49.3, 24.9, 13.1, 7.7; MS (ES+): m/z (rel. Intensity) 
422.2 (100), 423.2 (22) HRMS (ES+) calcd for (C22H24N5O2S):422.1651; found: 422.1646; CHN analysis: Calculat-
ed: C:62.69%, H:5.50%, N:16.61%, S:7.61. Found C:61.97%, H:5.45%, N:15.83%, S:7.81%. 
 
5,6-Dimethyl-3-(2-(methylsulfonyl)phenyl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine AWF945 
 
 
 
 
 
 
 
General procedure 3.4 The crude product was purified by trituration with EtOAc and Et2O to afford AWF945 
(49%). Melting point: 116-118 oC   1H NMR(400 MHz, DMSO-d6) δ 8.58 (d, J = 4.6 Hz, 1H), 8.24 (s, 1H), 8.10 (dd, 
J = 7.9, 0.9 Hz, 1H), 7.98 (t, J = 6.0 Hz, 1H), 7.81 (td, J = 7.7, 1.6 Hz, 1H), 7.76 (td, J = 7.6, 1.1 Hz, 1H), 7.43 (d, J = 
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7.8 Hz, 1H), 7.32 (dd, J = 7.0, 5.2  Hz, 1H), 5.23 (d, J = 6.0 Hz, 2H), 2.95 (s, 3H), 2.39 (s, 3H), 2.31 (s, 3H); 13C NMR 
(101 MHz, DMSO-d6) δ 160.2, 158.4, 149.3, 146.0, 145.3, 143.8, 139.9, 137.5, 134.8, 133.6, 132.3, 129.0, 
127.8, 122.9, 122.0, 104.3, 97.0, 49.2, 42.7, 24.5, 13.1; MS (ES+): m/z (rel. Intensity) 408.2 (100), 409.2 (22) 
HRMS (ES+) calcd for (C21H22N5O2S):408.1494; found: 408.1490; CHN analysis: Calculated: C:61.90%, H:5.19%, 
N:17.19%, S:7.87. Found C:60.94%, H:5.43%, N:15.99%, S:7.12%. 
5,6-Dimethyl-3-(4-(2-morpholinoethoxy)phenyl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWF946) 
 
 
 
 
 
 
General procedure 3.4 The crude product was purified by column chromatography eluting with 6% MeOHin 
EtOAc, (~1% NEt3) to afford the free amine AWF946. (0.11 g, 62%). Melting point: 120-122 oC   1H NMR(400 
MHz, DMSO-d6) δ 8.57 (d, J = 4.3 Hz, 1H), 8.44 (s, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.85 (t, J = 5.8 Hz, 1H), 7.78 (t, J = 
7.5 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.30 (t, J = 6.0 Hz, 1H), 6.98 (d, J = 8.4 Hz, 2H), 5.19 (d, J = 5.8 Hz, 2H), 4.11 
(t, J = 5.1 Hz, 2H), 3.60 (br s, 4H), 3.3 (br s, 4H) 2.71 (br s, 2H), 2.49 (s, 3H), 2.30 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 159.3, 158.5, 156.6, 149.3, 145.8, 143.8, 140.5, 137.4, 126.7, 126.2 (2C), 122.8, 121.7, 115.0 (2C), 
106.4, 96.5, 66.6 (2C), 65.7, 57.6, 54.1 (2C), 49.3, 24.8, 13.2; MS (ES+): m/z (rel. Intensity) 459.3.3(100), 460.3 
(30) HRMS (ES+) calcd for (C26H31N6O2):459.2508; found: 459.2502; CHN analysis: Calculated: C:68.10%, 
H:6.59%, N:18.33%. Found C:67.43%, H:6.54%, N:17.90%. 
 
 
 
 
 
5,6-Dimethyl-3-(4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-
a]pyrimidin-7-amine (AWF947) 
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General procedure 3.4 The crude product was purified by column chromatography eluting with EtOAc to 5% 
MeOH:EtOAc to afford the Boc protected product. (0.10 g, 53%). Melting point: 102-104 oC   1H NMR(400 
MHz, DMSO-d6) δ 8.57 (d, J = 3.5 Hz, 1H), 8.44 (s, 1H), 8.05 (d, J = 8.1 Hz, 2H), 7.85 (s, 1H), 7.78 (t, J = 7.3 Hz, 
1H), 7.38 (d, J = 7.6 Hz, 1H), 7.30 (d, J = 5.5 1H), 6.97 (d, J = 8.1 Hz, 2H), 5.19 (d, J = 5.3 Hz, 2H), 4.08 (t, J = 4.8 
Hz, 2H), 2.69 (t, J = 4.9  2H), 2.51 (s, 4H), 2.48 (s, 3H), 2.34 (br s, 4H), 2.30 (s, 3H), 2.16 (s, 3H); 13C NMR (101 
MHz, DMSO-d6) δ 159.3, 158.5, 156.6, 149.3, 145.8, 143.8, 140.5, 137.4, 126.7, 126.0, 122.8, 121.7, 115.0, 
106.4, 96.5, 66.0, 57.2, 55.3, 53.5, 49.3, 46.2, 24.8, 13.2; MS (ES+): m/z (rel. Intensity) 472.3(100), 473.2 (30) 
HRMS (ES+) calcd for (C27H34N7O):472.2825; found: 472.2818; CHN analysis: Calculated: C:67.76%, H:7.05%, 
N:20.79%. Found C:67.72%, H:6.98%, N:20.33%. 
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Chapter 4 Lead Optimisation and Advanced Biological Evalua-
tion 
4.1 Early-Lead Optimisation Summary (Chapter 3) 
 
The early lead development carried out in the previous chapter is depicted below in Fig 4.1 with the DMPK 
properties of these important analogues displayed. 
 
 
 
 
 
 
 
Fig 4.1 Early-lead optimisation as discussed throughout Chapter 3. 
Removal of the unsaturated aryl ring systems at the 3-position, seen in earlier pyrazolopyrimidine analogues 
such as AWF918 or AWZ9014 resulted in greatly improved aqueous solubility. Compounds lacking 3-position 
substituents or with small substituents had very poor metabolic stability. Incorporation of a tetrahydropyran 
(THP) ring at the 3-position produced AWZ9036 (Fig 4.1); this THP analogue possessed the best balance of 
whole-cell anti-Wolbachia activity and DMPK properties seen during work on the pyrazolopyrimidine 
chemotype so far. It was still necessary to enhance these DMPK properties to meet the desired ranges as 
defined earlier in Chapter 1 Section 7.2 these are shown below in Table 4.1. 
 
 
EC50 
(nM) 
LogD 
7.4 
Aq.Sol 
(µM) 
H.M.Cl 
(µL/min/mg) 
R.HepsCl  
(µL/min 10-6) 
Human 
PPB (%) 
Desired <100 1-4 >50 <20 <20 <99 
Acceptable 100-300 0-1,4-5 20-50 20-60 20-60 <99.5 
Poor 300+ <0, 5+ <20 >60 >60 >99.5 
Table 4.1 A table highlighting appropriate and inappropriate potency and DMPK values.  
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Whilst the table displays that analogues possessing EC50 values lower than 100 nM are considered good, a 
more desirable target was set at <30 nM. It was observed that analogues possessing higher potency were 
more likely to translate to acceptable in vivo efficacy.  
The in vitro whole-cell potency and DMPK properties for the first pyrazolopyrimidines substituted with 
saturated ring systems (See Chapter 3) are displayed below in Fig. 4.2 
.  
Fig 4.2 DMPK properties and whole-cell anti-Wolbachia activity for AWZ9035 and AWZ9036. 
These analogues served as the starting points for further optimisation of pyrazolopyrimidine compounds 
discussed below. 
4.2 Lead optimisation 
4.2.1 R1 position optimisation; saturated heterocyclic rings. 
 
As the binding site of metabolising enzymes are generally lipophilic, more polar compounds tend to undergo 
reduced metabolism.1,2 As such, reducing the overall hydrophobicity of the saturated ring system in 
compounds can be achieved by reducing the ring size.3–5 Reducing saturated heterocyclic ring size has 
successfully been employed to reduce metabolism in a variety of drug discovery programs. One example of 
this is seen during the optimisation of a series of γ-secretase inhibitors by Stepan et al is summarised below in 
Fig4.3. Within this work the THP ring in 1a was reduced in size to give 2a and subsequently 3a with improved 
metabolic stability. The authors also acknowledged a link that reducing LogD7.4 results in improved metabolic 
stability which has previously been noted in some of our analogues (Chapter 2).5 
 
 
 
 
Fig 4.3 Reducing ring size from a tetrahydropyran to an oxetane ring to improve compound metabolic stability. 
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Another example of reducing in saturated ring size to produce more promising DMPK properties was seen 
during the optimisation of a series of anti-cancer aurora kinase inhibitors (Fig 4.4). During this work, reducing 
the ring size of 4a with a 4-fluoro piperidine ring to a 3-difluoro pyrrolidine ring in 5a served to improve the 
bioavailability following oral dosing during in vivo mouse PK studies.3  
 
 
 
 
 
 
Fig 4.4 Reduction in 4-fluoro piperidine ring size to improve the oral bioavailability in a series of aurora kinase 
inhibitors. 
These examples further support the investigation of smaller saturated heterocyclic rings during the late-stage 
optimisation of our pyrazolopyrimidine analogues.  
Within the optimisation of compounds in other drug discovery projects, introduction of morpholine ring 
systems can result in improved activity.4,6 One example of the successful incorporation of a morpholine ring is 
represented in Fig 4.5, where a pyrrolidine ring has been replaced in 6a for a morpholine functionality in 7a 
during the optimisation of a set of hepatitis C virus NS5B inhibitors.6 The authors Dragovich et al., reported a 6-
fold increase in compound half-life when incubated with human liver microsomes upon introduction of this 
morpholine ring system (Fig 4.5). 
 
 
 
 
 
 
Fig 4.5 Introduction of a morpholine ring to greatly improve compound half-life when incubated with human 
liver microsomes. 
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This observed improvement in metabolic stability seems conserved upon incorporation of a morpholine ring to 
replace saturated nitrogen heterocycles. During a program optimising a series of cannabinoid receptor 2 
agonists, both a piperidine ring (9a) and a 4,4-difluoro piperidine ring (10a) resulted in inferior stability when 
incubated with rat liver microsomes to the respective morpholine analogue derivative 11a (Fig 4.6).4 
 
 
 
 
 
Fig. 4.6 Incorporation of various saturated nitrogen heterocycles during optimisation of cannabinoid receptor 
2 agonists. 
This improvement in metabolic stability also follows the trend that reduction in cLogD7.4 generally improves 
metabolic stability and should also benefit the aqueous solubility if introduced into our pyrazolopyrimidine 
analogues.4 Saturated heterocycles are also prone to metabolism at the heteroatom or at the position 
adjacent to the heteroatom.7 For this reason, we designed a number of analogues containing 4-N-Me 
piperidine at the 3- (R1) position (Fig 4.7) and a variety of nitrogen containing heterocycles (morpholine & 
pyrrolidine) with the nitrogen directly attached to the pyrazolopyrimidine core.  
The study of saturated heterocyclic ring systems at the 3-(R1) position of the pyrazolopyrimidine core was 
carried out in parallel to further study of a chloride substituent at the 6-(R3) position (Fig 4.7). The 
pyrazolopyrimidine analogues designed for synthesis following the successful incorporation of various 
saturated heterocyclic rings in previous drug discovery projects are displayed in Fig. 4.7.   
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Fig 4.7 Pyrazolopyrimidines with saturated heterocycles at the R1 position designed for synthesis. 
The first in this series of analogues was AWZ9049 (Fig 4.7) containing the tetrahydropyran ring. This target was 
prepared by coupling of the dihydropyran boronic ester 13a with the iodo intermediate 12a and subsequent 
hydrogenation of 14a as depicted in Scheme 4.1. 
 
Scheme 4.1 Synthesis of AWZ9049 via coupling of dihydropyran pinacol ester 
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The chosen synthesis of the 4-N-Me piperidinyl analogue, AWZ9050, is depicted below in Scheme 4.2. This 
utilises similar chemistry to the synthesis of AWZ9049, requiring hydrogenation of the piperidyl ring 
intermediate 17a which was carried out using palladium hydroxide on carbon and zinc bromide. Finally, Boc-
deprotection of 18a gave the desired 4-piperidyl pyrazolopyrimidine AWZ9050. (For experimental details see 
Appendix 1). 
 
 
Scheme 4.2 Synthesis of 4-N-Methyl piperidyl analogue AWZ9050. 
Analogues AWZ9051-3 all possess ring systems containing a C-N bond to the pyrazolopyrimidine core at the R1 
position. These compounds were synthesised by collaborators WuXi App Tech using Buchwald-Hartwig 
aminations from the Boc protected iodo intermediate 19a (Scheme 4.3). Boc-deprotection of the 
intermediates 20a-c gave the desired products AWZ9051-3 (See appendix 1 for experimental details). 
 
 
 
 
 
                  Scheme 4.3 Synthesis of pyrazolopyrimidines with various saturated nitrogen heterocycles. 
Compound AWZ9096 (Scheme 4.4 below) containing the 3-morpholinone ring was the final compound 
synthesised in this series and was prepared by a copper-mediated Goldberg reaction on 21a as displayed 
below in Scheme 4.4. 
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    Scheme 4.4 Goldberg reaction towards the 3-morpholinone analogue AWZ9096 
The results from the biological evaluation of these compounds are displayed below in Table 4.2. 
 
 
 
 
Table 
entry 
Molecule R1 
EC50 
(nM) 
LogD 
7.4 
Aq. Sol 
(µM) 
Human Mics 
CLint       
(µLmin-1mg-1) 
Rat Heps 
CLint  
(µLmin-110-6) 
PPB 
(%) 
1 AWZ9049 
 
73 3.4 7 83.92 108.5 96.3 
2 AWZ9050 
 
561 1.4 >1000 8.84 17.43 58 
3 AWZ9051 
 
9 2.3 49 72.89 72.90 93.8 
4 AWZ9052 
 
38 ND ND ND ND ND 
5 AWZ9053 
 
16 ND 11 116.8 >300 43 
6 AWZ9096 
 
1183 1.4 82 7.7 7.7 60 
NA – No activity at highest concentration (5 µM)  ND – Not determined  
   Table 4.2 in vitro whole-cell anti-Wolbachia and DMPK properties 
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AWZ9049 (table entry 1) which contained a THP ring at the R1 position maintained high potency (EC50 = 73 nM) 
as is seen in the first THP analogue (AWZ9036 EC50 = 52 nM). In this analogue, the chloro substituent at the R3 
position did appear to negatively impact both potency and DMPK properties; the solubility and metabolic 
stability decreased three-fold because of this alteration compared to the 6-methyl derivative AWZ9036 
(Chapter 3.6 – Scheme 3.7). While the 4-piperidyl analogue AWZ9050 in table entry 2 possessed an excellent 
DMPK profile (Aq. Sol = 1000 µM, clearance values <20), it suffered from an eight-fold drop in potency (EC50 = 
561 nM). The analogues AWZ9051-3 (entries 3-5) possessed very promising anti-Wolbachia activity however 
synthesis of these compounds was difficult. The Buchwald-Hartwig aminations to AWZ9051-3 provided very 
poor yields and purification proved troublesome requiring preparative-TLC in the final two steps. Also, despite 
promising whole-cell activity and acceptable aqueous solubility, these analogues did not possess any greatly 
improved metabolic stability over the THP analogue AWZ9049. Finally, the 3-morpholinone analogue 
AWZ9096 in table entry 6 displayed greatly reduced in vitro whole-cell activity (EC50 = 1183 nM), though 
significant gains were seen in aqueous solubility and metabolic stability.  
4.2.2 3-(R), 5-(H), 6-(R), Pyrazolopyrimidine 
Removal of the lipophilic methyl group at the 5-position of the pyrazolopyrimidine core could help enhance 
the aqueous solubility during optimisation of future analogues. A variety of pyrazolopyrimidines were designed 
for synthesis which were unsubstituted at the 5-position (R2= H). These analogues were prepared by the 
reaction of the necessary pyrazole 23a with the desired aldehyde 24a (Scheme 4.4). This reaction proceeds via 
an imine intermediate by reaction of the pyrazole amine and the aldehyde of the dicarbonyl. This imine 
intermediate then cyclises to give the pyrazolopyrimidine 25a upon addition of base (potassium tert-butoxide) 
to give the essential 5-H 7-hydroxy pyrazolopyrimidine (25a-b) which can then be subjected to the various 
reactions discussed extensively throughout this work to produce a variety of pyrazolopyrimidines.  
 
 
 
 
 
 
 
 
 
Scheme 4.5 Synthesis of pyrazolopyrimidines with unsubstituted R2 positions (R2=H) 
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Several of the important analogues from this series are displayed in Fig 4.8 alongside their respective 5-Me 
analogues. The 3-Cl analogues were obtained by treating the R1 analogues with NCS using chemistry discussed 
previously (See Chapter 3 Scheme 3.4). The 4-fluoro phenyl and 4-SO2Me phenyl analogues were prepared by 
the Suzuki coupling synthesis discussed earlier during the study of the R1 position (Chapter 3 Scheme 3.3) (See 
Appendix 1 for experimental details). The tetrahydropyran analogues were prepared by the introduction of a 
dihydropyran pinacol ester into the essential iodo-intermediate using the coupling reactions reviewed in the 
previous chapter (Scheme 3.3) 
  
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
  
 
 
 
 
 
  Fig 4.8 Comparison of 5-H analogues with their 6-Me parents. 
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The 5-H analogues in general show similar anti-Wolbachia activity compared to their respective 5-Me 
analogues, while possessing superior aqueous solubility. The 3-Cl analogue AWF948 experienced a significant 
improvement in metabolic stability as shown by the reduced clearance values upon removal of the 5-methyl 
group of AWF948 (>150) compared with AWF955 (<70). The 4-fluoro phenyl analogue AWF918 also 
experiences an improvement in aqueous solubility upon removal of the 5-methyl substituent giving AWZ9056 
(0.9 to 6 µM in). However, this does not result in any improvement to metabolic stability that is seen in other 
analogues. The 4-SO2Me phenyl analogue AWZ9014, with only moderate activity relative to other analogues 
(EC50 = 143 nM), benefited from over a 2-fold improvement in aqueous solubility upon removal of the 5-Me to 
give AWZ9060 (2 to 5 µM). AWZ9060 also possessed an excellent stability profile (Human microsomal 
clearance <3 µLmin-1mg-1, Rat Hepatocyte clearance 7.78 µLmin-110-6). Finally, the THP analogue AWZ9036 
displays an improvement to both potency and DMPK properties upon removal of this methyl group to give 
AWZ9057. This analogue was the current lead resulting from the work on the pyrazolopyrimidine chemotype 
at this point. 
This improvement to overall DMPK properties upon removal of the metyhyl seemed so conserved across our 
analogues that we incorporated this substitution pattern into our core motif during further optimisation 
studies. With the tetrahydropyran analogues possessing the best balance of potency and DMPK properties 
examined so far it was desirable to produce a more optimised route specific for producing these analogues. 
This was achieved by the reactions shown in Scheme 4.6 which involved production of the 3-THP 5-amino-
pyrazole 30a.  
 
 
 
Scheme 4.6 Optimised pathway to tetrahydropyran analogues 
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This synthesis involved mesylation of the commercially available alcohol 26a with mesyl chloride (MsCl); this 
proceeded with a good yield of 84%. The intermediate 27a was then substituted using sodium cyanide in 
DMSO to give the necessary nitrile 28a with a high yield of 72%. Following previously discussed chemistry the 
pyrazole 30a is obtained by treating the nitrile 28a with base (LDA) followed by ethyl formate to give the 
aldehyde 29a which cyclises upon treatment with hydrazine granting nearly quantitative yields over the two 
steps. Formation of the pyrazolopyrimidine core was again performed using a base catalysed procedure 
allowing the intermediate imine to form between the amine of the pyrazole 30a and the aldehyde of the 
necessary dicarbonyl compound 31a to give 32a. Finally, chlorination using 8 eq POCl3 and 3 eq NEt3 (Scheme 
4.6) provided the important 7-chloro pyrazolopyrimidine 33a in a moderate yield of 36% which could then be 
substituted with 2-pyridyl methanamine 34a-c as displayed below. It was important to adopt this synthesis to 
produce enough of the THP analogues for advanced biological evaluation. 
To improve further the metabolic stability of the current lead AWZ9057, the corresponding analogue with a 
methylated linker, AWZ9100 (R4 = Me) (Fig 4.9) was prepared. Methylation of the linker was explored in earlier 
analogues where a small decrease in activity was seen; previously methylation was the only alteration to the 
linker that did not completely remove anti-Wolbachia activity. The two stereoisomers of AWZ9100 (Fig 4.9) 
were also produced to determine any differences in activity and metabolic stability between the two enantio-
mers. The stereochemisomeric pure amines were purchased from Fluorochem and used as received (purity 
>95%); the measured in vitro whole cell potency and DMPK properties are shown in Fig 4.9. 
 
 
 
 
 
 
 
Fig 4.9 Structure of the lead tetrahydropyran analogue AWZ9100 with the pure stereoisomers. 
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Within the analogues above, methylation of the linker appears to significantly boost aqueous solubility when 
comparing AWZ9057 with AWZ9100. Considering the promising DMPK properties seen upon incorporation of 
a morpholine ring at the R1 position our collaborators WuXi App Tech produced the 3-morpholine 5-H ana-
logue (AWZ9102 – Scheme 4.6). This involved another copper catalysed Goldberg reaction to form the 3-
morpholinone intermediate 36a which was reduced to give the Boc-protected 3-morpholine analogue 37a. 
Compound AWZ9102 was then reached by Boc-deprotection of 37a as displayed in Scheme 4.6 alongside the 
measured in vitro whole-cell potency and DMPK properties. 
 
 
 
 
 
Scheme 4.7 Synthesis of the R1 morpholino compound AWZ9102 
Whilst the profile of AWZ9102 looks excellent, development work will be required to optimise this synthesis. 
With increased pressure to select a candidate, the current lead from this work, AWZ9100, was taken forward 
for advanced biological assessment to compare with lead candidates from other small-molecule templates.  
4.3 Advanced Biological Evaluation 
 
4.3.1 In vitro Brugia malayi microfilariae studies  
 
An in vitro mf assay was developed by the Liverpool School of Tropical medicine to allow for assessment of 
direct worm toxicity and activity against Wolbachia bacteria present within the mf of B. malayi. From 
observations concerning undesirable direct worm toxicity made on other templates within the programme, 
several important compounds containing the pyrazolopyrimidine chemotype were chosen for assessment 
against microfilaria (Mf) of B. malayi using DMSO as a negative control (Table 4.3). Direct worm toxicity of 
important compounds was assessed by using a microfilariae motility score at day 6. These values indicate the 
viability of the microfilariae following treatment with values ranging from 0 to 4 with scores near to zero 
suggesting that all microfilariae are immotile or dead (also displayed in the table below is the initial in vitro 
whole-cell potency). 
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Compound 
code 
R1 R
2 R3 EC50 
(nM) 
Mf     
motility 
score 
DMSO     4.0 
AWF911 Ph Me CH2CH=CH2 20 3.0 
AWF918 4-F Ph Me Me 20 2.3 
AWZ9014b 4-SO2Me Ph Me Me 100 3.3 
AWZ9013 4-OCF3 Ph Me Me 664 3.0 
AWF930 H Me Me 105 4.0 
AWF920 Ph Me Cl 11 0.0 
AWZ9031 
 
Me Me 873 3.0 
AWZ9049 
 
Me Cl 73 
0.0 
 
AWZ9051 
 
Me Cl 9 0.0 
AWZ90933 
 
Me Me 
43 
 
0.0 
AWZ9053 
 
Me Cl 43 0.0 
AWZ9067 
 
H CH2CF3 15 
0.0 
AWZ9069 
 
H Cl 22 0.0 
AWZ9055 
 
Me Cl 30 0.0 
 
Table 4.3 In vitro cell assay EC50 values for selected pyrazolopyrimidine and motility readouts describing direct 
Mf toxicity. 
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The preliminary in vitro mf screening results indicate that whilst some of the analogues within this template 
demonstrate undesired worm toxicity, this does not appear to be a template-wide issue. The direct toxicity 
observed during this in vitro mf study does not appear to be correlated to the in vitro potency against 
Wolbachia. Analysis of the compounds tested suggests that a chlorine or CH2CF3 functionality at the 6-position, 
although beneficial in terms of in vitro anti-Wolbachia activity, appears to increase direct toxicity to the 
worms. One of the desired parameters of any anti-Wolbachia compounds resulting from this work is that they 
only target the bacteria within the filarial nematodes (and not the nematode itself). For this reason, it was 
sensible to avoid Cl or CH2CF3 substitutions at the 6-position in any future target molecules. 
Following the use of the in vitro mf assay to screen for worm toxicity, several analogues from this work were 
tested for Brugia malayi potency at 5 µM compared to the current gold-standard, doxycycline. This potency 
was determined by the reduction in Wolbachia level in mf following treatment with our compounds in 
comparison to the vehicle control (DMSO) group.  The results from these assays are displayed within Fig 4.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.10 In vitro mf screening results for selected analogues 5 µM 
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These results indicate that several compounds from this work have the capacity to reduce Wolbachia from 
infected filariae with potency comparable to the current gold-standard, doxycycline. Of these analogues, the 
most potent are the 4-fluoro phenyl analogue AWF918 and the THP analogue AWZ9057, which demonstrated 
Wolbachia reduction comparable to doxycycline (87% of doxycycline’s activity). While the optimised THP 
analogue AWZ9100 had improved in vitro potency, this did not translate to increased Wolbachia reduction in 
the mf assay though it had similar potency to doxycycline. 
During the safety assessment of a range of analogues within the AWOL III drug discovery and development 
program, several pyrazolopyrimidine analogues were assessed for permeability, affinity for efflux transporter 
p-glycoprotein, CYP inhibition, hERG and cytotoxicity measurements. In the next section these studies will be 
described and the assessment of the pyrazolopyrimidine series discussed. 
4.3.2 Assessment of permeability, efflux ratio, in vitro toxicity and CYP inhibition 
of selected frontrunners. 
 
The permeability of a drug is measured by its ability to cross a cell membrane. This is an important factor to 
determine during drug discovery and drug development as permeability can affect the intestinal absorption, 
oral bioavailability, blood-brain barrier penetration and entry into cells. Modification of these properties can 
drastically alter efficacy or toxicity within the cell and elimination by the kidney and the liver. Therefore, it is 
vital to measure influx into and efflux out of cells. For example, a drug that is rapidly absorbed, highly 
bioavailable and cleared slowly could be suitable for once-daily dosing. Whereas a drug that is rapidly 
absorbed, highly bioavailable and cleared quickly due to being a substrate for efflux transporters could 
necessitate a multiple dosing regimen.8 
Drug compounds can enter cells transcellular (through the cells) or paracellular (between cells). Transcellular 
transport is the main method by which drug compounds enter cells; this can occur via passive diffusion, 
facilitated diffusion or active transport. Passive diffusion involves the movement of lipophilic solutes down a 
concentration gradient whereas charged, hydrophilic or zwitterions tend not to cross by this mechanism due 
to the hydrophobic nature of the phospholipid membrane. Facilitated diffusion is another form of passive 
diffusion across a biological membrane which is facilitated by a carrier and allows otherwise membrane 
impermeable molecules across. This however tends to be quite selective and in relevance to drug discovery, 
this method generally only favours organic molecules such as amino acids or sugars. Active transport is an 
energy driven process which allows the movement of a substrate against its concentration gradient. Active 
transport is assisted by transporters which can lead to selective efflux (removal from cells) or influx (uptake 
into cells) and several of these transporters are known to play a role in clinically relevant drug-drug 
interactions. 8 
The permeability glycoprotein-1 (pgp-1) efflux transporter is encoded for by the MDR1 gene; this efflux 
transporter is one of the main efflux transporters in many tissues. One of the most common methods for 
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determining intestinal permeability and detecting substrates for efflux transporters (pgp-1 and ABCG2) which 
is employed in early-stage drug discovery is the Caco-2 (human colorectal adenocarcinoma cell line) assay. This 
assay is performed by placing the dissolved test compound into one compartment of a two-compartment 
chamber separated by the Caco-2 cells and a semi permeable membrane.9,10 The amount of compound 
present within each side of the chamber can then be measured following incubation and the permeability or 
efflux potential of the compound calculated. 
By placing a compound in the compartment representing the intestinal lumen within the body (apical side) 
which is separated from the compartment representing the blood (basolateral side), the change in drug 
concentration from the apical to the basolateral side (a degree of the substrates affinity for efflux transporters) 
can be assessed. If the test compound is placed in the basolateral side then the change in concentration 
between the compartments will describe the permeability of the substrate (basolateral-apical). 11,12 Finally, 
these values can be compared to determine the relative ratio of a compounds ability to permeate a cell 
membrane over its affinity for efflux transporters (basolateral-apical)/(apical-basolateral) with low values (CFR 
values) suggesting that compounds are not substrates for efflux transporters. If the efflux ratio is greater than 
or equal to 2 then this indicates that drug efflux is occurring.  
Assessment of permeability and efflux ratio is valuable to gain a good understanding of drug efflux mechanism 
and to highlight any potential permeability issues.  Assessment of selected pyrazolopyrimidine compounds 
synthesised throughout this work for permeability and human pgp-1 recognition was conducted by our 
collaborators Eisai. These results are displayed in Table 4.4 alongside the structures for analogues tested. 
Compound 
  Permeability (x10-6cm/sec) 
CFR Structure 
 
LogD7.4 
LLC-
PK1, 
A-B 
LLC-
PK1, 
B-A 
LLC-
MDR1, 
A-B 
LLC-
MDR1, 
B-A 
AWZ9014 
 
3.3 15.6 6.8 12.1 7.3 1.4 
AWZ9030 
 
2.7 3.9 5.0 7.1 8.5 0.9 
                                                                          Chapter 4 _____________________________________                                                                                                
 
 
 
188 
 
AWZ9032 
 
3.4 20.5 7.4 17.8 9.0 1.4 
AWZ9037 
 
4.5 11.52 7.9 8.95 6.44 1.0 
LLC – Lilly Laboratories Cell, PK1 - Porcine proximal tubule kidney cell line, MDR1 – Multi-drug resistance pro-
tein A-B Apical – basolateral B-A Basolateral - apical 
Table 4.4 Permeability and efflux ratio of selected compounds. 
The results indicate that all tested analogues have good permeability demonstrated by the high LLC-PK1, A-B 
value and none of them are substrates for P-gp transporters and have a low efflux ratio demonstrated by the 
low CFR value (<2). Per our guidelines for the AWOL Target Candidate Profile (TCP) the desired value for 
permeability (B-A) is >10 x10-6cms-1 and the lower acceptable value is 2 x10d-6cms-1. These early analogues 
demonstrate promising permeability, all within the acceptable value range (2-10 x10d-6cms-1). 
Cardiotoxicity is another considerable problem which can lead to toxicity-related drug attrition during 
development so it is desirable to determine any potential for cardiotoxicity early during the discovery 
process.13,14 The human ether-a-go-go gene (hERG) controls the voltage-gated potassium channel in the heart 
which is involved in cardiac repolarisation. Inhibition of hERG causes longer QT periods which can result in 
potentially fatal ventricular tachyarrhythmia with several drugs known to produce this effect.15 Various patch 
clamp techniques are available for a range of cells to assess the electrophysiology of cells and the effects of 
drugs on such cell lines.  
Drug-drug interactions are another common reason for late-stage attrition of developing drug candidates due 
to one drug effecting the pharmacokinetics of another co-administered drug.16 This can result in toxic effects 
should induction of metabolising enzymes (CYPs) occur increasing the concentration of toxic metabolites or via 
CYP enzyme inhibition which can result in accumulation of a drug compound to high and harmful 
concentrations. For this reason, it is desirable to screen for any potential CYP inhibition that drug compounds 
under development may experience. Several selected analogues from the pyrazolopyrimidine chemotype were 
selected for CYP inhibition studies to determine any potential drug-drug interaction liability; these assays were 
also carried out by our collaborators Eisai. 
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To assess the potential safety related concerns of frontrunners within this template, many compounds were 
chosen for in vitro, hERG, CYP inhibition and cytotoxicity measurements. The important analogues selected for 
assessment are displayed in Table 4.5 with alongside the results from the inhibition studies.  
Compound 
hERG 
IT22938 
IC50 (µM) 
Cytotoxicity 
THP-1 IC50 
(µM) 
CYP Inhibitions IC50 (µM) 
CYP1A CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A 
AWF918 >33.33 >50 0.4 ND 22.9 20.4 >30 >30 
AWF930 >33.33 4.95 1.9 >>10µM >>10µM 18.4 >>10µM >>10µM 
AWF937 >33.33 >50 2.9 >>10µM 18.9 >>10µM >>10µM >>10µM 
AWZ9014 11.84 IP 19.4 >>10µM >>10µM 14.8 >>10µM >>10µM 
AWZ9036 >33.33 IP 13.1 >>10µM >>10µM >>10µM >>10µM >>10µM 
AWZ9048 >33.33 IP 0.6 >>10µM >>10µM 30.3 >>10µM >>10µM 
AWZ9057 >33.33 15.81 >>10µM >>10µM >>10µM >>10µM >>10µM >>10µM 
AWZ9067 10.54 IP 37.8 >>10µM >>10µM >>10µM >>10µM >>10µM 
THP-1 Human leukemic cell-line (acute monocytic leukaemia)         
Table 4.5 in vitro toxicology screening results for selected analogues. 
The acceptable limits for these readouts are as follows; hERG activity > 10 µM, cytotoxicity > 20 µM and CYP 
inhibition > 20 µM.   The results from the above screen (Table 4.5) are all negative except for CYP1A inhibition 
(highlighted in red). To further probe the prevalence of this CYP1A inhibition within this template, additional 
analogues were chosen for in vitro CYP inhibition screening and the results are documented within Table 4.6 
organised by decreasing metabolic stability. 
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Compound R1 R2 R3 
CYP Inhibitions IC50 (µM) 
Human Mics 
CLint 
(µL/min/mg) 
CYP1A 
(µM) 
CYP2C8 
(µM) 
CYP2C9 
(µM) 
CYP2C19 
(µM) 
CYP2D6 
(µM) 
CYP3A 
(µM) 
AWZ9013 4-OCF3 Ph Me Me 3 20.9 >>10 >>10 >>10 >>10 >>10 
AWZ9067 4-F Ph H CH2CF3 5.64 37.8 >>10 >>10 >>10 >>10 >>10 
AWZ9041 4-F Ph Me SO2Me 8.76 >>10 >>10 >>10 >>10 >>10 >>10 
AWZ9014 4-SO2Me Ph Me Me 9 19.4 >>10 >>10 14.8 >>10 >>10 
AWZ9057 THP H Me 9.42 >>10 >>10 >>10 >>10 >>10 >>10 
AWF912 4-Cl Ph Me H 9.71 22.4 >>10 >>10 >>10 >>10 >>10 
AWZ9031 
 
Me Me 14.65 >>10 39.4 >>10 >>10 >>10 >>10 
AWZ9055 
 
Me Cl 28.46 >>10 >>10 >>10 >>10 >>10 >>10 
AWZ9056 4-F Ph H Me 37.48 9.7 >>10 >>10 >>10 >>10 >>10 
AWZ9059 4-F Ph H Me 52.94 0.9 >>10 >>10 1.8 >>10 >>10 
AWF918 4-F Ph Me Me 55 0.4 ND 22.9 20.4 >30 >30 
AWZ9048 
 
Me Cl 75.36 0.6 >>10 >>10 30.3 >>10 >>10 
AWZ9058 2-pyridyl H Me 152.5 2.2 >>10 >>10 >>10 >>10 >>10 
AWF930 H Me Me 262 1.9 >>10 >>10 18.4 >>10 >>10 
AWF951 F Me Me 276.9 4.5 >>10 >>10 >>10 >>10 >>10 
AWF948 Cl Me Me 287 3.9 27.6 >>10 >>10 >>10 >>10 
Human Mics Clint (µL/min/mg) -  Clearance of a compound from human microsomal cells     
Table 4.6 CYP Inhibition studies of various pyrazolopyrimidine analogues compared to metabolic stability. 
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The screening results indicate that CYP1A inhibition is closely associated with metabolic stability, with 
compounds exhibiting high metabolic stability being weaker inhibitors of CYP1A which is shown by their higher 
IC50 values. In addition to all the safety screening studies, a variety of pyrazolopyrimidine compounds were 
evaluated for in vivo PK and PD properties during optimisation of this template, these studies are discussed in 
the following section. 
4.3.3 In vivo assays. 
 
During early lead optimisation of this chemotype, one of the analogues reported earlier, AWZ9014 was 
selected as the early lead in this template. Due to its balance of in vitro potency and DMPK properties (Fig 
4.11), AWZ9014 was evaluated for in vivo PK and PD properties. Initially, the PK profile of AWZ9014 was tested 
at 50 mg/kg and 100 mg/kg with a single oral dose to SCID mice using SSV as a dosing vehicle and the results 
from these studies are displayed below (Chart 4.1 and Table 4.7).  
 
 
 
 
 
Fig 4.11 Structure of AWZ9014 studied for in vivo PK PD profile with measured in vitro whole-cell activity and 
DMPK properties. 
 
 
 
 
 
 
 
 
Chart 4.1 in vivo PK profile of AWZ9014 using SSV as an oral dosing vehicle 
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Dosage (Oral) 50 mg/kg 100 mg/kg 
T1/2 (h) 2.99 2.44 
Cmax (ng/mL) 13067 27800 
Tmax (h) 1.33 1.67 
AUC0-t ng.h/mL 82209 162617 
  Table 4.7 in vivo PK profile of AWZ9014 using SSV as an oral dosing vehicle 
Despite poor aqueous solubility, AWZ9014 demonstrated an excellent in vivo PK profile. This study shows that 
AWZ9014 displayed high exposure, an acceptable half-life with a dose-proportional increase in AUC after 
doubling the dose from 50 mg/kg to 100 mg/kg. While the in vitro potency for AWZ9014 was lower than 
several other analogues in this template it was considered that the impressive PK profile could compensate for 
the lower compound potency. AWZ9014 was taken forward for assessment within the in vivo larval PD study. 
This study was limited by the amount of AWZ9014 in stock at the time and it was only possible to dose 
AWZ9014 at 50 mg/kg for 14 days and the results are displayed within Table 4.8. The compounds were 
incubated before DNA extraction and performing qPCR to calculate the reduction of Wolbachia Surface Protein 
(wsp) copy number to untreated controls. 
Compound Dose and duration Wsp reduction* 
DOX 50 mg/kg qd 07d 91.99% 
DOX 50 mg/kg qd 14d 98.54% 
AWZ9014 50 mg/kg bid 14d 52.98% 
*Median % reduction of vehicle control 
Table 4.8 Results from the AWZ9014 in vivo PD study using SSV  
At 50 mg/kg the Wolbachia depletion displayed by AWZ9014 was insufficient to reach the 90% reduction in 14 
days as seen with the current gold-standard, doxycycline. However, in-house computational PK/PD studies 
predicted that at higher dosing levels AWZ9014 would attain Wolbachia reduction levels comparable to 
doxycycline. Several compounds from other templates within the project were selected for PK studies using a 
lipid formulation consisting of 55% PEG300, 25% propylene glycol and 20% water (PEG300 formulation) as the 
dosing vehicle. AWZ9014 was chosen for analysis within an in vivo PK study dosing at 50 mg/kg using PEG300 
as the oral dosing vehicle to help improve drug exposure. The results from this study are displayed below in 
Table 4.9 and Chart 4.2 alongside the 50 mg/kg results using SSV as the dosing vehicle. 
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Dosage (Vehicle) 50 mg/kg (PEG300) 50 mg/kg (SSV) 
T1/2 (h) 8.09 2.99 
Cmax (ng/mL) 10650 13067 
Tmax (h) 0.5 1.33 
AUC0-t ng.h/mL 93529 82209 
 Chart 4.2 and Table 4.9 in vivo PK profile for AWZ9014b using PEG300 as a vehicle. 
In comparison with the PK profile seen when using SSV, PEG300 results in an increased half-life and slightly 
increased drug exposure.  In the light of this study result, a further in vivo PD study was carried out at 50 
mg/kg using the PEG300 formulation as the delivery vehicle, the results from this assay are displayed in Table 
4.10. 
 
Compound Dose and duration Wsp reduction* 
DOX 50 mg/kg qd 07d 82.7% 
DOX 50 mg/kg qd 14d 96.2% 
AWZ9014 50 mg/kg bid 14d 46.2% 
*Median % reduction of vehicle control 
 Table 4.10 Results from the AWZ9014 in vivo PD study using PEG300 
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However, the slightly improved drug exposure did not appear to result in an improved capacity of AWZ9014 to 
deplete Wolbachia in vivo. The in vivo PD studies did not yet provide any proof-of-concept result for this 
template; further investigation on this template was temporarily halted until a significant breakthrough could 
be made in terms of analogues with superior in vitro efficacy and DMPK properties.  
The compound AWZ9100 (Fig 4.12) was identified following several rounds of lead optimisation from 
compound AWZ9014 as depicted in Fig 4.12 and discussed earlier. Following promising improvement of 
AWZ9100 (in terms of in vitro potency and DMPK properties) this molecule was selected for in vivo PK and PD 
evaluations. 
 
 
 
 
 
   
 
 
Fig 4.12 Summary of lead optimisation (Chapter 2 - 4) 
The PK profiles of the new lead AWZ9100, was assessed within the in vivo SCID mouse model at 50mg/kg and 
100 mg/kg using the PEG300 formulation as the oral dosing vehicle, and the PK profile is displayed in Chart 4.3 
and Table 4.11 below. 
 
 
 
 
 
 
Chart 4.3 in vivo PK profiles of AWZ9100 using PEG300. 
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Dosage (Oral) 50 mg/kg 100 mg/kg 
T1/2 (h) 0.58 1.1 
Cmax (ng/mL) 5200 25700 
Tmax (h) 0.42 0.33 
AUC0-t ng.h/mL 8462 41005 
Chart 4.3 and Table 4.11 in vivo PK profiles of AWZ9100 using PEG300 
AWZ9100 demonstrates an acceptable PK profile especially at the higher dosing level. While experiencing a 
short half-life, the compound is rapidly absorbed following oral dosing and the associated increase in Cmax and 
AUC with increased dosing is significantly higher than expected. Although the PK profiles of AWZ9100 were 
not as good as AWZ9014, its higher potency might compensate for the reduced exposure in the PD study. 
However, despite improvement of potency was made from AWZ9014 to AWZ9100, it was still insufficient to 
provide a positive outcome when tested within the Brugia malayi larval model (30% reduction at 150 mgkg-1 
twice-daily dosing for 14 days). The in vivo efficacy studies carried out on various other small molecule 
templates within the drug discovery program demonstrated that the greatest level of Wolbachia reduction 
(>99.9%) is only observed in analogues with much superior in vitro potency and DMPK properties. A rough 
guideline of properties for analogues, which possess this superior reduction, is in vitro potency 0.01nM – 0.001 
nM and Rat/Human clearance values <5.  It would be necessary to optimise this pyrazolopyrimidine 
chemotype further to improve the overall properties to allow them to be successful at reducing Wolbachia 
levels in vivo with levels comparable to leads resulting from other small-molecule discovery projects within the 
program. 
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4.4 Conclusions  
 
Many pyrazolopyrimidines (190) have been synthesised, many of which have demonstrated low nanomolar 
activity against Wolbachia with much superior DMPK properties over the initial hit AWF911. Several synthetic 
pathways have been explored which allow for modification of the core at key positions (R1-5) around the 
pyrazolopyrimidine core. The overall hit to lead optimisation carried out during this work is summarised in Fig 
4.13. 
 
 
 
 
 
 
 
 
 
 
Fig 4.13 Summary of the hit to lead optimisation carried out during this work 
Work on the pyrazolopyrimidine chemotype was halted during discovery efforts due to superior small-
molecule templates within the AWOL III drug discovery and development project allowing all resources to be 
focused on the priority areas to produce a successful candidate. Should additional funding be secured for 
further discovery efforts, the current lead from this work AWZ9100, will be a very promising starting molecule 
for the onward late lead optimisation to deliver a suitable backup candidate for the project. There are several 
options for modification to both the pyrazolopyrimidine core and substituents which could allow for 
improvement of both metabolic stability and compound potency, these are discussed briefly below. 
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4.5 Future Work 
 
Positions around the pyrazolopyrimidine core which could be further explored for additional optimisation of 
these compounds are highlighted in Fig 4.14.  
 
 
 
 
 
 
 
Fig 4.14  General pyrazolopyrimidine core for future optimisation.  
Exploration of the 2-position (R6) and further exploration of the 6 position (R3) to determine the optimum 
substituents at these points around the pyrazolopyrimidine core. The 6-position has been successfully 
modified using the chemistry discussed throughout the current SAR studies (Chapter 2) as can the 2-position 
by synthesis of the initial pyrazole with the necessary substitution pattern (Scheme 4.8). 
 
Scheme 4.8 Optimised synthesis for varying all essential positions for SAR study around the pyrazolopyrimidine 
core. 
Optimisation of these positions may prove promising with a lipophilic substituent at the 6-position from 
observations made throughout this work and then offsetting this added lipophilicity with a polar group at the 
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R6 position to maintain/improve aqueous solubility. Further to study of these positions, another potential 
approach for the improvement of these analogues could be a scaffold morphing strategy by inserting an 
additional nitrogen atom into the pyrimidine core.  
Installation of the extra nitrogen can be performed following the work of Yaakov W.A et al.,17 as summarised in 
Scheme 4.9 with the proposed mechanism for the formation of this core.17  
 
 
 
 
 
 
 
 
 
Scheme 4.9 Formation of the pyrazolotriazine core following the work of Yaacob W.A et al.,17 
A plausible procedure to incorporate a nitrogen at the 6-position of the pyrazolopyrimidine core to allow study 
of this scaffold during future work can be adapted from the work of Leifox et al., and is depicted below in 
Scheme 4.9.18,19 
 
 
 
 
 
 
Scheme 4.10 Synthesis of the pyrazolo 1,3,5-triazine18,19 
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4.6 Experimental 
 
Biological Evaluation 
In Vitro screening – Materials and Methods1 
Cell Culture 
The C6/36 (wAlbB) cell line is a mosquito (Aedes albopictus) derived cell line stably infected with Wolbachia 
pipientis (wAlbB). To create this cell line, the supernatant from cultured Aa23 cells (A. albopictus) naturally 
infected with the W. pipientis strain wAlbB was harvested and filtered to remove whole cells. This supernatant 
was used to inoculate C6/36 cells (ECACC No. 89051705), resulting in a stably Wolbachia-infected cell line 
C6/36 (wAlbB).1,11–12 Cells were incubated at 26 °C and subpassaged every 7 days using a 1-in-4 dilution in 
Leibovitz media (Life Technologies, Loughborough, UK) supplemented with 20% fetal bovine serum (FBS; Fisher 
Scientific, Loughborough, UK), 2% tryptose phosphate broth (Sigma-Aldrich, Poole, UK), and 1% non-essential 
amino acids (Sigma-Aldrich).  
Anti-Wolbachia HCS Assay Setup 
C6/36 (wAlbB) cells were subpassaged 6–8 days before plating out at a density of 2000 viable cells per well in a 
384-well CellCarrier plate (PerkinElmer, Llantrisant, UK), suspended in Leibovitz media with the additives 
described in the “Cell Culture” section. All compounds were dissolved in DMSO with each compound added to 
a single well at a final concentration of 5 µM (resulting in <1% final DMSO concentration). Control samples per 
plate consisted of 12 wells of vehicle control (DMSO) and 6 wells of the following controls: 5 µM doxycycline 
(positive control— the gold standard for Wolbachia reduction; SigmaAldrich) and a suboptimal 50 nM 
doxycycline concentration. Each well held a final volume of 100 µL, except for the outer wells, which contained 
130 µL of phosphate-buffered saline (PBS; SigmaAldrich). After 7 days of 26 °C sterile incubation, 25 µL of 
staining media containing 60 µM of SYTO 11 DNA dye (Life Technologies) was added to each well. After a 15 
min incubation, all media was removed from each well and replaced with fresh media (no stain). Using the 
Operetta high-content automated imaging system (PerkinElmer), five fields per well were imaged using a 
confocal 60× objective with the Fluorescein filter (excitation filter: 460–490; emission filter: 500–550). The 
PerkinElmer software Harmony was trained to first identify the cell nucleus and cytoplasm, followed by the 
spot edge ridge (SER) texture analysis, which was used to score each intact cell on the complexity of the 
cytoplasm.2  
 
Anti-Wolbachia HCS Assay Results Analysis 
Using the vehicle and positive (Wolbachia reduction) controls, a threshold was set to indicate if each cell was 
classed as infected or uninfected. Wolbachia-infected cells (vehicle control) have a complex cytoplasm texture 
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(high SER texture score), whereas Wolbachia-uninfected cells (doxycycline-treated positive control) have a 
uniform cytoplasm texture (low SER texture score). From this analysis, the following readouts were calculated 
per well: cell number, SER texture score, and percentage of Wolbachia-infected cells. Z' factor (Z') validation of 
each plate was calculated using the percentage of Wolbachia-infected cells value from the vehicle and positive 
controls. The 14 Vehicle controls have a high Wolbachia load and therefore a high percentage of cells classed 
as infected with Wolbachia. Positive control (doxycycline-treated) cells have a low Wolbachia load and 
therefore a low percentage of Wolbachia-infected cells. All compound sample wells were then analysed and 
normalized (along with the positive controls) against the vehicle (untreated) control to give a percentage 
reduction of Wolbachia-infected cells. In addition, using the cell number analysis, any compounds with a host 
cell number amounting to less than 50% of the vehicle control were classed as toxic and retested at a reduced 
compound concentration. All compounds that were >90% of the positive control’s percentage reduction of 
Wolbachia-infected cells were classed as strong hits (because they were similar to or greater than the 5 µM 
doxycycline positive control). Compounds that yield infection rates between 50% and 90% of the positive 
control were classed as moderate hits because they were similar to the suboptimal (50 nM) doxycycline 
control. All hit compounds were then reconfirmed in a full dose response to define their potency. 
In vitro mf studies 
 
SSV – standard suspension vehicle (0.5% sodium carboxymethyl cellulose; 0.5% benzyl alcohol, 0.4% Tween 80, 
0.9% NaCl) 
PEG300 – 55% polyethylene glycol 300, 25% propylene glycol, 20% water 
 
Optimisation of an ex vivo microfilariae (mf) B. malayi screen 
 
An ex vivo mf assay was developed by the Liverpool School of Tropical medicine to provide a link between the 
insect cell based in vitro assay and the in vivo B. malayi screen. The validation of this new assay that enables 
greater throughput whilst still allowing the assessment of our compounds ability to reduce Wolbachia load in 
the targeted parasite. Since microfilariae are the more abundantly produced worm stage within our laboratory 
models, we can screen many more compounds using this resource in the ex vivo assay, allowing the resultant 
best performing compounds to be prioritised for screening against adult worm’s ex vivo or in vivo. This reduces 
the use of animals, whilst allowing us to gather important information which feeds back into the drug 
discovery process. 
Within the ex vivo mf assay; compounds are incubated with 8000 mf B. malayi per well (five wells per 
compound) for 6 days, before DNA is extracted and qPCR performed to compare wsp:gst ratio of drug treated 
vs control wells, full experimental details for the assay are documented below. 
 
General biology experimental3 
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Animals  
Male BALB/c SCID were purchased from Harlan Laboratories, UK, while male CB.17 SCID mice and BALB/c WT 
mice were purchased from Charles River, UK. Male Meriones unguiculatus (Mongolian gerbils; jirds) were 
purchased from either Charles River, UK or Janvier Laboratories, France. Rodents shipped to REFOTDE, Buea, 
Cameroon, were maintained in conventional housing with Halliday et al. daily cage cleaning and changing of 
food. Food, water and bedding were sterilised by autoclaving. For B. malayi experiments, animals were kept at 
the Biomedical Services Unit (BSU), University of Liverpool, UK in specific pathogen-free (SPF) conditions. All 
experiments carried out in Cameroon were approved by the Animal Care Committee, REFOTDE. All 
experiments on animals in the UK were approved by the ethical committees of the University of Liverpool and 
LSTM, and were conducted per Home Office (UK) requirements. The life cycle of B. malayi (Bm) was 
maintained in mosquitoes and susceptible Meriones gerbils at LSTM. To generate infective Bm larvae (BmL3) 
for infections, female adult Aedes aegypti mosquitoes were fed with Bm microfilariae (mf) collected from 
infected gerbils by catheterisation, as previously described, followed by mixing with human blood and feeding 
through an artificial membrane feeder (Hemotek®). Blood-fed mosquitoes were reared for 14 days to allow for 
development to L3. The L3 were collected from infected mosquitoes by crushing and concentration using a 
Baermann’s apparatus and RPMI medium. 
 
Implantation of adult macrofilariae 
Bm macrofilariae were collected from infected SCID mice and were grouped into batches of 13 adults. Male 
BALB/c SCID and BALB/c WT mice were placed under surgical anaesthesia using isofluorane and were given s.c. 
injection of bruprenorphine before 13 Bm macrofilariae were placed into the peritoneal cavity by making a 
small incision to the skin and abdominal cavity wall in the upper right quadrant. The incisions were re-sutured 
after implant and animals were individually housed after surgery. For Onchocerca implants, rodents were 
placed under surgical anaesthesia using i.p. injections of ketamine and medetomidine. Onchocercomata were 
thoroughly cleaned of bovine tissue, washed in several changes of RPMI + PSN and small sections of the adult 
worms were exposed by partial rupture of the capsule. Groups of 8–15 motile O. ochengi male macrofilariae or 
4 prepared O. ochengi nodules were implanted into the peritoneal cavity or to the cutaneous tissue of the 
upper side of the neck (for s.c nodule implants). All wounds were re-sutured after surgery and animals were 
individually housed and closely monitored for the recovery period (7 days post-op). 
Drug treatments 
Drugs were dissolved in standard suspension vehicle (0.5% sodium carboxymethyl cellulose; 0.5% benzyl 
alcohol; 0.4% Tween 80; 0.9% NaCl) or PEG300 (55% polyethylene glycol 300; 25% propylene glycol; 20% 
water). 
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General chemistry experimental 
 
Air- and moisture-sensitive reactions were performed in oven dried glassware sealed with rubber septa under 
an atmosphere of nitrogen from a manifold or balloon. Anhydrous solutions and sensitive liquids were 
transferred via syringe or stainless-steel cannula. Reactions were stirred using Teflon-coated magnetic stir 
bars. Organic solutions were concentrated using a Buchi rotary evaporator with a diaphragm vacuum pump. 
 
Purification of solvents and reagents  
 
Anhydrous solvents were either purchased from Sigma Aldrich or dried and distilled immediately prior to use 
under a constant flow of dry nitrogen. Tetrahydrofuran was distilled from Na, dichloromethane and Et3N were 
distilled from CaH2. All reagents were purchased from Sigma Aldrich, Alfa Aesar, Frontier Scientific, Apollo 
Scientific, Fluorochem and were used without any purification unless otherwise indicated. 
 
Purification of products 
 
Thin layer chromatography (TLC) was performed on 0.25 mm Merck silica gel 60 F254 plates and visualised by 
ultraviolet light. U.V. inactive compounds were visualised using iodine, p-anisaldehyde solution, ninhydrin or 
potassium permanganate followed by gentle heating. Flash column chromatography was performed on ICN 
ecochrom 60 (32-63 mesh) silica gel eluting with various solvent mixtures and using an airline to apply 
pressure. 
 
Analysis 
 
Melting points were determined by a Gallenkamp apparatus and are uncorrected. 1H NMR spectra were 
recorded on Bruker AMX 400 (400 MHz) spectrometer and reported as chemical shit on parts per million (ppm, 
δ) relative to tetramethylsilane as the internal reference, integration, multiplicity (s = singlet, br s = broad 
singlet, d = doublet, t = triplet, q =quartet, sex = sextat, m = multiplet), coupling constant (J, Hz), assignment. 
13C NMR spectra were recorded on Bruker AMX400 (101 MHz) spectrometer and reported in terms of chemical 
shit (ppm, δ) relative to residual solvent peak. Mass spectra (MS) and high resolution mass spectra (HRMS) 
were recorded on a VG analytical 7070E machine, Fisons TRIO spectrometers using electron ionisation (EI) and 
chemical ionisation (CI), and Micromass LCT mass spectrometer using electron spray ionisation (ESI). All mass 
values are within error limits of ±5 ppm. Elemental analyses (%C, %H, %N) were either determined by the 
University of Liverpool Microanalysis Laboratory or the London Metropolitan University Elemental Analysis 
Service. Reported percentages are within error limits of ±0.5 %. 
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(Tetrahydro-2H-pyran-4-yl)methyl methanesulfonate (27a)20 
 
 
 
To solution of (tetrahydro-2H-pyran-4-yl)methanol (15 g, 129.0 mmol) in DCM (90 mL) was added NEt3 (23.4 
mL, 167.7 mmol). The solution was allowed to cool to 0 oC before adding MsCl (12.0 mL, 155.6 mmol) slowly 
over 15 minutes followed by stirring at 0 oC for 15 minutes. The reaction was allowed to stir at 25 oC overnight 
before removing the volatiles under reduced pressure and diluting the resultant residue with saturated Na2CO3 
(100 mL). The crude product was extracted with EtOAc (4x80 mL), the combined organics were washed with 
saturated NH4Cl (80 mL) and dried over MgSO4 before evaporating to dryness to give crude (tetrahydro-2H-
pyran-4-yl)methyl methanesulfonate as a yellow solid (21 g) which was used without further purification 
(21.11 g, 84%); MS (CI+ NH4): m/z (rel. Intensity) [M+H+] 195 (46), [M+NH4+] 212.1 (100; HRMS (CI+) calcd for 
[(C7H18NO4S)+H]:212.0951; found: 212.0960 
 
2-(Tetrahydro-2H-pyran-4-yl)acetonitrile (28a)21 
 
 
 
To tetrahydro-2H-pyran-4-yl)methyl methanesulfonate (6.27 g, 32.31  mmol) in DMSO (50 mL) was added 
NaCN (2.69 g, 54.94 mmol). The reaction was heated to 80oC and stirred overnight. The reaction was allowed 
to cool to room temperature, diluted with water (100 mL), extracted with EtOAc (4x150 mL), dried over MgSO4 
and evaporated to dryness. The crude product was purified by column chromatography eluting with 60% 
EtOAc:Hexane to give 2-(tetrahydro-2H-pyran-4-yl)acetonitrile as a yellow oil (2.9 g). (72%);1H NMR (400 MHz, 
DMSO-d6) δ 3.85 (dd, J = 11.0, 3.8 Hz, 2H), 3.29 (td, J = 11.8, 1.8 Hz, 2H), 1.90 – 1.78 (m, 3H), 1.62 (dd, J = 12.9, 
1.8 Hz, 2H), 1.28 (qd, J = 12.3, 4.4 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 119.7, 66.9 (2C), 31.9 (2C), 31.8, 
23.5; MS (CI+ CH4): m/z (rel. Intensity) [M-CN] 99.1 (100).   
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3-Oxo-2-(tetrahydro-2H-pyran-4-yl)propanenitrile (29a)22 
 
 
 
To tetrahydro-2H-pyran-4-yl)methyl methanesulfonate (3.0 g, 23.97 mmol) at -78oC was added 1M LDA in THF 
(28.76 mL, 28.76 mmol) and the reaction was allowed to stir at -78 oC for 20 minutes. Ethyl formate (3.86 mL, 
47.93 mmol) was added to the reaction which was allowed to stir for 50 minutes before diluting with NH4Cl (30  
mL). The mixture was then acidified to pH 2-3 with 1M HCl and extracted with EtOAc (5x100mL) and 
concentrated under vacuum to give crude PM07-75-01 as a yellow solid (3.7 g) which was used without further 
purification. MS (CI+ CH4): m/z (rel. Intensity)[M+H] 154.1 (100) 
4-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-amine (30a) 
 
 
 
 
To a solution of 3-oxo-2-(tetrahydro-2H-pyran-4-yl)propanenitrile (1.81 g, 11.82 mmol) in EtOH (4 mL) was 
added hydrazine monohydrate (1.89 mL, 36.63 mmol) and AcOH (1.80  mL, 31.91 mmol). The reaction was 
allowed to stir at 60oC overnight before removing the volatiles under reduced pressure and purifying the crude 
product by column chromatography eluting with EtOAc to 10% MeOH in EtOAc to give 4-(tetrahydro-2H-pyran-
4-yl)-1H-pyrazol-5-amine 30a (1.86 g). 87%; 1H NMR (400 MHz, DMSO-d6) δ 11.46 (br s, 1H), 7.41 (s, 1H), 4.45 
(br s, 2H), 4.16 (dd, J = 11.5, 3.5 Hz, 2H), 3.66 (td, J = 11.5, 1.8 Hz, 2H), 2.83 (tt,  J = 11.8, 3.5Hz 1H), 2.01 (dd, J = 
12.6, 1.8 Hz, 2H), 1.74 (qd, J = 12.4, 4.3 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 151.3, 127.5, 110.0, 67.9 (2C), 
33.7 (2C), 30.0; MS (CI+ CH4): m/z (rel. Intensity)[M+H] 168.1 (100); HRMS (CI+) calcd for 
[(C8H13N3O)+H]:168.1131; found: 168.1130  
General procedure 4.1 - 5-H pyrazolopyrimidine cyclisations  
To a mixture of 1H-pyrazol-3-amine (9.87 mmol, 1.00 eq) in THF (10.00 mL) was added ethyl 2-chloro-3-oxo-
propanoate (9.87 mmol, 1.00 eq). The mixture was allowed to stir at 70 °C for 2 h until starting material was 
consumed demonstrated by TLC (Petroleum ether: Ethyl acetate= 1: 1). After cooling to room temperature, 
tBuOK (14.80 mmol, 1.50 eq) was added and the mixture was allowed to stir overnight. The mixture was acidi-
fied with 4M HCl/EtOAc to adjust the pH to 5-6 and concentrated to give the crude solid 
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6-Methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-ol (32a) 
 
 
 
 
Synthesised via general procedure 4.1, reaction mixture was acidified to pH 3-4 with 4M HCl in dioxane and 
volatiles removed to give crude 6-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-ol as a 
yellow solid which was used without further purification; (0.52 g, 75%); MS (CI+ CH4): m/z (rel. Intensity)[ 
M+H] 234.1 (18); HRMS (CI+) calcd for [(C7H6N3Cl2)+H]:234.1237; found: 234.1248        
 
General procedure 4.2 for the synthesis of 7-chloro-5-methyl-pyrazolo[1,5-a]pyrimidines 
 
 
 
To the pyrazolo-pyrimidine compound (1 equiv) and was added POCl3 (10 equiv) and the solution stirred under 
reflux overnight. The reaction was allowed to cool to room temperature, volatiles removed under reduced 
pressure before pouring onto crushed ice. The reaction mixture was then basified with 2M NaOH and aqueous 
extracted with EtOAc. The combined organic extracts were washed with brine, dried over MgSO4 and evapo-
rated to dryness to give the product.  
 
3,7-Dichloro-6-methylpyrazolo[1,5-a]pyrimidine  
 
 
 
Synthesised via general procedure 4.2 as a yellow solid. (0.172 g, 36%); 1H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 
1H), 8.45 (s, 1H), 2.43 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 152.8, 144.2, 142.6, 137.2, 118.1, 99.8, 14.9; MS 
(CI+ CH4): m/z (rel. Intensity)[ M+H] 202.0 (100), 204.0 (65); HRMS (CI+) calcd for [(C7H6N3Cl2)+H]:201.9933; 
found: 201.9943 
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6-Methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-ol (33a) 
 
 
 
 
Synthesised via general procedure 4.2 to give 33a as a yellow solid. (0.99 g, 36%); 1H NMR (400 MHz, DMSO-
d6) δ 8.47 (s, 1H), 8.19 (s, 1H), 3.94 (dt, J = 11.4, 2.9 Hz, 2H), 3.52 – 3.45 (m, 2H), 3.19 – 3.11 (m, 1H), 2.41 (s, 
3H), 1.89 – 1.76 (m, 4H); 13C NMR (101 MHz, DMSO-d6) δ 150.3, 145.6, 142.5, 136.1, 116.6, 116.2, 67.7, 33.4, 
30.9, 14.8; MS (CI+ CH4): m/z (rel. Intensity)[M+H] 252.1 (100), 254.1 (33); HRMS (CI+) calcd for 
[(C12H15N3ClO)+H]: 252.0898; found: 252.0907 
 
3,6,7-Trichloropyrazolo[1,5-a]pyrimidine 
 
 
 
 
Synthesised via general procerdure 4.2. (0.395 g, 66%); 1H NMR (400 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.61 (s, 
1H); 13C NMR (101 MHz, DMSO-d6) δ 149.8, 143.9, 137.5, 132.2, 117.1, 101.2; MS (CI+ CH4): m/z (rel. Intensi-
ty)[M+H] 221.9 (100), 223.9  (98); HRMS (CI+) calcd for [(C6H3N3Cl3)+H]:221.9387; found: 221.9395 
 
General procedure 4.3 for the synthesis of 5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-amines23 
 
 
 
To the chlorinated pyrazolo-pyrimidine (1 equiv) in DMF was added the aryl-amine (1 equiv) and K2CO3 (1.2 
equiv). The solutions were stirred at 60oC in overnight, once completed the reactions were evaporated to 
dryness, diluted with EtOAc before washing with water and brine. Organics were dried using MgSO4 before 
loading the crude product to silica gel and purifying by column chromatography eluting with 60% EtOAc in 
hexanes.  
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3-Chloro-6-methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF955) 
 
 
 
 
Synthesised via general procedure 4.3 to give AWF955 as an off-white solid. (31 mg, 29%); Melting point: 173-
175 oC   1H NMR (400 MHz, DMSO-d6) δ 8.56 (d, J = 4.2 Hz, 1H), 8.28 (t, J = 5.9 Hz, 1H), 8.22 (s, 1H), 8.09 (s, 1H), 
7.80 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.31 (m, 1H), 5.17 (d, J = 5.9 Hz, 2H), 2.36 (s, 3H); 13C NMR (101 
MHz, DMSO-d6) δ 158.1, 153.7, 149.4, 146.1, 144.2, 141.1, 137.6, 122.9, 121.6, 97.3, 95.9, 48.1, 14.7; MS 
(ES+): m/z (rel. Intensity)[M+H] 274.1 (100), 276.1  (33); HRMS (ES+) calcd for [(C13H13N535Cl)+H]:274.0859; 
found: 274.0862; CHN analysis: Calculated: C:57.04%, H:4.42%, N:25.59%.  Found C:55.85%, H:4.43%, 
N:24.81%. 
3-Chloro-6-methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF956) 
 
 
 
 
Synthesised via general procedure 4.3 to give AWF956 as an off-white solid. (37 mg, 35%); Melting point: 126-
130 oC   1H NMR (400 MHz, DMSO-d6) δ 8.86 (d, J = 4.8 Hz, 2H), 8.23 (s, 1H), 8.18 – 8.09 (m, 2H), 7.49 (t, J = 4.8 
Hz, 1H) 5.36 (d, J = 6.0 Hz, 2H), 2.40 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 166.7, 158.1, 153.4, 146.4, 144.4, 
141.1, 120.5, 97.5, 95.7, 49.1, 14.5; MS (ES+): m/z (rel. Intensity)[M+H] 275.1 (100), 277.1  (30); HRMS (ES+) 
calcd for [(C12H12N635Cl)+H]:275.0809; found: 275.0809; CHN analysis: Calculated: C:52.47%, H:4.04%, 
N:30.59%.  Found C:52.15%, H:4.24%, N:28.97%. 
 
3,6-Dichloro-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWF957) 
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Synthesised via general procedure 4.3 (0.163 g, 83%); Melting point: 161-163 oC   1H NMR (400 MHz, DMSO-
d6) δ 8.69 (t, J = 5.9 Hz, 1H), 8.53 (d, J = 4.4 Hz, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 7.80 (t, J = 7.8 Hz, 1H), 7.38 (d, J = 
7.8 Hz, 1H), 7.30 (d, J = 6.1 Hz 1H), 5.31 (d, J = 6.2 Hz, 2H); MS (ES+): m/z (rel. Intensity)[M+H] 294.0 (100), 
296.0  (50); 13C NMR (101 MHz, DMSO-d6) δ 157.6, 150.9, 149.2, 144.5, 143.8, 142.2, 137.5, 122.9, 121.4, 97.6, 
96.3, 48.2; HRMS (ES+) calcd for [(C12H10N535Cl2)+H]:294.0313; found: 294.0307; CHN analysis: Calculated: 
C:49.00%, H:3.08%, N:23.81%.  Found C:48.87%, H:3.12%, N:23.19%.  
 
(R)-6-Methyl-N-(1-(pyridin-2-yl)ethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWF960) 
 
 
 
 
 
Synthesised via general procedure 4.3 to give AWF960 as a white solid (58 mg, 14%); Melting point: 119-120 
oC   1H NMR (500 MHz, DMSO-d6) δ 8.61 (d, J = 4.5 Hz, 1H), 8.01 (s, 1H), 7.98 (s, 1H), 7.82 (td, J = 7.7, 1.8 Hz, 
1H), 7.66 (d, J = 9.1 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.33 (ddd, J = 7.5, 4.5, 0.9 Hz, 1H), 5.65 (dq, J = 13.7, 6.8 Hz, 
1H), 3.93 (dd, J = 10.4, 2.7 Hz, 2H), 3.46 (td, J = 11.3, 2.7 Hz, 2H), 3.08 – 3.01 (m, 1H), 2.37 (s, 3H), 1.89 – 1.74 
(m, 4H), 1.55 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 162.0, 152.1, 149.5, 145.5, 144.6, 140.7, 
137.8, 123.2, 121.4, 112.8, 96.3, 67.8(2C), 53.5, 33.5, 30.9, 24.9, 14.8; MS (ES+): m/z (rel. Intensity)[M+H] 
338.2 (100), 339.2  (13); HRMS (ES+) calcd for [(C19H24N5O)+H]:338.1981; found: 338.1968; CHN analysis: Cal-
culated: C:67.63%, H:6.87%, N:20.76%.  Found C:66.46%, H:6.89%, N:19.86%.  
(S)-6-Methyl-N-(1-(pyridin-2-yl)ethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWF961) 
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Synthesised via general procedure 4.3 to give AWF961 as a white solid (45 mg, 17%); Melting point: 119-120 
oC   1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, J = 4.8 Hz, 1H), 8.01 (s, 1H), 7.98 (s, 1H), 7.82 (td, J = 7.7, 1.5 Hz, 
1H), 7.68 (d, J = 9.1 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.33 (dd, J = 6.8, 4.8 Hz, 1H), 5.65 (dq, J = 13.5, 6.6 Hz, 1H), 
3.92 (d, J = 10.9 Hz, 1H), 3.46 (td, J = 11.2, 2.8 Hz, 1H), 3.09 – 2.99 (m, 1H), 2.76 (s, 3H), 1.87 – 1.73 (m, 1H), 
1.55 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 162.0, 152.1, 149.5, 145.5, 144.6, 140.7, 137.8, 123.2, 
121.4, 112.8, 96.3, 67.8 (2C), 53.5, 33.5, 30.9 (2C), 24.9, 14.8; MS (ES+): m/z (rel. Intensity)[M+H] 338.2 (100), 
339.2  (13); HRMS (ES+) calcd for [(C19H24N5O)+H]:338.1981; found: 338.1977; CHN analysis: Calculated: 
C:67.63%, H:6.87%, N:20.76%.  Found C:66.57%, H:6.66%, N:19.90%. 
 
6-Methyl-N-(1-(pyridin-2-yl)ethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9100) 
 
 
 
 
 
Synthesised via general procedure 4.3 to give AWZ9100 as a white solid (48 mg, 51%); 1H NMR (400 MHz, 
DMSO-d6) δ 8.61 (d, J = 4.6 Hz, 1H), 8.01 (s, 1H), 7.98 (s, 1H), 7.81 (t, J = 7.1 Hz, 1H), 7.66 (d, J = 9.0 Hz, 1H), 
7.50 (d, J = 7.8 Hz, 1H), 7.32 (dd, J = 7.1, 4.6 Hz, 1H), 5.69 – 5.60 (m, 1H), 3.92 (d, J = 10.8 Hz, 2H), 3.46 (td, J = 
11.0, 2.5 Hz, 2H), 3.09 – 2.99 (m, 1H), 2.37 (s, 3H), 1.85 – 1.76 (m, 4H), 1.55 (d, J = 6.6 Hz, 3H); 13C NMR (101 
MHz, DMSO-d6) δ 162.0, 152.2, 149.5, 145.5, 144.6, 140.7, 137.8, 123.2, 121.4, 112.8, 96.3, 67.8(2C), 53.5, 
33.5, 30.9, 24.9, 14.8; MS (ES+): m/z (rel. Intensity)[M+H] 338.2 (100), 339.2  (13); HRMS (ES+) calcd for 
[(C19H24N5O)+H]:338.1981; found: 338.1968; CHN analysis: Calculated: C:67.63%, H:6.87%, N:20.76%.  Found 
C:66.92%, H:6.85%, N:20.48%.  
 
 
 
 
 
 
                                                                          Chapter 4 _____________________________________                                                                                                
 
 
 
210 
 
4.7 References  
 
(1)  St. Jean, D. J.; Fotsch, C. Mitigating Heterocycle Metabolism in Drug Discovery. J. Med. Chem. 2012, 55 
(13), 6002–6020. 
(2)  Klebe, G. The Foundations of Protein–Ligand Interaction BT  - From Molecules to Medicines: Structure 
of Biological Macromolecules and Its Relevance in Combating New Diseases and Bioterrorism; 
Sussman, J. L., Spadon, P., Eds.; Springer Netherlands: Dordrecht, 2009; pp 79–101. 
(3)  Kerekes, A. D.; Esposite, S. J.; Doll, R. J.; Tagat, J. R.; Yu, T.; Xiao, Y.; Zhang, Y.; Prelusky, D. B.; Tevar, S.; 
Gray, K.; Terracina, G. A.; Lee, S.; Jones, J.; Liu, M.; Basso, A. D.; Smith, E. B. Aurora Kinase Inhibitors 
Based on the Imidazo[1,2-A]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral 
Absorption and Exposure. J. Med. Chem. 2011, 54 (1), 201–210. 
(4)  Gleave, R. J.; Beswick, P. J.; Brown, A. J.; Giblin, G. M. P.; Goldsmith, P.; Haslam, C. P.; Mitchell, W. L.; 
Nicholson, N. H.; Page, L. W.; Patel, S.; Roomans, S.; Slingsby, B. P.; Swarbrick, M. E. Synthesis and 
Evaluation of 3-Amino-6-Aryl-Pyridazines as Selective CB2 Agonists for the Treatment of Inflammatory 
Pain. Bioorg. Med. Chem. Lett. 2010, 20 (2), 465–468. 
(5)  Stepan, A. F.; Karki, K.; McDonald, W. S.; Dorff, P. H.; Dutra, J. K.; DiRico, K. J.; Won, A.; Subramanyam, 
C.; Efremov, I. V; O’Donnell, C. J.; Nolan, C. E.; Becker, S. L.; Pustilnik, L. R.; Sneed, B.; Sun, H.; Lu, Y.; 
Robshaw, A. E.; Riddell, D.; O’Sullivan, T. J.; Sibley, E.; Capetta, S.; Atchison, K.; Hallgren, A. J.; Miller, E.; 
Wood, A.; Obach, R. S. Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide 
Derivatives as γ-Secretase Inhibitors. J. Med. Chem. 2011, 54 (22), 7772–7783. 
(6)  Dragovich, P. S.; Blazel, J. K.; Ellis, D. A.; Han, Q.; Kamran, R.; Kissinger, C. R.; LeBrun, L. A.; Li, L.-S.; 
Murphy, D. E.; Noble, M.; Patel, R. A.; Ruebsam, F.; Sergeeva, M. V; Shah, A. M.; Showalter, R. E.; Tran, 
C. V; Tsan, M.; Webber, S. E.; Kirkovsky, L.; Zhou, Y. Novel HCV NS5B Polymerase Inhibitors Derived 
from 4-(1’,1’-dioxo-1’,4’-dihydro-1’lambda(6)-benzo[1’,2’,4’]thiadiazin-3’-yl)-5-Hydro Xy-2H-Pyridazin-
3-Ones. Part 5: Exploration of Pyridazinones Containing 6-Amino-Substituents. Bioorg. Med. Chem. 
Lett. 2008, 18 (20), 5635–5639. 
(7)  Kalgutkar, A. S.; Dalvie, D. K.; O’Donnell, J. P.; Taylor, T. J.; Sahakian, D. C. On the Diversity of Oxidative 
Bioactivation Reactions on Nitrogen-Containing Xenobiotics. Curr. Drug Metab. 2002, 3 (4), 379–424. 
(8)  Cyprotex Guide book. "Everything You Need to Know about ADME"; 2015. 
(9)  Elsby, R.; Surry, D. D.; Smith, V. N.; Gray, A. J. Validation and Application of Caco-2 Assays for the in 
Vitro Evaluation of Development Candidate Drugs as Substrates or Inhibitors of P-Glycoprotein to 
Support Regulatory Submissions. Xenobiotica 2008, 38 (7–8), 1140–1164. 
                                                                          Chapter 4 _____________________________________                                                                                                
 
 
 
211 
 
(10)  FDA. US FDA Draft Guidance for Industry Drug Interaction Studies - Study, Design, Data, Analysis, 
Implications for Dosing and Labelling Recommendations; 2012. 
(11)  Japanese Ministry of Health, Labour and Welfare (JMHLW) Guideline on Drug-Drug Interactions (2014). 
(12)  European Medicines Agency (EMA) Guideline on the Investigation of Drug Interactions (21 June 2012). 
(13)  Hann, M. M.; Keserü, G. M. Finding the Sweet Spot: The Role of Nature and Nurture in Medicinal 
Chemistry. Nat Rev Drug Discov 2012, 11 (5), 355–365. 
(14)  Leeson, P. D.; Young, R. J. Molecular Property Design: Does Everyone Get It? ACS Med. Chem. Lett. 
2015, 6 (7), 722–725. 
(15)  Huttunen, K. M.; Raunio, H.; Rautio, J. Prodrugs—from Serendipity to Rational Design. Pharmacol. Rev. 
2011, 63 (3), 750 LP-771. 
(16)  Jones, C. L.; Yeung, B. K. S.; Manjunatha, U.; Shi, P.-Y.; Bodenreider, C.; Diagana, T. T. Drug Discovery 
for the Developing World: Progress at the Novartis Institute for Tropical Diseases. Nat Rev Drug Discov 
2015, 14 (6), 442–444. 
(17)  Al-Adiwish, W. M.; Tahir, M. I. M.; Siti-Noor-Adnalizawati, A.; Hashim, S. F.; Ibrahim, N.; Yaacob, W. A. 
Synthesis, Antibacterial Activity and Cytotoxicity of New Fused pyrazolo[1,5-A]pyrimidine and 
pyrazolo[5,1-c][1,2,4]triazine Derivatives from New 5-Aminopyrazoles. Eur. J. Med. Chem. 2013, 64, 
464–476. 
(18)  Lefoix, M.; Mathis, G.; Kleinmann, T.; Truffert, J.-C.; Asseline, U. Pyrazolo[1,5-a]-1,3,5-Triazine C-
Nucleoside as Deoxyadenosine Analogue: Synthesis, Pairing, and Resistance to Hydrolysis. J. Org. 
Chem. 2014, 79 (7), 3221–3227. 
(19)  Chu, C. K.; Watanabe, K. A.; Fox, J. J. Nucleosides. 117. Synthesis of 4-Oxo-8-(β-D-Ribofuranosyl)-3H-
pyrazolo[1,5-a]-1,3,5-Triazine (OPTR) via 3-Amino-2N-Carbamoyl-4-(β-D-Ribofuranosyl)pyrazole (ACPR) 
Derivatives. J. Heterocycl. Chem. 1980, 17 (7), 1435–1439. 
(20)  Ryono, D. E.; Cheng, P. T. W.; Bolton, S. A.; Chen, S. S.; Shi, Y.; Meng, W.; Tino, J. A.; Zhang, H.; Sulsky, 
R. B. Novel N-Heterocyclic Phosphonates and Phosphinates as Glucokinase Activators for Treatment of 
Type II Diabetes., WO2008005964A2, January 10, 2008. 
(21)  Speake, J. D.; Beck, B. C.; Fan, W. Preparation of Pyridinylthiazole Derivatives as Antiparasitic Agents., 
PCT Int. Appl., WO2016183173A1, November 17, 2016. 
(22)  Laurent, A.; Rose, Y. Preparation of 4-aminopyrrolo[2,3-E]pyrimidine Derivatives as Btk Protein Kinase 
Inhibitors., PCT Int. Appl., WO2015074135A1 May 28, 2015. 
(23)  Hwang, J. Y.; Windisch, M. P.; Jo, S.; Kim, K.; Kong, S.; Kim, H. C.; Kim, S.; Kim, H.; Lee, M. E.; Kim, Y.; 
                                                                          Chapter 4 _____________________________________                                                                                                
 
 
 
212 
 
Choi, J.; Park, D.-S.; Park, E.; Kwon, J.; Nam, J.; Ahn, S.; Cechetto, J.; Kim, J.; Liuzzi, M.; No, Z.; Lee, J. 
Discovery and Characterization of a Novel 7-aminopyrazolo[1,5-A]pyrimidine Analog as a Potent 
Hepatitis C Virus Inhibitor. Bioorg. Med. Chem. Lett. 2012, 22 (24), 7297–7301. 
 
                                                                          Appendix 1 _____________________________________                                                                                                
 
 
 
213 
 
 
 
Appendix 1 
 
WuXi App Tech Experimental 
 
 
 
 
 
 
 
 
 
                                                                          Appendix 1 _____________________________________                                                                                                
 
 
 
214 
 
Appendix 1 WuXi App Tech Experimental 
 
 
 
Synthesis of 4-(4-fluorophenyl)-1H-pyrazol-5-amine (2) 
 
 
 
 
To a mixture of NaOEt (3.02 g, 44.40 mmol, 1.20 Eq) in EtOH (50 mL) at 0 °C was added 2-(4-fluorophenyl) 
acetonitrile (5.00 g, 37.00 mmol, 1.00 Eq). The mixture was stirred at 0 °C for 5 min. Then ethyl formate (6.85 g, 
92.50 mmol, 2.50 Eq) was added. The mixture was heated to 85 °C and stirred for 1 h. TLC (Petroleum ether: 
EtOAc=5: 1) showed SM was consumed. The mixture was concentrated to give a residue. The residue was 
dissovled in H2O (50 mL) and adjusted to pH3~4 with HCl (aq., 2 N). Then the mixture was extrated with EtOAc 
(50 mL*3). The organic layer was washed with brine (50 mL*2), dried over Na2SO4 and concentrated to give 2-
(4-fluorophenyl)-3-oxo-propanenitrile (6.00 g, crude) as a yellow solid. 
NH2-NH2.H2O (3.68 g, 73.56 mmol, 2.00 Eq) was added to a mixture of 2-(4-fluorophenyl)-3-oxo-
propanenitrile (6.00 g, 36.78 mmol, 1.00 Eq) in EtOH (50 mL), followed by AcOH (N/A, 52.46 mmol, 1.43 Eq) . 
After being stirred at 85 °C for 2 hr, the reaction mixture was cooled to 25 °C and concentrated to give a 
residue. The residue was diluted with H2O (50 mL). The mixture was extracted with EtOAc (50 mL*3). The 
combined organic layer was washed with brine (50 mL*2), dried over Na2SO4 and concentrated to give 4-(4-
fluorophenyl)-1H-pyrazol-5-amine (5.70 g, crude) as a yellow solid which was used in the next step without 
purification. 
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Synthesis of 3-(4-fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-ol (4) 
 
 
 
 
A mixture of 4-(4-fluorophenyl)-1H-pyrazol-5-amine (5.50 g, 31.04 mmol, 1.00 Eq), ethyl 2-methyl-3-oxo-
butanoate (4.92 g, 34.14 mmol, 1.10 Eq) and TsOH (534.51 mg, 3.10 mmol, 0.10 Eq) in toluene (50 mL) was 
stirred at 120 °C for 2 hr. LCMS showed starting material was comsumed and the major peak is the desired 
product. The mixture was concentrated to give a residue which was triturated with EtOAc (20 mL). The mixture 
was filtered and the filtrated was dried under vacuum to give 3-(4-fluorophenyl)-5,6-dimethyl-pyrazolo[1,5-
a]pyrimidin-7-ol (5.20 g, 20.21 mmol, 65% yield) as a white solid. 
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Synthesis of 7-chloro-3-(4-fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidine (Intermediate B) 
 
 
 
 
To a mixture of 3-(4-fluorophenyl)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ol (5.00 g, 19.44 mmol, 1.00 Eq) 
and POCl3 (8.94 g, 58.32 mmol, 3.00 Eq) in MeCN (50 mL) was added TEA (3.93 g, 38.88 mmol, 2.00 Eq). The 
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mixture was stirred at 120 °C for 8 hr. LCMS showed starting material was consumed. The mixture was cooled 
to 25 °C, poured into water slowly and extracted with EtOAc (50 mL*3). The combined organic layer was 
washed with brine (50mL*2), dried over Na2SO4 and concentrated to give a residue which was purified by 
chromatography (EtOAc/Petroleum ether = 1/8) to give 7-chloro-3-(4-fluorophenyl)-5,6-dimethyl-pyrazolo[1,5-
a]pyrimidine (2.70 g, 9.79 mmol, 50% yield) as a yellow solid.            
1H NMR (400 MHz, CHLOROFORM-d): δ 8.37 (s, 1 H), 7.96 - 8.07 (m, 1 H), 7.08 - 7.20 (m, 1 H), 2.68 (s, 3 H), 2.47 
(s, 3 H). 
LCMS (Method 5-95AB): RT =0.928 min / 1.5 min, M+H+ = 276.1 
 
 
Synthesis of AWZ9001~9004 & AWZ9024~9026 
 
 
 
 
A mixture of 7-chloro-3-(4-fluorophenyl)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidine (200.00 mg, 725.40 µmol, 1.00 
Eq), RNH2 (870.48 µmol, 1.20 Eq) and TEA (146.81 mg, 1.45 mmol, 2.00 Eq) in DMF (2 mL) was stirred at 110 °C 
for 4 hr. LCMS showed starting material was consumed and desired mass. The mixture was diluted with water 
(5 mL) and the precipitate was collected by filtration and purified by prep-HPLC (FA or HCl) to give target 
compounds as a light yellow solid. 
 
AWZ9001 
1H NMR (400 MHz, DMSO-d6): δ 8.50 (s, 1 H), 8.18 (dd, J=8.72, 5.58 Hz, 2 H), 7.21 (t, J=8.91 Hz, 2 H), 6.93 (t, 
J=5.58 Hz, 1 H), 3.90 (q, J=6.11 Hz, 2 H), 3.48 (t, J=4.27 Hz, 4 H), 2.57 (t, J=6.09 Hz, 2 H), 2.51 - 2.53 (m, 3 H), 2.38 
(br. s., 4 H), 2.29 (s, 3 H). 
LCMS (Method 5-95AB): RT =0.593 min / 1.5 min, M+H+ = 370.3 
 
AWZ9002 
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1H NMR (400 MHz, DMSO-d6): δ 8.49 (s, 1 H), 8.23 (s, 1 H), 8.13 - 8.20 (m, 2 H), 7.15 - 7.25 (m, 2 H), 6.90 (t, 
J=5.58 Hz, 1 H), 3.87 (q, J=6.02 Hz, 2 H), 2.56 (t, J=6.21 Hz, 2 H), 2.50 - 2.53 (m, 2 H), 2.48 (s, 3 H), 2.28 - 2.46 (m, 
6 H), 2.27 (s, 3 H) 2.16 (s, 3 H). 
LCMS (Method 5-95AB): RT =0.661 min / 1.5 min, M+H+ = 383.1 
AWZ9003 
1H NMR (400 MHz, DMSO-d6): δ 8.49 (s, 1H), 8.13-8.21 (m, 3H), 7.18-7.25 (m, 2H), 7.00 (t, J=5.33 Hz, 1H), 3.88 
(q, J=5.90 Hz, 2H), 2.56 (t, J=6.34 Hz, 2H), 2.49 (s, 3H), 2.30 (s, 3H), 2.24 (s, 6H) 
LCMS (Method 5-95AB): RT =0.676 min / 1.5 min, M+H+ = 328.1 
 
AWZ9024 
1H NMR (400 MHz, DMSO-d6) : δ 8.74 (d, J=4.89 Hz, 1H), 8.48 (s, 1H), 8.21 (br. s., 1H), 7.97-8.07 (m, 2H), 7.88 (d, J=7.78 
Hz, 2H), 7.65 (br. s., 1H), 7.26 (t, J=8.97 Hz, 2H), 6.23 (br. s., 1H), 2.55 (s, 3H), 2.32 (s, 3H), 1.72 (d, J=6.78 Hz, 3H) 
LCMS (Method 5-95AB): RT =0.787 min / 1.5 min, M+H+ = 362.0 
AWZ9025 
1H NMR (400 MHz, DMSO-d6) : δ 8.85 (d, J=4.89 Hz, 1H), 8.59 (s, 1H), 8.49 (t, J=7.47 Hz, 1H), 8.14-8.21 (m, 2H), 
8.08 (d, J=7.78 Hz, 1H), 7.91 (t, J=6.53 Hz, 1H), 7.20-7.32 (m, 2H), 5.01 (s, 2H), 3.06 (s, 3H), 2.59 (s, 3H), 2.29 (s, 
3H) 
LCMS (Method 5-95AB): RT =0.808 min / 1.5 min, M+H+ = 362.1 
 
Synthesis of AWZ9007-8 
 
 
 
 
A mixture of 7-chloro-3-(4-fluorophenyl)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidine (200.00 mg, 725.40 µmol, 1.00 
Eq) , RNH2 (797.94 µmol, 1.10 Eq) , Cs2CO3 (354.52 mg, 1.09 mmol, 1.50 Eq) , BINAP (90.34 mg, 145.08 µmol, 
0.20 Eq) and diacetoxypalladium (16.29 mg, 72.54 µmol, 0.10 Eq) in tol. (5 mL) was stirred at 110 °C for 16 hr 
under N2 protection. The color of the mixture turned brown. LCMS showed starting material consumed. The 
mixture was diluted with EtOAc (30 mL) and washed with brine (20 mL*2). The organic layer was dried over 
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Na2SO4and concentrated to give a residue. The residue was purified by trituration (MeOH, 15 mL; 2 N HCl, 0.5 
mL; EtOAc, 20 mL) or prep-HPLC (HCl) to give target compounds as a yellow solid. 
AWZ9007 
1H NMR (400 MHz, DMSO-d6): δ 8.53 (br. s., 1H), 8.09-8.25 (m, 3H), 7.89 (t, J=7.28 Hz, 1H), 7.20-7.30 (m, 3H), 
7.04 (t, J=6.09 Hz, 1H), 2.62 (s, 3H), 2.15 (s, 3H) 
LCMS (Method 5-95AB): RT =0.811 min / 1.5 min, M+H+ = 334.0 
 
AWZ9008 
1H NMR (400 MHz, DMSO-d6): δ 9.92 (br. s., 1H), 8.55 (s, 1H), 8.16-8.23 (m, 2H), 8.13 (d, J=3.01 Hz, 1H), 7.70 
(dt, J=3.07, 8.69 Hz, 1H), 7.23-7.31 (m, 2H), 7.13 (dd, J=3.70, 9.10 Hz, 1H), 2.61 (s, 3H), 2.06 (s, 3H) 
LCMS (Method 5-95AB): RT =0.919 min / 1.5 min, M+H+ = 352.0 
 
 
 
 
 
 
 
 
 
 
5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-ol (3). 
 
 
 
To a suspension of compound 1 and compound 2 (10.00 g, 76.84 mmol) in toluene (200 mL) was added 4-
methylbenzenesulfonic acid hydrate (1.46 g, 7.68 mmol). The mixture was stirred at 110 oC for 3 hours. TLC 
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(petroleum ether: ethyl acetate = 3:1) showed the starting material disappeared. The mixture was cooled to 25 
oC and water (200 mL) was added slowly. After stirred for10 minutes, the precipitate was collected by suction 
filtration to give pure compound 3 (10.00 g, 61.28 mmol, 80% yield) as a white solid. 
7-chloro-5,6-dimethylpyrazolo[1,5-a]pyrimidine (4) 
 
 
 
To a suspension of compound 3 (10.00 g, 61.28 mmol) in MeCN (100 mL) was added POCl3 (82.00 g, 534.79 
mmol) one portion at 25 oC. The mixture was stirred at 80 oC for 6 hours. TLC (petroleum ether: ethyl acetate = 
3:1) showed the starting material disappeared. The mixture was cooled to 25 oC, then pour slowly into water 
(150 mL). The mixture was adjusted to pH about 7 with K2CO3. The mixture was extracted with ethyl acetate 
(100 mL*3). The combined organic layer was dried over sodium sulfate, concentrated to give crude product 
which was purified by chromatography (petroleum ether: ethyl acetate =10:1 to 5:1) to give pure compound 4 
(9.00 g, 49.55 mmol, 81% yield) as white solid. MS: 182.1 (M+H+). 
 
7-chloro-3-iodo-5,6-dimethylpyrazolo[1,5-a]pyrimidine (5) 
 
 
 
 
 
To a solution of compound 4 (1.00 g, 5.51 mmol) in MeCN (10 mL) was added NIS (1.24 g, 5.51 mmol). The 
mixture was stirred at 25 °C under nitrogen atmosphere for 2 hr, TLC (petroleum ether: ethyl acetate = 3:1) 
showed the starting material disappeared completely. The mixture was concentrated to give a residue which 
was purified by chromatography (petroleum ether: ethyl acetate = 10:1 to 5:1) to give compound 5 (1.20 g, 
3.90 mmol, 71% yield) as a white solid. MS: 308.0 (M+H+) 
3-iodo-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (7) 
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A mixture of compound 5 (1.20 g, 3.90 mmol), compound 6 (421.98 mg, 3.90 mmol) and K2CO3 (1.08 g, 7.80 
mmol) in DMF (10 mL) was stirred at 60 °C for 2 hr. TLC (petroleum ether: ethyl acetate = 3:1) showed the 
starting material disappeared. After water (20 mL) was added, the precipitate was collected by suction 
filtration to give compound 7 (800.00 mg, 2.11 mmol, 54% yield) as a pale yellow solid. MS: 380.0 (M+H+) 
tert-butyl(3-iodo-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate  (8) 
 
 
 
 
 
A mixture of compound 7 (1.00 g, 2.64 mmol), DIPEA (681.65 mg, 5.27 mmol), DMAP (161.09 mg, 1.32 mmol) 
and Boc2O (1.15 g, 5.27 mmol) in THF (20 mL) was stirred at 70 °C for 2 hr. TLC (petroleum ether: ethyl acetate 
= 3:1) showed starting material was consumed completely and a new spot was formed. Removed the solvent 
under vacuum, the residue was purified by chromatography (petroleum ether/ ethyl acetate=10:1 to 3:1) to 
give compound 8 (1.00 g, 2.09 mmol, 79% yield) as a white solid. MS: 480.1 (M+H+). 
 
3-(2-chlorophenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine  (10) 
 
 
 
 
 
A suspension of (2-chlorophenyl)boronic acid (39.15 mg, 250.36 µmol), compound 8 (100.00 mg, 208.63 µmol), 
Na2CO3 (44.23 mg, 417.26µmol) and ditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron (13.60 mg, 
20.86 µmol) in dioxane (10 mL)  and water (2 mL) was stirred  at 100°C under nitrogen atmosphere for 2 hr. TLC 
(petroleum ether/ethyl acetate= 3:1) showed starting material was consumed and a new spot formed . 
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Removed solvent under vocuum to give a residue which was purified directly by chromatography (petroleum 
ether/ethyl acetate=10:1 to 3:1) to give compound 10 (60.00 mg, 129.32 µmol, 62% yield) as a pale yellow oil. 
 
 
3-(2-chlorophenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine(AWZ9009) 
 
 
 
 
 
To a solution compound (60.00 mg, 129.32 µmol) in ethyl acetate (3 mL) was added HCl/EtOAc (4 M, 3.00 mL) .The 
solution was stirred for 2 hr at 25 °C and a white precipitate formed. TLC (petroleum ether/ethyl acetate= 3:1) showed 
the starting material was consumed completely. Filtrated the precipitate by filter and washed with ethyl acetate (2 mL) 
to give a residue which was purified by prep-HPLC (FA) to give AWZ9009 (13.70 mg, 33.43 µmol, 26% yield) as a gray 
solid. 
LCMS (Method 30-90CD, ESI): RT =1.318min: 2 min, M+H+ =364.1 
1H NMR (400MHz, DMSO-d6)  = 8.58 (d, J=4.1 Hz, 1H), 8.40 (s, 1H), 8.00 - 7.90 (m, 2H), 7.81 (dt, J=1.8, 7.7 Hz, 
1H), 7.53 (dd, J=1.1, 7.9 Hz, 1H), 7.44 - 7.37 (m, 1H), 7.34 - 7.24 (m, 1H), 5.22 (d, J=6.1 Hz, 1H), 2.44 (s, 1H), 2.32 
(s, 1H). 
 
The above general procedure was followed for the syntheses of AWZ9014. 
LCMS (Method 30-90CD, ESI): RT =1.055min: 2 min, M+H+ =408.1 
1H NMR (400MHz, DMSO-d6)  = 8.69 (s, 1H), 8.56 (d, J=4.8 Hz, 1H), 8.42 (d, J=8.7 Hz, 2H), 8.00 (t, J=6.1 Hz, 1H), 
7.90 (d, J=8.7 Hz, 2H), 7.79 (dt, J=1.8, 7.7 Hz, 1H), 7.40 (d, J=7.9 Hz, 1H), 7.30 (dd, J=5.3, 7.1 Hz, 1H), 5.24 (d, 
J=6.0 Hz, 1H), 3.20 (s, 1H), 2.54 (s, 3H), 2.33 (s, 1H) 
 
tert-butyl(3-(3-chlorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate  (12) 
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A suspension of (3-chlorophenyl)boronic acid (39.15 mg, 250.36 µmol), compound 8 (100.00 mg, 208.63 µmol), 
Na2CO3 (44.23 mg, 417.26 µmol), ditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron(13.60 mg, 20.86 
µmol) in dioxane (10 mL)  and water (2 mL) was stirred  at 100°C under nitrogen atmosphere for 2 hr. TLC 
(petroleum ether/ethyl acetate= 3:1) showed starting material was consumed and a new spot formed . 
Removed solvent under vocuum to give a residue which was purified directly by TLC (petroleum ether/ethyl 
acetate=3:1) to give compound 12 (60.00 mg, 129.32 µmol, 62% yield) as a pale yellow oil. 
3-(3-chlorophenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine(AWZ9010) 
 
 
 
 
 
To a solution compound (60.00 mg, 129.32 µmol) in ethyl acetate (3 mL) was added HCl/EtOAc (4 M, 3.00 mL) .The 
solution was stirred for 2 hr at 25 °C and a white precipitate formed. TLC (petroleum ether/ethyl acetate= 3:1) showed 
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the starting material was consumed completely. Filtrated the precipitate by filter and washed with ethyl acetate (2 mL) 
to give AWZ9010 (42.50 mg, 106.17 µmol, 82 % yield) as a white solid. 
 
LCMS (Method 5-95AB, ESI): RT =0.740min: 2 min, M+H+ =364.1 
1H NMR (400MHz, DMSO-d6)  = 8.76 (d, J=4.9 Hz, 1H), 8.44 (s, 2H), 8.30 (br. s., 1H), 8.01 (d, J=8.4 Hz, 2H), 7.85 (d, J=8.2 
Hz, 1H), 7.74 (br. s., 1H), 7.46 (d, J=8.4 Hz, 2H), 5.52 (br. s., 2H), 2.56 (s, 3H), 2.30 (s, 3H). 
AWZ9012 
 
LCMS (Method 5-95AB, ESI): RT =0.802min: 2 min, M+H+ =398.2 
1H NMR (400MHz, DMSO-d6)  = 8.76 (d, J=5.0 Hz, 1H), 8.54 (s, 1H), 8.28 (d, J=7.8 Hz, 4H), 7.86 (d, J=7.5 Hz, 1H), 7.73 (d, 
J=7.9 Hz, 1H), 5.49 (br. s., 2H), 2.56 (s, 3H), 2.30 (s, 3H). 
AWZ 9013 
For AWZ9014 see below 
 
LCMS (Method 5-95AB, ESI): RT =0.797min: 2 min, M+H+ =414.2 
1H NMR (400MHz, DMSO-d6)  = 8.75 (d, J=5.1 Hz, 1H), 8.45 (s, 1H), 8.28 (t, J=7.8 Hz, 1H), 8.10 (d, J=8.4 Hz, 2H), 7.84 (d, 
J=7.7 Hz, 1H), 7.72 (t, J=5.6 Hz, 1H), 7.41 (d, J=8.3 Hz, 2H), 5.52 (br. s., 2H), 2.56 (s, 3H), 2.30 (s, 3H). 
AWZ9015 
 
LCMS (Method 5-95AB, ESI): RT =0.764min: 2 min, M+H+ =373.1 
1H NMR (400MHz, DMSO-d6)  = 8.81 (d, J=5.0 Hz, 1H), 8.54 (s, 1H), 8.42 (t, J=7.5 Hz, 1H), 8.27 (d, J=8.5 Hz, 3H), 7.96 (d, 
J=8.0 Hz, 1H), 7.87 - 7.76 (m, 3H), 5.55 (d, J=3.9 Hz, 2H), 2.56 (s, 3H), 2.30 (s, 3H)
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Tert-butyl (5,6-dimethyl-3-(4-(methylsulfonyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-yl 
methyl)carbamate (3) 
 
 
 
 
 
 
To a mixture of tert-butyl N-(3-iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(3 g, 6.26 mmol, 1 eq), (4-methylsulfonylphenyl)boronic acid (1.5 g, 7.51 mmol, 1.2 eq), Na2CO3 (1.33 g, 12.5 
mmol, 2 eq) in dioxane (40 mL) and H2O (4 mL) was added ditert-
butyl(cyclopentyl)phosphane;dichloropalladium;iron (408 mg, 626 µmol, 0.1 eq), the mixture was de-gassed 
and then heated at 110 °C for 3 hour under N2.  TLC (Petroleum ether: EtOAc=5: 1) showed that tert-butyl N-(3-
iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed completely. TLC 
(Petroleum ether: EtOAc=1: 1) showed that a major new spot. The mixture was concentrated in vacuo. The 
residuewas purified by column chromatography on silcal gel (Petroleum ether: Ethyl acetate=1: 1 to 1: 
3). Compound tert-butyl N-[5,6-dimethyl-3-(4-methylsulfonylphenyl) pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (3 g, 5.4 mmol, 86% yield, 91% purity) was obtained as a grey solid. 
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1H NMR (400MHz, CDCl3-d) 8.41 (s, 2H), 8.33 (d, J=8.41 Hz, 2H), 7.99 (d, J=8.53 Hz, 2H), 7.65 (d, J=1.63 Hz, 1H), 7.55 (d, 
J=7.78 Hz, 1H), 7.13 - 7.23 (m, 1H), 5.16 - 5.34 (m, 1H), 4.75 - 4.85 (m, 1H), 3.09 (s, 3H), 2.58 - 2.68 (m, 3H), 2.03 - 2.15 
(m, 3H), 1.50 (s, 3H), 1.32 (s, 6H). 
tert-butyl 4-(4-bromo-7-chloro-1H-indazol-3-yl)piperidine-1-carboxylate (AWZ9014b_B2) 
 
 
 
 
 
 
 
A solution of tert-butyl N-[5,6-dimethyl-3-(4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (3 g, 5.9 mmol, 1 eq) in HCl/EtOAc (40 mL) was stirred at 10-15 °C for 12 hour. TLC 
(EtOAc) showed that most of tert-butyl N-[5,6-dimethyl-3-(4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-
yl]-N-(2-pyridylmethyl)carbamate was consumed and a major new spot. The mixture was concentrated.  The 
residue was dissloved in DCM/MeOH (1:1, 100 mL) and basified by strongly basic anion exchange resin, 
concentrated to give a crude product. The crude product was purified by trituration from (Petroleum ether: 
EtOAc: DCM=5: 1: 1) to give a the product (purity: 97%) which was purified by trituration from (Petroleum 
ether : EtOAc: DCM=3: 1: 1) for twice to give ompound 5,6-dimethyl-3-(4-methylsulfonylphenyl)-N-(2-
pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (2.25 g, 5.44 mmol, 92% yield, 98% purity) as a light yellow 
solid. 
LCMS (Method 5-95AB, ESI): RT =0.563 min / 1.5 min, M+H+ =408.0. 
1H NMR (400MHz, DMSO-d6) 8.71 (d, J=5.15 Hz, 1H), 8.61 (s, 1H), 8.37 (d, J=8.53 Hz, 2H), 8.04 - 8.19 (m, 2H), 7.90 (d, 
J=8.53 Hz, 2H), 7.69 - 7.76 (m, 1H), 7.57 - 7.67 (m, 1H), 5.40 (d, J=4.77 Hz, 2H), 3.21 (s, 3H), 2.55 (s, 3H), 2.30 (s, 3H). 
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5,6-dimethyl-3-(4-(methylsulfonyl)phenyl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9014b_B3) 
 
 
 
 
 
 
To a mixture of 5,6-dimethyl-3-(4-methylsulfonylphenyl)-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(50.00 mg, 122.70 µmol, 1.00 eq) in MeOH (2.00 mL) was added methanesulfonic acid (35.38 mg, 368.11 µmol, 
3.00 eq) in dropwise. The mixture was stirred at 15-20 °C for 12 hours. The mixture was concentrated to give a 
residue. The residue was triturated with EtOAc/MTBE/Petroleum ether (5 mL/5 mL/10 mL) to give 5,6-
dimethyl-3-(4-methylsulfonylphenyl)-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine;methanesulfonic 
acid (43.40 mg, 81.01 µmol, 66% yield, 94% purity) as a grey solid. 
LCMS (Method 5-95 AB): RT=0.644min/1.5 min, [M+H]+=408.2 
1H NMR (400MHz, DMSO-d6) δ 8.82 (d, J=4.8 Hz, 1H), 8.54 (s, 1H), 8.42 (t, J=7.7 Hz, 1H), 8.13-8.34 (m, 3H), 
7.81-8.01 (m, 4H), 5.52 (br. s., 2H), 3.21 (s, 3H), 2.57 (s, 3H), 2.39 (s, 6H), 2.28 (s, 3H). 
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3-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ol (3). 
 
 
 
 
 
To a solution of 4-(4-fluorophenyl)-1H-pyrazol-5-amine (2 g, 11.29 mmol, 1.00 Eq) and ethyl 2-
oxocyclopentanecarboxylate (1.76 g, 11.29 mmol, 1.00 Eq) in toluene (20 mL) was added TsOH (194 mg, 1.13 
mmol, 0.10 Eq). The mixture was stirred at 110 °C for 12 hrs. TLC (Petroleum ether: Ethyl acetate=1: 2) showed 
that starting material was consumed completetly. The mixture was cooled to 30 °C and filtered, washed with 
Petroleum ether (20 mL), concentrated in vacuo to afford 3-(4-fluorophenyl)-6,7-dihydro-5H- 
cyclopenta[BLAH]pyrazolo[BLAH]pyrimidin-8-ol (2.3 g, 8.54 mmol, 76% yield) as a gray solid. 
1H NMR (400 MHz, DMSO-d6):  12.06 - 12.40 (m, 1 H) 8.10 (s, 1 H) 7.55 - 7.64 (m, 2 H) 7.29 (t, J=8.85 Hz, 2 H) 
2.91 - 3.00 (m, 2 H) 2.71 (t, J=7.25 Hz, 2 H) 2.03 - 2.15 (m, 2 H). 
 
8-chloro-3-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine (4) 
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A solution of 3-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[BLAH]pyrazolo [BLAH]pyrimidin-8-ol (2.3 g, 8.54 
mmol, 1.00 Eq) in POCl3 (20 mL) was stirred at 80 °C for3 hr. TLC (Petroleum ether: Ethyl acetate=2: 1) showed 
that starting material was consumed completetly. The mixture was cooled to 30 °C and poured into a stirring 
water (100 mL) slowly. The solution was extected with EtOAc (150 mL*3). The organic layers were washed with 
brine (100 mL*3), dried over Na2SO4, concentrated to afford 8-chloro-3-(4-fluoro- phenyl)-6,7-dihydro-5H-
cyclopenta[BLAH] pyrazolo[BLAH]pyrimidine (2 g, 6.95 mmol, 81% yield) as a light green solid. 
1H NMR (400 MHz, DMSO-d6):  8.72 (s, 1 H) 8.12 - 8.18 (m, 2 H) 7.29 (t, J=8.97 Hz, 2 H) 3.10 (s, 2 H) 3.03 (t, 
J=7.40 Hz, 2 H) 2.21 (t, J=7.47 Hz, 2 H). 
3-cyclopropyl-4-iodo-1H-pyrazolo[3,4-b]pyridine (AWZ9018) 
 
To a solution of 8-chloro-3-(4-fluorophenyl)-6,7-dihydro-5H- cyclopenta [BLAH]pyrazolo[BLAH]pyrimidine (100 
mg, 347.56 µmol, 1.00 Eq) and 2-morpholinoethanamine (45 mg, 347.56 µmol, 1.00 Eq) in DMF (2 mL) was 
added Et3N (70 mg, 695.12 µmol, 2.00 Eq) . The mixture was stirred at 100 °C for 1 hr. LCMS showed that the 
starting material was consumed completetly. The mixture was dissolved in DMSO (2 mL) and purified by prep-
HPLC (Base) to AWZ9018 (24 mg, 62.92 µmol, 18% yield) as a white solid. 
 
The above general procedure were followed for the syntheses of AWZ9021. 
 
 
N1-(3-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl)-N2,N2-dimethylethane-
1,2-diamine (AWZ9018) 
1H NMR (400MHz, DMSO-d6) 8.51 (s, 1 H) 8.24 - 8.29 (m, 1 H) 8.12 - 8.19 (m, 2 H) 7.35 - 7.41 (m, 1 H) 7.22 (s, 2 H) 3.68 
- 3.77 (m, 2 H) 3.18 - 3.24 (m, 2 H) 2.89 (s, 2 H) 2.52 - 2.56 (m, 2 H) 2.23 (s, 6 H) 2.06 - 2.16 (m, 2 H). 
LCMS (Method 5-95AB, ESI): RT =0.725 min / 2 min, M+H+ =340.0. yield: 25%. 
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3-(4-fluorophenyl)-N-(pyridin-2-ylmethyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine 
(AWZ9021) 
1H NMR (400MHz, DMSO-d6) 8.55 - 8.60 (m, 1 H) 8.30 - 8.36 (m, 1 H) 8.17 (dd, J=8.91, 5.65 Hz, 2 H) 7.81 (d, J=1.76 Hz, 
1 H) 7.38 (d, J=7.91 Hz, 1 H) 7.32 (dd, J=7.15, 5.14 Hz, 1 H) 7.23 (t, J=8.97 Hz, 2 H) 4.97 (d, J=6.40 Hz, 2 H) 3.03 (s, 2 H) 
2.85 (s, 2 H) 1.94 - 2.05 (m, 2 H). 
 
LCMS (Method 10-80CD, ESI): RT =1.554 min / 2 min, M+H+ =360.1. yield: 42%. 
 
N1-(3-(4-fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)ethane-1,2- diamine (AWZ9027). 
 
 
 
 
 
 
  
A mixture of compound 1 (100.00 mg, 0.36 mmol), ethane-1, 2-diamine (43.60 mg, 0.73 mmol) in DMF (6 
mL) was stirred for 16 hr at 60 °C. LCMS showed the starting material was disappeared. The mixture was 
purified directly by prep-HPLC (FA) to AWZ9027 (50.00 mg, 46% yield) as white solid. 
LCMS (Method 0-60CDAB, ESI): RT =1.003 min / 2 min, M+H+ =300.0 
1H NMR (400MHz, DMSO-d6)  = 8.50 (s, 1H), 8.37 (br. s., 1H), 8.19 (dd, J=5.6, 8.8 Hz, 2H), 7.22 (t, J=9.0 Hz, 2H), 3.99 (t, 
J=6.0 Hz, 2H), 3.01 (t, J=5.8 Hz, 2H), 2.49 (s, 3H), 2.26 (s, 3H). 
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N1-(3-(4-fluorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)-2-methylpropane-1,2-diamine (AWZ9028) 
 
 
 
 
 
To a mixture of compound 1 (100.00 mg, 362.70 µmol, 1.00 eq) and 2-methylpropane-1,2-diamine (63.94 mg, 
725.40 µmol, 2.00 eq) in DMF (6 mL) was added K2CO3 (100.26 mg, 725.40 µmol, 2.00 eq) in one portion at 20 °C 
under N2. The mixture was stirred at 20 °C for 12 h, then was heated to 40 °C and stirred for 2 hours. TLC 
(petroleum ether/ethyl acetate= 1/1) showed compound 1 was consumed completely. The mixture was 
concentrated in reduced pressure at 20 °C. The residue was purified by prep-HPLC (FA) to get AWZ9028 (109.51 
mg, 334.48 µmol, 92.22% yield, 100% purity) as white solid. 
LCMS M+H+ =328.1, rt = 1.081 min, purity 100% 
1H NMR (400 MHz, CHLOROFORM-d)  8.38 (br. s., 1H), 8.18 (s, 1H), 8.02 (dd, J=5.58, 8.22 Hz, 2H), 7.12 (t, J=8.72 
Hz, 2H), 6.36 (br. s., 1H), 3.78 (br. s., 2H), 2.55 (s, 3H), 2.29 (br. s., 3H), 1.37 (s, 6H) 
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tert-butyl(5,6-dimethyl-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (3) 
 
 
 
 
 
A suspension of compound 1 (150.00 mg, 312.95 µmol, 1.00 eq), [6-(trifluoromethyl)-3-pyridyl]boronic acid 2 
(71.70 mg, 375.54 µmol, 1.20 eq), Na2CO3 (66.34 mg, 625.90 µmol, 2.00 eq)  and ditert-
butyl(cyclopentyl)phosphane;dichloropalladium;iron (20.40 mg, 31.30 µmol, 0.10 eq) in dioxane (10 mL) and 
water (2 mL) was stirred at 100 °C under nitrogen atmosphere for 12 hrs. TLC (petroleum ether/ethyl acetate= 
3/1) showed compound 1 was consumed completely and a new spot was formed. Removed solvent under 
vacuum to give a residue which was purified directly by prep-TLC (petroleum ether/ethyl acetate= 3/1) to give 
compound 3 (112.00 mg, 224.67 µmol, 71.79% yield, 98.1% purity) as a yellow solid. 
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5,6-dimethyl-N-(pyridin-2-ylmethyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9029) 
 
 
 
A mixture of compound 3 (113.00 mg, 226.68 µmol, 1.00 eq) in HCl/EtOAc (6 mL) was stirred at 20 °C for 4 hrs. 
TLC (petroleum ether/ethyl acetate= 3/1) showed compound 3 was consumed completely. The mixture was 
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concentrated in vacuo and purified by prep-HPLC (FA) to get AWZ9029 (33.30 mg, 83.59 µmol, 36.88% yield, 
99.7% purity) as white solid. 
LCMS M+H+ =399.0, rt = 1.221 min, purity 99.7% 
1H NMR (400 MHz, METHANOL-d4)  9.47 (s, 1H), 8.73 (d, J=8.16 Hz, 1H), 8.50-8.56 (m, 2H), 7.77-7.84 (m, 2H), 
7.46 (d, J=7.91 Hz, 1H), 7.29-7.35 (m, 1H), 5.27 (s, 2H), 2.59 (s, 3H), 2.37 (s, 3H) 
 
 
tert-butyl(6-methyl-3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate 
(3). 
 
 
 
 
 
A suspension of compound 1 (150 mg, 0.3 mmol), (1-methylpyrazol-4-yl) boronic acid 2 (47.29 mg, 0.38 mmol),                   
ditert-butyl (cyclopentyl) phosphane;dichloropalladium;iron (20.40 mg, 0.32 mmol), Na2CO3 (66.34 mg, 0.63 
mmol) in dioxane (10 mL), water (2 mL) was stirred  at 100°C under nitrogen atmosphere for 2 hr. TLC 
(petroleum ether/ethyl acetate=3:1) showed starting material was consumed and a new spot formed. 
Removed solvent under vacuum to give a residue which was purified directly by TLC (petroleum ether/ethyl 
acetate=3:1) to give compound 3 (70.00 mg, 52% yield) as pale yellow oil. 
 
5,6-dimethyl-3-(1-methyl-1H-pyrazol-4-yl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9030) 
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To a solution compound 3 (70.00 mg, 0.16 mmol)   in EtOAc (3 mL) was added HCl/EtOAc (4 M, 3.00 mL). The 
solution was stirred for 2 hr at 25 °C and a white precipitate was formed. TLC (petroleum ether/ethyl 
acetate=3:1) showed the starting material was consumed completely. Filtrate the precipitate which was 
purified by prep-HPLC (FA) to give AWZ9030 (20.00 mg, 37% yield) as white solid. 
LCMS (Method 5-95AB, ESI): RT =0.661 min / 2 min, M+H+ =334.1 
1H NMR (400MHz, DMSO-d6)  = 8.56 (d, J=4.8 Hz, 1H), 8.24 (s, 1H), 8.09 (s, 1H), 7.89 (s, 1H), 7.83 - 7.72 (m, 2H), 
7.37 (d, J=8.2 Hz, 1H), 7.33 - 7.26 (m, 1H), 5.18 (d, J=5.8 Hz, 2H), 3.88 (s, 3H), 2.48 (s, 3H), 2.29 (s, 3H). 
 
 
 
 
tert-butyl(5,6-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidin-7-
yl)(pyridin-2-ylmethyl)carbamate (2) 
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To a mixture of tert-butyl N-(3-iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(100 mg, 208.63 µmol, 1 eq) , Pin2B2 (79 mg, 312.95 µmol, 1.5 eq) and KOAc (41 mg, 417.26 µmol, 2 eq) in 
DMSO (4 mL) was de-gassed and then heated at 100 °C for 1 hour under N2. LCMS showed the starting material 
was consumed completely and 40 % of the desired product tert-butyl N-[5,6-dimethyl-3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate, 30 % of the by-product 
tert-butyl N-[3-[7-[tert-butoxycarbonyl(2-pyridylmethyl)amino]-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-3-yl]-
5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate. The mixture was filtered and 
concentrated in vacuo to give a crude solution, which was used in the next step without purification. 
 
 
3-(3-cyclopropyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-N-methylbenzamide (4) 
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To a mixture of tert-butyl N-[5,6-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (100 mg, 208.60 µmol, 1 eq) , 4-bromo-1,3,5-trimethyl-
pyrazole (39 mg, 208.60 µmol, 1 eq) ,Pd(dppf)Cl2 (15 mg, 20.86 µmol, 0.1 eq) and K2CO3 (57 mg, 417.20 µmol, 2 
eq) in DMSO (4 mL) and H2O (1 mL) was de-gassed and then heated at 110 °C for 1 hr under N2. LCMS showed 
the starting material was consumed completely and only about 18 % of desired product. The mixture 
was added water (30 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine (30 mL) 
and dried over Na2SO4, concentrated  in vacuo to give a residue, which was purified by prep-TLC (Petroleum 
ether: Ethyl acetate=1: 2) to afford the tert-butyl N-[5,6-dimethyl-3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (50 mg, crude) as a brown oil. 
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5,6-dimethyl-N-(pyridin-2-ylmethyl)-3-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9031) 
 
 
 
 
 
 
A solution of tert-butyl N-[5,6-dimethyl-3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (50 mg, 108.33 µmol, 1 eq) in HCl/EtOAc (5 mL) was stirred at 30 °C for 12 hour 
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. LCMS showed that starting material was consumed completetly. The mixture solution was concentrated. The 
residue was mixed with DMSO (3 mL) and purified by prep-HPLC (HCOOH) to afford 5,6-dimethyl-N-(2-
pyridylmethyl)-3-(1,3,5-trimethylpyrazol-4-yl)pyrazolo[1, 5-a]pyrimidin-7-amine (13 mg, 35.69 µmol, 32% yield) 
as a white solid. 
 
1H NMR (400MHz, DMSO-d6) 8.56 - 8.60 (m, 1 H) 7.96 (s, 1 H) 7.77 - 7.84 (m, 2 H) 7.40 - 7.44 (m, 1 H) 7.28 - 7.35 (m, 1 
H) 5.15 - 5.21 (m, 2 H) 3.70 (s, 3 H) 2.40 (s, 3 H) 2.30 (s, 3 H) 2.18 (s, 3 H) 2.09 (s, 3 H) 
LCMS (Method 5-95AB, ESI): RT =0.699 min / 1.5 min, M+H+ =362.1 
 
 
 
 
 
 
 
 
Synthesis of 1-bromo-2-chloro-4-(methylsulfonyl)benzene (2) 
 
 
 
                                                                          Appendix 1 _____________________________________                                                                                                
 
 
 
240 
 
 
To a mixture of 2-chloro-4-methylsulfonyl-aniline (300.00 mg, 1.46 mmol, 1.00 eq)  in ACETONITRILE (5.00 mL) 
was added n-butyl nitrite (225.63 mg, 2.19 mmol, 1.50 eq)  in one portion at 0 °C under N2. The mixture was 
stirred at 0 °C for 30 min. Then CuBr (418.51 mg, 2.92 mmol, 2.00 eq) was added to the mixture. The mixture 
was heated to 65 °C and stirred for 1.5 hrs. TLC (petroluem ether: ethyl acetate=3: 1) showed  most of 
the starting material  was consumed. The mixture was diluted with EtOAc (100 mL) and washed with saturated 
brine (20*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by 
silica gel chromatography (ethyl acetate: petroleum ether=3: 1) to afford 1-bromo-2-chloro-4-methylsulfonyl-
benzene (700.00 mg, 2.60 mmol, 59% yield) as white solid. 
1H NMR (300 MHz, CHLOROFORM-d) δ 7.67 - 7.72 (m, 1 H) 7.83 - 7.89 (m, 1 H) 8.02 - 8.06 (m, 1 H) 
Synthesis of tert-butyl (3-(2-chloro-4-(methylsulfonyl)phenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-
yl)(pyridin-2-ylmethyl)carbamate (4)  
 
 
 
 
To a mixture of tert-butyl N-[5,6-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (120.00 mg, 250.32 µmol, 1.00 eq) and 1-bromo-2-chloro-4-
methylsulfonyl-benzene (101.21 mg, 375.49 µmol, 1.50 eq) in DMF (5.00 mL) was added Pd(dppf)Cl2 (18.32 mg, 
25.03 µmol, 0.10 eq) in one portion at 25 °C under N2. The mixture was heated to 110 °C and stirred for 1 
hours. TLC (ethyl acetate: petroluem ether=3:1) showed the starting material was consumed and the MS of 
desired product was detceted. The mixture was extracted with ethyl acetate (30 mL*2). The combined organic 
phase was washed with saturated brine (10 mL*5), dried with anhydrous Na2SO4, filtered and concentrated in 
vacuo.The residue was combined with EW1701-44-P1 to  purify by prep-TLC (ethyl acetate:petroluem 
ether=3:1) to afford tert-butyl N-[3-(2-chloro-4-methylsulfonyl-phenyl)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-
7-yl]-N-(2-pyridylmethyl)carbamate (80.00 mg, 147.59 µmol, 59% yield) as white solid. 
LCMS (Method 5-95AB): RT =0.791min / 1.5 min, M+H+ = 542.1 
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Synthesis of 3-(2-chloro-4-(methylsulfonyl)phenyl)-5,6-dimethyl-N-(pyridin-2-ylmethyl) pyrazolo[1,5-
a]pyrimidin-7-amine(AWZ9032) 
 
 
 
 
 
tert-butyl N-[3-(2-chloro-4-methylsulfonyl-phenyl)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (80.00 mg, 147.59 µmol, 1.00 eq)  in HCl/EtOAc (5.00 mL) was stirred at 25 °C and 
stirred for 3 hours. LCMS showed the starting material was consumed and the MS of desired product was de-
tected. The mixture was concentrated in reduced pressure. The residue was diluted with ethyl acetate (60 mL) 
and saturated NaHCO3 (20 mL). The organic phase was separated and washed with saturated brine (10 mL*2), 
dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by prep-TLC (ethyl 
acetate: petroluem ether= 3: 1) to afford 3-(2-chloro-4-methylsulfonyl-phenyl)-5,6-dimethyl-N-(2-
pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (38.00 mg, 85.99 µmol, 58% yield)  as yellow solid. 
LCMS (Method 5-95AB): RT =0.720min / 1.5 min, M+H+ = 442.0 
1H NMR (400 MHz, DMSO-d6) δ 2.32 (s, 3 H) 2.47 (s, 3 H) 3.31 (s, 3 H) 5.22 - 5.28 (m, 2 H) 7.28 - 7.34 (m, 1 H) 
7.39 - 7.44 (m, 1 H) 7.77 - 7.84 (m, 1 H) 7.90 - 7.95 (m, 1 H) 8.01 - 8.06 (m, 2 H) 8.41 - 8.46 (m, 1 H) 8.54 - 8.58 
(m, 1 H) 8.59 - 8.62 (m, 1 H)  
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tert-butyl(5,6-dimethyl-3-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (3) 
 
 
 
 
 
 
To a mixture of tert-butyl N-(3-iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(200 mg, 417.27 µmol, 1 eq), tributyl(2-pyridyl)stannane (215 mg, 584.18 µmol, 1.4 eq), CuI (16 mg, 83.45 
µmol, 0.2 eq)  in dioxane (5 mL) was added Pd(PPh3)4 (48.22 mg, 41.73 µmol, 0.10 eq). The mixture was de-
gassed and then heated at 100 °C for 2 hour under N2. TLC (Petroleum ether: Ethyl acetate=1: 1) showed 
that the starting material was consumed completely. The mixture was added EtOAc (40 mL) and washed with a 
solution of KF (10 %, 20 mL). The organic layer was washed with brine (20 mL), dired over Na2SO4 and 
concentrated in vacuo to give a residue, which was purified by chromatography on silcal gel to afford the crude 
product (purity: 80 %). The crude was purified by prep-HPLC (FA) to afford tert-butyl N-[5,6-dimethyl-3-(2-
pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (80 mg, 182.11 µmol, 44% yield, 98% 
purity) as a yellow solid. 
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5,6-dimethyl-3-(pyridin-2-yl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9033) 
 
 
 
 
 
 
 
A solution of tert-butyl N-[5,6-dimethyl-3-(2-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (90 mg, 209.06 µmol, 1 eq) in HCl/EtOAc (5 mL) was stirred at 30 °C  for 12 
hour. LCMS showed that starting material was consumed completetly. A solid was forming. The mixture 
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solution was concentrated. The solid was dissloved in MeOH (15 mL) and mixed with Anion exchange resin. The 
mixture was filtered and concentrated. The residue was added deionized water (50 mL) and lyophilized to 
afford 5,6-dimethyl-3-(2-pyridyl)-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (60 mg, 181.60 µmol, 
87% yield) as a yellow solid.  
 
1H NMR (400MHz, DMSO-d6) 9.08 - 9.16 (m, 1 H) 8.76 - 8.82 (m, 1 H) 8.62 - 8.72 (m, 2 H) 8.38 - 8.51 (m, 2 H) 8.10 - 
8.18 (m, 1 H) 7.68 - 7.76 (m, 1 H) 7.61 (br. s., 2 H) 5.48 (d, J=5.27 Hz, 2 H) 2.62 (s, 3 H) 2.33 (s, 3 H) 
LCMS (Method 5-95AB, ESI): RT =0.680 min / 1.5 min, M+H+ =331.0 
 
 
 
 
tert-butyl(5,6-dimethyl-3-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (3) 
 
 
 
 
 
 
To a mixture of tert-butyl N-(3-iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(150 mg, 312.95 µmol, 1 eq), cyclopropylboronic acid (269 mg, 3.13 mmol, 10 eq), Pd(dppf)Cl2 (23 mg, 31.30 
µmol, 0.1 eq) in DMF (4 mL) was added Cs2CO3 (204 mg, 625.90 µmol, 2 eq). The mixture was de-gassed and 
then heated at 100 °C for 12 hour under N2. TLC (Petroleum ether: EtOAc=1: 1) showed the starting material 
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was consumed completely. The mixture was added water (20 mL) and extracted with EtOAc (40 mL). The 
organic layer was washed brine (20 mL*3), dried over Na2SO4, concentrated in vacuo to give a residue, which 
was purified by column chromatography on silcal gel (Petroleum ether: EtOAc=1: 1 to 1: 3, 3 % DCM) to afford 
the tert-butyl N-(3-cyclopropyl-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate (30 
mg, 76.24 µmol, 24% yield) as a light yellow solid. 
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3-cyclopropyl-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9035) 
 
 
 
 
 
 
 A solution of tert-butyl N-(3-cyclopropyl-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (40 mg, 101.66 µmol, 1 eq) in HCl/EtOAc (5 mL)was stirred at 30 °C for 12 hour. LCMS 
showed that the reaction was complated. The mixture was concentrated to a residue. The residue was 
added Et3N (0.3 mL) and DMSO (3 mL), purified by prep-HPLC (Base) to afford 3-cyclopropyl-5,6-dimethyl-N-(2-
pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (13 mg, 44.99 µmol, 44% yield) as a white solid. 
1H NMR (400MHz, DMSO-d6) 8.53 - 8.57 (m, 1 H) 7.74 - 7.80 (m, 1 H) 7.72 (s, 1 H) 7.63 - 7.70 (m, 1 H) 7.32 - 7.37 (m, 1 
H) 7.25 - 7.31 (m, 1 H) 5.12 (d, J=5.90 Hz, 1 H) 2.41 (s, 3 H) 2.26 (s, 3 H) 1.87 - 1.94 (m, 1 H) 0.84 (d, J=8.28 Hz, 2 H) 0.72 
(d, J=3.51 Hz, 2 H). 
LCMS (Method 5-95AB, ESI): RT =0.652 min / 1.5 min, M+H+ =294.0 
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 tert-butyl (3-(3,6-dihydro-2H-pyran-4-yl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (3) 
 
 
 
 
 
 A mixture of tert-butyl N-(3-iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(200.00 mg, 417.27 µmol, 1.00 eq) , 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(131.49 mg, 625.90 µmol, 1.50 eq) , ditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron (27.20 mg, 
41.73 µmol, 0.10 eq) and Na2CO3 (88.45 mg, 834.53 µmol, 2.00 eq) in dioxane (20.00 mL) and H2O (4.00 mL) 
was stirred at 100 °C for 4 hour under N2 protection. The color of the mixture was turned black. TLC (Petrole-
um ether:EtOAc=1:1) showed starting material consumed. The mixture was concentrated to give a residue. The 
residue was purified by prep-TLC (Prteoleum ether: EtOAc=1:1) to give tert-butyl N-[3-(3,6-dihydro-2H-pyran-4-
yl)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (100.00 mg, 229.61 µmol, 55% 
yield) as a yellow solid.  
 
 tert-butyl (5,6-dimethyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (4) 
 
 
 
 
 
 A mixture of tert-butyl N-[3-(3,6-dihydro-2H-pyran-4-yl)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (100.00 mg, 229.61 µmol, 1.00 eq) and Pd/C (10.00 mg) in MeOH (3.00 mL) was 
stirred at 25-35 °C for 1 hour under H2 (15 psi). TLC (Petroleum ether: EtOAc=1:1) showed starting material 
consumed. The mixture was filtered and the filtrate was concentrated to give a residue. The residue was puri-
fied by prep-TLC (Petroleum ether: EtOAc=1:1) to give tert-butyl N-(5,6-dimethyl-3-tetrahydropyran-4-yl-
pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate (100.00 mg, crude) as a colorless oil. 
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5,6-dimethyl-N-(pyridin-2-ylmethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9036) 
 
 
 
 
 
 A mixture of tert-butyl N-(5,6-dimethyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (100.00 mg, 228.56 µmol, 1.00 eq) in HCl/EtOAc (4 M, 5.00 mL) was stirred at 25-
30 °C for 1 hour . LCMS showed starting material consumed and MS of desired product. The mixture was con-
centrated to give a residue. The residue was purified by prep-TLC (Petroleum ether:EtOAc=1:2) to give 5,6-
dimethyl-N-(2-pyridylmethyl)-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-amine (45.00 mg, 132.03 
µmol, 57% yield, 99% purity) as a light yellow solid. 
LCMS (Method 5-95AB): RT =0.560 min / 1.5 min, M+H+ = 338.0 
1H NMR (400 MHz, METHANOL-d4) :  8.79 (dd, J=5.71, 0.82 Hz, 1 H) 8.49 (td, J=7.94, 1.32 Hz, 1 H) 8.07 (d, 
J=8.16 Hz, 1 H) 7.99 (s, 1 H) 7.91 (t, J=6.53 Hz, 1 H) 5.82 (s, 2 H) 3.98 - 4.07 (m, 2 H) 3.58 (td, J=11.14, 3.58 Hz, 2 
H) 3.17 (tt, J=10.49, 5.25 Hz, 1 H) 2.70 (s, 3 H) 2.37 (s, 3 H) 1.73 - 1.85 (m, 1 H). 
 
 
 
3-(4-fluorophenyl)-2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ol (3). 
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To a solution of 4-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-amine (7.20 g, 37.66 mmol, 1.00 eq)  and ethyl 2-
oxocyclopentanecarboxylate (7.06 g, 45.19 mmol, 1.20 eq)  was added TsOH.H2O (716.31 mg, 3.77 mmol, 0.10 
eq). The mixture was stirred at 110°C for 12 hrs. TLC (petroleum ether/ ethyl acetate=1:1) showed that starting 
material was consumed completely. The mixture was cooled to 30°C and concentrated in vacuo. The residue 
was triturated with petroleum ether : ethyl acetate=2 : 1 (15 mL) to afford 3-(4-fluorophenyl)-2-methyl-6,7-
dihydro-5H-cyclopenta[BLAH]pyrazolo[BLAH]pyrimidin-8-ol (6.50 g, 20.65 mmol, 54% yield, 90% purity)  as 
black brown solid 
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8-chloro-3-(4-fluorophenyl)-2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5a]pyrimidine (4). 
 
 
 
 
 
A solution of 3-(4-fluorophenyl)-2-methyl-6,7-dihydro-5H-cyclopenta[BLAH]pyrazolo[BLAH]pyrimidin-8-ol (2.00 
g, 7.06 mmol, 1.00 eq)  in POCl3 (8 mL) was stirred at 110°C for 8 hr. TLC (petroleum ether : ethyl acetate=1:2) 
showed that starting material was consumed completely. The mixture was cooled to 30°C and poured into a 
stirring water (100 mL) slowly. The solution was extected with Ethyl acetate (100 mL*3). The 
combined organic layer was washed with brine (50 mL*3), dried with Na2SO4, concentrated in vacuo, the 
residue was triturated with petroleum ether : ethyl acetate=20 : 1 (21 mL) to afford 8-chloro-3-(4-
fluorophenyl)-2-methyl-6,7-dihydro-5H-cyclopenta[BLAH]pyrazolo[BLAH]pyrimidine (800.00 mg, 2.65 mmol, 
37% yield)  as dark yellow solid. 
 
3-(4-fluorophenyl)-2-methyl-N-(pyridin-2-ylmethyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-
amine (AWZ9037) 
 
 
 
 
 
 
To a solution of 8-chloro-3-(4-fluorophenyl)-2-methyl-6,7-dihydro-5H-
cyclopenta[BLAH]pyrazolo[BLAH]pyrimidine (100.00 mg, 331.40 µmol, 1.00 eq) and 2-pyridylmethanamine 
(46.59 mg, 430.82 µmol, 1.30 eq) in DMF (3.00 mL) was added Et3N (100.60 mg, 994.20 µmol, 3.00 eq). The 
mixture was stirred at 70°C for 3 hrs. TLC (petroleum ether : ethyl acetate= 3 : 1) showed that starting material 
was consumed completely. The mixture was cooled to 30°C, then solid was precipitate after added a few drops 
of water. The mixture was stirred at room temperature for 1 hour. The solid was collected by filtration and 
triturated with ethyl acetate (3 mL) and a few drops of methanol for 1 h to afford 3-(4-fluorophenyl)-2-methyl-
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N-(2-pyridylmethyl)-6,7-dihydro-5H-cyclopenta[BLAH]pyrazolo[BLAH]pyrimidin-8-amine (54.00 mg, 140.56 
µmol, 42% yield, 97.2% purity) as white solid. 
LCMS (Method 5-95AB, ESI): RT =0.828 min / 2 min, M+H+ =374.0.yield:42.4% 
1H NMR (400MHz, DMSO-d6) 8.58 - 8.57 (d, J=4.4 Hz, 1 H) 8.21 - 8.19 (t, J=6.8 Hz, 1 H) 7.80 - 7.76 (m, 3 H) 7.37 - 7.35 
(d, J=8 Hz, 1 H) 7.28 - 7.24 (m, 3 H) 4.94 - 4.93 (d, J=6.4 Hz, 2 H) 2.99 - 2.96 (t, J=7.4 Hz, 2 H) 2.79 - 2.75 (t, J=7.8 Hz, 2 H) 
2.55 (s, 3 H) 1.97 -1.93 (t, J=7.4 Hz, 2 H) 
 
 
Synthesis of ethyl 2-(methylsulfonyl)-3-oxobutanoate (2) 
 
 
 
 
 
 
To a mixture of ethyl 3-oxobutanoate (2.00 g, 15.37 mmol, 1.00 eq) in THF (20.00 mL) was added NaH (922.08 
mg, 23.06 mmol, 1.50 eq) in portions at 0 °C under N2 protection. The mixture was stirred at 0 °C for 30 min. 
Then methane;methanesulfonyl chloride (3.89 g, 30.74 mmol, 2.00 eq)  was added to the mixture and the mxi-
ture was warmed to 25 °C and stirred for 2 hrs. TLC (petroluem ether: ethyl acetate = 5: 1) showed the starting 
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material was consumed completely. The mixture was diluted with ethyl acetate (60 mL*2) and washed with 
saturated brine (40 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The residue 
was putified by silica gel chromatography (petroleum ether: ethyl acetate = 20: 1~10:1~5: 1) to afford ethyl 2-
methylsulfonyl-3-oxo-butanoate (1.00 g, crude) as yellow liquid. 
 
 
 
Synthesis of 3-(4-fluorophenyl)-5-methyl-6-(methylsulfonyl)pyrazolo[1,5-a]pyrimidin-7-ol (3) 
 
 
 
 
 To a mixture of 4-(4-fluorophenyl)-1H-pyrazol-5-amine (1.64 g, 9.24 mmol, 1.00 eq) in toluene (20.00 mL) was 
added TsOH.H2O (175.79 mg, 924.17 µmol, 0.10 eq) in portions at 25 °C under N2. TLC (petroluem ether: ethyl 
acetate = 5: 1) showed the starting material was consumed completed. The mixture was concentrated in vacuo. 
The residue was putified by trituation (Ethyl acetate=5 mL) to afford 3-(4-fluorophenyl)-5-methyl-6-
methylsulfonyl-pyrazolo[1,5-a]pyrimidin-7-ol (750.00 mg, 2.33 mmol, 25% yield) as yellow solid. 
LCMS (Method 10-80CD): RT =0.702 min / 2 min, M+H+ = 332.1 
1H NMR (400 MHz, DMSO-d6) δ 2.73 - 2.75 (m, 3 H) 3.32 - 3.34 (m, 3 H) 7.30 - 7.37 (m, 2 H) 7.59 - 7.66 (m, 2 H) 8.21 - 
8.24 (m, 1 H) 
 
 
 
Synthesis of 3-(4-fluorophenyl)-5-methyl-6-(methylsulfonyl)pyrazolo[1,5-a]pyrimidin-7-ole (4) 
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3-(4-fluorophenyl)-5-methyl-6-methylsulfonyl-pyrazolo[1,5-a]pyrimidin-7-ol (200.00 mg, 622.41 µmol, 1.00 
eq) and DMAC (300.00 uL)  was added to POCl3 (32.45 mg, 211.62 µmol, 0.34 eq) in one portion at 25 °C under 
N2. The mixture was  heated to 110 °C and stirred for 14  hours. TLC (Dichloromethane : Methanol=10:1) 
showed the starting material was consumed and the desired product was detected compared with standard 
sample. The mixture was concentrated  then  azeotroped  with toluene (3mL*3) in vacuo to afford 7-chloro-3-
(4-fluorophenyl)-5-methyl-6-methylsulfonyl-pyrazolo[1,5-a]pyrimidine (300.00 mg, crude) as brown solid. The 
crude product was used directly for next step without purufication. 
 
Synthesis of 3-(4-fluorophenyl)-5-methyl-6-(methylsulfonyl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9041) 
 
 
 
 
 
To a mixture of 7-chloro-3-(4-fluorophenyl)-5-methyl-6-methylsulfonyl-pyrazolo[1,5-a]pyrimidine (200.00 mg, 
588.63 µmol, 1.00 eq) and 2-pyridylmethanamine (82.75 mg, 765.22 µmol, 1.30 eq) in DMA (5.00 mL) was add-
ed Et3N (2.19 g, 21.64 mmol, 36.77 eq) in one portion  under N2. The mixture was stirred at 25 °C for 0.5 
hrs.  TLC (petroluem ether: ethyl acetate=3: 1) showed the starting material was consumed and a new spot. 
The mixture was poured into water (20 mL). The mixture was diluted with ethyl acetate (30 mL), washed with 
saturated brine (10 mL*4), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was 
purified by prep-TLC (Petroleum ether: Ethyl acetate=3: 1)  followed by trituation with dichloromethane (2 mL) 
to afford 3-(4-fluorophenyl)-5-methyl-6-methylsulfonyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(48.00 mg, 116.66 µmol, 20% yield) as  light yellow solid. 
LCMS (Method 5-95AB): RT =0.846min / 1.5 min, M+H+ = 412.0 
1H NMR (400 MHz, DMSO-d6): δ2.77 (s, 3 H) 3.42 - 3.43 (m, 3 H) 5.65 - 5.68 (m, 2 H) 7.23 - 7.29 (m, 2 H) 7.30 - 
7.35 (m, 1 H) 7.45 - 7.49 (m, 1 H) 7.79 - 7.85 (m, 1 H) 8.14 - 8.19 (m, 2 H) 8.51 - 8.54 (m, 1 H) 8.68 (s, 1 H) 9.61 - 
9.66 (m, 1 H) 
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8-chloro-3-(4-fluorophenyl)-6,7-dihydro-5H-pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidine (5) 
 
 
 
 
 
To a solution of POCl3 (5 mL) was added tert-butyl 3-(4-fluorophenyl)-8-hydroxy-5,7-
dihydropyrazolo[BLAH]pyrrolo[BLAH]pyrimidine-6-carboxylate (500 mg, 1.35 mmol, 1 eq) . The mixture was 
stirred at 80 °C for 4 hour . TLC (Petroleum ether: EtOAc=0:1) showed that starting material was consumed 
completetly. The mixture was added into a stirring water (50 mL) slowly and extracted with EtOAc (50 mL*2). 
The combined organic layers were washed with brine (50 mL), concentrated. The residue (100 mg, 346.37 µmol) 
was used with out purification. 
 
tert-butyl8-chloro-3-(4-fluorophenyl)-5H-pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate (6) 
 
 
 
 
 
 
To a solution of 8-chloro-3-(4-fluorophenyl)-6,7-dihydro-5H-pyrazolo[BLAH]pyrrolo[BLAH]pyrimidine (100 mg, 
346.37 µmol, 1 eq) in H2O (6 mL) and THF (6 mL) was added NaHCO3 (58 mg, 692.74 µmol, 2 eq) , Boc2O (151.19 
mg, 692.74 µmol, 2 eq). The mixture was stirred at 30 °C for 12 hour. TLC (Petroleum ether: EtOAc=5: 1) 
showed that a new spot. The mixture was concentrated. The residue was purified by chromatography on silica 
gel (Petroleum ether: EtOAc=10: 1) to afford tert-butyl 8-chloro-3-(4-fluorophenyl)-5,7-
dihydropyrazolo[BLAH]pyrrolo[BLAH]pyrimidine-6-carboxylate (100 mg, 257.19 µmol, 74% yield) as a yellow 
solid. 
 
tert-butyl3-(4-fluorophenyl)-8-((pyridin-2-ylmethyl)amino)-5H-pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidine-6(7H)-
carboxylate (7) 
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To a solution of tert-butyl 8-chloro-3-(4-fluorophenyl)-5,7-dihydropyrazolo[BLAH]pyrrolo[BLAH]pyrimidine-6-
carboxylate (80 mg, 205.75 µmol, 1 eq) in DMF (3 mL) was added phenylmethanamine (26 mg, 246.90 µmol, 
1.2 eq) and Et3N (42 mg, 411.50 µmol, 2 eq). The mixture was stirred at 80 °C for 1 hour. TLC (Petroleum ether: 
EtOAc=2: 1) showed that starting material was consumed completetly. To the mixture was added water (40 
mL), and the solution was extracted with EtOAc (30 mL*2). The combined organic layers were washed with 
brine (30 mL*2), dried over Na2SO4, concentrated. The residue was purified by chromatography on silica gel 
(Petroleum ether: EtOAc=1: 1) to afford tert-butyl 3-(4-fluorophenyl)-8-(2-pyridylmethylamino)-5,7-
dihydropyrazolo [BLAH]pyrrolo[BLAH]pyrimidine-6-carboxylate (70 mg, 152.01 µmol, 74% yield) as a yellow 
solid. 
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6-chloro-5-methylpyrazolo[1,5-a]pyrimidin-7-ol (3) 
 
 
 
To a solution of 1H-pyrazol-3-amine (2.5 g, 30.1 mmol, 1 eq) and methyl 2-chloro-3-oxo-butanoate (4.5 g, 30.1 
mmol, 1 eq) in toluene (20 mL) was added TsOH.H2O (572 mg, 3 mmol, 0.1 eq). The mixture was stirred at 100 
°C for 20 mins. A light yellow solid was forming. TLC (EtOAc) showed that 1H-pyrazol-3-amine was consumed 
completetly and a new spot. The mixture was cooled to room temperature. The solid was filtered and was 
washed (Petroleum ether, 20 mL) to give 6-chloro-5-methyl-pyrazolo[1,5-a]pyrimidin-7-ol (5 g, 27.2 mmol, 91% 
yield) as a grey solid. 
1H NMR (400MHz, DMSO-d6) 7.91 (d, J=2.01 Hz, 1H), 6.18 (d, J=1.88 Hz, 1H), 2.45 (s, 3H). 
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6,7-dichloro-5-methylpyrazolo[1,5-a]pyrimidine (4)  
 
 
 
To a solution of 6-chloro-5-methyl-pyrazolo[1,5-a]pyrimidin-7-ol (3 g, 16.3 mmol, 1 eq) in CH3CN (10 mL) was 
added POCl3 (41 g, 267.32 mmol, 16 eq) The mixture was stirred at 100 °C for 16 hours. TLC (EtOAc) showed 
that about half of 6-chloro-5-methyl-pyrazolo[1,5-a]pyrimidin-7-ol was consumed. TLC (Petroleum 
ether/EtOAc=10/1) showed that three new spots. Desired product was detected by LCMS. The mixture was 
cooled to room temperature and added into a strring water (150 mL) slowly. The mixture was extracted with 
EtOAc (150 mL*2). The organic layers were washed with brine (100 mL*2), dried over Na2SO4 and concentrated 
to give 6,7-dichloro-5-methyl-pyrazolo[1,5-a]pyrimidine (2 g, crude) as a brown oil. 
1H NMR (400MHz, CDCl3-d) 8.18 (d, J=2.38 Hz, 1H), 6.73 (d, J=2.38 Hz, 1H), 2.75 (s, 3H). 
 
 
 
 
 
6,7-dichloro-3-iodo-5-methylpyrazolo[1,5-a]pyrimidine (5) 
 
 
 
To a solution of 6,7-dichloro-5-methyl-pyrazolo[1,5-a]pyrimidine (1 g, 5 mmol, 1 eq) in CH3CN (3 mL) was added 
NIS (1.1 g, 5 mmol, 1 eq). The mixture was stirred at 12 °C for 0.5 h. TLC (Petroleum ether/EtOAc=3/1) showed 
that 6,7-dichloro-5-methyl-pyrazolo[1,5-a]pyrimidine was consumed completetly and a major spot. Desired 
mass was detected by LCMS. The mixture was concentrated. The residue was purified by chromatography on 
silica gel (Petroleum ether/EtOAc=10/1, 5/1, 2/1) to give 6,7-dichloro-3-iodo-5-methyl-pyrazolo[1,5-
a]pyrimidine (900 mg, 2.7 mmol, 55% yield) as a brown solid. 
1H NMR (400MHz, CDCl3-d) 8.19 (s, 1H), 2.81 (s, 3H) 
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6-chloro-3-iodo-5-methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (7) 
 
 
 
 
 
To a solution of 6,7-dichloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidine (1 g, 3 mmol, 1 eq) in DMF (5 mL) was 
added Et3N (617 mg, 6.1 mmol, 2 eq) and 2-pyridylmethanamine (396 mg, 3.7 mmol, 1.2 eq). The mixture was 
stirred at 60 °C for 1.5 hours under N2. TLC (Petroleum ether/EtOAc=2/1) showed that 6,7-dichloro-3-iodo-5-
methyl-pyrazolo[1,5-a]pyrimidine was consumed completetly and a major new spot. To the mixture was added 
water (20 mL) slowly, then a grey solid was forming. The residue was filtered and concentrated to give 6-
chloro-3-iodo-5-methyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (900 mg, 2.2 mmol, 74% yield) as 
a grey solid. 
1H NMR (400MHz, DMSO-d6) 8.49-8.55 (m, 1H), 8.37-8.45 (m, 1H), 8.15 (s, 1H), 7.78 (td, J=7.72, 1.76 Hz, 1H), 
7.35 (d, J=7.91 Hz, 1H), 7.28 (dd, J=6.90, 5.40 Hz, 1H), 5.35 (d, J=6.15 Hz, 2H), 2.52-2.52 (m, 3H). 
 
 
 tert-butyl (6-chloro-3-iodo-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (8) 
 
 
 
 
 
To a solution of 6-chloro-3-iodo-5-methyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (900 mg, 2.3 
mmol, 1 eq) in CH3CN (20 mL) was added Boc2O (590 mg, 2.7 mmol, 1.2 eq), DMAP (28 mg, 225.2 µmol, 0.1 eq). 
The mixture was stirred at 50 °C for 1 hour. TLC (Petroleum ether/EtOAc=5/1) showed that 6-chloro-3-iodo-5-
methyl-N-(2-pyridylmethyl)pyrazolo [1,5-a]pyrimidin-7-amine was consumed completetly and a major new 
spot. The mixture was concentrated. The residue was purified by chromatography on silica gel (Petroleum 
ether/EtOAc=10/1, 5/1, 2/1) to give tert-butyl N-(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (1 g, 2 mmol, 89% yield) as a light brown solid. 
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LCMS (Method 5-95AB, ESI): RT =0.542 min / 1.5 min, M+H+ =311.0. 
1H NMR (400MHz, DMSO-d6) 8.23 (d, J=4.77 Hz, 1H), 7.97 (s, 1H), 7.52-7.63 (m, 2H), 7.05 (s, 1H), 4.86-5.13 
(m, 2H), 2.63-2.66 (m, 3H), 1.25 (s, 9H). 
 
6-chloro-3-(4-fluorophenyl)-5-methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9046) 
 
 
 
 
 
 
 
To a solution of tert-butyl N-(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (150 mg, 300 µmol, 1 eq) and (4-fluorophenyl)boronic acid (63 mg, 450 µmol, 1.5 eq) 
in dioxane (5 mL) and H2O (1 mL) was added Cs2CO3 (195 mg, 600 µmol, 2 eq), ditert-
butyl(cyclopentyl)phosphane;dichloropalladium;iron (19 mg, 30 µmol, 0.1 eq). The mixture was stirred at 80 °C 
for 1.5 hours under N2. TLC (Petroleum ether/EtOAc=5/1) showed that no new spot. LCMS showed that a major 
peak of desired product. The mixture was concentrated directly. The residue was purified by chromatography 
on silica gel (Petroleum ether/EtOAc=10/1, 2/1) to give tert-butyl N-[6-chloro-3-(4-fluorophenyl)-5-methyl-
pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (100 mg, 213 µmol, 71% yield) as a yellow solid. 
A solution of tert-butyl N-[6-chloro-3-(4-fluorophenyl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (100 mg, 213 µmol, 1 eq) in HCl/EtOAc (10 mL) was stirred at 15 °C for 4 hours. TLC 
(Petroleum ether/EtOAc=1/1) showed that tert-butyl N-[6-chloro-3-(4-fluorophenyl)-5-methyl-pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate was consumed completetly and a new spot. The mixture was 
concentrated. The residue was purified by trituration from (Petroleum ether/EtOAc/DCM=10/1/1, 12 mL). The 
solid was dissolved in MeOH (10 mL) and basified by strong basic anion exchange resin to give 6-chloro-3-(4-
fluorophenyl)-5-methyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (60.00 mg, 156.93 µmol, 73% 
yield, 96.2% purity) as a grey solid. 
LCMS (Method 5-95AB, ESI): RT =0.725 min / 1.5 min, M+H+ =368.0. 
1H NMR (400MHz, DMSO-d6) 8.60 (s, 1H), 8.52-8.56 (m, 1H), 8.38-8.45 (m, 1H), 8.13-8.19 (m, 2H), 7.80 (d, 
J=1.63 Hz, 1H), 7.36-7.42 (m, 1H), 7.21-7.32 (m, 3H), 5.39 (d, J=6.02 Hz, 2H), 2.56 (s, 3H). 
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tert-butyl (6-chloro-3-(3,6-dihydro-2H-pyran-4-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (11) 
 
 
 
 
 
 
To a solution of tert-butyl N-(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (150 mg, 300 µmol, 1 eq) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane (82 mg, 390 µmol, 1.3 eq) in dioxane (10 mL) and H2O (1 mL) was added Cs2CO3 (195 mg, 
600 µmol, 2 eq), ditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron (19 mg, 30 µmol, 0.1 eq). The 
mixture was stirred at 80 °C for 2 hours under N2. TLC (Petroleum ether/EtOAc=1/1) showed thattert-butyl N-
(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed 
completetly and a major new spot. Desired product was detected by LCMS. The mixture was concentrated. The 
residue was purified by chromatography on silica gel (Petroleum ether/EtOAc=1/2) to give tert-butyl N-[6-
chloro-3-(3,6-dihydro-2H-pyran-4-yl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate 
(100 mg, 219 µmol, 73% yield) as a yellow oil. 
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tert-butyl (6-chloro-5-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (12)  
 
 
 
 
 
 
To a solution of tert-butyl N-[6-chloro-3-(3,6-dihydro-2H-pyran-4-yl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-
(2-pyridylmethyl)carbamate (100 mg, 219 µmol, 1 eq) in MeOH (10 mL) was added Pd/C (50 mg). The mixture 
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was stirred at 15 °C for 12 hours under H2 (15 psi). TLC (Petroleum ether/EtOAc=1/1) showed that about 80% of 
tert-butyl N-[6-chloro-3-(3,6-dihydro-2H-pyran-4-yl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate was consumed and a new major spot. LCMS showed that a major peak of desired 
product and about 10% of by-product tert-butyl N-(5-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-
7-yl)-N-(2-pyridylmethyl)carbamate. The mixture was filtered and concentrated. The residue was purified by 
prep-TLC (Petroleum ether/EtOAc=1/2) to give tert-butyl N-(6-chloro-5-methyl-3-tetrahydropyran-4-yl-
pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate (60 mg, 131 µmol, 60% yield) as a light yellow oil. 
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6-chloro-5-methyl-N-(pyridin-2-ylmethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9049) 
 
 
 
 
 
 
A solution of tert-butyl N-(6-chloro-5-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (60 mg, 131 µmol, 1 eq) in HCl/EtOAc (4 M, 8 mL, 244 eq) was stirred at 15 °C for 1 
hour. TLC (EtOAc) showed that tert-butyl N-(6-chloro-5-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-
a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed completetly and a new major spot. The mixture 
was concentrated directly to remove the solvent. The residue was dissolved in MeOH (20 mL) and basified by 
strong basic anion exchange resin, then the mixture was filtered and concentrated, which was purified by 
trituration from (Petroleum ether/EtOAc/DCM=10/1/1, 12 mL) to give 6-chloro-5-methyl-N-(2-pyridylmethyl)-
3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-amine (15 mg, 41 µmol, 31% yield, 97% purity) as a white 
solid. 
LCMS (Method 5-95AB, ESI): RT =0.546 min / 1.5 min, M+H+ =358.1. 
1H NMR (400MHz, DMSO-d6) 8.64-8.68 (m, 1H), 8.01-8.08 (m, 1H), 7.86 (s, 1H), 7.62-7.67 (m, 1H), 7.55-7.60 
(m, 1H), 5.48 (s, 2H), 3.90-3.97 (m, 2H), 3.43-3.51 (m, 2H), 2.53-2.56 (m, 2H), 2.44 (s, 3H), 1.73-1.89 (m, 3H). 
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tert-butyl (6-chloro-5-methyl-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-
yl)(pyridin-2-ylmethyl)carbamate (14) 
 
 
 
 
 
 
To a solution of tert-butyl N-(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (150 mg, 300 µmol, 1 eq) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)-3,6-dihydro-2H-pyridine (80 mg, 360 µmol, 1.2 eq) in dioxane (10 mL) and H2O (1 mL) was added Cs2CO3 
(195 mg, 600 µmol, 2 eq), ditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron (19 mg, 30 µmol, 0.1 eq). 
The mixture was stirred at 80 °C for 2 hours under N2. TLC (Petroleum ether/EtOAc=1/1) showed that tert-butyl 
N-(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed 
completetly and TLC (Dichloromethane/Methanol=10/1) showed that  a major new spot. Desired product was 
detected by LCMS. The mixture was concentrated. The residue was purified by chromatography on silica gel 
(Petroleum ether/EtOAc=1/3, Dichloromethane/Methanol=20/1, 15/1) to give tert-butyl N-[6-chloro-5-methyl-
3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (100 mg, 
213 µmol, 71% yield) as a yellow oil. 
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tert-butyl (6-chloro-5-methyl-3-(1-methylpiperidin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (15)  
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To a solution of tert-butyl N-[6-chloro-5-methyl-3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (100 mg, 213 µmol, 1 eq) in MeOH (8 mL) was added Pd(OH)2 
(149 mg, 1 mmol, 5 eq), ZnBr2 (96 mg, 426 µmol, 2 eq). The mixture was stirred at 15 °C for 16 hrs under H2 (15 
psi). TLC (Dichloromethane/Methanol=10/1) showed that most of tert-butyl N-[6-chloro-5-methyl-3-(1-methyl-
3,6-dihydro-2H-pyridin-4-yl)pyrazol [1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate was consumed and 
several spots. LCMS showed that several peaks, desired product was detected. The mixture was filtered and 
concentrated. The residue was purified by prep-TLC (CHCl3/Methanol/H2O= 30/5/1) to give tert-butyl N-[6-
chloro-5-methyl-3-(1-methyl-4-piperidyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (25 mg, 
42 µmol, 20% yield, 80% purity) as a light yellow oil. 
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6-chloro-5-methyl-3-(1-methylpiperidin-4-yl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9050) 
 
 
 
 
 
 
A solution of tert-butyl N-[6-chloro-5-methyl-3-(1-methyl-4-piperidyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (25 mg, 53 µmol, 1 eq) in HCl/EtOAc (4 M, 5.00 mL, 377 eq) was stirred at 15 °C for 2 
hours. LCMS showed that  tert-butyl N-[6-chloro-5-methyl-3-(1-methyl-4-piperidyl)pyrazolo[1,5-a]pyrimidin-7-
yl]-N-(2-pyridylmethyl)carbamate was consumed completetly and a major peak of desired product. The mixture 
was concentrated to remove the solvent. The residue was purified by prep-HPLC (Column: Boston Green ODS 
150*30 5u; Condition: 0.225%FA-ACN; Gradient Time (min): 11; FlowRate(ml/min): 25) and basified by strongly 
basic anoin exchange resin to give 6-chloro-5-methyl-3-(1-methyl-4-piperidyl)-N-(2-pyridylmethyl)pyrazolo[1,5-
a]pyrimidin-7-amine (10 mg, 26 µmol, 50% yield, 98.2% purity) as a light yellow solid. 
LCMS (Method 0-60AB, ESI): RT =0.690 min / 1.5 min, M+H+ =371.2. 
1H NMR (400MHz, DMSO-d6) 8.51 (d, J=4.27 Hz, 1H), 7.89 (s, 1H), 7.75-7.82 (m, 1H), 7.37-7.42 (m, 1H), 7.26-
7.32 (m, 1H), 5.42 (s, 2H), 3.28-3.30 (m, 2H), 3.02-3.12 (m, 1H), 2.70-2.80 (m, 2H), 2.65 (s, 3H), 2.55 (s, 3H), 
2.09-2.18 (m, 2H), 1.99 (br. s., 2H). 
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6-chloro-5-methyl-3-morpholino-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9051) 
 
 
 
 
 
 
To a solution of tert-butyl N-(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (50 mg, 100.1 µmol, 1 eq) and morpholine (43.58 mg, 500.3 µmol, 5 eq) in THF (1 mL) 
was added [2-(2-aminoethyl)phenyl]-chloro-palladium;ditert-butyl-[2-(2,4,6-
triisopropylphenyl)phenyl]phosphane (13.7 mg, 20 µmol, 0.2 eq). Then tBuOK (1 M, 200.1 uL, 2 eq) in THF was 
added to the mixture. The mixture was stirred at 60 °C for 12 h under N2. TLC (Petroleum ether/EtOAc=1/1) 
showed that most of tert-butyl N-(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate was consumed and several new spots. To the mixture was added water (20 mL) and 
extracted with EtOAc (20 mL*2). The organic layers were washed with brine (20 mL), dried over Na2SO4 
and concentrated. The residue was purified by prep-TLC (Petroleum ether/EtOAc=1/1) to give tert-butyl N-(6-
chloro-5-methyl-3-morpholino-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate (10 mg, 43.6 
µmol, 21% yield) as a brown oil. 
A solution of tert-butyl N-(6-chloro-5-methyl-3-morpholino-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (40 mg, 87 µmol, 1 eq) in HCl/EtOAc (4 M, 4 mL, 183 eq) was stirred at 18 °C for 12 
hours. TLC (Petroleum ether/EtOAc=1/2) showed that tert-butyl N-(6-chloro-5-methyl-3-morpholino-
pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed completetly and a new major 
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spot. LCMS showed that a major peak of desired product. The mixture was concentrated to remove the 
solvent. The residue was purified by prep-HPLC (Column: Boston Green ODS 150*30 5u; Condition: 0.225% FA-
ACN). The product was basified by strong basic anion exchange resin to give 6-chloro-5-methyl-3-morpholino-
N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (6.5 mg, 17.6 µmol, 20% yield, 97% purity) as a light 
yellow solid. 
LCMS (Method 5-95AB, ESI): RT =0.615 min / 1.5 min, M+H+ =359.1. 
1H NMR (400MHz, DMSO-d6)  8.54 (d, J=5.02 Hz, 1H), 8.18-8.27 (m, 1H), 7.75-7.85 (m, 2H), 7.35 (d, J=7.91 Hz, 
1H), 7.25-7.32 (m, 1H), 5.32 (br. s., 2H), 3.73-3.79 (m, 4H), 3.15 (d, J=4.39 Hz, 4H), 2.45 (s, 3H). 
The above general procedure was followed for the syntheses of AWZ9052. 
6-chloro-5-methyl-3-morpholino-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9052) 
LCMS (Method 5-95AB, ESI): RT =0.606 min / 1.5 min, M+H+ =357.1. 
1H NMR (400MHz, DMSO-d6)  8.54 (d, J=4.64 Hz, 1H), 8.16-8.24 (m, 1H), 7.76-7.83 (m, 2H), 7.36 (s, 2H), 5.26-
5.35 (m, 2H), 3.08-3.15 (m, 4H), 2.46 (s, 3H), 1.62-1.68 (m, 4H), 1.49-1.54 (m, 2H). 
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3-bromo-6,7-dichloro-5-methylpyrazolo[1,5-a]pyrimidine (2) 
 
 
 
To a solution of 6,7-dichloro-5-methyl-pyrazolo[1,5-a]pyrimidine (800 mg, 4 mmol, 1 eq) in CH3CN (20 mL) was 
added NBS (940 mg, 4.8 mmol, 1.2 eq) at 0 °C.  The mixture was stirred at 0 °C for 10 min. TLC (Petroleum 
ether/EtOAc=10/1) showed that starting material was consumed completetly. To the mixture was added water 
(50 mL) and extracted with EtOAc (40 mL*2). The organic layers were washed with brine (60 mL), dried over 
Na2SO4 and concentrated. The residue was purified by chromatography on silica gel (Petroleum 
ether/EtOAc=10/1) to give 3-bromo-6,7-dichloro-5-methyl-pyrazolo[1,5-a]pyrimidine (1 g, 3.7 mmol, 90% yield) 
as a yellow solid. 
1H NMR (400MHz, CDCl3-d)  8.16 (s, 1H), 2.79 (s, 3H) 
 
 
6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-ol (4) 
 
 
 
 
 
To a solution of 3-bromo-6,7-dichloro-5-methyl-pyrazolo[1,5-a]pyrimidine (400 mg, 1.4 mmol, 1 eq) and 2-
pyridylmethanamine (184 mg, 1.7 mmol, 1.2 eq) in DMF (4 mL) was added Et3N (431 mg, 4.3 mmol, 3 eq). The 
mixture was stirred at 60 °C for 0.5 hr under N2. TLC (Petroleum ether/EtOAc=1/1) showed that 3-bromo-6,7-
dichloro-5-methyl-pyrazolo[1,5-a]pyrimidine was consumed completetly and a major new spot. To the mixture 
was added water (8 mL), a white solid was forming. Then the mixture was filtered and concentrated. The 
residue was used in the next step without purification to give 3-bromo-6-chloro-5-methyl-N-(2-
pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (400 mg, 1.1 mmol, 80% yield) as a grey solid. 
1H NMR (400MHz, DMSO-d6) 8.35-8.61 (m, 2H), 8.21 (s, 1H), 7.72-7.84 (m, 1H), 7.24-7.43 (m, 2H), 5.36 (d, 
J=6.03 Hz, 2H), 2.52-2.55 (m, 3H). 
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Tert-butyl(3-bromo-6-chloro-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbam- ate (5) 
To a solution of 3-bromo-6-chloro-5-methyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (400 mg, 1.1 
mmol, 1 eq) in THF (10 mL) was added DMAP (13 mg, 113 µmol, 0.1 eq), Boc2O (493 mg, 2.3 mmol, 2 eq). The 
mixture was stirred at 60 °C for 1 hour. TLC (Petroleum ether/EtOAc=1/1) showed that 3-bromo-6-chloro-5-
methyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine was consumed completetly and a new major 
spot. The mixture was concentrated. The residue was purified by chromatography on silica gel (Petroleum 
ether/EtOAc=5/1, 2/1) to give tert-butyl N-(3-bromo-6-chloro-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (450 mg, 964.2 µmol, 85% yield, 97% purity) as a yellow solid. 
1H NMR (400MHz, CDCl3-d) 8.18-8.34 (m, 1H), 7.95 (s, 1H), 7.51-7.64 (m, 2H), 7.05 (t, J=5.83 Hz, 1H), 4.90-
5.10 (m, 2H), 2.63 (s, 3H), 1.23-1.42 (m, 9H) 
Tert-butyl(6-chloro-3-(3,3-difluoropyrrolidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)(pyrid- ine-2-
ylmethyl)carbamate (7) 
 
 
 
 
 
 
To a solution of tert-butyl N-(3-bromo-6-chloro-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (50 mg, 110.4 µmol, 1 eq) and 3,3-difluoropyrrolidine (24 mg, 220.9 µmol, 2 eq) in 
THF (1 mL) was added [2-(2 aminoethyl)phenyl]-chloro-palladium;ditert-butyl-[2-(2,4,6-triisopropylphenyl)ph- 
enyl]phosphane (15 mg, 22.1 µmol, 0.2 eq). Then tBuOK (1 M, 220.9 uL, 2 eq) in the THF was added  to the 
mixture. The mixture was stirred at 65 °C for 12 h under N2. TLC (Petroleum ether/EtOAc=2/1) showed that 
about 80% of tert-butyl N-(6-chloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate was consumed and several spots. To the mixture was added water (20 mL) and 
extracted with EtOAc (20 mL*2). The organic layers were washed with brine (20 mL), dried over Na2SO4 
and concentrated. The residue was purified by prep-TLC (Petroleum ether/EtOAc=2/1) to give tert-butyl N-[6-
chloro-3-(3,3-difluoropyrrolidin-1-yl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate 
(15 mg, 62.6 µmol, 14% yield) as a brown oil. 
LCMS (Method 5-95AB, ESI): RT =0.845 min / 1.5 min, M+H+ =479.1. 
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6-chloro-3-(3,3-difluoropyrrolidin-1-yl)-5-methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9053) 
 
 
 
 
 
 
A solution of tert-butyl N-[6-chloro-3-(3,3-difluoropyrrolidin-1-yl)-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (30 mg, 62.64 µmol, 1 eq) in HCl/EtOAc (4 M, 8 mL, 511 eq) was stirred at 20 °C for 12 
hours. LCMS showed that tert-butyl N-[6-chloro-3-(3,3-difluoropyrrolidin-1-yl)-5-methyl-pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylme thyl)carbamate was consumed completely and a major peak of desired 
product. The mixture was concentrated. The residue was purified by prep-HPLC (Column: Boston Green ODS 
150*30 5u; Condition: 0.225%FA-ACN). The salt product was dissolved in MeOH (15 mL) and basified by strong 
basic anion exchange resin to give 6-chloro-3-(3,3-difluoropyrrolidin-1-yl)-5-methyl-N-(2-
pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (8 mg, 20.4 µmol, 33% yield, 96.6% purity) as a light yellow 
solid. 
LCMS (Method 5-95AB, ESI): RT =0.758 min / 1.5 min, M+H+ =379.1. 
1H NMR (400MHz, DMSO-d6) 8.53 (d, J=4.39 Hz, 1H), 8.21 (s, 1H), 7.74-7.84 (m, 2H), 7.25-7.37 (m, 2H), 5.32 
(d, J=6.02 Hz, 2H), 3.68 (s, 2H), 3.49 (t, J=7.03 Hz, 2H), 2.46 (s, 5H) 
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2-formyl-4-morpholinobutanenitrile (2) 
 
 
 
 
To a solution of 4-morpholinobutanenitrile (2 g, 13 mmol, 1 eq) in THF (20 mL) was added LDA (2 M, 13 mL, 2 
eq) slowly at -70 °C. The mixture was stirred at -70 °C for 1 h under N2. Then methyl formate (2 g, 32.4 mmol, 
2.5 eq) was added to the mixture directly. The mixture was stirred at -70 °C for 0.5 h under N2.  TLC (Ethyl 
acetate) showed that 4-morpholinobutanenitrile was consumed completely and a major new spot at (254 nm). 
To the mixture was added NH4Cl (10%, 5 mL) and water (60 mL), extracted with EtOAc (60 mL). The water layer 
was concentrated to give 2-formyl-4-morpholino-butanenitrile (1.5 g, crude) in water (40 mL) as a light yellow 
liqud. The product havd a good solubility in water. 
1H NMR (400MHz, CDCl3-d)  8.22 (s, 1H), 3.81 (br. s., 2H), 3.70-3.76 (m, 2H), 3.58-3.67 (m, 1H), 2.67 (d, J=7.65 
Hz, 6H), 2.46-2.50 (m, 2H). 
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4-(2-morpholinoethyl)-1H-pyrazol-5-amine (3) 
 
 
 
 
To a solution of 2-formyl-4-morpholino-butanenitrile (1.5 g, 8.2 mmol, 1 eq) in H2O (20 mL)was added AcOH 
(988 mg, 16.5 mmol, 2 eq), N2H4.H2O (2.1 g, 41.2 mmol, 5 eq). The mixture was stirred at 70 °C for 2 hours. TLC 
(CHCl3/Methanol/H2O=80/18/2) showed that 2-formyl-4-morpholino-butanenitrile was consumed completetly 
and several new spots. Desired product was detected by the standard sample. To the mixture was added water 
(50 mL) and extracted with EtOAc (40 mL*2). The water layer was concentrated and lyophilizated to give 4-(2-
morpholinoethyl)-1H-pyrazol-3-amine (8 g, crude) as a grey which contained lots of salts. 
LCMS (Method 0-60CD, ESI): RT =0.297 min / 4.0 min, M+H+ =197.2. 
 
6-chloro-5-methyl-3-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidin-7-ol (5) 
 
 
 
 
 
To a solution of 4-(2-morpholinoethyl)-1H-pyrazol-3-amine (7.5 g, 7.64 mmol, purity: 20%, 1 eq) and methyl 2-
chloro-3-oxo-butanoate (1.2 g, 7.6 mmol, 1 eq) in H2O (15 mL) was added TsOH.H2O (145 mg, 764.3 µmol, 0.1 
eq). The mixture was stirred at 80 °C for 2 hours under N2. TLC (Dichloromethane/Methanol=10/1) showed that 
the material 4-(2-morpholinoethyl)-1H-pyrazol-3-amine was consumed completely and a major new spot. 
LCMS showed that a major peak of desired product. The mixture was concentrated directly. The residue was 
purified by chromatrography on silica gel (Dichloromethane/Methanol=15/1, 10/1) to give 6-chloro-5-methyl-
3-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidin-7-ol (1.2 g, crude) as a brown solid, which contained some salts. 
LCMS (Method 0-60CD, ESI): RT =1.301 min / 4.0 min, M+H+ =297.1. 
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4-(2-(6,7-dichloro-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)ethyl)morpholine (6) 
 
 
 
 
 
To a solution of 6-chloro-5-methyl-3-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidin-7-ol (1 g, 3.4 mmol, 1 eq) in 
POCl3 (20 mL) was added N,N-diethylaniline (1 g, 6.7 mmol, 2 eq). The mixture was stirred at 100 °C for 2 hours 
under N2. LCMS showed that 6-chloro-5-methyl-3-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidin-7-ol was 
consumed completetly and a major peak of desired product. The mixture was concentrated to remove POCl3 
and mixed with EtOAc (100 mL), then added into a stirring water (150 mL). The mixture was extracted with 
EtOAc (100 mL*2). But only a little product in the organic layers. Most of the salt (HCl) product was in water. A 
grey solid was forming after 12 h. Then the solid was filtered and concentrated.  The residue was used in the 
next step without purification to give 4-[2-(6,7-dichloro-5-methyl-pyrazolo[1,5-a]pyrimidin-3-
yl)ethyl]morpholine (200 mg, 634.5 µmol, 19% yield) as a grey solid. 
1H NMR (400MHz, DMSO-d6) 8.26-8.32 (m, 1H), 3.95-3.99 (m, 2H), 3.84-3.89 (m, 2H), 3.32-3.35 (m, 2H), 3.26-
3.29 (m, 2H), 3.00-3.06 (m, 4H), 2.67 (s, 3H) 
 
6-chloro-5-methyl-3-(2-morpholinoethyl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9055) 
 
 
 
 
 
 
 
To a solution of 4-[2-(6,7-dichloro-5-methyl-pyrazolo[1,5-a]pyrimidin-3-yl)ethyl]morpholine (180 mg, 571.1 
µmol, 1 eq) and 2-pyridylmethanamine (74 mg, 685.3 µmol, 1.2 eq) in DMF (8 mL) was added Et3N (173 mg, 1.7 
mmol, 3 eq). The mixture was stirred at 60 °C for 1 hour. LCMS showed that 4-[2-(6,7-dichloro-5-methyl-
pyrazolo[1,5-a]pyrimidin-3-yl)ethyl]morpholine was consumed completetly and a major peak of desired 
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product. The mixture was concentrated to remove TEA. The mixture was purified by prep-HPLC (Column: 
Boston Green ODS 150*30 5u; Condition: 0.225%FA-ACN). The product was basified by strong basic anion 
exchange resin to give 6-chloro-5-methyl-3-(2-morpholinoethyl)-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-
7-amine (98 mg, 240.6 µmol, 42% yield, 95% purity) as a white solid. 
LCMS (Method 10-80CD, ESI): RT =1.263 min / 2.0 min, M+H+ =387.1. 
1H NMR (400MHz, DMSO-d6) 8.53 (d, J=4.27 Hz, 1H), 8.19-8.25 (m, 1H), 7.99 (s, 1H), 7.73-7.82 (m, 1H), 7.33-
7.37 (m, 1H), 7.26-7.31 (m, 1H), 5.31-5.40 (m, 2H), 3.55-3.61 (m, 4H), 2.75-2.81 (m, 2H), 2.54-2.57 (m, 2H), 2.48 
(s, 3H), 2.43 (br. s., 4H).
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ethyl 2-methyl-3-oxopropanoate (2) 
 
 
A solution of ethyl propanoate (25.00 g, 244.79 mmol, 1.00 eq) and ethyl formate (36.27 g, 489.58 mmol, 2.00 
eq) in DCM (200.00 mL) at 0 °C was added TiCl4 (92.86 g, 489.58 mmol, 2.00 eq) followed by TEA (59.45 g, 
587.50 mmol, 2.40 eq) dropwise under N2 protection. The reaction mixture was stirred at 0 °C for 1 h and at 
10-15 °C for another 1 h. TLC (Petroleum ether/EtOAc=1/1) showed a new spot under 254 nm.  The reaction 
mixture was poured into ice water and extrated with DCM (100 mL*3). The organic layer was washed with 
brine (100 mL*3), dried over Na2SO4 and concentrated to give ethyl 2-methyl-3-oxo-propanoate (50.00 g, 
crude) as a brown oil which used directly for next step without further purification. 
6-methylpyrazolo[1,5-a]pyrimidin-7-ol (4) 
 
 
 
A mixture of ethyl 2-methyl-3-oxo-propanoate (35.00 g, 268.94 mmol, 1.00 eq), 1H-pyrazol-3-amine (17.88 g, 
215.15 mmol, 0.80 eq) in THF (300.00 mL) was stirred at 60 °C for 1 hour. TLC (Petroleum ether/EtOAc=4/1) 
showed all of ethyl 2-methyl-3-oxo-propanoate was consumed and two new spots. The reaction mixture was 
used directly for next step without further work up and purification. 
To a mixture of  ethyl 3-((1H-pyrazol-3-yl)imino)-2-methylpropanoate (52.00 g, 266.37 mmol, 1.00 eq) in THF 
(300.00 mL) obtained from last step at 0 °C was added tBuOK (29.89 g, 266.37 mmol, 1.00 eq) in portions and 
the mixture was stirred at 10-15 °C for 30 mins. Solids were precipitated. TLC (DCM/MeOH=10/1) showed all of 
ethyl (3E)-2-methyl-3-(1H-pyrazol-3-ylimino)propanoate was consumed and a new spot. The mixture was 
cooled to 0 °C and acified with HCl/EtOAc (4 M) to pH7. The mixture was concentrated to give 6-
methylpyrazolo[1,5-a]pyrimidin-7-ol (60.00 g, crude) as a light yellow solid contained KCl. 
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7-chloro-6-methylpyrazolo[1,5-a]pyrimidine (5) 
 
 
 
To a mixture of 6-methylpyrazolo[1,5-a]pyrimidin-7-ol (20.00 g, 67.05 mmol, 1.00 eq) in POCl3 (246.00 g, 1.60 
mol, 23.93 eq). The mixture was stirred at 100 °C for 10 hours. LCMS showed all of 6-methylpyrazolo[1,5-
a]pyrimidin-7-ol was consumed and a new major peak with desired MS. The mixture was concentrated to give 
a residue. The reaction was quenched by slowly adding to water. The residue was dissoveled in EtOAc (200 mL) 
and washed with brine (100 mL*2). The organic layer was dried over Na2SO4 and concentrated to give 7-
chloro-6-methyl-pyrazolo[1,5-a]pyrimidine (7.00 g, crude) as a brown solid. 
LCMS (Method 0-60 CD): RT=1.323 min/2 min, [M+H]+=168.1. 
 
7-chloro-3-iodo-6-methylpyrazolo[1,5-a]pyrimidine (6) 
 
 
 
A mixture of 7-chloro-6-methyl-pyrazolo[1,5-a]pyrimidine (6.50 g, 38.78 mmol, 1.00 eq) and NIS (8.73 g, 38.78 
mmol, 1.00 eq) in CH3CN (60.00 mL) was stirred at 10-15 °C for 1 hour. TLC (Petroleum ether/EtOAc=3/1) 
showed all of 7-chloro-6-methyl-pyrazolo[1,5-a]pyrimidine was consumed and a new spot. The mixture was 
concentrated to give a residue. The residue was purified by chromatography (Petroleum ether/EtOAc=20/1; 
10/1; 5/1) to give 7-chloro-5-iodo-6-methyl-pyrazolo[1,5-a]pyrimidine (6.00 g, 20.44 mmol, 52% yield) as a 
brown solid. 
1H NMR (400MHz, CHLOROFORM-d) δ 8.43 (s, 1H), 8.15-8.21 (m, 1H), 2.49 (s, 3H). 
 
 
 
 
3-iodo-6-methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (8) 
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A mixture of 7-chloro-5-iodo-6-methyl-pyrazolo[1,5-a]pyrimidine (2.00 g, 6.81 mmol, 1.00 eq), 2-
pyridylmethanamine (736.92 mg, 6.81 mmol, 1.00 eq) and Et3N (1.38 g, 13.63 mmol, 2.00 eq) in DMF (2.00 mL) 
was stirred at 60 °C for 2 hours.  TLC (Petroleum ether/EtOAc=2/1) showed all of 7-chloro-5-iodo-6-methyl-
pyrazolo[1,5-a]pyrimidine was consumed and a new spot. The mixture was diluted with EtOAc (40 mL) and 
washed with brine (20 mL*3). The organic layer was dried over Na2SO4 and concentrated to give a residue. The 
residue was triturated with EtOAc (20 mL) to give 3-iodo-6-methyl-N-(2-pyridylmethyl)pyrazolo[1,5-
a]pyrimidin-7-amine (1.10 g, 3.01 mmol, 44% yield) as a light yellow solid. 
1H NMR (400MHz, CHLOROFORM-d) δ 8.69 (d, J=4.8 Hz, 1H), 8.15 (s, 1H), 8.04 (s, 1H), 7.73 (dt, J=1.7, 7.6 Hz, 
2H), 7.27-7.32  (m, 2H), 5.17 (d, J=5.5 Hz, 2H), 2.50 (s, 3H). 
 
tert-butyl (3-iodo-6-methylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (9) 
 
 
 
 
 
A mixture of 3-iodo-6-methyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (1.10 g, 3.01 mmol, 1.00 
eq), Boc2O (1.31 g, 6.02 mmol, 2.00 eq) and DMAP (36.77 mg, 301.00 µmol, 0.10 eq) in THF (30.00 mL) was 
stirred at 15-20 °C for 1 hour. TLC (Petroleum ether/EtOAc=1/1) showed all of 3-iodo-6-methyl-N-(2-
pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine was consumed and a new major spot. The mixture was 
concentrated to give a residue. The residue was purified by chromatography (Petroleum ether/EtOAc=10/1; 
5/1; 2/1) to give tert-butyl N-(3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(1.20 g, 2.44 mmol, 81% yield, 94.8% purity) as a light brown solid. 
LCMS (Method 10-80 CD): RT=1.467 min/2 min, [M+H]+=466.1. 
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1H NMR (400MHz, CHLOROFORM-d) δ 8.32 (s, 1H), 8.03 (s, 1H), 7.50-7.59 (m, 1H), 7.38 (d, J=7.8 Hz, 1H), 7.04-
7.13 (m, 2H), 5.16-5.26 (m, 2H), 2.02 (s, 3H), 1.24 (s, 9H). 
 
6-methyl-N-(pyridin-2-ylmethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9057 
 
 
 
 
 
 
A mixture of 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (169.31 mg, 805.95 µmol, 
1.50 eq), tert-butyl N-(3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate (250.00 
mg, 537.30 µmol, 1.00 eq), Pd(dppf)Cl2 (78.63 mg, 107.46 µmol, 0.20 eq) and Cs2CO3 (350.13 mg, 1.07 mmol, 
2.00 eq) in dioxane (3.00 mL) and H2O (500.00 uL) was stirred at 80 °C for 12 hours under N2 protection. LCMS 
showed all of tert-butyl N-(3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was 
consumed and a new major peak with desired MS. TLC (Petroleum ether/EtOAc=2/1) showed all of tert-butyl 
N-(3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed and a new 
spot.  The mixture was concentrated to give a residue. The residue was purfied by chromatography (Petroleum 
ether/EtOAc=5/1; 3/1; 2/1) to give tert-butyl N-[3-(3,6-dihydro-2H-pyran-4-yl)-6-methyl-pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (150.00 mg, 355.88 µmol, 66% yield) as a yellow solid. 
A mixture of tert-butyl N-[3-(3,6-dihydro-2H-pyran-4-yl)-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (150.00 mg, 355.88 µmol, 1.00 eq) in MeOH (5.00 mL) was added Pd/C (50.00 mg). 
The mixture was stirred at 15-20 °C for 3 hours under H2 (15 PSI). TLC (Petroleum ether/EtOAC=1/1) showed all 
of tert-butyl N-[3-(3,6-dihydro-2H-pyran-4-yl)-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate was consumed and a new spot. The mixture was filtered and the filtrate was 
concentrated to give tert-butyl N-(6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (100.00 mg, crude) as a green solid and it was used directly for the next step. 
A mixture of tert-butyl N-(6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (150.00 mg, 354.18 µmol, 1.00 eq) in HCl/EtOAc (4 M, 4.00 mL) was stirred at 15-25 
°C for 12 hours. LCMS showed all of tert-butyl N-(6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-
yl)-N-(2-pyridylmethyl)carbamate was consumed and a new peak with desired MS.  The mixture was 
concentrated to give a residue. The residue was dissovled in MeOH (10 mL) and basified with basic resin and 
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concentrated to give a residue. The residue was triturated with MeOH (2 mL) to give 6-methyl-N-(2-
pyridylmethyl)-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-amine (15.80 mg, 46.41 µmol, 13% yield, 
95% purity) as a light yellow solid. 
LCMS (Method 5-95 AB): RT=0.572 min/1.5 min, [M+H]+=324.3. 
1H NMR (400MHz, DMSO-d6) δ 8.56 (d, J=3.5 Hz, 1H), 8.06 (br. s., 1H), 7.95 (s, 2H), 7.79 (t, J=7.3 Hz, 1H), 7.23-
7.43 (m, 2H), 5.13 (d, J=5.8 Hz, 2H), 3.92 (d, J=10.3 Hz, 2H), 3.46 (t, J=10.5 Hz, 2H), 2.95-3.10 (m, 1H), 2.33 (s, 
3H), 1.72-1.91 (m, 4H). 
 
 
7-chloro-6-methyl-3-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidine (3) 
 
 
 
 
To a solution of 7-chloro-3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidine (200 mg, 681 µmol, 1 eq) and tributyl(2-
pyridyl)stannane (251 mg, 681 µmol, 1 eq) in toluene (8 mL) was added CATACXIUM A-PD-G2 (45 mg, 68.2 
µmol, 0.1 eq). The mixture was stirred at 80 °C for 12 hours under N2. TLC (Petroleum ether: EtOAc=2: 1) 
showed that about 70% of 7-chloro-3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidine was consumed and a major 
new spot. LCMS showed that about half of 7-chloro-3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidine was consumed 
and 20% desired product. To the mixture was added KF (30 mL, 10%) and extracted with EtOAc (30 mL*2). The 
organic layers were washed with brine (40 mL), dried over Na2SO4 and concentrated. The residue was purified 
by prep-TLC (Petroleum ether: EtOAc=2: 1) to obtain 7-chloro-6-methyl-3-(2-pyridyl)pyrazolo[1,5-a]pyrimidine 
(60 mg, 245.2 µmol, 36% yield) as a light yellow soild. 
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6-methyl-3-(pyridin-2-yl)-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9058) 
 
 
 
 
 
 
 
To a solution of 7-chloro-6-methyl-3-(2-pyridyl)pyrazolo[1,5-a]pyrimidine (60 mg, 245 µmol, 1 eq) and 2-
pyridylmethanamine (32 mg, 294 µmol, 30 uL, 1.2 eq) in DMF (5 mL) was added Et3N (74 mg, 736 µmol, 102 uL, 
3 eq). The mixture was stirred at 60 °C  for 4 hours. TLC (Petroleum ether: EtOAc=1: 1) showed that 7-chloro-6-
methyl-3-(2-pyridyl)pyrazolo[1,5-a]pyrimidine was consumed completetly and a new major spot. To the 
mixture was added water (10 mL) slowly, then a light yellow solid was forming. The solid was 
filtered and concentrated. The residue was purified by trituration from (Petroleum ether: EtOAc: MeOH=1: 1: 
1, 6 mL) to obtain 6-methyl-3-(2-pyridyl)-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (38 mg, 115.3 
µmol, 47% yield, 96% purity) as a light yellow solid. 
1H NMR (400MHz, DMSO-d6)  8.69 (s, 1 H), 8.58 (d, J=4.14 Hz, 1 H), 8.54 (dt, J=4.77, 0.88 Hz, 1 H), 8.47 (d, J=8.03 Hz, 1 
H), 8.37 (t, J=6.15 Hz, 1 H), 8.19 (s, 1 H), 7.81 (tdd, J=7.69, 7.69, 3.51, 1.82 Hz, 2 H), 7.40 (d, J=7.78 Hz, 1 H), 7.32 (dd, 
J=6.96, 5.33 Hz, 1 H), 7.15 (ddd, J=7.40, 4.83, 1.07 Hz, 1 H), 5.21 (d, J=6.15 Hz, 2 H), 2.41 (s, 3 H). 
LCMS (Method 5-95AB, ESI): RT =0.545 min / 1.5 min, M+H+ =317.1. 
3-cyclopropyl-6-methyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9059) 
 
 
 
 
 
 
A mixture of tert-butyl N-(3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(250.00 mg, 537.30 µmol, 1.00 eq), cyclopropylboronic acid (923.08 mg, 10.75 mmol, 20.00 eq), Pd(dppf)Cl2 
(58.97 mg, 80.60 µmol, 0.15 eq) and Cs2CO3 (350.13 mg, 1.07 mmol, 2.00 eq) in dioxane (3.00 mL) and H2O 
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(500.00 uL) was stirred at 90 °C for 12 hours under N2 protection. LCMS showed about all of tert-butyl N-(3-
iodo-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed and a new peak 
with desired MS. TLC (Petroleum ether/EtOAc=1/1) showed the rf value of tert-butyl N-(3-iodo-6-methyl-
pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was similar with tert-butyl N-(3-cyclopropyl-6-
methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate. The mixture was diluted with EtOAc (20 
mL) and washed with brine (10 mL*1). The organic layer was dried over Na2SO4 and concentrated to give a 
residue. The residue was purified by TLC (Petroleum ether/EtOAc=1/1) twice to give tert-butyl N-(3-
cyclopropyl-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate (400.00 mg, 1.00 mmol, 93% 
yield, 95% purity) as a brown oil. 
A mixture of tert-butyl N-(3-cyclopropyl-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (100.00 mg, 263.54 µmol, 1.00 eq) in HCl/EtOAc (4 M, 2.00 mL, 30.36 eq) was stirred 
at 15-25 °C for 8 hours. LCMS showed all of tert-butyl N-(3-cyclopropyl-6-methyl-pyrazolo[1,5-a]pyrimidin-7-
yl)-N-(2-pyridylmethyl)carbamate was consumed and desired MS. TLC (EtOAc) showed all of tert-butyl N-(3-
cyclopropyl-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate and three new spot. The 
mixture was concentrated to give a residue. The residue was purified by prep-TLC (EtOAc/NH3.H2O=100/1) to 
give 3-cyclopropyl-6-methyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (10.50 mg, 35.97 µmol, 13% 
yield, 95.7% purity) as a light yellow solid. 
LCMS (Method 5-95 AB): RT=0.608 min/1.5 min, [M+H]+=280.3. 
1H NMR (400MHz, DMSO-d6) δ 8.56 (d, J=4.4 Hz, 1H), 8.02 (t, J=6.2 Hz, 1H), 7.94 (s, 1H), 7.74-7.85 (m, 2H), 
7.26-7.39 (m, 2H), 5.12 (d, J=6.3 Hz, 2H), 2.33 (s, 3H), 1.88-1.98 (m, 1H), 0.76-0.90 (m, 4H). 
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3-iodo-6-methyl-N-(1-(pyridin-2-yl)ethyl)pyrazolo[1,5-a]pyrimidin-7-amine (3). 
 
 
 
 
 
To a mixture of 7-chloro-3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidine (500.00 mg, 1.70 mmol, 1.00 eq) in DMF 
(5.00 mL) was added 7-chloro-3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidine (500.00 mg, 1.70 mmol, 1.00 eq), 
TEA (344.05 mg, 3.40 mmol, 2.00 eq). The mixture was stirred at 60 °C for 10 h. TLC (Petroleum ether/Ethyl 
acetate=2/1) showed 7-chloro-3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidine was consumed completely and a 
new spot. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (50 mL*2). The 
combined organic layers were washed with saturated brine (40 mL), dried with anhydrous Na2SO4, filtered and 
concentrated in vacuo. The residue was purified by chromatography (Petroleum ether/Ehyl acetate=10/1 ~1/1) 
to get 3-iodo-6-methyl-N-[1-(2-pyridyl)ethyl]pyrazolo[1,5-a]pyrimidin-7-amine (500.00 mg, 1.29 mmol, 76 % 
yield, 98% purity) as a yellow oil. 
LCMS (Method 5-95AB, ESI): RT =0.594 min / 1.5 min, M+H+ =380.0. 
 
3-(4-fluorophenyl)-6-methyl-N-(1-(pyridin-2-yl)ethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9061). 
 
 
 
 
 
 
 
A mixture of   3-iodo-6-methyl-N-[1-(2-pyridyl)ethyl]pyrazolo[1,5-a]pyrimidin-7-amine (120.00 mg, 316.46 
µmol, 1.00 eq), (4-fluorophenyl)boronic acid (57.56 mg, 411.39 µmol, 1.30 eq), Pd(dppf)Cl2 (23.16 mg, 31.65 
µmol, 0.10 eq), Cs2CO3 (206.22 mg, 632.91 µmol, 2.00 eq) in dioxane (2.00 mL) and H2O (400.00 uL) was de-
gassed and refilled with N2. Then stirred at 110 °C for 2 hrs. TLC (Ethyl acetate/Petroleum ether=1/1) showed 
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3-iodo-6-methyl-N-[1-(2-pyridyl)ethyl]pyrazolo[1,5-a]pyrimidin-7-amine was consumed completely and a new 
spot. LCMS showed a major peak with desired product mass. The mixture was diluted with water (50 
mL) and extracted with ethyl acetate (50 mL*2). The combined organic layers were washed with saturated 
brine (40 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by 
chromatography (Petroleum ether/Ethyl acetate=10/1~ 1/1)  followed by prep-HPLC to get 3-(4-fluorophenyl)-
6-methyl-N-[1-(2-pyridyl)ethyl]pyrazolo[1,5-a]pyrimidin-7-amine (11.40 mg, 31.77 µmol, 10% yield, 96.8% 
purity) as a white solid. 
LCMS (Method 5-95AB, ESI): RT =0.772 min / 2 min, M+H+ =348.3.  
1H NMR (400MHz, DMSO-d6) 8.62 (s, 2H), 8.15-8.18 (m, 3H), 7.80-7.86 (m, 2H), 7.51-7.53 (d, J=8.0 Hz, 1H), 
7.32-7.35 (m, 1H), 7.21-7.25 (m, 2H), 5.68-5.73 (m, 2H), 2.42 (s, 3H), 1.58-1.60 (d, J=8.0 Hz, 3H). 
  
 
 
tert-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate (3) 
 
 
 
 
 
To a solution of 7-chloro-3-iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidine (200 mg, 650 µmol, 1 eq) in DMF (5 
mL) was added Et3N (197 mg, 2 mmol, 3 eq) and 1-(2-pyridyl)cyclopropanamine (131 mg, 975 µmol, 1.5 eq). 
The mixture was stirred at 75 °C for 12 h. TLC (Petroleum ether/EtOAc=5/1) showed that about 30% of 6,7-
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dichloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidine was consumed and two major new spots. LCMS showed 
that 34% of 6,7-dichloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidine was not consumed, desired mass and by-
product's mass was detected. The mixture was stirred at 85 °C for another 12 h. LCMS showed that  6,7-
dichloro-3-iodo-5-methyl-pyrazolo[1,5-a]pyrimidine was still remained and about 50% of desired product. To 
the mixture was added water (50 mL) and extracted with EtOAc (40 mL*2). The organic layers were washed 
with brine (60 mL), dried over Na2SO4 and concentrated. The residue was purified by prep-TLC (Petroleum 
ether/EtOAc=3/1) to give 3-iodo-5,6-dimethyl-N-[1-(2-pyridyl)cyclopropyl]pyrazolo[1,5-a]pyrimidin-7-amine 
(60 mg, 148 µmol, 23% yield) as a yellow solid. 
1H NMR (400MHz, CDCl3-d)  8.51-8.58 (m, 1H), 7.96 (s, 1H), 7.60-7.67 (m, 1H), 7.52 (d, J=7.91 Hz, 1H), 7.24 (s, 
1H), 7.10-7.17 (m, 1H), 2.53 (s, 3H), 2.13 (s, 3H), 1.93 (d, J=3.01 Hz, 2H), 1.54 (d, J=3.14 Hz, 2H). 
 
3-(4-fluorophenyl)-5,6-dimethyl-N-(1-(pyridin-2-yl)cyclopropyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9066) 
 
 
 
 
 
 
 
To a solution of 3-iodo-5,6-dimethyl-N-[1-(2-pyridyl)cyclopropyl]pyrazolo[1,5-a]pyrimidin-7-amine (80 mg, 197 
µmol, 1 eq) and (4-fluorophenyl)boronic acid (41 mg, 296 µmol, 1.5 eq) in dioxane (4 mL) and H2O (400 uL) was 
added Cs2CO3 (128 mg, 394 µmol, 2 eq), ditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron (13 mg, 
19.7 µmol, 0.1 eq). The mixture was stirred at 90 °C for 1 hour under N2. TLC (Petroleum ether/EtOAc=5/1) 
showed that 3-iodo-5,6-dimethyl-N-[1-(2-pyridyl)cyclopropyl]pyrazolo[1,5-a]pyrimidin-7-amine was consumed 
completely and a major new spot. The mixture was concentrated directly. The residue was purified by 
chromatography on silica gel (Petroleum ether/EtOAc=5/1, 2/1) to give the crude product (purity: 90%), which 
was purified by prep-HPLC (Column: Phenomenex Gemini 150*25mm*10um; Condition: water (0.05% 
ammonia hydroxide v/v)-ACN; Gradient Time(min): 11; FlowRate(ml/min): 25; Injections: 5) to give 3-(4-
fluorophenyl)-5,6-dimethyl-N-[1-(2-pyridyl)cyclopropyl]pyrazolo[1,5-a]pyrimidin-7-amine (10.5 mg, 26.8 µmol, 
14% yield, 95.2% purity) as a white solid. 
LCMS (Method 5-95AB, ESI): RT =0.666 min / 1.5 min, M+H+ =374.5. 
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1H NMR (400MHz, DMSO-d6) 8.47-8.53 (m, 1H), 8.32 (s, 1H), 8.03-8.10 (m, 2H), 7.73-7.79 (m, 1H), 7.66 (s, 
1H), 7.20-7.26 (m, 1H), 7.13 (t, J=8.91 Hz, 2H), 2.51 (s, 3H), 2.17 (s, 3H), 1.84-1.90 (m, 2H), 1.58-1.64 (m, 2H). 
 
 
 
 
Ethyl 4,4,4-trifluoro-2-formylbutanoate (2) 
 
 
 
To a solution of ethyl 4,4,4-trifluorobutanoate (1 g, 5.9 mmol, 1 eq) and methyl formate (530 mg, 8.8 mmol, 
1.5 eq) in DCM (15 mL) was added TiCl4 (2.2 g, 11.8 mmol, 2 eq) dropwise at 0 °C, then TEA (1.5 g, 14.7 mmol, 
2.5 eq) was added to the mixture dropwise at 0 °C. The mixture was stirred at 0 °C for 1 hr under N2. Then the 
temperature was warmed to 15 °C and the mixture was stirred at 15 °C for another 1 hr. TLC (Petroleum 
ether/EtOAc=5/1) showed that a major spot (254 uv nm), and the spot of ethyl 4,4,4-trifluorobutanoate 
couldn't found at 254 nm.  The mixture was added into water (40 mL) and extracted with EtOAc (40 mL*2). The 
organic layers were washed with brine (50 mL), dried over Na2SO4 and concentrated to give ethyl 4,4,4-
trifluoro-2-formyl-butanoate (1.4 g, crude) as a light brown oil. 
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1H NMR (400MHz, CDCl3-d)  11.61-11.77 (m, 1H), 3.99-4.07 (m, 2H), 3.87 (d, J=7.16 Hz, 1H), 2.66 (d, J=10.36 
Hz, 2H), 1.01 (s, 3H). 
6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-ol (4) 
  
 
 
To a solution of 1H-pyrazol-5-amine (400 mg, 4.8 mmol, 1 eq) and ethyl 4,4,4-trifluoro-2-formyl-butanoate 
(953 mg, 4.8 mmol, 1 eq) in toluene (8 mL) was added TsOH.H2O (91.5 mg, 481 µmol, 0.1 eq). The mixture was 
stirred at 90 °C for 12 hours. TLC (EtOAc) showed that 1H-pyrazol-5-amine was consumed completetly and a 
new major spot (blue colour at 254 nm). The mixture was cooled to room temperature. The mixture 
was filtered and washed with EtOAc (3 mL) to give 6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-ol (449.5 
mg, 2.1 mmol, 43% yield) as a grey solid. 
1H NMR (400MHz, DMSO-d6) 8.06 (s, 1H), 7.92 (d, J=1.88 Hz, 1H), 6.22 (d, J=2.01 Hz, 1H), 3.47 (m, 2H). 
 
 
7-chloro-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidine (5) 
 
 
 
A solution of 6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-ol (450 mg, 2.1 mmol, 1 eq) in POCl3 (12.7 g, 
82.8 mmol, 40 eq) was stirred at 120 °C for 16 hours under N2. TLC (EtOAc) showed that more than 50% of 6-
(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-ol was consumed. TLC (Petroleum ether/EtOAc=1/1) showed 
that two new major spots. Tthe mixture was concentrated to give 7-chloro-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-
a]pyrimidine (500 mg, crude) as a yellow solid. 
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7-chloro-3-iodo-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidine (6) 
 
 
 
To a solution of 7-chloro-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidine (400 mg, 848.9 µmol, purity: 50%, 1 
eq) in CH3CN (10 mL) was added NIS (286 mg, 1.3 mmol, 1.5 eq) at 0 °C. The mixture was stirred at 18 °C for 1 
hour. TLC (Petroleum ether/EtOAc=5/1) showed that 7-chloro-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidine 
was consumed completetly and two major spots. The mixture was concentrated. The residue was purified by 
chromatography on silica gel (Petroleum ether/EtOAc=10/1, 5/1) to give 7-chloro-3-iodo-6-(2,2,2-
trifluoroethyl)pyrazolo[1,5-a]pyrimidine (300 mg, 746.91 µmol, 88% yield, 90% purity) as a black brown solid. 
LCMS (Method 5-95AB, ESI): RT =0.828 min / 1.5 min, M+H+ =362. 
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3-iodo-N-(pyridin-2-ylmethyl)-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-amine (8) 
 
 
 
 
 
To a solution of 7-chloro-3-iodo-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidine (300 mg, 746.9 µmol, 1 eq) 
and 2-pyridylmethanamine (121 mg, 1.1 mmol, 1.5 eq) in DMF (5 mL) was added TEA (226.7 mg, 2.2 mmol, 3 
eq). The mixture was stirred at 60 °C for 1 hour. TLC (Petroleum ether/EtOAc=5/1) showed that 7-chloro-3-
iodo-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidine was consumed completetly and a major new spot. To 
the mixture was added water (5 mL) and then a grey solid was forming. It was filtered and washed with water 
(2 mL) and concentrated to give 3-iodo-N-(2-pyridylmethyl)-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-
amine (200 mg, 462 µmol, 62% yield) as a grey solid. 
1H NMR (400MHz, CDCl3-d)  8.70 (d, J=4.77 Hz, 1H), 8.26-8.34 (m, 1H), 8.20 (s, 1H), 8.08 (s, 1H), 7.75 (td, 
J=7.65, 1.63 Hz, 1H), 7.29-7.36 (m, 2H), 5.09 (d, J=4.89 Hz, 2H), 3.66 (q, J=9.91 Hz, 2H 
3-(4-fluorophenyl)-N-(pyridin-2-ylmethyl)-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9067) 
 
 
 
 
 
 
To a solution of 3-iodo-N-(2-pyridylmethyl)-6-(2,2,2-trifluoroethyl)pyrazolo [1,5-a]pyrimidin-7-amine (100 mg, 
231 µmol, 1 eq) and (4-fluorophenyl)boronic acid (64.6 mg, 461.7 µmol, 2 eq) in dioxane (10 mL) and H2O (1 
mL) was added ditert-butyl(cyclopentyl)phosphane;dichloropalladium;iron (15 mg, 23.1 µmol, 0.1 eq), Cs2CO3 
(150 mg, 461.7 µmol, 2 eq). The mixture was stirred at 100 °C for 5 hours under N2. TLC (Petroleum 
ether/EtOAc=1/1) showed that about 80% of 3-iodo-N-(2-pyridylmethyl)-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-
a]pyri- midin-7-amine was consumed and a major new spot. Desired product's mass was detected by 
LCMS. The mixture was concentrated. The residue was purified by chromatography on silica gel (Petroleum 
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ether/EtOAc=2/1, 1/1) to give a crude product, which was purified by prep-HPLC (Column: Boston Green ODS 
150*30 5u; Condition: 0.225%FA-ACN). The product was basified by strongly basic anion exchange resin to give 
3-(4-fluorophenyl)-N-(2-pyridylmethyl)-6-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrimidin-7-amine (19 mg, 45 
µmol, 19% yield, 94.5% purity) as a white solid. 
LCMS (Method 5-95AB, ESI): RT =0.794 min / 1.5 min, M+H+ =402.5. 
1H NMR (400MHz, MeOD-d4) 8.56-8.61 (m, 1H), 8.38 (s, 1H), 8.14-8.20 (m, 1H), 7.96-8.04 (m, 2H), 7.79-7.85 
(m, 1H), 7.42-7.48 (m, 1H), 7.32-7.37 (m, 1H), 7.15 (s, 2H), 5.24 (s, 2H), 3.78 (d, J=10.42 Hz, 2H). 
 
 
 
(tetrahydro-2H-pyran-4-yl)methyl methanesulfonate (2)   
 
 
To a solution of tetrahydropyran-4-ylmethanol (5.00 g, 43.04 mmol, 1.00 eq) in DCM (30.00 mL) was added 
Et3N (5.66 g, 55.95 mmol, 7.75 mL, 1.30 eq). The mixture was cooled to 0 °C and MsCl (5.92 g, 51.65 mmol, 
4.00 mL, 1.20 eq) was added slowly by dropwise over 15 mins. After 15 mins, the mixture was stirred at 25 °C 
for 12 hrs. TLC (Petroleum ether: Ethyl acetate= 1: 1) showed tetrahydropyran-4-ylmethanol was consumed 
completely and a new spot with similar polarity as tetrahydropyran-4-ylmethanol. The mixture was diluted 
with saturated Na2CO3 (100 mL) and extrated with EtOAC (150 mL *3). Then the combined layers were washed 
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with saturated NH4Cl (200 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo to give 
tetrahydropyran-4-ylmethyl methanesulfonate (7.50 g, crude) as a yellow solid. 
1H NMR (400MHz, CDCl3) 4.04-4.06 (d, J=8.0 Hz, 2H), 3.96-4.00 (dd, J=8.0 Hz, J=4.0 Hz, 2H), 3.35-3.42 (td, 
J=12.0 Hz, J=4.0 Hz, 2H), 3.00 (s, 3H), 1.95-2.05 (m, 2H), 1.65-1.68 (m, 2H), 1.32-1.48 (m, 2H).
2-(tetrahydro-2H-pyran-4-yl)acetonitrile (3). 
 
 
 
To a mixture of tetrahydropyran-4-ylmethyl methanesulfonate (6.50 g, 33.46 mmol, 1.00 eq) in DMSO (50.00 
mL) was added NaCN (2.84 g, 57.95 mmol, 1.73 eq). The mixture was stirred at 80 °C for 14 h. TLC (Petroleum 
ether: Ethyl acetate= 3: 1) showed tetrahydropyran-4-ylmethyl methanesulfonate was consumed completely 
and a major new spot. The mixture was diluted with water (100 mL) and extraected with EtOAc (150 mL*5). 
The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The 
residue was purified by chromatography (Petroleum ether: Ethyl acetate= 10: 1~ 3: 1) to give 2-
tetrahydropyran-4-ylacetonitrile (3.40 g, 27.16 mmol, 81% yield) as a yellow liquid. 
1H NMR (400 MHz, CDCl3) 3.98-4.02 (dd, J=12.0 Hz, J=4.0 Hz, 2H), 3.36-3.42 (td, J=12.0 Hz, 2H), 3.30-3.32 (d, 
J=8.0 Hz, 2H), 1.89-1.95 (m, 1H), 1.72-1.76 (dd, J=12.0 Hz, J=4.0 Hz, 2H), 1.41-1.45 (m, 2H). 
3-oxo-2-(tetrahydro-2H-pyran-4-yl)propanenitrile (4). 
 
 
 
To a mixture of  2-tetrahydropyran-4-ylacetonitrile (2.40 g, 19.17 mmol, 1.00 eq) in THF (20.00 mL) was added 
LDA (2 M, 14.38 mL, 1.50 eq) at -70 °C~- 65 °C. After 20 mins, HCO2Et (3.38 g, 38.35 mmol, 3.75 mL, 2.00 
eq) was added into the mixture, then stirred at -70 °C~ -65 °C for 40 mins. TLC (Petroleum ether: Ethyl acetate= 
1: 1) showed 2-tetrahydropyran-4-ylacetonitrile was consumed completely and several new spots. The mixture 
was diluted with saturated NH4Cl (30 mL) and adjust pH to 3~4 with HCl (1 N), extracted with EtOAc (100 
mL*5). The combined organic layers were concentrated to remove the solvents and afford give 3-oxo-2-
tetrahydropyran-4-yl-propanenitrile (3.70 g, crude) as a yellow solid which was used in the next step without 
purification. 
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4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-amine (5) 
 
 
 
To a mixture of 3-oxo-2-tetrahydropyran-4-yl-propanenitrile (3.70 g, 24.15 mmol, 1.00 eq) in EtOH (3.00 
mL) was added N2H4-H2O (3.81 g, 76.09 mmol, 3.70 mL, 3.15 eq) and AcOH (3.89 g, 64.73 mmol, 3.70 mL, 2.68 
eq). The mixture was stirred at 60 °C for 2 h. TLC (Ethyl acetate: Petroleum ether= 2: 1) showed 3-oxo-2-
tetrahydropyran-4-yl-propanenitrile was consumed completely. The mixture was concentrated directly to 
remove the solvent. The residue was purified by chromatography (Ethyl acetate: Petroleum ether= 1: 1 to 
EtOAc) to give  4-tetrahydropyran-4-yl-1H-pyrazol-3-amine (3.40 g, 20.33 mmol, 84% yield) as a yellow oil.  
1H NMR (400 MHz, DMSO-d) 7.11 (s, 1H), 3.85-3.88 (dd, J=12.0 Hz, J=4.0 Hz 2H), 3.39 (s, 2H), 2.53-2.57 (m, 
1H), 1.68-1.71 (dd, J=12.0 Hz, 2H), 1.38-1.49 (m, 2H) 
6-chloro-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-ol (7) 
 
 
 
 
 
The mixture of 4-tetrahydropyran-4-yl-1H-pyrazol-3-amine (1.50 g, 8.97 mmol, 1.00 eq) and methyl 2-chloro-3-
oxo-propanoate (1.35 g, 9.87 mmol, 1.10 eq) in THF (20.00 mL) was stirred at 60 °C for 2 h. Then tBuOK (1.51 g, 
13.46 mmol, 1.50 eq) was added into and stirred at 30 °C for 2 h. TLC (Dichloromethane: Methanol= 10: 1) 
showed 4-tetrahydropyran-4-yl-1H-pyrazol-3-amine was consumed completely and a new spot. The mixture 
was adjust to pH=3~4 with HCl/MeOH (4 M), then was concentrated to remove the solvent to give 6-chloro-3-
tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-ol (3.00 g, crude) as a yellow solid which can used in the next 
step directly. 
6,7-dichloro-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidine (8) 
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A mixture of 6-chloro-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-ol (3.00 g, 11.83 mmol, 1.00 eq), N,N-
diethylaniline (1.77 g, 11.83 mmol, 1.90 mL, 1.00 eq) in POCl3 (100.00 mL) was stirred at 100 °C for 16 h. TLC 
(Petroleum ether: Ethyl acetate= 5: 1) showed a major new spot. The mixture was concentrated to remove the 
POCl3. The balck residue was purified by chromatography (Petroleum ether: Ethyl acetate= 10: 1~3: 1) to give 
6,7-dichloro-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (1.20 g, 4.23 mmol, 36% yield, 96% purity) as a 
yellow solid. 
LCMS (Method 5-95AB, ESI): RT =0.745 min / 1.5 min, M+H+ =272.2 
6-chloro-N-(pyridin-2-ylmethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9069) 
 
 
 
 
 
 
To a mixture of 6,7-dichloro-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (86.00 mg, 316.03 µmol, 1.00 eq) 
2-pyridylmethanamine (41.01 mg, 379.24 µmol, 38.69 uL, 1.20 eq) in DMF (2.00 mL) was added Et3N (63.96 mg, 
632.06 µmol, 87.62 uL, 2.00 eq). The mixture was stirred at 60 °C for 16 h. TLC (Petroleum ether: Ethyl 
acetate= 2: 1) showed 6,7-dichloro-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine was consunmed 
completely and a new major spot. LCMS showed a major peak with desired mass. The mixture was diluted with 
water (15 mL), then filtered to get the filter cake which was washed with EtOAc (2 mL) and MeOH (1 mL) to 
afford 6-chloro-N-(2-pyridylmethyl)-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-amine (21.40 mg, 61.31 
µmol, 19% yield, 98.5% purity) as a light yellow solid 
LCMS (Method 5-95AB, ESI): RT =0586 min / 1.5 min, M+H+ =344.1. 
1H NMR (400 MHz, DMSO-d6)   8.53-8.54 (d, J=4.0 Hz, 1H), 8.46-8.49 (t, J=8.0 Hz, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 
7.77-7.81 (td, J=8.0 Hz, 1H), 7.35-7.37 (d, J=8.0 Hz, 1H), 7.28-7.31 (m, 1H), 5.28-5.29 (d, J=4.0 Hz, 2H), 3.92-3.94 
(d, J=8.0 Hz, 2H), 3.43-3.49 (m, 2H), 3.02-3.10 (m, 1H), 1.81-1.85 (m, 4H) 
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Tert-butyl (6-chloro-5-methyl-3-(3-oxomorpholino)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (2) 
 
 
 
 
 
 
 
To a solution of tert-butyl N-(3-bromo-6-chloro-5-methyl-pyrazolo[1,5-a]pyrimi- din-7-yl)-N-(2-
pyridylmethyl)carbamate (1 g, 2.2 mmol, 1 eq) and morpholin-3-one (290 mg, 2.9 mmol, 1.3 eq) in dioxane (40 
mL) was added CuI (1.7 g, 8.8 mmol, 4 eq), N,N'-dimethylethane-1,2-diamine (1.6 g, 17.7 mmol, 1.9 mL, 8 eq). 
The mixture was stirred at 110 °C  for 4 hrs under N2. TLC (Petroleum ether: EtOAc=2: 1) showed that 
about most of tert-butyl N-(3-bromo-6-chloro-5-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate was consumed and two new spots. The mixture was filtered and the filtrate was 
concentrated. The residue was purified by chromatography on silica gel (Petroleum ether: EtOAc=5: 1, 1: 1, 1: 
2) to provide tert-butyl N-[6-chloro-5-methyl-3-(3-oxomorpholin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (600 mg, crude) as a brown yellow oil. 
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4-(6-chloro-5-methyl-7-((pyridin-2-ylmethyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)morpholin-3-one (AWZ9096) 
 
 
 
 
 
 
A solution of tert-butyl N-[6-chloro-5-methyl-3-(3-oxomorpholin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (150 mg, 317 µmol, 1 eq) in HCl/EtOAc (4 M, 10 mL, 126 eq) was stirred at 30 °C  for 
12 hours. LCMS showed tert-butyl N-[6-chloro-5-methyl-3-(3-oxomorpholin-4-yl)pyrazolo[1,5-a]pyrimidin-7-
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yl]-N-(2-pyridylmethyl)carbamate was consumed completetly and a major peak with desired mass. The 
mixture was concentrated. The residue was dissolved in DCM/MeOH (1: 1, 20 mL) and basified by strong basic 
anion exchange resin. The crude product was purified by trituration from (Petroleum ether: EtOAc: DCM=3: 3: 
1, 7 mL) to provide 4-[6-chloro-5-methyl-7-(2-pyridylmethyl- amino)pyrazolo[1,5-a]pyrimidin-3-yl]morpholin-3-
one (57 mg, 150 µmol, 47% yield, 98% purity) as a light yellow solid. 
1H NMR (400MHz, DMSO-d6)  8.69 (d, J=4.5 Hz, 1 H), 8.25 (s, 1 H), 8.01 (br. s., 1 H), 7.74 (t, J=7.7 Hz, 1 H), 
7.34 (d, J=7.8 Hz, 1 H), 7.29-7.31 (m, 1 H), 5.44 (d, J=4.9 Hz, 2 H), 4.41 (s, 2 H), 4.07-4.13 (m, 4 H), 2.60 (s, 3 H). 
 
LCMS (Method 5-95AB, ESI): RT =0.552 min / 1.5 min, M+H+ =373.1. 
 
 
 
 
 
 
 
Tert-butyl (6-chloro-5-methyl-3-(3-oxomorpholino)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-
ylmethyl)carbamate (2) 
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To a solution of tert-butyl N-(3-iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(2 g, 4.2 mmol, 1 eq) in dry DMSO (40 mL) was added KOAc (819 mg, 8.3 mmol, 2 eq), Pin2B2 (1.3 g, 5 mmol, 1.2 
eq), Pd(dppf)Cl2 (152 mg, 208.5 µmol, 0.05 eq). The mixture was stirred at 60 °C for 1 hour under N2. TLC 
(Petroleum ether: EtOAc=1: 1) showed tert-butyl N-(3-iodo-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate was consumed completetly and three major spots. Desired product and by-product 
[7-[tert-butoxycarbonyl(2-pyridylmethyl)amino]-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-3-yl]boronic acid and 
tert-butyl N-[2-[7-[tert-butoxycarbonyl(2-pyridylmethyl)amino]-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-3-yl]-
5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylme- thyl)carbamate was detected by LCMS.  H2O (40 
mL) was added to the mixture. The aqueous layer was extracted with EtOAc (40 mL*2). The organic layer was 
washed brine (40 mL), drived over Na2SO4, concentrated. The residue was purified by chromatography on silica 
gel (Petroleum ether: EtOAc=5: 1, 1: 1, 1: 2) to give a mixture of tert-butyl N-[5,6-dimethyl-3-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate and [7-[tert-
butoxycarbonyl(2-pyridyl- methyl)amino]-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-3-yl]boronic acid (1 g ) as 
brown oil. 
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Tert-butyl (3-hydroxy-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (3) 
 
 
 
 
 
 
To a mixture of tert-butyl N-[5,6-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate and [7-[tert-butoxycarbonyl(2-pyridylmethyl)amino]-5,6-
dimethyl-pyrazolo[1,5-a]pyrimi-din-3-yl]boronic acid (1 g) in THF (20 mL) was added NaOH (2 M, 6.3 mL, 6 eq) 
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and H2O2 (2.4 g, 21 mmol, 2 mL, 30% purity, 10 eq). The mixture was stirred at 25 °C for 12 hours. TLC 
(Petroleum ether: EtOAc= 1: 2) showed that two material were consumed completetly and a new major spot. 
To the mixture was added water (50 mL) followed by HCl (1 N, 10 mL). The aqueous layer was extracted with 
EtOAc (50 mL*2). The organic layers were washed with brine (60 mL), dried over Na2SO4 
and concentrated. The residue was purified by chromatography on silica gel (Petroleum ether: EtOAc=1: 1, 1: 
2) to provide tert-butyl N-(3-hydroxy-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridyl- 
methyl)carbamate (700 mg, 1.7 mmol, 82% yield, 90% purity) as a yellow solid. 
1H NMR (400MHz, DMSO-d6)  8.9-8.93 (m, 1H), 8.40-8.47 (m, 1H), 7.70-7.94 (m, 2H), 7.40-7.49 (m, 1H), 7.24-
7.27 (m, 1H), 5.03-5.18 (m, 1H), 4.56-4.62 (m, 1H), 2.43 (s, 3H), 1.91-1.99 (m, 3H), 1.24-1.16 (m, 9 H). 
 
tert-butyl (3-(difluoromethoxy)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)ca rbamate (4) 
 
 
 
 
 
 
To a solution of tert-butyl N-(3-hydroxy-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (300 mg, 812 µmol, 1 eq) in THF (10 mL) was added KOH (3.5 M, 2.3 mL, 10 eq). The 
mixture was stirred at 25 °C  for 12 hours under chloro(difluoro)methane (15 psi). TLC (Petroleum 
ether: EtOAc=1: 1) showed that around half of tert-butyl N-(3-hydroxy-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-
7-yl)-N-(2-pyridylmethyl)carbamate was consumed and a new major spot. To the mixture was added water (30 
mL) and the resultant mixture was extracted with EtOAc (40 mL*2). The organic layers were washed with brine 
(40 mL), dried over Na2SO4 and concentrated. The residue was purified by chromatography on silica gel 
(Petroleum ether: EtOAc=1: 1) to give tert-butyl N-[3-(difluoromethoxy)-5,6-dimethyl-pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (80 mg, 191 µmol, 23% yield) as light yellow oil. 
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3-(difluoromethoxy)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9097) 
 
 
 
 
 
 
A solution of tert-butyl N-[3-(difluoromethoxy)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (80 mg, 191 µmol, 1 eq) in HCl/EtOAc (4 M, 5 mL, 105 eq) was stirred at 30 °C  for 2 
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hours. LCMS  showed most of tert-butyl N-[3-(difluoromethoxy)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-
(2-pyridylmethyl)carbamate was consumed and a major peak with desired mass. The mixture was 
concentrated. The residue was basified with two drops of TEA and then purified by prep-HPLC (FA, Column: 
Phenomenex Synergi C18 150*30mm*4um; Condition: water(0.225%FA)-ACN) to give 3-(difluoromethoxy)-5,6-
dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (27 mg, 83 µmol, 43% yield, 98% purity) as a 
light grey solid. 
1H NMR (400MHz, DMSO-d6)  8.68-8.69 (d, J=4.8 Hz, 1H), 7.95 (s, 1H), 7.71-7.75 (td, J=7.6, 2.0 Hz, 1H), 7.46 
(br. s., 1H), 7.32-7.34 (d, J=7.6 Hz, 1H), 7.26 (m, 1H), 6.51-6.88 (t, J=148.4, 1H), 5.12-5.14 (d, J=5.2 Hz, 2H), 2.55 
(s, 3H), 2.38 (s, 3 H). 
LCMS (Method 10-80CD, ESI): RT =1.275 min / 2.0 min, M+H+ =320.1. 
 
 
 
Tert-butyl (5,6-dimethyl-3-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylme- thyl)carbamate (2) 
 
 
 
 
 
 
 
To a solution of tert-butyl N-[5,6-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (200 mg, 417 µmol, 1 eq) in MeOH (3 mL) and DCM (3 mL), 
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H2O (500 uL)  was added sodium;trifluoromethanesulfinate (130 mg, 834 µmol, 130 uL, 2 eq), CuCl (83 mg, 834 
µmol, 20 uL, 2 eq), NaHCO3 (30%, 0.1 mL, 2 eq). Then to the mixture was added 2-hydroperoxy-2-methyl-
propane (752 mg, 8.3 mmol, 800 uL, 20 eq) dropwise.  The mixture was stirred at 25 °C  for 1 hour. TLC 
(Petroleum ether: EtOAc=1: 1) showed tert-butyl N-[5,6-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)pyrazolo[1,5-a]pyrimidin -7-yl]-N-(2-pyridylmethyl)carbamate was consumed completetly and a new major 
spot. The mixture was filtered and the filtrate was concentrated. The residue was purified by chromatography 
on silica gel (Petroleum ether: EtOAc=5: 1, 2: 1) to give tert-butyl N-[5,6-dimethyl-3-
(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (100 mg, 237 µmol, 57% yield) 
as a light yellow oil. 
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5,6-dimethyl-N-(pyridin-2-ylmethyl)-3-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9099) 
 
 
 
 
 
 
A solution of tert-butyl N-[5,6-dimethyl-3-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (80 mg, 189.83 µmol, 1.00 eq) in HCl/EtOAc (4 M, 4 mL, 84 eq) was stirred at 28 
°C  for 3 hours. LCMS showed tert-butyl N-[5,6-dimethyl-3-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-
(2-pyridylmeth- yl)carbamate was consumed completetly and a major peak with desired mass. The mixture 
was concentrated. The residue was dissolved in MeOH and basified with three drops of Et3N, then it was 
purified by prep-HPLC (Column: Phenomenex Synergi Max-RP 250*50mm*10 um; Condition: 
water(0.225%FA)-ACN) to get crude product which was purified by prep-TLC (Petroleum ether: Ethyl 
acetate=1: 1) to give 5,6-dimethyl-N-(2-pyridylmethyl)-3-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-amine 
(15 mg, 45 µmol, 24% yield, 97% purity) as a white solid. 
1H NMR (400MHz, DMSO-d6)  8.68 (d, J=4.64 Hz, 1 H), 8.15 (s, 1 H), 7.74 (td, J=7.65, 1.76 Hz, 1 H), 7.59 (br. s., 
1 H), 7.29 - 7.36 (m, 2 H), 5.18 (d, J=5.14 Hz, 2 H), 2.59 (s, 3 H), 2.41 (s, 3 H). 
LCMS (Method 5-95CD, ESI): RT =0.635 min / 1.5 min, M+H+ =322.1. 
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 methyl 2-methyl-3-oxopropanoate (2)  
 
 
 
A solution of methyl propanoate (20.00 g, 227.01 mmol, 21.74 mL, 1.00 eq) and ethyl formate (25.23 g, 340.52 
mmol, 27.42 mL, 1.50 eq) in DCM (200.00 mL) was degassed and purged with N2 for 3 times. TiCl4 (86.99 g, 
454.02 mmol, 50.28 mL, 99% purity, 2.00 eq) and TEA (57.43 g, 567.53 mmol, 78.67 mL, 2.50 eq) was added 
dropwise to above mixture at 0 °C successively. The mixture was stirred at 0 °C for 1 h under N2 atmosphere. 
Then the temperature was warmed to 20 °C and the mixture was stirred at 20 °C for another 1 h.  TLC 
(Petroleum ether: Ethyl acetate=10: 1) showed a major spot at UV 254 nm (the starting materials methyl 
propanoate and ethyl formate couldn't be observed at 254 nm). The mixture was diluted with water (500 mL) 
and the resultant mixture was extracted with DCM (400mL*2). The organic layers were washed with brine 
(200mL*2), dried over Na2SO4 and concentrated. The crude product purified by column chromatography (SiO2, 
Petroleum ether: Ethyl acetate=100: 1 to 10: 1) to give methyl 2-methyl-3-oxo-propanoate (18.00 g, crude) as 
a yellow oil. 
 
 
 
6-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-ol (3). 
 
 
 
 
 
A mixture of 4-tetrahydropyran-4-yl-1H-pyrazol-5-amine (300.00 mg, 1.79 mmol, 1.00 eq) and ethyl 2-methyl-
3-oxo-propanoate (279.54 mg, 2.15 mmol, 1.20 eq) in THF (10.00 mL) was stirred at 60 °C for 2 h. Then the 
mixture was cooled to 28 °C, t-BuOK (241.03 mg, 2.15 mmol, 1.20 eq) was added into the reaction mixture. 
The mixture was stirred at 26 °C for 13 h. TLC (Dichloromethane: Methanol=10: 1) indicated 4-
tetrahydropyran-4-yl-1H-pyrazol-5- amine was consumed completely and two new spots were formed. The 
reaction mixture was concentrated under reduced pressure to remove THF to give a residue. The residue was 
diluted with EtOAc (10 mL). The mixture was acidified with HCl/EtOAc to pH=3. The resulting solution was 
                                                                          Appendix 1 _____________________________________                                                                                                
 
 
 
307 
 
concentrated under reduced pressure to give the crude product 6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-
a]pyrimidin-7-ol (428.60 mg, crude) as a yellow soild which was used next step without purification. 
 
7-chloro-6-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidine (4). 
 
 
 
 
 
To a mixture of 6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a] pyrimidin-7-ol (500.00 mg, 2.14 mmol, 1.00 
eq) in POCl3 (25.00 mL) was added N,N-DIETHYLANILINE (479.03 mg, 3.21 mmol, 515.09 uL, 1.50 eq). The 
mixture was stirred at 110 °C for 20 h. TLC (Petroleum ether: Ethyl acetate=5: 1) indicated 6-methyl- 3-
tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-ol was consumed completely, a new spot was formed. The 
reaction minxture was evaporated to dryness and azeotroped with toluene to remove residue POCl3 to give a 
residue. The residue was purified by column chromatography (Petroleum ether: Ethyl acetate=20: 1 to 5: 1) to 
gove 7-chloro-6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (183.00 mg, 727.03 µmol, 33.97% 
yield) as a yellow soild. 
LCMS (Method 0-60 AB, ESI): RT =0.855 min / 1.5 min, M+H+ =252.1. 
1H NMR (400 MHz, CHLOROFORM-d)  ppm 8.31 (s, 1H), 8.04 (s, 1H), 4.07 - 4.13 (m, 2H), 3.56 - 3.69 (m, 3H), 
3.26 (tt, J=10.51, 5.30 Hz, 1H), 2.48 (s, 3H), 1.98 (dd, J=9.54, 3.64 Hz, 4H). 
 
6-methyl-N-(1-(pyridin-2-yl)ethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9100) 
Batch 1: 
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To a solution of 7-chloro-6-methyl-3-tetrahydropyran-4-yl- pyrazolo[1,5-a]pyrimidine (80.00 mg, 317.83 µmol, 
1.00 eq) in DMF (3.00 mL) were added TEA (160.81 mg, 1.59 mmol, 220.28 uL, 5.00 eq) and 1-(2-
pyridyl)ethanamine (38.83 mg, 317.83 µmol, 1.00 eq). The mixture was stirred at 65 °C for 20 h. TLC 
(Petroleum ether: Ethyl acetate=2: 1) showed 7-chloro-6-methyl-3- tetrahydropyran-4-yl-pyrazolo[1,5-
a]pyrimidine was consumed completely and a new spot. The reaction mixture was diluted with water (10 mL) 
and extracted with EtOAc (10 mL*3). The combined organic layers were washed with brine (10 mL * 2), dried 
over anhydrous NaSO4, filtered and concentrated under reduced pressure to give a residue. The residue was 
purified by prep-HPLC (Condition: water(0.05% HCl)-ACN; Column: Phenomenex Synergi C18 
150*30mm*4um), and alkalized with strong-base anion exchange resin to give  6-methyl-N-[1-(2-
pyridyl)ethyl]-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-amine (32.00 mg, 93.79 µmol, 29.51% yield, 
98.9% purity) as a white soild. 
LCMS (Method 5-95 AB, ESI): RT =0.629 min / 1.5 min, M+H+ =338.1. 
1H NMR(400 MHz, CHLOROFORM-d)  ppm 8.65 (d, J=4.77 Hz, 1H), 7.99 (s, 1H), 7.91 (s, 1H), 7.67 (td, J=7.65, 
1.76 Hz, 1H), 7.34 - 7.36 (d, J=8.00 Hz, 1H), 7.29 - 7.28 (t, J=4.00 Hz, 1H), 7.20 - 7.25 (m, 1H), 5.48 - 5.62 (m, 1H), 
4.08 (dd, J=10.92, 3.14 Hz, 2H), 3.62 (td, J=11.61, 2.26 Hz, 2H), 3.21 (tt, J=11.62, 4.13 Hz, 1H), 2.35 (s, 3H), 1.88 
- 2.02 (m, 4H), 1.68 - 1.69 (d, J=6.65 Hz, 3H). 
 
Batch 2: 
 
 
 
 
 
 
To a mixture of 7-chloro-6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (200.00 mg, 794.57 µmol, 
1.00 eq) in DMF (3.00 mL) was added 1-(2-pyridyl)ethanamine (145.61 mg, 1.19 mmol, 1.50 eq) and TEA 
(160.80 mg, 1.59 mmol, 220.28 uL, 2.00 eq). The mixture was stirred at 65 °C for 12 h. TLC (Ethyl acetate: 
Petroleum ether= 2: 1) showed the 7-chloro-6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine was 
consumed completely and three new spots were formed. The mixture was diluted with water (40 mL) and the 
resultant mixture was extracted with ethyl acetate (100 mL*3). The combined organic layers were washed 
with saturated brine (40 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by chromatography (Petroleum ether: Ethyl acetate= 5: 1 to 1: 2) to give 6-methyl-N-[1-
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(2-pyridyl)ethyl]-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-amine (71.20 mg, 206.79 µmol, 26% yield, 
98% purity) as a light yellow solid. 
1H NMR (400 MHz, DMSO-d6)  ppm 8.59-8.60 (d, J=4.0 Hz,1H), 8.00 (s, 1H), 7.97 (s, 1H), 7.79-7.83 (td, J=8.0 
Hz, 1H), 7.65-7.67 (d, J=8.0 Hz,1H), 7.48-7.50 (d, J=8.0 Hz,1H), 7.31-7.34 (d, J=8.0 Hz, J=4.0 Hz, 1H), 5.62-5.66 
(m, 1H), 3.90-3.93 (m, 2H), 3.42-3.48 (td, J=12.0 Hz, J=4.0 Hz, 2H), 3.01-3.06 (m, 1H), 2.36 (s, 3H), 1.17-1.83 (m, 
4H), 1.54-155 (d, J=4.0 Hz, 3H). 
LCMS (Method 5-95 AB, ESI): RT =0.616 min / 1.5 min, M+H+ =338.2. 
 
 
Tert-butyl (6-methyl-3-(3-oxomorpholino)pyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (2) 
 
 
 
 
 
 
 
To a solution of tert-butyl N-(3-iodo-6-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate 
(250 mg, 537 µmol, 1 eq) and morpholin-3-one (81 mg, 806 µmol, 1.5 eq) in dioxane (15 mL) was added N,N'-
dimethylethane-1,2-diamine (189 mg, 2.1 mmol, 231 uL, 4 eq), CuI (205 mg, 1.1 mmol, 2 eq). The mixture was 
stirred at 80 °C for 3 hours under N2. TLC (EtOAc) showed most of tert-butyl N-(3-iodo-6-methyl-pyrazolo[1,5-
a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed and a new major spot. The mixture was filtered 
and concentrated. The residue was purified by chromatography on silica gel (Petroleum ether: EtOAc=1: 1, 
DCM: MeOH=15: 1) to give tert-butyl N-[6-methyl-3-(3-oxomorpholin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (150 mg, 342 µmol, 64% yield) as a yellow oil. 
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Tert-butyl (6-methyl-3-morpholinopyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (3) 
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To a solution of tert-butyl N-[6-methyl-3-(3-oxomorpholin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (150 mg, 342 µmol, 1 eq) in THF (5 mL) was added BH3-Me2S (10 M, 342 uL, 10 eq) at 
0 °C. The mixture was stirred at 25 °C for 12 hours under N2. TLC (EtOAc) showed tert-butyl N-[6-methyl-3-(3-
oxomorpholin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate was consumed completetly 
and a new major spot. To the mixture was added MeOH (5 mL) slowly at 0 °C and glycerunum (3 mL). The 
mixture was stirred at 25 °C for 12 h. LCMS showed that a major peak with desired mass. Then to the mixture 
was added water (40 mL) and extracted with EtOAc (30 mL*2). The organic layers were combined and washed 
with brine (30*3 mL), dried over Na2SO4 and concentrated. The residue was purified by chromatography on 
silica gel (Petroleum ether: EtOAc=1: 1, DCM: MeOH=25: 1) to give tert-butyl N-(6-methyl-3-morpholino-
pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate (100 mg, 235 µmol, 69% yield) as brown oil. 
 
 
6-methyl-3-morpholino-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9102) 
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A solution of tert-butyl N-(6-methyl-3-morpholino-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (120 mg, 282 µmol, 1 eq) in HCl/EtOAc (4 M, 10 mL, 141 eq) was stirred at 25 °C for 
12 hours. LCMS showed starting material was consumed completetly and a major peak of desired product. The 
mixture was concentrated directly and basified by TEA. The residue was purified by prep-HPLC (Column: 
Boston Green ODS 150*30 5u; Condition: water (0.225%FA)-ACN). The FA salt of product was basified by 
stronge bacis anion exchange resin to give 6-methyl-3-morpholino-N-(2-pyridylmethyl)pyrazolo[1,5-
a]pyrimidin-7-amine (58 mg, 176 µmol, 62% yield, 98% purity) as a light yellow solid. 
1H NMR (400MHz, CDCl3-d)  8.66 (d, J=4.27 Hz, 1 H), 7.96 (s, 1 H), 7.75 (s, 1 H), 7.70 (td, J=7.65, 1.76 Hz, 1 H), 
7.56 (t, J=5.58 Hz, 1 H), 7.30 (d, J=7.91 Hz, 1 H), 7.22 - 7.27 (m, 1 H), 5.11 (d, J=5.90 Hz, 2 H), 3.90 - 3.97 (m, 4 H), 
3.22 - 3.29 (m, 4 H), 2.44 (s, 3 H). 
LCMS (Method 10-80CD, ESI): RT =1.019 min / 2.0 min, M+H+ =325.1. 
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Tert-butyl (3-(fluoromethoxy)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(pyridin-2-ylmethyl)carbamate (2) 
 
 
 
 
 
To a solution of tert-butyl N-(3-hydroxy-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-
pyridylmethyl)carbamate (150 mg, 406 µmol, 1 eq) in THF (8 mL) was added KOH (3.5 M, 464 uL, 4 eq), then 
bromo(fluoro)methane (458 mg, 4.1 mmol, 10 eq) at 0 °C was added in one portion. The mixture was stirred 
at 26 °C for 1 hour under N2. TLC (Petroleum ether: EtOAc=1: 1) showed tert-butyl N-(3-hydroxy-5,6-dimethyl-
pyrazolo[1,5-a]pyrimidin-7-yl)-N-(2-pyridylmethyl)carbamate was consumed completetly and a major new 
spot. The reaction mixture was concentrated. The residue was purified by chromatography on silica gel 
(Petroleum ether: EtOAc=2: 1, 1: 2) to give tert-butyl N-[3-(fluoromethoxy)-5,6-dimethyl-pyrazolo[1,5-
a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate (100 mg, 249 µmol, 61% yield) as a light yellow oil. 
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3-(fluoromethoxy)-5,6-dimethyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9110) 
 
 
 
 
 
 
To a solution of tert-butyl N-[3-(fluoromethoxy)-5,6-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-
pyridylmethyl)carbamate (100 mg, 249 µmol, 1 eq) in MeOH (5 mL) was added HCl/EtOAc (4 M, 5 mL, 80 eq). 
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The mixture was stirred at 26 °C  for 12 hours. LCMS showed tert-butyl N-[3-(fluoromethoxy)-5,6-dimethyl-
pyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-pyridylmethyl)carbamate was consumed completetly and two major peaks 
of desired product and by-product 3-(methoxymethoxy)-5,6-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-
a]pyrimidin-7-amine. The mixture was concentrated directly. The residue was purified by prep-HPLC (Column: 
Phenomenex Synergi C18 150*30mm*4um; Condition: water (0.05%HCl)-ACN) followed by basification by 
strong basic anion exchange resin to give 3-(fluoromethoxy)-5,6-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-
a]pyrimi- din-7-amine (14 mg, 43 µmol, 17% yield, 93% purity) as a light yellow solid. 
1H NMR (400MHz, CDCl3-d)  8.66 (d, J=4.77 Hz, 1 H), 7.94 (d, J=1.76 Hz, 1 H), 7.71 (td, J=7.65, 1.76 Hz, 1 H), 
7.38 (br. s., 1 H), 7.32 (d, J=7.78 Hz, 1 H), 7.22-7.27 (m, 1 H), 5.62-5.80 (m, 2 H), 5.10 (d, J=5.65 Hz, 2 H), 2.53 (s, 
3 H), 2.36 (s, 3 H). 
LCMS (Method 10-80CD, ESI): RT =1.378 min / 2.0 min, M+H+ =302.0. 
 
 
 
6-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidine-5,7-diol (3) 
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To a solution of 4-tetrahydropyran-4-yl-1H-pyrazol-3-amine (1 g, 6 mmol, 1 eq) and 2-methylpropanedioic acid 
(706 mg, 6 mmol, 1 eq) in CH3CN (10.00 mL) was added T3P (7.6 g, 24 mmol, 7 mL, 4 eq). The mixture was 
stirred at 80 °C for 12 hrs. TLC (EtOAc) showed starting material was consumed completetly. The mixture was 
filtered and the filter cake was concentrated. The residue was purified by trituration from H2O/EtOH (1/1, 20 
mL) to provide 6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine-5,7-diol (1 g, 4 mmol, 67% yield) as 
a grey solid. 
1H NMR (400MHz, DMSO-d6) 11.41 (br. s., 1H), 7.79 (br. s., 1H), 3.91 (d, J=10.3 Hz, 4H), 2.88-2.96 (m, 1H), 
1.86 (s, 3H), 1.71-1.76 (m, 2H), 1.60-1.62 (m, 2 H). 
LCMS: M+H+ =250.1. 
 
5,7-dichloro-6-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidine (4) 
 
 
 
 
 
To a solution of 6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine-5,7-diol (1 g, 4 mmol, 
1 eq) in POCl3 (33 g, 215 mmol, 20 mL, 54 eq) was added N,N-diethylaniline (1.2 g, 8 mmol, 1.3 mL, 2 eq). The 
mixture was stirred at 100 °C  for 4 hours under N2. TLC (Petroleum ether: EtOAc=3: 1) indicated that a new 
major spot. Desired product was detected by LCMS. The mixture was concentrated directly. The residue was 
purified by chromatography on silica gel (Petroleum ether: EtOAc=5: 1, 3: 1, 2: 1) to afford 5,7-dichloro-6-
methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (1 g, crude) as a grey solid. 
1H NMR (400MHz, CDCl3-d)  8.03 (s, 1H), 4.07 (dd, J=10.4, 2.4 Hz, 2H), 3.59 (td, J=11.2, 3.3 Hz, 2H), 3.14-3.29 
(m, 1H), 2.54 (s, 3H), 1.87-2.00 (m, 4 H). 
LCMS: M+H+ =286.0. 
 
5,7-difluoro-6-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidine (6) 
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To a solution of 5,7-dichloro-6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (400 mg, 1.4 mmol, 
1 eq) in ACN (20 mL) was added CsF (1.1 g, 7 mmol, 5 eq). The mixture was stirred at 60 °C for 16 hrs in a 
sealed tube. TLC (Petroleum ether: EtOAc=3: 1) several new spots. LCMS showed 31% of by-product 5-chloro-
6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-ol, 40% of by-product 5-chloro-7-fluoro-6-methyl-
3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine and 16% of desired product. Then the mixture was stirred at 
70 °C for 24 hrs.  LCMS showed 31% of by-product 5-chloro-6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-
a]pyrimidin-7-ol, 16% of by-product 5-chloro-7-fluoro-6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-
a]pyrimidine and 40% of desired product. The mixture was filtered and the filtrate was concentrated. The 
residue was purified by chromatography on silica gel (Petroleum ether: EtOAc=5: 1, 3: 1) to give 5,7-difluoro-6-
methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (70 mg, crude) as a light yellow oil which was used in 
the next step without further purification.. 
LCMS: M+H+ =254.2. 
 
 
 
 
5-fluoro-6-methyl-N-(pyridin-2-ylmethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine (AWZ9117) 
 
 
 
 
 
 
 
To a solution of 5,7-difluoro-6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (50 mg, 197 µmol, 
1 eq) and 2-pyridylmethanamine (21 mg, 197 µmol, 20 uL, 1 eq) in ACN (3 mL) was added TEA (40 mg, 395 
µmol, 55 uL, 2 eq). The mixture was stirred at 10 °C for 5 mins. Light yellow solid was formed. LCMS showed 
starting material was consumed completetly and a major peak with desired mass. The mixture was filtered. 
The filter cake was dissolved in ACN. One drop of HCl (1N) was added to the mixture. The solution was purified 
by prep-HPLC (column: Agela ASB 150*25mm*5um; mobile phase: [water (0.225%TFA)-ACN];B%: 15%-
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45%,11min). The fraction was basified with NaHCO3 (5%, 10 mL). The basified mixture was extracted with DCM 
(20 mL*2). The organic layers were concentrated. The residue was purified by chromatography on silica gel 
(DCM: MeOH=20: 1) to afford 5-fluoro-6-methyl-N-(2-pyridylmethyl)-3-tetrahydropyran-4-yl-pyrazolo[1,5-
a]pyrimidin-7-amine (16 mg, 46 µmol, 23% yield, 99.3% purity) as a light yellow solid. 
1H NMR (400MHz, CDCl3-d)  8.68 (d, J=4.8 Hz, 1H), 7.87 (s, 1H), 7.81 (br. s., 1H), 7.73 (td, J=7.7, 1.7 Hz, 1H), 
7.27-7.34 (m, 2H), 5.15 (d, J=5.5 Hz, 2H), 4.06 (dd, J=11.6, 2.8 Hz, 2H), 3.58 (td, J=11.6, 2.2 Hz, 2H), 3.11 (tt, 
J=11.6, 4.2 Hz, 1H), 2.36 (s, 3H), 1.80-1.97 (m, 4 H). 
LCMS (Method: 5-95AB, ESI): RT =0.692 min / 1.5 min, M+H+ =342.1.  
5-chloro-6-methyl-N-(pyridin-2-ylmethyl)-3-(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine 
(AWZ9125) 
 
 
 
 
 
 
To a solution of 5,7-dichloro-6-methyl-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine (50 mg, 174 µmol, 
1 eq) and 2-pyridylmethanamine (23 mg, 230 µmol, 21 uL, 1.2 eq) in ACN (4 mL) was added TEA (35 mg, 349 
µmol, 48 uL, 2 eq). The mixture was stirred at 60 °C for 12 hours. TLC (Petroleum ether: EtOAc=1: 2) showed all 
of starting material was consumed and a major spot. To the mixture was added H2O (1 mL). Then the 
suspension was stirred at 20 °C for 2 h and filtered. The filter cake was dried in vacuo to afford 5-chloro-6-
methyl-N-(2-pyridylmethyl)-3-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidin-7-amine (36 mg, 96 µmol, 55% 
yield, 94.8% purity) as a white solid. 
1H NMR (400MHz, CDCl3-d)  8.67 (d, J=4.6 Hz, 1H), 7.89 (s, 1H), 7.65-7.79 (m, 2H), 7.26-7.34 (m, 2H), 5.16 (d, 
J=5.3 Hz, 2H), 4.05 (dd, J=11.2, 3.1 Hz, 2H), 3.54-3.64 (m, 2H), 3.19 (m, 4.0 Hz, 1H), 2.50 (s, 3H), 1.79-1.98 (m, 4 
H). 
LCMS (Method: 5-95CD, ESI): RT =0.954 min / 1.5 min, M+H+ =358.1. 
